Program at a Glance

CROI 2015
Conference on Retroviruses and Opportunistic Infections

February 23-26, 2015
Seattle, Washington
CONTENTS

CROI FOUNDATION ................................................................. 2
IAS—USA .................................................................................. 2
CROI 2015 PROGRAM COMMITTEE ........................................... 3
Scientific Program Committee ............................................... 3
Community Liaison Subcommittee ......................................... 4
EXTERNAL REVIEWERS ............................................................. 5
COMMERCIAL SUPPORT ......................................................... 6
CONTINUING MEDICAL EDUCATION ....................................... 7
Accreditation Statement ......................................................... 7
Objectives ............................................................................... 7
Statement of Need .................................................................. 7
CME Credit Information ......................................................... 7
Claiming CME Credits or a Certificate of Participation .......... 7
Faculty Financial Disclosure ............................................... 7
Drug and Product Disclaimer ............................................... 7
GENERAL INFORMATION ........................................................ 8
Overview ............................................................................... 8
Americans with Disabilities Act ............................................. 8
Ebola Precautions ................................................................ 8
Welcome Reception ............................................................. 8
Meals .................................................................................... 8
Overflow Accommodations for Session Rooms .................... 9
USB Flash Drive ................................................................. 9
Website ............................................................................... 9
Webcasts and Podcasts ....................................................... 9
Mobile App ......................................................................... 9
Wi-Fi Access at the Conference ............................................ 9
Badges ............................................................................... 9
Child Care .......................................................................... 9
Conference Etiquette ......................................................... 9
CONFERENCE SERVICES ......................................................... 10
HOTEL INFORMATION ............................................................ 11
ORAL SESSIONS ................................................................... 13
POSTER SESSIONS, BY CATEGORY ....................................... 41
POSTER LISTINGS, BY CATEGORY ......................................... 44
CONFERENCE SCHEDULE OVERVIEW .................................. 126
CONVENTION CENTER FLOOR PLANS ............................... 127
# CROI FOUNDATION

The CROI Foundation operates exclusively for the charitable and educational purpose of organizing, promoting, and presenting the Conference on Retroviruses and Opportunistic Infections (CROI).

## Roles and Responsibilities of the CROI Foundation Board of Directors

- Works closely with the CROI Scientific Program Committee (CROI PC) and the CROI Secretariat to accomplish the mission of CROI
- Approves nominations for members of the CROI PC and the CROI PC Chair and Vice Chairs
- Ensures that the CROI PC is responsible for the scientific program content of CROI
- Enters into and oversees the partner agreement with the CROI Secretariat
- Has the sole and absolute discretion to veto any policies, procedures, or actions taken or proposed to be taken by the CROI PC or the CROI Secretariat that would pose a substantial risk of preventing the Foundation at any time from qualifying or continuing to qualify as a 501(c)(3) organization or that might cause the loss of such qualification
- Oversees the long-term financial and administrative integrity of CROI

## Composition of the CROI Foundation Board of Directors

The Board of Directors comprises current and previous CROI Chairs and Vice Chairs and selected members of the CROI PC.

### CROI Foundation Board Members

<table>
<thead>
<tr>
<th>Name</th>
<th>Affiliation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Constance A. Benson, MD</td>
<td>President&lt;br&gt;University of California San Diego&lt;br&gt;San Diego, CA, US</td>
</tr>
<tr>
<td>John M. Coffin, PhD, Secretary-Treasurer</td>
<td>Tufts University&lt;br&gt;Boston, MA, US</td>
</tr>
<tr>
<td>Elaine J. Abrams, MD</td>
<td>International Center for AIDS Care and Treatment Programs&lt;br&gt;Columbia University&lt;br&gt;New York, NY, US</td>
</tr>
<tr>
<td>Susan P. Buchbinder, MD</td>
<td>San Francisco Department of Public Health&lt;br&gt;University of California San Francisco&lt;br&gt;San Francisco, CA, US</td>
</tr>
<tr>
<td>Judith S. Currier, MD, MsC</td>
<td>University of California Los Angeles&lt;br&gt;Los Angeles, CA, US</td>
</tr>
<tr>
<td>Kevin M. De Cock, MD</td>
<td>Centers for Disease Control and Prevention&lt;br&gt;Nairobi, Kenya</td>
</tr>
<tr>
<td>Scott M. Hammer, MD</td>
<td>Columbia University Medical Center/New York—Presbyterian Hospital&lt;br&gt;New York, NY, US</td>
</tr>
<tr>
<td>John W. Mellors, MD</td>
<td>University of Pittsburgh&lt;br&gt;Pittsburgh, PA, US</td>
</tr>
<tr>
<td>Julie M. Overbaugh, PhD</td>
<td>Fred Hutchinson Cancer Research Center&lt;br&gt;Seattle, WA, US</td>
</tr>
<tr>
<td>Robert T. Schooley, MD</td>
<td>University of California San Diego&lt;br&gt;San Diego, CA, US</td>
</tr>
<tr>
<td>Mario Stevenson, PhD</td>
<td>University of Miami&lt;br&gt;Miami, FL, US</td>
</tr>
</tbody>
</table>

---

# IAS—USA

The International Antiviral Society—USA is a 501(c)(3) not-for-profit professional education organization. The IAS—USA serves as the Conference Secretariat for CROI.

The mission of the IAS—USA is to improve the treatment, care, and quality of life for people with HIV, hepatitis C virus, or other viral infections through high-quality, relevant, balanced, and needs-oriented education and information for practitioners and scientists who are actively involved in medical care and research.

### Executive Director: Donna M. Jacobsen

**Address:** 425 California Street, Suite 1450<br>San Francisco, CA 94104-2120

**Phone:** 415-544-9400

**Website:** www.iasusa.org
CROI 2015 PROGRAM COMMITTEE

The Scientific Program Committee (PC) is a team of experts in their given field who volunteer to organize the scientific program for CROI. Members are selected based on their area of scientific expertise and their commitment to the mission of the conference. Initial terms are 3 years; subsequent terms are based on previous participation and interest level. Members are nominated by the PC and approved by the CROI Foundation Board of Directors. The “goodwill ambassadors” of CROI, PC members are also responsible for identifying topics and speakers that will ensure innovative programming; strategic planning; abstract review and program development; and organizing, conducting, and convening workshops, symposia, and special sessions.

Scientific Program Committee

Scott M. Hammer, MD
CROI 2015 Chair
Columbia University Medical Center/New York–Presbyterian Hospital
New York, NY, US

Julie M. Overbaugh, PhD
CROI 2015 Vice Chair
Fred Hutchinson Cancer Research Center
Seattle, WA, US

Susan P. Buchbinder, MD
CROI 2015 Vice Chair
San Francisco Department of Public Health
University of California San Francisco
San Francisco, CA, US

Elaine J. Abrams, MD
ICAP at Columbia University
New York, NY, US

Galit Alter, PhD
Ragon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology, and Harvard University
Boston, MA, US

Constance A. Benson, MD
University of California San Diego
San Diego, CA, US

Bruce J. Brew, MD, MBBS
St. Vincent’s Hospital
Sydney, Australia

Ellen G. Chadwick, MD
Northwestern University
Ann and Robert J. Lurie Children’s Hospital of Chicago
Chicago, IL, US

Richard E. Chaisson, MD
The Johns Hopkins University
Baltimore, MD, US

John M. Coffin, PhD
Tufts University
Boston, MA, US

Judith S. Currier, MD, MSc
University of California Los Angeles
Los Angeles, CA, US

Kevin M. De Cock, MD
Centers for Disease Control and Prevention
Nairobi, Kenya

Wafaa M. El-Sadr, MD, MPH
ICAP at Columbia University
New York, NY, US

Courtney V. Fletcher, PharmD
University of Nebraska Medical Center College of Pharmacy
Omaha, NE, US

Dana H. Gabuzda, MD
Dana-Farber Cancer Institute and Harvard University
Boston, MA, US

Sharon L. Hillier, PhD
Magee-Womens Hospital of UPMC
University of Pittsburgh
Pittsburgh, PA, US

James A. Hoxie, MD
University of Pennsylvania
Philadelphia, PA, US

Peter W. Hunt, MD
University of California San Francisco
San Francisco, CA, US

Harold W. Jaffe, MD
Centers for Disease Control and Prevention
Atlanta, GA, US

Ilesh V. Jani, MD, PhD
Instituto Nacional de Saúde
Maputo, Mozambique

Frank Kirchhoff, PhD
Institute of Molecular Virology
Ulm, Germany

Dennis L. Kolson, MD, PhD
University of Pennsylvania
Philadelphia, PA, US

Richard A. Koup, MD
Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health
Bethesda, MD, US

Hermione Lyall, MD
Imperial College Healthcare National Health Service Trust
London, England
Community Liaison Subcommittee

The Community Liaison Subcommittee is a group of community educators and advocates that provides feedback to the PC about the content and structure of the scientific program in general and specifically related to scientific topics of interest to the HIV/AIDS-affected community.

Heidi M. Nass, JD
AIDS Treatment Activists Coalition
Madison, WI, US

Jeff Taylor
AIDS Treatment Activists Coalition
Palm Springs, CA, US

Morenike Ukpong, FWACS, MBA, BChD
Obafemi Awolowo University
Ife-Ife, Nigeria

Steven F. Wakefield
HIV Vaccine Trials Network
Fred Hutchinson Cancer Research Center
Seattle, WA, US
We gratefully acknowledge the contributions of the following, who served as volunteer external reviewers of abstracts for CROI 2015.

Edward P. Acosta, PharmD
University of Alabama at Birmingham
Birmingham, AL, US

Peter L. Anderson, PharmD
University of Colorado
Aurora, CO, US

Till Bärnighausen, MD, PhD, ScD, MSc
Harvard University
Boston, MA, US

John M. Blandford, PhD
Centers for Disease Control and Prevention
Atlanta, GA, US

Marta Boffito, MD, PhD
Chelsea and Westminster Hospital and National Health Service Foundation Trust
London, United Kingdom

William Borkowsky, MD
New York University School of Medicine
New York, NY, US

Corey Casper, MD
Fred Hutchinson Cancer Research Center
Seattle, WA, US

Nicolas Chomont, PhD
Vaccine and Gene Therapy Institute of Florida
Port St Lucie, FL, US

David B. Clifford, MD
Washington University School of Medicine
Saint Louis, MO, US

Susan E. Cohn, MD
Northwestern University
Chicago, IL, US

Eric S. Daar, MD
Harbor—University of California Los Angeles Medical Center
Torrance, CA, US

Charles W. Flexner, MD
The Johns Hopkins University
Baltimore, MD, US

Patricia M. Flynn, MD
St. Jude Children’s Research Hospital
Memphis, TN, US

Monica Gandhi, MD, MPH
University of California San Francisco
San Francisco, CA, US

J. Gerardo García-Lerma, PhD
Centers for Disease Control and Prevention
Atlanta, GA, US

Carlo Giaquinto, MD
University of Padova
Padova, Italy

Francisco Gonzalez-Scarano, MD
University of Texas
San Antonio, TX, US

Steven K. Grinspoon, MD
Massachusetts General Hospital and Harvard University
Boston, MA, US

Huldrych F. Gunthard, MD
University Hospital Zurich
Zurich, Switzerland

Beatrice H. Hahn, MD
University of Pennsylvania
Philadelphia, PA, US

James G. Hakim, MD
University of Zimbabwe
Harare, Zimbabwe

Timothy B. Hallett, PhD
Imperial College London
London, United Kingdom

P. Richard Harrigan, MD
British Columbia Centre for Excellence in HIV/AIDS
Vancouver, BC, Canada

Diane V. Havlir, MD
University of California San Francisco
San Francisco, CA, US

Priscilla Y. Hsue, MD
University of California San Francisco
San Francisco, CA, US

Susan E. Krown, MD
AIDS Malignancy Consortium
New York, NY, US

Scott L. Letendre, MD
University of California San Diego
San Diego, CA, US

Sharon R. Lewin, MD
The Doherty Institute for Infection and Immunity
Melbourne, Australia

Susanna Naggie, MD, MHS
Duke Clinical Research Institute
Durham, NC, US

Jean-Michel Pawlotsky, MD, PhD
Henri Mondor University Hospital
Creteil, France

Sharon A. Riddler, MD
University of Pittsburgh
Pittsburgh, PA, US

Kenneth E. Sherman, MD
University of Cincinnati
Cincinnati, OH, US

Serena S. Spudich, MD, MA
Yale University
Guilford, CT, US

David L. Wyles, MD
University of California San Diego
San Diego, CA, US

Robert Yarchoan, MD
National Cancer Institute
Bethesda, MD, US
COMMERCIAL SUPPORT

The Conference on Retroviruses and Opportunistic Infections (CROI) is largely supported by the registration fees of participants. In addition, the organizers seek grants from commercial companies, particularly from companies with competing products. These companies have no input in or control over the selection of faculty or content of the presentations.

CROI 2015 has, to date, received grant support commitments from the following commercial companies:

**Platinum**

Gilead Sciences, Inc  
Merck & Co, Inc  
ViiV Healthcare

**Gold**

Bristol-Myers Squibb  
Janssen Therapeutics, Division of Janssen Products, LP

**Silver**

AbbVie

Additional support has been provided by Mylan, Inc
CONTINUING MEDICAL EDUCATION

Accreditation Statement

The International Antiviral Society–USA (IAS–USA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education (CME) for physicians.

The IAS–USA designates this live activity for a maximum of **28 AMA PRA Category 1 Credits™**. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Since 2006, the IAS–USA has held Accreditation with Commendation. In so doing, the IAS–USA belongs to an elite group of organizations in the United States that have been awarded this prestigious status, which, in the words of the ACCME, is “reserved for programs that are truly exceptional.”

Objectives

After participating in CROI 2015, learners will be able to:

- Describe current basic science research on the pathogenesis of HIV and on advances toward a cure
- Discuss the most recent findings from clinical trials in the field of HIV and the implications of these data for state-of-the-art treatment strategies
- Review current epidemiologic data on the prevalence of HIV infection, transmission, treatment, and linkage to and retention in care in populations worldwide, and discuss the implications of these data for public-health program planning

Statement of Need

Since HIV was identified, the scientific response to the global pandemic has been a coordinated effort among basic researchers, clinical investigators, health care providers, epidemiologists, and community leaders to move information and potential treatment options from research to clinical trials and out to affected communities as quickly as possible. CROI was founded in 1993 by researchers working in the field of HIV/AIDS and its complications, as a science-focused forum for exchanging current research findings among their international peers. CROI continues to focus on scientific exchange, providing an environment in which basic science researchers, translational researchers, clinical investigators, epidemiologists, and public health experts meet to present and discuss the latest research into different facets of HIV and its complications.

CME Credit Information

Physicians (MD, DO, and international equivalents) are eligible to receive CME credit for participation in CROI 2015. Other practitioners and clinicians can receive a Certificate of Participation verifying their attendance, as required by the American Medical Association (AMA).

Claiming CME Credits or a Certificate of Participation

During the conference, daily evaluations will be e-mailed to all CROI participants to the e-mail account they used to register for the conference. On Thursday, February 26, 2015, all CROI participants will receive a final e-mail that will contain their registration confirmation number and a link to the overall CROI evaluation. To obtain CME credits or a Certificate of Participation for CROI, this final evaluation must be completed by Tuesday, March 31, 2015. Once the evaluation is submitted, participants will receive the link to claim and print their certificate.

To determine the number of CME credits or hours that you can claim, calculate your time spent attending the conference, including plenary sessions, symposia, themed discussions, etc. For example, if you attended 2 plenary talks (8:30 AM to 9:30 AM), a themed discussion (1:30 PM to 2:30 PM), and a symposium (4:00 PM to 6:00 PM), you would have a total of 4 hours to apply toward CME credits for that day. At the end of CROI, please add the total hours you attended for your certificate. You may claim a maximum of **28 AMA PRA Category 1 Credits™** for this activity.


Faculty Financial Disclosure

It is the policy of the IAS–USA to ensure balance, independence, objectivity, and scientific rigor in all its educational activities. All faculty members (speakers, presenters, etc) participating in IAS–USA-sponsored activities are required to disclose to the program audience any financial interests within the past 12 months that could be perceived to influence, or give the appearance of potentially influencing, the written or oral presentation. (The ACCME defines a financial interest as an interest in any amount.) The information is intended to make the IAS–USA audience aware of author and contributor interests and commitments with commercial companies or other entities, enabling the audience members to form their own judgments about such associations.

Each author or contributor is required to complete this financial disclosure declaration. In accordance with IAS–USA policy, the IAS–USA will identify and resolve ahead of time any possible conflicts of interest that may influence CME activities with regard to exposition or conclusion. Disclosure information will be included with the Program and Abstracts eBook on the web.

Drug and Product Disclaimer

This activity may contain information about the investigational uses of drugs or products that are not approved by the US Food and Drug Administration. Please consult full prescribing information before using any medication or product mentioned in this activity.
Overview
The 2015 Conference on Retroviruses and Opportunistic Infections (CROI) will take place at the Washington State Convention Center in Seattle, WA, from February 23 to February 26, 2015. CROI was established in 1993 to provide a forum for basic scientists and clinical investigators to present, discuss, and critique their investigations into the epidemiology and biology of human retroviruses and associated diseases. The synergy of basic science and clinical investigation has been a major contributor to the success of the meeting. CROI is the preeminent HIV research meeting in the world and attracts more than 4000 HIV and AIDS research leaders internationally. The goal of the conference is to help researchers translate their laboratory and clinical findings into tangible progress against the HIV pandemic. CROI has facilitated the presentation of important discoveries in the field, thereby accelerating progress in HIV and AIDS research.

Americans with Disabilities Act
CROI 2015 endeavors to comply fully with the legal requirements of the Americans with Disabilities Act (ADA). If you require assistance on-site, please visit the Seattle Visitor Center and Concierge Services in the Upper Pike Street Lobby during the conference.

Ebola Precautions
Attendees who have recently returned from an Ebola-prevalent area are expected to follow the guidance of their institutions, local health departments, or the Centers for Disease Control and Prevention (CDC) as applicable with respect to monitoring and travel. CDC guidance can be found online: http://www.cdc.gov/vhf/ebola/exposure/monitoring-and-movement-of-persons-with-exposure.html.

Welcome Reception
All registered CROI attendees are invited to join us for a Welcome Reception immediately following the Opening Reception on February 23, 2015. This will be a private event hosted at Nordstrom’s Flagship store in Downtown Seattle just a minutes walk from the Convention Center at Sixth and Pine Streets (enter using the Sixth Avenue entrance).

This unique Welcome Reception will offer attendees the opportunity to network with colleagues and experience a private shopping environment while enjoying passed hors d’oeuvres and beverages in a beautiful and unique setting.

Please join us for this exclusive event!

Meals
Morning coffee and light continental breakfast will be available to conference registrants from 9:30 AM to 10:00 AM, Tuesday, Wednesday, and Thursday, on the 6th floor. An afternoon snack break will be available at 2:30 PM in the Poster Hall and before the special session on Tuesday evening. Attendees are on their own for lunch each day. Below is a list of food service options located in the Convention Center or within a short walking distance.

At the Convention Center
820 Pike Street — Pan Asian Cuisine
Crêpes Voilá
Cyber Dogs — Internet Café
Espresso Caffé Dior
Goldberg’s Deli
Subway Sandwiches
Taco Del Mar
The Juicy Café
Tully’s Coffee
Wild Rye Café Bakery

Within 4 Blocks of the Convention Center
Benihana
Blueacre Seafood
Blue C Sushi
Daily Grill
Dragonfish Asian Cafe
FareStart
FOX Sports Grill
Gameworks
Gordon Biersch Brewery Restaurant
Il Fornaio
MOD Superfast Pizza
Morton’s The Steakhouse
Ebar (Nordstrom Downtown Seattle)
Marketplace Café (Nordstrom Downtown Seattle)
The Grill (Nordstrom Downtown Seattle)
NYC Hyatt Deli Market
P.F. Chang’s China Bistro — Seattle
Palomino
Pike Place Chowder — Pacific Place
Potbelly Sandwich Shop
RN74
Rock Bottom Restaurant & Brewery
Ruth’s Chris Steak House
Soup’s On!
Starbucks Coffee Company
Sullivan’s Steakhouse
Tango Restaurant & Lounge
Tap House Grill
Thai Ginger
The Capital Grille
The Cheesecake Factory
The Elephant and Castle Pub & Restaurant
Toss’d Custom Salads
Urbane Northwest (Hyatt at Olive 8)

Overflow Accommodations for Session Rooms
The 4AB Auditorium is the designated overflow area. Headsets and up to 4 screens will provide live audio and video feed throughout the conference.

USB Flash Drive
Each participant is supplied a USB flash drive at badge pickup with a copy of the eAbstract book. The Program at a Glance and Program and Abstracts eBook are also available online to be loaded onto the USB flash drive. Downloads can be completed at the Cyber Cafe or directly from the conference website.

Website
For additional information about the conference please visit the website at www.CROIconference.org.

Mobile App
CROI 2015 has a mobile App to enhance your conference experience. The App enables you to schedule sessions, view abstracts, e-mail session notes, receive announcements, and more. Search “CROI 2015” in your mobile device App store, and download the conference App. The mobile App supports iOS and Android devices. Access is restricted to registered attendees only. Your log-in information and password will be provided to you on site with your registration materials.

Wi-Fi Access at the Conference
Complimentary Wi-Fi access is provided at the Washington State Convention Center. Network information is as follows:
Network name: CROI 2015
Password: iasusa2015

Badges
Badge pickup will be available at the registration lobby; please bring government-issued photo identification that clearly shows your name. You must wear your name badge to gain entry to all official meeting activities, including the poster sessions. DO NOT LOSE YOUR BADGE. Unfortunately, payment of an additional registration fee ($730) will be required to replace a lost badge. Also, if you notice that your affiliation or the affiliations of other attendees are incorrect, please inform conference staff in the office of the Conference Secretariat.

Child Care
Children are not permitted entry into any meeting room, including the poster area. If you should require child care, please contact the concierge of your hotel or the Visitor Information Center on Level One at the Washington State Convention Center.

Conference Etiquette
Please ensure all cell phones and pagers are off or are placed in SILENT mode. No flash photography is permitted in session rooms.

Webcasts and Podcasts
Plenaries, symposia, scientific overviews, oral abstract sessions, and themed discussions will be webcast and podcast. Webcasts are also available as streaming video for the Apple iPad and iPhone. Visit www.CROIconference.org or www.CROIwebcasts.org to access the CROI 2015 webcasts and podcasts. Webcasts will be available within 24 hours of the end of the relevant session.
# CONFERENCE SERVICES
## AT THE WASHINGTON STATE CONVENTION CENTER

<table>
<thead>
<tr>
<th>Services</th>
<th>Location</th>
<th>Hours</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Seattle Visitor Center and Concierge Services</td>
<td>Upper Pike Street Lobby</td>
<td>Monday to Friday 9:00 AM–5:00 PM</td>
<td>Full-service concierge assistance, including maps, guides, tickets, restaurant reservations, tours, ground transportation, and personal services</td>
</tr>
<tr>
<td></td>
<td>Level 1</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Bag and Coat Check</td>
<td>Hall 4C-3, 4 Level 4</td>
<td>Monday 7:00 AM–7:30 PM, Tuesday 7:00 AM–8:00 PM, Wednesday to Thursday 7:30 AM–6:30 PM</td>
<td>Bag and coat check are free of charge.</td>
</tr>
<tr>
<td>Cyber Cafe</td>
<td>4D Skybridge Level 4</td>
<td>Sunday 3:00 PM–5:00 PM, Monday to Wednesday 7:00 AM–7:00 PM, Thursday 7:00 AM–6:00 PM</td>
<td>Computers with Internet access available for webcasts, abstract searches, and messages</td>
</tr>
<tr>
<td>Media Center</td>
<td>Room 400 Level 4</td>
<td>Monday 9:00 AM–7:00 PM, Tuesday to Thursday 8:00 AM–6:00 PM</td>
<td>There is no on-site press registration. Registered press can pick up press kits and obtain location for press conferences.</td>
</tr>
<tr>
<td>Badge Pickup</td>
<td>Hall 4C-3, 4 Level 4</td>
<td>Sunday 3:00 PM–6:00 PM, Monday 7:00 AM–7:00 PM, Tuesday 7:00 AM–6:00 PM, Wednesday 8:00 AM–6:00 PM, Thursday 8:00 AM–12:00 PM</td>
<td>Location to pick up badges and conference materials</td>
</tr>
<tr>
<td>Attendee Services</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Housing Information</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Scholarship Badge Pickup</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Media Badge Pickup</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Speaker Ready Room and Electronic Poster Drop-off</td>
<td>Room 620 Level 6</td>
<td>Sunday 3:00 PM–6:00 PM, Monday to Thursday 7:30 AM–6:00 PM</td>
<td>Oral abstract, invited, and themed discussion session speakers must drop off presentations at least 24 hours before their presentation.</td>
</tr>
<tr>
<td>Personal Considerations Room</td>
<td>Room 507 Level 5</td>
<td>Sunday 3:00 PM–6:00 PM, Monday 7:00 AM–7:00 PM, Tuesday 7:00 AM–6:00 PM, Wednesday 8:00 AM–6:00 PM, Thursday 7:00 AM–6:00 PM</td>
<td>The Personal Considerations Room is a room set aside for those who require a short-term private space for personal health needs. Use of this room is on a first-come, first-served basis.</td>
</tr>
<tr>
<td>New Mother's Room</td>
<td>Room 416 Level 4</td>
<td>Sunday 3:00 PM–6:00 PM, Monday 7:00 AM–7:00 PM, Tuesday 7:00 AM–6:00 PM, Wednesday 8:00 AM–6:00 PM, Thursday 7:00 AM–6:00 PM</td>
<td>The New Mother's Room is a room set aside for nursing mothers who require a short-term private room. Use of this room is on a first-come, first-served basis.</td>
</tr>
</tbody>
</table>

*Poster presenters must submit an electronic version of their poster for placement on the CROI website before their assigned session.*
HOTEL INFORMATION

CROI 2015 hotels are listed below. For more detailed housing information, please visit the CROI 2015 conference website: www.CROI2015.org/housing. Conference attendees are required to stay in one of the official conference hotels. The few exceptions to this include registrants who live in the Seattle area (ie, within a 50-mile radius of the Washington State Convention Center) and registrants who are sharing a room with an approved CROI attendee with accommodations booked via the CROI housing system.

Sheraton Seattle Hotel
1400 Sixth Avenue
Seattle, WA 98101
PH: +1 206 621 9000

Crowne Plaza Seattle Downtown
1113 6th Avenue
Seattle, WA 98101
PH: +1 206 464 1980

The Fairmont Olympic Hotel
411 University Street
Seattle, WA 98101
PH: +1 206 621 1700

Hilton Seattle
1301 6th Avenue S
Seattle, WA 98101
PH: +1 206 460 7456

Grand Hyatt Seattle
721 Pine Street
Seattle, WA 98101
PH: +1 206 774 1234

Hyatt at Olive 8
1635 8th Avenue
Seattle, WA 98101
PH: +1 206 695 1234

Mayflower Park Hotel
405 Olive Way
Seattle, WA 98101
PH: +1 206 623 8700

Motif Seattle
1415 Fifth Avenue
Seattle, WA 98101
PH: +1 206 971 8000

Renaissance Seattle Hotel
515 Madison Street
Seattle, WA 98104
PH: +1 206 583 0300

W Seattle
1112 4th Avenue
Seattle, WA 98101
PH: +1 206 264 6000

The Westin Seattle
1900 5th Avenue
Seattle, WA 98101
PH: +1 206 728 1000
ORAL SESSIONS

MONDAY, FEBRUARY 23, 2015

Session W1 Workshop
9:00 am – 12:30 pm
Program Committee Workshop for New Investigators and Trainees

Target audience: This workshop is directed toward new trainees (eg, undergraduate students, graduate students, postdoctoral fellows, and physician fellows) and new investigators (both international and domestic).

Level of knowledge: It is assumed that participants have been conducting active research in the field for less than 3 years.

Objectives: At the completion of the session, participants will be able to:

- Describe the major areas of HIV investigation being presented at the conference.
- Identify the top 3 to 5 research questions in the field of retroviruses and opportunistic infections today.
- Describe some of the proposed solutions for addressing the challenges presented globally by a variety of retroviruses and opportunistic infections.

Workshop Conveners
Scott M. Hammer, Columbia University Medical Center/New York-Presbyterian Hospital, New York, NY, US
John W. Mellors, University of Pittsburgh, Pittsburgh, PA, US

1 A Path to an HIV Vaccine
Galit Alter
Ragon Institute of MGH, MIT and Harvard, Cambridge, MA, US

2 Animal Models of HIV Prevention and Cure
Guido Silvestri
Emory University, Decatur, GA, US

3 HIV Prevention 2.0: What’s Next?
Susan P. Buchbinder
San Francisco Department of Public Health, San Francisco, CA, US

4 Pathogenesis of HIV Complications
Peter W. Hunt
University of California San Francisco, San Francisco, CA, US

5 HIV Cure Research
John M. Coffin
Tufts University, Boston, MA, US

Session MD Presentation
1:00 pm – 2:00 pm
Martin Delaney Presentation: How to End the HIV Epidemic: Community Perspectives

Moderator
Steven F. Wakefield, HIV Vaccine Trials Network, Fred Hutchinson Cancer Research Center, Seattle, WA, US

Panelists
Connie Celum, University of Washington, Seattle, WA, US
Damon L. Jacobs, Private Practice Psychologist, Brooklyn, NY, US
Matthew V. Sharp, Shanti Project, Berkeley, CA, US

Session W2 Workshop
2:30 pm – 4:30 pm
Clinical Trial Design and Analysis

Target audience: This session is directed to clinicians and scientists who are interested in designing or interpreting clinical trial results.

Level of knowledge: It is assumed that participants are familiar with the basic design of randomized and observational clinical studies.

Objectives: At the completion of the session, participants will be able to:

- Describe strategies for evaluating the effectiveness of interventions.
- Interpret adherence measures.
- Evaluate study design with infrequent endpoints.

Workshop Conveners
Susan P. Buchbinder, San Francisco Department of Public Health, San Francisco, CA, US
Richard E. Chaisson, The Johns Hopkins University, Baltimore, MD, US

7 Getting SMART About Innovative Designs for Studying Effectiveness: The Case of Adaptive Implementation Interventions
Daniel Almirall
University of Michigan, Ann Arbor, MI, US

8 The Clinical Pharmacology of Medication Adherence
Terrence Blaschke
Stanford University, Stanford, CA, US

9 Epidemiological and Biostatistical Issues in Studying Rare Events in HIV
Stephen J. Gange
Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, US
Session W3 Workshop
2:30 pm – 4:30 pm
Frontiers in Laboratory Science

Target audience: This session is directed to investigators and clinicians interested in learning about the main technological and conceptual developments in life sciences that are influencing HIV research or hold a significant potential for research.

Level of knowledge: It is assumed that participants are familiar with the main technological and data analysis approaches used in HIV research.

Objectives: At the completion of the session, participants will be able to:
• Recognize the potential of and directions in the field of big data analysis.
• Describe developments in immunophenotyping and in single-cell analyses.
• Use the basic concepts of integration site analysis to understand current directions in HIV latency research.

Workshop Conveners
Galit Alter, Ragon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology, and Harvard University, Cambridge, MA, US
Amalio Telenti, The J. Craig Venter Institute, La Jolla, CA, US

10 Measuring Immunity 1 Cell at a Time
Mario Roederer
Vaccine Research Center, NIAID, NIH, Bethesda, MD, US

11 Studying Heterogeneity With Single Cell RNA-Sequencing
Simon Quenneville
Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland

12 Integration-Site Analysis
Frederic D. Bushman
University of Pennsylvania School of Medicine, Philadelphia, PA, US

13 Discovery and Modeling of Genomic Regulatory Networks With Big Data
Hamid Bolouri
Fred Hutchinson Cancer Research Center, University of Washington, Seattle, WA, US

Opening Session
5:00 pm – 7:00 pm
Welcome: Opening Session

Opening Session Hosts
Scott M. Hammer, Columbia University Medical Center/New York-Presbyterian Hospital, New York, NY, US
Julie M. Overbaugh, Fred Hutchinson Cancer Research Center, Seattle, WA, US
Susan P. Buchbinder, San Francisco Department of Public Health, San Francisco, CA, US

Session NL1 Lecture
Bernard Fields Lecture
18 Hepatitis C: Light at the End of the Tunnel
Charles M. Rice
The Rockefeller University, New York, NY, US

Session NL2 Lecture
N’Galy-Mann Lecture
19 Antiretroviral Therapy: Past, Present, and Future
David A. Cooper
Kirby Institute, University of New South Wales, Sydney, Australia
TUESDAY, FEBRUARY 24, 2015

Session PL-1 Plenary
8:30 am – 9:00 am
PrEP for HIV Prevention: What We Know and What We Still Need to Know for Implementation

Raphael J. Landovitz
University of California Los Angeles, Los Angeles, CA, US

Session PL-2 Plenary
9:00 am – 9:30 am
Specific HIV Integration Sites Linked to Clonal Expansion and Persistence of Cells

Stephen H. Hughes
National Cancer Institute, Frederick, MD, US

Session O-1 Oral Abstracts
Room 6AB
10:00 am – 12:15 pm
Session O-1 Oral Abstracts

Moderators
Sharon L. Hillier, Magee-Womens Hospital of UPMC, University of Pittsburgh, Pittsburgh, PA, US
Jorge Sanchez, Impacta Peru CTU, Barranco, Peru

10:00 22LB Pragmatic Open-Label Randomised Trial of Preexposure Prophylaxis: The PROUD Study
Sheena McCormack; David Dunn
On behalf of the PROUD Study Group
MRC Clinical Trials Unit at University College London, London, United Kingdom

10:15 23LB On Demand PrEP With Oral TDF-FTC in MSM: Results of the ANRS Ipergay Trial
Jean-Michel Molina; Catherine Capitant; Bruno Spire; Gilles Pialoux; Christian Chilialac; Isabelle Charreau; Cecile Tremblay; Laurence Meyer; Jean-Francois Defraissy
On behalf of the ANRS Ipergay Study Group
1University of Paris Diderot, Paris, France; 2Inserm SC10 US019, Villejuif, France; 3Inserm U912, Marselle, France; 4Hopital Tenon, APHP, Paris, France; 5Hopital de la Croix Rousse, Lyon, France; 6ANRS, Paris, France; 7CHUM, Montreal, Canada

10:30 24 Near Elimination of HIV Transmission in a Demonstration Project of PrEP and ART
Jared Baeten; Renee Heffron; Lara Kidoguchi; Nelly Mugo; Elly Katabira; Elizabeth Bukusi; Stephen Asimwe; Jessica Haberer; Deborah Donnell; Connie Celum
1University of Washington, Seattle, WA, US; 2Kenya Medical Research Institute, Nairobi, Kenya; 3Makerere University College of Health Sciences, Kampala, Uganda; 4Kabwohe Clinical Research Centre, Kabwohe, Uganda; 5Massachusetts General Hospital, Harvard Medical School, Boston, MA, US; 6Fred Hutchinson Cancer Research Center, University of Washington, Seattle, WA, US

10:45 25 Scale-Up of Preexposure Prophylaxis in San Francisco to Impact HIV Incidence
Robert M. Grant; Albert Liu; Jen Hecht; Susan P. Buchbinder; Shannon Weber; Pierre-Cedric Couch; Steven Gibson; Stephanie Cohen; David Glidden

11:00 26LB FACTS 001 Phase III Trial of Pericoital Tenofovir 1% Gel for HIV Prevention in Women
Helen Rees; Sinead A. Delany-Morettwe; Carl Lombard; Deborah Baron; Ravi Pandhe; Landon Myer; Jill L. Schwartz; Gustavo F. Doncel; Glenda Gray
On behalf of the FACTS 001 Study Team
1Wits Reproductive Health and HIV Institute, Johannesburg, South Africa; 2South African Medical Research Council, Cape Town, South Africa; 3University of Cape Town, Cape Town, South Africa; 4Perinatal HIV Research Unit, Soweto, South Africa; 5CONRAD, Arlington, VA, US

11:15 27 Effect of Oral and Gel Tenofovir on Genital HSV Shedding in Immunocompetent Women
Rachel A. Bender Ignacio; Tara Pertl; Amalia S. Magaret; Sharanya Rajagopal; Meei-Lee W. Huang; Christine M. Johnston; Stacy Selke; Jeanne M. Mazzarotto; Anna Wald
1University of Washington, Seattle, WA, US; 2US Centers for Disease Control and Prevention (CDC), Atlanta, GA, US

11:30 28 Injectable Contraception Use and Women’s Risk for HSV-2 Acquisition
Mary K. Grabowski; Ronald H. Gray; Fred Makumbi; Joseph Kagaayi; Andrew D. Redd; Fred Natlugoda; Maria J. Wawer; David Serwadda; Thomas C. Quinn; Aaron A. Tobian
1Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, US; 2Rakai Health Sciences Program, Kasisizi, Uganda; 3National Institute of Allergy and Infectious Diseases (NIAID), Bethesda, MD, US; 4Makerere University College of Health Sciences, Kampala, Uganda; 5Johns Hopkins University, Baltimore, MD, US
11:45  29  Effect of Financial Incentives on Linkage to Care and Viral Suppression: HPTN 065
Wafaa M. El-Sadr1; Bernard M. Branson2; Gheetha Beauchamp3; H. Irene Hall4; Lucia V. Torian5; Barry S. Zingman6; Garret Lum7; Rick Elion8; Theresa Gamble9; Deborah Donnelly10

12:00  30  Medical Male Circumcision of HIV-Infected Men Reduces Long-Term Penile HIV Shedding
Jordyn L. Manucci1; Godfrey Kigozi2; Mary K. Grabowski3; David Serwadda4; Ronald H. Gray5; Maria J. Wawer6; Fred Nalugoda7; Andrew D. Redd8; Thomas C. Quinn9; Aaron A. Tobian10
1Johns Hopkins University School of Medicine, Baltimore, MD, US; 2Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, US; 3Makerere University College of Health Sciences, Kampala, Uganda; 4National Institute of Allergy and Infectious Diseases (NIAID), Bethesda, MD, US

Session 0-2 Oral Abstracts  Room 613
10:00 am – 12:00 pm
Prevention, Diagnosis, and Treatment of Pediatric HIV Infection

Moderators
Carey Farquhar, University of Washington, Seattle, WA, US
Annette H. Sohn, TREAT Asia/amfAR — The Foundation for AIDS Research, Bangkok, Thailand

10:00  31LB PROMISE: Efficacy and Safety of 2 Strategies to Prevent Perinatal HIV Transmission
Mary Glenn Fowler1; Min Qin2; Susan A. Fiscus3; Judith S. Currier4; Bonus Makanani5; Francis Martinson6; Tsungai Chipato7; Renee Browning8; David Shapiro9; Lynne Mofenson10
On behalf of the IMPAACT PROMISE Team
1Johns Hopkins University School of Medicine/Makerere University, Baltimore, MD, US; 2Harvard School of Public Health, Boston, MA, US; 3University of North Carolina at Chapel Hill, Chapel Hill, NC, US; 4University of California Los Angeles, Los Angeles, CA, US; 5Univ of Malawi, Blantyre, Malawi; 6University of North Carolina Project—Malawi, Lilongwe, Malawi; 7Univ of Zimbabwe, Harare, Zimbabwe; 8NIAID/NIH, Bethesda, MD, US; 9National Institute of Child Health and Human Development, Bethesda, MD, US

10:15  32  Most Breastfeeding Women With High Viral Load Are Still Undiagnosed in Sub-Saharan Africa
David Maman1; Helena Huerga2; Irene Mukusi3; Benson Chilima4; Beatrice Kirubi5; Gilles Van Cutsem6; Charles Masiku7; Elisabeth Szmueli8; Thomas Ellman9; Jean-François Etard10
1Epicentre/Médecins Sans Frontières, Paris, France; 2Ministry of Health, Lilongwe, Malawi; 3Médecins Sans Frontières, Cape Town, South Africa; 4National AIDS and STDs Control Program, Nairobi, Kenya; 5Médecins Sans Frontières, Nairobi, Kenya; 6Médecins Sans Frontières, Cape Town, South Africa; 7Médecins Sans Frontières, Lilongwe, Malawi; 8Médecins Sans Frontières, Paris, France

10:30  33  Delayed HIV Detection in Infants Exposed to ARV Prophylaxis During Breastfeeding
Caroline C. King1; Julie A. Nelson2; Carrie Ziemniak3; Michael G. Hudgens4; Gerald Tegha5; Charles S. Chasela6; Denise J. Jamieson7; Deborah Persaud8; Charles M. van der Horst9; Athena P. Kourtis10
1US Centers for Disease Control and Prevention (CDC), Atlanta, GA, US; 2University of North Carolina at Chapel Hill, Chapel Hill, NC, US; 3Johns Hopkins University, Baltimore, MD, US; 4UNC Project, Lilongwe, Malawi; 5University of Witwatersrand, Johannesburg, South Africa

10:45  34  Evaluation of the Alere q for Point-of-Care Early Infant HIV Diagnosis in South Africa
Nei-Yuan Hsiao1; Max Kroon2; Lorna Dunning3; Landon Myer4
1University of Cape Town, Cape Town, South Africa; 2University of Cape Town, Cape Town, South Africa

11:00  35  Early ART and Sustained Virological Suppression Limits HIV Proviral DNA Reservoir: CHER Evidence
Helen A. Payne1; Sarah Watters2; Marvin Hsiao3; Robin Callard4; Abdul Babiker5; Mark F. Cotton6; Kennedy Otwombe7; Avy Violar8; Diana M. Gibb9; Nigel J. Klein10
1University College London, London, United Kingdom; 2University of Cape Town, Cape Town, South Africa; 3University of Cape Town, Cape Town, South Africa

11:15  36  Long-Term Outcomes of HIV-Infected Children Initiating NVP vs LPV/r-Based Treatment
Linda Barlow-Mosha1; Konstantia Angelidou2; Mohendran Archary3; Avy Violar4; Jane Lindsey5; Lynne Mofenson6; Patrick Jean-Philippe7; Paul E Palumbo8; Benjamin Chi9
On behalf of the IMPAACT P1060 Protocol Team
1Makerere University—Johns Hopkins University Research Collaboration, Kampala, Uganda; 2Harvard School of Public Health, Center for Biostatistics in AIDS Research, Boston, MA, US; 3National Institutes of Health, Bethesda, MD, US; 4Gelse School of Medicine at Dartmouth, Lebanon, NH, US; 5Henry M. Jackson Foundation for the Advancement of Military Medicine, Rockville, MD, US; 6University of North Carolina at Chapel Hill, Chapel Hill, NC, US; 7University of Witwatersrand, Johannesburg, South Africa; 8University of KwaZulu-Natal, Durban, South Africa; 9IMPAACT, SilverSpring, MD, US
11:30 37 Structural Cardiovascular Changes Are Reversible in HIV-Infected Children in Zambia and Uganda.
Julia M. Kenny; Adrian Cook; Grace Miremba; Dorica Masaku; Priscilla Wavamunno; Florence Odongo; Alicia Rapala; John Deanfield; Diana M. Gibb; Nigel J. Klein
1University of Washington, Seattle, WA, US; 2Seattle Biomed, Seattle, WA, US; 3King County, Seattle, WA, US; 4University College London, London, United Kingdom; 5Joint Clinical Research Centre, Kampala, Uganda; 6University Teaching Hospital, Lusaka, Zambia

11:45 38LB ART With Weekends Off Is Noninferior to Continuous ART in Young People on EFV+2NRTI
Karina M. Butler
On behalf of the BREATHER Trial Team
Our Lady’s Children’s Hospital, Dublin, Ireland

Session O-3 Oral Abstracts
Room 615
10:00 am – 12:00 pm
Cellular Dynamics, Sensing, and Viral Restriction
Moderators
Jaisri Lingappa, University of Washington, Seattle, WA, US
Aine McKnight, Queen Mary University of London, London, United Kingdom

10:00 39 Envelope Trimer Numbers Required for Entry Steer HIV-1 Infectivity and Entry Kinetics
Oliver Brandenberg; Carsten Magnus; Peter Rusert; Roland Regoes; Alexandra Mano
1ETH Zurich, Zurich, Switzerland; 2University of Zurich, Zurich, Switzerland

10:15 40 HIV-1 Accessory Protein Function: Evaluating VPU-Dependent Host Factor Degradation
Prashant Jain; Kevin Ollivier; Quy Nguyen; Paul De Jesus; Sumit Chanda
Sanford-Burnham Medical Research Institute, La Jolla, CA, US

10:30 41 HIV-1 Adaptation to Humans Involved Interactions of Vpr With the DNA Damage Response
Oliver I. Fregoso; Michael Emerman
Fred Hutchinson Cancer Research Center, University of Washington, Seattle, WA, US

10:45 42 The HIV-1 Protease Can Interact With RNA to Dramatically Enhance Its Activity
Marc Potempa; Ellen Nalivka; Soo-Kyung Lee; Celia A. Schiffer; Ronald Swanstrom
1University of North Carolina, Chapel Hill, NC, US; 2University of Massachusetts Medical School, Worcester, MA, US

11:00 43 PQBP1 Is a Retrovirus-Specific Sensor Mediating cGAS/IRF3-Dependent Innate Responses
Sunnie M. Yoh; Monika Schneider; Stephen Soonthornvarachin; Rana Akleh; Kevin Ollivier; Paul De Jesus; Chunhai Ruan; Elsa de Castro; Pedro Ruiz; Adolfo Garcia-Sastre
1Sanford-Burnham Medical Research Institute, La Jolla, CA, US; 2University of Michigan, Ann Arbor, MI, US; 3Icahn School of Medicine at Mount Sinai, New York, NY, US

11:15 44 Murcosal HIV-1 Transmission Specifically Selects for Type 1 Interferon-Resistant Viruses
Shilpa Iyer; Frederic Bibollet-Ruche; Christiana M. Shaw; Weiyu Zhang; Yingyli Li; Timothy Decker; George M. Shaw; Persephone Borrow; Beatrice H. Hahn
1University of Pennsylvania, Philadelphia, PA, US; 2University of Oxford, London, United Kingdom

11:30 45 The Dynamics of HIV-1 RNA Near the Plasma Membrane During Virus Assembly
Luca Sardo; Steven C. Hatch; Jianbo Chen; Olga A. Nikolaitchik; Ryan C. Burdick; De Chen; Christopher J. Westlake; Stephen Lockett; Vinay K. Pathak; Wei-Shau Hu
Frederick National Laboratory for Cancer Research, Frederick, MD, US

11:45 46LB Mechanisms of Dendritic Cell-Mediated Transfer of HIV-1 to CD4+ T Lymphocytes
Mickael M. Menager; Wendy Lin; Jarrod S. Johnson; Kristen Dancel-Manning; Nicolas Manel; Feng-Xia Liang; Dan R. Littman
1Skirball Institute of Biomolecular Medicine, New York, NY, US; 2Seattle Biomedical Research Institute, Seattle, WA, US; 3Institute Curie, Paris, France

Session O-4 Oral Abstracts
Room 6D
10:00 am – 12:15 pm
New Discoveries in HIV Pathogenesis
Moderators
Irini Sereti, National Institute of Allergy and Infectious Diseases, Bethesda, MD, US
Donald Sodora, Seattle Biomed, Seattle, WA, US

10:00 47 Inflammation Persists Despite Early Initiation of ART in Acute HIV Infection
Netanya S. Utay; Jintanat Ananworanich; Suteera Pinyakorn; Adam Rupert; Duanghathai Sutthichom; Suwanna Puttasawas; Bonnie M. Slika; Nelson L. Michael; Daniel C. Douek; Irini Sereti
1University of Texas Medical Branch at Galveston, Galveston, TX, US; 2US Military HIV Research Program, Silver Spring, MD, US; 3South East Asia Research Collaboration with Hawaii, Bangkok, Thailand; 4National Institutes of Health (NIH), Frederick, MD, US; 5Leidos Biomedical Research, Inc, Frederick, MD, US
10:15  48  HIV Burden and Biomarker Associations With Colonic HIV RNA During Acute HIV Infection
James L. Fletcher; Trevor A. Crowell; Robin Dewar; Irini Sereti; Bonnie Slikke; Nitiya Chomcheuy; Rungsun Rerkritmitr; Nelson L. Michael; Nicolas Chomont; Jintanat Ananworanich

On behalf of the RV254/SEARCH010 Study Group

1US Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, MD, US; 2SEARCH, Thai Red Cross AIDS Research Centre, Bangkok, Thailand; 3Virus Isolation and Serological Lab, National Cancer Institute at Frederick, Frederick, MD, US; 4National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Bethesda, MD, US; 5Department of Medicine, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand; 6Vaccine and Gene Therapy Institute Florida, Port St. Lucie, FL, US

10:30  49  Identification and Characterization of Individual HIV-Infected CD4 T Cells Ex Vivo
Joseph Casazza; Irene Primmer; David Ambrozak; Constantinos PetrovS; Sara Ferrando-Martinez; Perla Del Rio-Estrada; Gustavo Reyes-Teran; Ezequiel Ruiz-Mateos; John Mascola; Richard A. Koup

1Vaccine Research Center, NIAID, NIH, Bethesda, MD, US; 2Instituto Nacional de Enfermedades Respiratorias, Mexico City, Mexico; 3HU Virgen del Rocío/IBIS, Sevilla, Spain

10:45  50  Efficacy of HIV-1 Monoclonal Antibody Immunotherapy in Acute HIV-Infected Macaques
Diane L. Bolton; Amanda Pegu; Keyun Wang; Kathleen McGinnis; Kathryn Foulds; Sriinivas Rao; Merlin L. Robb; Nelson L. Michael; John Mascola; Richard A. Koup

1US Military HIV Research Program, Silver Spring, MD, US; 2National Institute of Allergy and Infectious Diseases (NIAID), Bethesda, MD, US

11:00  51  HIV-1 Infections With Multiple Founders Are Associated With Higher Viral Loads
Holly Janes; Sodsai Tovanabutra; Joshua Herbeck; Supachai Rerks-Ngarm; Merlin L. Robb; Nelson L. Michael; Peter Gilbert; Jerome H. Kim; Morgane Rolland

On behalf of the Step/HVTN502 and RV144 study teams


11:15  52  Post-Treatment Controllers Have Particular NK Cells With High Anti-HIV Capacity: VISCOUTI Study
Daniel Scott-Algara; Céline Didier; Vincent Arnold; Jean-Saville Cummings; Faroudy Boufassa; Olivier Lambotte; Laurent Hocqueloux; Asier Saez-Cirion; Christine Rouxoux

1Institut Pasteur, Paris, France; 2CESP U1018 Inserm, Le Kremlin-Bicêtre, France; 3Laboratoire de Virologie, EA 3620—Université Paris Descartes Hôpital Necker, Paris, France; 4Service des Maladies Infectieuses et Tropicales CHR d’Orléans—La Source, Orléans, France; 5Hôpital Bicêtre, Le Kremlin-Bicêtre, France

11:30  53  Antiretroviral Therapy Preserves Polyfunctional HIV-1—Specific CD8 T Cells With Stem-Cell—Like Properties
Selena Vigano; Jordi J. Negron; Eric S. Rosenberg; Bruce D. Walker; Mathias Lichterfeld; Xu G. Yu

1The Ragon Institute of MGH, MIT and Harvard, Cambridge, MA, US; 2Massachusetts General Hospital, Harvard Medical School, Boston, MA, US

11:45  54LB  In Vitro Retroposition and Interferon-Alpha Resistance of Transmitted HIV-1 Variants
Zachary Ende; Martin Deymer; Anghard Fenton-May; Daniel T. Caibone; William Kilembe; Susan Allen; Persephone Borrow; Eric Hunter

1Emory University, Atlanta, GA, US; 2Rutgers University, New Brunswick, NJ, US

12:00  55LB  HVTN505 Breakthrough Sequences Show HIV Vaccine-Associated Differences in Env-gp120
Morgane Rolland; Allan deCamp; Breana M. Hall; Sodsai Tovanabutra; Mario Roederer; Scott M. Hammer; Magdalena Sobieszczky; Peter B. Gilbert; Jerome H. Kim; James Mullins

On behalf of the HVTN505 Sieve Analysis Group


Session TD-B Themed Discussion

Room 615

1:30 pm – 2:30 pm

Next Generation of Next-Generation Sequencing

Themed Discussion Leader

Davey M. Smith, University of California San Diego, San Diego, CA, US
254 Present Applications of a High-Throughput, Single Measure HIV Genomic Incidence Assay
Sung Yong Park; Tanzy Love; Nolan Goeken; Robert Bolan; Alan S Perelson; Michael Dube; Ha Youn Lee
1Keck School of Medicine at University of Southern California, Los Angeles, CA, US; 2University of Rochester School of Medicine and Dentistry, Rochester, CA, US; 3Los Angeles Gay and Lesbian Center, Los Angeles, CA, US; 4Los Alamos National Laboratory, Los Alamos, CA, US

255 A Comprehensive Analysis of Primer IDs to Study Heterogeneous HIV-1 Populations
David Seifert; Armin Töpfer; Francesca Di Giallonardo; Stefan Schmutz; Huldrych F. Günther; Volkmar Roth; Nikolai Beerenwinkel; Karin J. Metzner
1ETH Zurich, Basel, Switzerland; 2University Hospital Zurich, Zurich, Switzerland; 3University of Basel, Basel, Switzerland

593 Analysis of Resistance Haplotypes Using Primer IDs and Next Gen Sequencing of HIV RNA
Valerie F. Boltz; Jason Rausch; Wei Shao; Charles Coomer; John W. Mellors; Mary Kearney; John M. Coffin
1National Institutes of Health (NIH), Frederick, MD, US; 2Leidos, Frederick, MD, US; 3University of Pittsburgh, Pittsburgh, PA, US; 4Tufts University, Boston, MA, US

Session TD-C Themed Discussion
Room 613
1:30 pm – 2:30 pm
HIV/CMV Interactions in Transmission and Pathogenesis

Theme Discussion Leader
Victor Appay, Institut National de la Santé et de la Recherche Médicale, Paris, France

300 Effect of CMV and HIV Replication on T-Cell Exhaustion and Senescence During ART
Jennifer M. Dan; Marta Massanella; David M. Smith; Eric S. Daar; Michael P. Dube; Richard Haubrich; Sheldon Morris; Sara Gianella Weibel
1University of California San Diego, La Jolla, CA, US; 2University of Southern California Keck School of Medicine, Los Angeles, CA, US

301 HIV Myeloid Derived Suppressor Cells Control Cytomegalovirus Inflammation by IL-27
Ankita Garg; Stephen Spector
University of California San Diego, La Jolla, CA, US

302 Persistent Elevation of Inflammation Markers in HIV+ Persons With CMV Disease
Melissa Schechter; Bruno Andrade; Eleanor M. Wilson; Virginia Sheikh; Sonya Krishnan; Margaret Caplan; Gregg Roby; Adam Rupert; Peter Burbelo; Irini Sereti
1NIH, Leidos Biomedical Inc., Fredrick, MD, US; 2National Institute of Allergy and Infectious Diseases, Bethesda, MD, US; 3NIH, Leidos Biomedical Inc., Fredrick, MD, US; 4National Institute of Dental and Craniofacial Research, Bethesda, MD, US

303 sCD163 Increase in HIV/CMV-Coinfected Subjects Included in ICONA Cohort
Serena Vita; Miriam Lichtner; Giulia Marchetti; Claudia Mascia; Esther Merlini; Paola Cicconi; Vincenzo Vullo; Pier Luigi Viale; Alberto Costantini; Antonella d’Arminio Monforte
On behalf of the ICONA Foundation Study
1University of Rome La Sapienza, Polo Pontino, Latina, Italy; 2San Paolo Hospital, Milano, Italy; 3University of Rome La Sapienza, Rome, Italy; 4University of Ancona, Ancona, Italy; 5University of Bologna, Bologna, Italy

304 Genital CMV Shedding Predicts Syphilis Acquisition in HIV-Infected MSM on ART
Sara Gianella Weibel; David M. Smith; Eric Daar; Michael Dube; Andrea Lisco; Christophe Vanpouille; Richard Haubrich; Sheldon Morris
1University of California San Diego, La Jolla, CA, US; 2Los Angeles Biomedical Research Institute at Harbor–UCLA Medical Center, Torrance, CA, US; 3University of Southern California Keck School of Medicine, Los Angeles, CA, US; 4National Institute of Allergy and Infectious Diseases, Bethesda, MD, US; 5National Institute of Child Health and Human Development, Bethesda, MD, US

Session TD-F Themed Discussion
Room 6D
1:30 pm – 2:30 pm
Leaky Latency

Themed Discussion Leader
Monique Nijhuis, University Medical Center Utrecht, Utrecht, Netherlands

392 Defective HIV-1 Proviruses Can Be Transcribed Upon Activation
Ya-Chi Ho; Ross Pollack; Patrick Yong; Robert F. Siliciano
Johns Hopkins University School of Medicine, Baltimore, MD, US

391 Influenza Vaccination Increases HIV-1 Transcription During Antiretroviral Therapy
Christina C. Yek; Sara Gianella; Montserrat Plana; Pedro Castro; Felipe García; Marta Massanella; David M. Smith
1University of California San Diego, San Diego, CA, US; 2University of Barcelona, Barcelona, Spain

427 Measurements of Viral Transcription in Elite Suppressor CD4+ T Cells
Christopher W. Pohlmeier; C. Karin Bullen; Greg Laird; Alyssa R. Martin; Victoria Walker-Sperling; Stanley U. Chioma; Robert F. Siliciano; Joel Blankson
Johns Hopkins University School of Medicine, Baltimore, MD, US

384 Minor Contribution of Host-HIV Readthrough Transcripts to the Level of HIV-1 gag RNA
Alexander Pasternak; Una O’Doherty; Ben Berkhour
1Academic Medical Center University of Amsterdam, Amsterdam, Netherlands; 2University of Pennsylvania, Philadelphia, PA, US

379 Characterizing the Active HIV Reservoir on ART: Cell-Associated HIV RNA and Viremia
Feiyou Hong; Elizabeth Fyne; Anthony R. Cillo; Margaret A. Bedison; Dianna Koontz; John W. Mellors
University of Pittsburgh, Pittsburgh, PA, US
Program and Agenda

Session TD-Q Themed Discussion
Room 6AB
1:30 pm – 2:30 pm
Fat Without Borders: Metabolic Complications in Resource-Limited Settings
Themed Discussion Leader
Miriam Rabkin, Columbia University Mailman School of Public Health, Chapel Hill, NC, US

778 Obesity and Inflammation in Resource-Diverse Settings of ART Initiation
Kristine M. Erlandsen1, Nikhil Gupta1, Javier R. Lama2, Patcharaphan Sugandhavesa3, Thando Mwelase3, Ashwin Balagopals4, David Asmuth5, Thomas B. Campbell1, Amita Gupta1
On behalf of the AS17S and NWCS19 study team
1University of Colorado, Aurora, CO, US; 2Johns Hopkins University, Baltimore, MD, US; 3Impacta Peru Clinical Trials Unit, Lima, Peru; 4Chiang Mai University, Chiang Mai, Thailand; 5University of Witwatersrand, Johannesburg, South Africa; 6University of California Davis, Sacramento, CA, US

779 Body Composition Outcomes at 96 Weeks in the SECOND-LINE RCT DXA Substudy
Mark A. Boyd1, Janaki Amin1, Patrick W. Mallon2, Jennifer F. Hoy3, Samuel Ferret4, Waldo Belloso4, Praphan Phanuphaksan4, Sean Emery5, David A. Cooper1
On behalf of the SECOND-LINE study group
1University of New South Wales Australia, Sydney, Australia; 2University College Dublin, Dublin, Ireland; 3Monash University/Alfred Hospital, Melbourne, Australia; 4Hospital Saint Louis, Paris, France; 5Hospital Italiano, Buenos Aires, Argentina; 6Thai Red Cross AIDS Research Centre, Bangkok, Thailand

780 Bone Quality by Quantitative Ultrasound at the Radius Does Not Differ in ART-Naïve HIV+ and HIV- Rwandan Women
Eugene Mutimura1, Qiu Hu Shi1, Donald R. Hoover1, Kathryn Anastas2, Emmanuel Rudakemwa1, Jean Claude Dusingize1, Jean D’Amour1, Sinayobye1, Michael Yin2
1Regional Alliance for Sustainable Development, Kigali, Rwanda; 2School of Health Sciences and Practice, New York Medical College, New York, NY, US; 3State University of New Jersey, New Brunswick, NJ, US; 4Albert Einstein College of Medicine and Montefiore Medical Center, Bronx, NY, US; 5King Faisal Hospital, Kigali, Rwanda; 6Columbia University Medical Center, New York, NY, US

781 Predictors and Outcomes of Incident High Cholesterol in Adults on ART in South Africa
Denise Evans1, Alana T. Brennan2, Faith Moyo3, David Spencer3, Kay Mahomed4, Mhairi Maskew5, Lawrence Long4, Sydney Rosen5, Matt P. Fox6
1University of the Witwatersrand, Johannesburg, South Africa; 2Boston University, Boston, MA, US; 3Right to Care, Johannesburg, South Africa

782 Metabolic Changes and Second-Line ART in Africa (2LADY/ANRS 12169 Trial)
Amandine Couri1, Assane Diouf1, Sabrina Eymard-Duvernay2, Adrien Sawadogo3, Liliane Ayangma4, Louise Fortes-Dequenourov5, Jean-Marc Mben6, Eric Delaporte7, Laura Ciaffi8, Sinata Kouilla-Shiro9
1IRD/UM 1, Montpellier, France; 2CHU Sourou Sanou, Bobo Dioulasso, Burkina Faso; 3CRCF, Dakar, Senegal; 4Yaounde Military Hospital, Yaounde, Cameroon; 5FMSB/University Yaounde 1, Yaounde, Cameroon; 6ANRS Research Center, Yaounde, Cameroon

Session TD-S Themed Discussion
Room 6C
1:30 pm – 2:30 pm
Hormonal Contraceptives: Enduring Controversy
Themed Discussion Leader
Betsy Herold, Albert Einstein College of Medicine, Bronx, NY, US

859 Estrogen Replacement in Healthy Postmenopausal Women Reduces %CCR5+ CD4+ T Cells
Amie Meditz1, Samantha MalWhinney2, Kemie Moreau2, Kelsey Melander1, Joy Folkvord2, Wendy Koht1, Margaret Wieman1, Elizabeth Connick1
1Boulder Community Health, Boulder, CO, US; 2University of Colorado Anschutz Medical Campus, Aurora, CO, US

858 CCR5 Expression in HIV-Uninfected Women Receiving Hormonal Contraception
Athe Tsibris1, Gaia Sciaranghella1, Cuimei Wang1, Kerry Murphy1, Zaher Mehri2, Ruth M. Greenblatt3, Mardge Cohen4, Elizabeth Golub5, Heather Watts6, Mary A. Young7
1Brigham and Women’s Hospital, Harvard Medical School, Cambridge, MA, US; 2Ragon Institute of MIT, MGH and Harvard, Boston, MA, US; 3Georgetown University Medical Center, Washington, DC, US; 4Albert Einstein College of Medicine, Bronx, NY, US; 5University of Vermont College of Medicine, Burlington, VT, US; 6University of California San Francisco, San Francisco, CA, US; 7Stroger Hospital and Rush University and CORE Center, Chicago, IL, US

860 Progesterone Increases Are Associated With HIV Susceptibility Factors in Women
Alison Y. Sawa1, Tammy Evans-Stickfaden1, L Davis Lupo2, Alfredo Aguire3, Anandi Sheth4, Igho Olutokun5, Clyde E. Hart6, Richard E. Haaland7
1US Centers for Disease Control and Prevention (CDC), Atlanta, GA, US; 2Emory University School of Medicine, Atlanta, GA, US

861 Changes in Vaginal Microbiota and Cytokines in HIV-1-Seronegative Women Initiating DMMA
Alison C. Roxby1, David N. Fredricks1, Katherine Odem-Davis1, Kristjana H. Asbjörnsdóttir1, Linnet Masese1, Tina L. Fiedler, Walter Jaoko1, James N. Kiarie1, Julie M. Overbaugh1, R Scott McClelland1
1University of Washington, Seattle, WA, US; 2Fred Hutchinson Cancer Research Center, University of Washington, Seattle, WA, US; 3University of Nairobi, Nairobi, Kenya
CIRCUMCISION: Evolving Knowledge and Practice

Themed Discussion Leader

1086 Mobile VMMC Teams in Tanzania See Older Clients and Have Higher Followup Rates
Augustino M. Hellari1; Dorica Boyee1; Hally Mahler1; Marya Plotkin1; Touma Ng’wanakilala1; Kelly Curran2; Tigistu Ashengo3; Hawa Mziray3; Erick Mlanga3; Sifuni Koshuma3
1Jhpiego, Dar es Salaam, United Republic of Tanzania; 2Jhpiego, Baltimore, MD, US; 3US Agency for International Development, Dar es Salaam, United Republic of Tanzania; 4Ministry of Health and Social Welfare, Iringa, United Republic of Tanzania

1087 High Acceptability of PrePex™ Device in Routine Programmatic Settings in Rwanda
Eugene Rugwizangoga1; Beata Mukarugwiro1; Jovite Sinzahera1; Alphonse Mutaburakwa1; Gloriose Abayisenga1; J.D. Nitakakirabo1; Ngeruka Leon1; Eugene Zimulinda1; Kelly Curran2; Tigistu Ashengo3
1Jhpiego/Rwanda, Kigali, Rwanda; 2Jhpiego, an Affiliate of Johns Hopkins University, Washington, DC, US; 3US Department of Defense, Rwanda, Kigali, Rwanda; 4Rwanda Military Hospital, Kigali, Rwanda

1089 Potential Protection From HIV Transmission by Penile Cuttings in Papua New Guinea
Ivy H. Shih1; Lester Asugeni1; Matthew David1; Paul Horwood1; Parana Hewage Mangalarasi1; David Mc Laren1; Rachael Tommbe1; Andrew Valley1; Arnold Wainie1; Stuart G. Turville1
1The Kirby Institute, Sydney, Australia; 2Pacific Adventist University, Port Moresby, Papua New Guinea; 3James Cook University, Cairns, Australia; 4University of Papua New Guinea, Port Moresby, Papua New Guinea; 5Papua New Guinea Institute of Medical Health, Goroka, Papua New Guinea

1084 HSV-2 Shedding From Male Circumcision Wounds Among HIV-Infected Men
Mary K. Grabowski1; Godfrey Kigozi2; Ronald H. Gray3; Jordyn L. Manucci4; David Serwadda2; Eshan U. Patel5; Fred Nalugoda2; Maria J. Wawer6; Thomas C. Quinn7; Aaron A. Tobian8; Beata Mukarugwiro1; 1Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, US; 2Rakai Health Sciences Program, Kalisizo, Uganda; 3Johns Hopkins University School of Medicine, Baltimore, MD, US; 4Makerere University College of Health Sciences, Kampala, Uganda; 5National Institute of Allergy and Infectious Diseases (NAIAD), Bethesda, MD, US

1088 Self-Selection of Circumcision Acceptors, Risk Compensation and Effectiveness of Circumcision Among Service Recipients, Rakai, Uganda
Joseph Kagaayi1; Xiangrong Kong1; Godfrey Kigozi2; Fred Nalugoda2; Steven J. Reynolds3; David Serwadda2; Nelson K. Sevankambo2; Maria J. Wawer4; Ronald H. Gray5
1Rakai Health Sciences Program, Entebbe, Uganda; 2Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, US; 3Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, US; 4Makerere University College of Health Sciences, Kampala, Uganda; 5Makerere University College of Health Sciences, Kampala, Uganda

1085 Neurocognitive Function in Africans Failing First-Line ART and Responses to Second Line
Andrew D. Kambungu1; Jennifer Thompson1; James Hakim2; Dinah Tumukunde3; Joep van Oosterhout4; Anne Hoppe4; Charles Kwobrah5; Sarah Walker2; Nicholas Paton4
On behalf of the EARNEST Trial Team
1Infectious Diseases Institute, Makerere University Kampala, Kampala, Uganda; 2University College London, London, United Kingdom; 3Joint Clinical research Centre, Kampala, Uganda; 4Queen Elizabeth Central Hospital, Malawi, Blantyre, Malawi; 5AMPATH, Kenya, Eldoret, Kenya; 6University of Zimbabwe, Harare, Zimbabwe; 7Dignitas International, Zomba, Malawi; 8National University of Singapore, Singapore, Singapore; 9Moi University College of Health Sciences, Eldoret, Kenya; 10Joint Clinical Research Centre, Kampala, Uganda

4:00 56 Randomized Clinical Trial of Antiretroviral Therapy for Prevention of HAND
Fujie Zhang1; Robert Heaton1; Hao Wu1; Hua Jin2; Hongxin Zhao3; Yin Yu4; Donald Franklin5; Weiwei Mu6; Florin Vaida7; Scott Letendre8
1Chinese Center for Disease Control and Prevention, Beijing, China; 2University of California San Diego (UCSD), San Diego, CA, US; 3Capital Medical University, Beijing You’an Hospital, Beijing, China; 4Capital Medical University Beijing Ditan Hospital, Beijing, China; 5Peking University, Beijing, China

4:15 57 Neurocognitive Function in Africans Failing First-Line ART and Responses to Second Line
Andrew D. Kambungu1; Jennifer Thompson1; James Hakim2; Dinah Tumukunde3; Joep van Oosterhout4; Anne Hoppe4; Charles Kwobrah5; Sarah Walker2; Nicholas Paton4
On behalf of the EARNEST Trial Team
1Infectious Diseases Institute, Makerere University Kampala, Kampala, Uganda; 2University College London, London, United Kingdom; 3Joint Clinical research Centre, Kampala, Uganda; 4Queen Elizabeth Central Hospital, Malawi, Blantyre, Malawi; 5AMPATH, Kenya, Eldoret, Kenya; 6University of Zimbabwe, Harare, Zimbabwe; 7Dignitas International, Zomba, Malawi; 8National University of Singapore, Singapore, Singapore; 9Moi University College of Health Sciences, Eldoret, Kenya; 10Joint Clinical Research Centre, Kampala, Uganda

4:30 58 Compartmentalized HIV Rebound in the CNS After ART Interruption
Sara Gianella Weibel1; Michelli Faria de Oliveira2; Konrad Scheffler1; Matt Strain1; Antonio De la Torre2; Scott Letendre3; David M. Smith3; Sergei L. Kosakovsky Pond3; Ronald J. Ellis3; Dietmar Fuchs2; Richard Price2; Magnus Gisslen2
1University of Gothenburg, Gothenburg, Sweden; 2University of Gothenburg, Gothenburg, Sweden; 3Mathematical Sciences, Chalmers University of Technology, Gothenburg, Sweden, Gothenburg, Sweden; 4University of New South Wales, Sydney, Australia; 5Division of Biological Chemistry, Biocenter, Medical University, Innsbruck, Austria, Innsbruck, Austria; 6University of California San Francisco, San Francisco, CA, US

4:45 559 Impaired Blood-Brain Barrier Integrity Is Associated With Neuronal Injury in HIV
Birgitta Anesten1; Lars Hagberg1; Henrik Zetterberg2; Staffan Nilsson3; Bruce J. Brew4; Dietmar Fuchs2; Richard Price2; Magnus Gisslen2
1University of Gothenburg, Gothenburg, Sweden; 2University of Gothenburg, Gothenburg, Sweden; 3Mathematical Sciences, Chalmers University of Technology, Gothenburg, Sweden, Gothenburg, Sweden; 4University of New South Wales, Sydney, Australia; 5Division of Biological Chemistry, Biocenter, Medical University, Innsbruck, Austria, Innsbruck, Austria; 6University of California San Francisco, San Francisco, CA, US
5:00  60  Cortical and Subcortical Brain Volumes in Primary HIV Infection
Patrick W. Wright\textsuperscript{a}; Ashmit Pyakurel\textsuperscript{a}; Kevin Robertson\textsuperscript{a}; Julia Peterson\textsuperscript{b}; Henrik Zetterberg\textsuperscript{c}; Dietmar Fuchs\textsuperscript{d}; Richard Price\textsuperscript{e}; Dieter Meyerhoff\textsuperscript{f}; Serena Spudich\textsuperscript{g}; Beau Ances\textsuperscript{h}
\textsuperscript{a}Washington University School of Medicine, Saint Louis, MO, US; \textsuperscript{b}Yale University School of Medicine, New Haven, CT, US; \textsuperscript{c}University of California San Francisco, San Francisco, CA, US; \textsuperscript{d}Innsbruck Medical University, Innsbruck, Austria; \textsuperscript{e}University of Gothenburg, Gothenburg, Sweden

5:15  61  IRF4 Transcription Factor Associated With Integrated HIV DNA in Brain Macrophages
Benjamin B. Gelman\textsuperscript{a}; Joshua G. Lisiñiczica\textsuperscript{a}; Tetyana P. Buzhdyan\textsuperscript{a}; Vipulkumar Patel\textsuperscript{a}; Tyler Clement\textsuperscript{a}; Samantha A. Trevino\textsuperscript{a}; Kristofer R. Jennings\textsuperscript{a}; Dennis L. Kolson\textsuperscript{a}
\textsuperscript{a}University of Texas Medical Branch, Galveston, TX, US; \textsuperscript{b}University of Pennsylvania, Philadelphia, PA, US

5:30  62  Longitudinal Assessment of Blood Brain Barrier Disruption in Primary HIV Infection
Elham Rahimi\textsuperscript{a}; Fang-yong Li\textsuperscript{a}; Alex Russell\textsuperscript{a}; Julia Peterson\textsuperscript{a}; Lars Hagberg\textsuperscript{a}; Henrik Zetterberg\textsuperscript{a}; Richard Price\textsuperscript{a}; Magnus Gissén\textsuperscript{a}; Serena Spudich\textsuperscript{a}
\textsuperscript{a}Yale University School of Medicine, New Haven, CT, US; \textsuperscript{b}Yale Center for Analytical Sciences, Yale University, New Haven, CT, US; \textsuperscript{c}University of Gothenburg, Gothenburg, Sweden; \textsuperscript{d}University of California San Francisco, San Francisco, CA, US

5:45  63  Declining Prevalence of HIV-Associated Neurocognitive Disorders in More Recent Years
Carmela Pinnetti\textsuperscript{a}; Raffaella Libertone; Pietro Balestra; Patrizia Lorenzini; Martina Ricottini; Samanta Menichetti; Carmela Pinnetti\textsuperscript{a}; Mauro Zaccarelli; Adriana Ammassari; Andrea Antinori
National Institute for Infectious Diseases, Lazzaro Spallanzani, Rome, Italy

Session S-1 Symposium Room 6C
4:00 pm – 6:00 pm
Harnessing Antibodies for Prevention and Therapeutics

Target audience: This session is directed to scientists and clinicians interested in the potential therapeutic and prophylactic applications of anti-HIV antibodies.

Level of knowledge: It is assumed that participants are familiar with basic immunologic principles, antibody structure, and HIV envelope variability.

Objectives: At the completion of the session, participants will be able to:
- List cutting-edge approaches for the delivery of protective and curative antibodies.
- Describe emerging approaches to enhance monoclonal antibody activity against virus.
- Describe new advances in the ability to elicit antibodies that resemble neutralizing antibodies through vaccination.

Symposium Conveners
Leonidas Stamatakos, Fred Hutchinson Cancer Research Center, University of Washington, Seattle, WA, US
Susan Zolla-Pazner, New York University, Langone Medical Center, New York, NY, US

4:00  64  Potentiating Protective Antibody Activity: A Systems Serology Approach
Margaret E. Ackerman
Thayer School of Engineering, Dartmouth College, Hanover, NH, US

4:30  65  Impact of Repetitive Protein Boosting on RV305 HIV-1 Vaccine-Induced Antibodies
Georgia D. Tomaras
Duke University Medical Center, Durham, NC, US

5:00  66  Immunoprophylaxis by Gene Transfer: Shortcut to an HIV Vaccine
Phil Johnson
Children’s Hospital of Philadelphia, Philadelphia, PA, US

5:30  67  Broadly Neutralizing Antibodies for HIV-1 Eradication Strategies
Dan H. Barouch
Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, US

Session S-2 Symposium Room 6D
4:00 pm – 6:00 pm
Current Issues in HIV-Related Malignancies

Target audience: This session is directed to those interested in development and management of cancers in HIV.

Level of knowledge: It is assumed that participants have some basic knowledge of types of cancers seen in HIV.

Objectives: At the completion of the session, participants will be able to:
- Discuss differences in malignancy incidence and presentation, including in resource-limited settings around the world.
- Describe new concepts in viral-induced oncogenesis.
- Describe new therapies for lymphoma in HIV-infected individuals.
- Examine major barriers for treatment of cancers in resource-limited settings.

Symposium Conveners
Margaret Z. Borok, University of Zimbabwe, College of Health Sciences, Harare, Zimbabwe
Robert Yarchoan, National Cancer Institute, Bethesda, MD, US

4:00  68  HIV-Associated Malignancies: The Worldwide Epidemic
James J. Goedert
National Cancer Institute, Bethesda, MD, US

4:30  69  Viral Oncogenesis: Evolving Concepts
Shannon C. Kenney
University of Wisconsin, Madison, WI, US
5:00  70  AIDS Lymphoma: Advances and Existing Challenges  
Ariela Noy  
Memorial Sloan Kettering Cancer Center, New York, NY, US

5:30  71  HIV Malignancies in Low- and Middle-Income Countries: A Double Burden of Disease  
Jackson Orem  
Uganda Cancer Institute, Kampala, Uganda

Session S-3 Symposium  
Room 6AB  
4:00 pm – 6:00 pm  
Current Imperatives in HIV Prevention and Treatment

Target audience: This session is directed to researchers, public health professionals, and educators interested in global HIV and public health.

Level of knowledge: It is assumed that participants are familiar with HIV program scale-up and global disease burden.

Objectives: At the completion of the session, participants will be able to:

• Define trends in HIV/AIDS and sexually transmitted infection epidemiology among different groups.
• Describe the epidemiology of HIV among men who have sex with men in Africa, and associated challenges.
• Assess broader impact on health programs and behavioral science of HIV/AIDS service scale-up.

Symposium Conveners  
Wafaa M. El-Sadr, ICAP at Columbia University, New York, NY, US  
Lucy Ng’ang’a, CDC Center for Global Health, Division of Global AIDS/HIV, Nairobi, Kenya

4:00  72  How Has HIV Prevention Affected the Spread of Other Sexually Transmitted Infections?  
Marie Laga  
Institute of Tropical Medicine, Antwerp, Belgium

4:30  73  HIV Risks and Vulnerabilities Among Gay Men and Other Men Who Have Sex With Men Across Sub-Saharan Africa  
Stefan Baral  
Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, US

5:00  74  An Expanded Behavioral Paradigm for Treatment and Prevention of HIV-1  
Thomas J. Coates  
University of California Los Angeles, Los Angeles, CA, US

5:30  75  Social Protection, Financial Incentives, and Prevention of HIV  
David Wilson  
World Bank, Washington, DC, US

Special Session  
Room 6E  
6:30 pm – 7:30 pm  
Special Session: Ebola Virus Disease: Responding to the Challenge

Moderators  
Kevin M. De Cock, Centers for Disease Control and Prevention, Nairobi, Kenya  
Wafaa M. EI-Sadr, ICAP at Columbia University, New York, NY, US

6:30  76  The Médecins Sans Frontières Experience With the Current Ebola Outbreaks  
Gilles Van Cutsem  
Médecins Sans Frontières, Mowbray, Cape Town, South Africa

7:00  77  Ebola Vaccines, Passive Immunotherapy, and Antiviral Treatment  
H. Clifford Lane  
National Institute of Allergy and Infectious Diseases, Bethesda, MD, US
WEDNESDAY, FEBRUARY 25, 2015

Session PL-1 Plenary 4AB Auditorium
8:30 am – 9:00 am

Preventing Pediatric HIV and Managing HIV-Infected Children: Where Are We Now and Where Are We Going?

Diana M. Gibb
University College London, London, United Kingdom

Session PL-2 Plenary 4AB Auditorium
9:00 am – 9:30 am

Directing Chronic Virus Infection Through Viral Regulation of Innate Immune Defenses

Michael Gale
University of Washington, Center for Innate Immunity and Infectious Disease, Seattle, WA, US

Session 0-6 Scientific Overview and Oral Abstracts Room 615
10:00 am – 12:00 pm

Intracellular and Clinical Pharmacology, Drug Interactions, and Adherence

Moderators
Reina Bendayan, University of Toronto, Toronto, ON, Canada
Marta Boffito, Chelsea and Westminster Hospital, NHS Foundation Trust/Imperial College, London, United Kingdom

10:00 80 Scientific Overview: The Clinical Pharmacology of HIV Prevention
Marta Boffito
Chelsea and Westminster Hospital, NHS Foundation Trust/Imperial College, London, United Kingdom

10:30 81 Intracellular Pharmacokinetics of Sofosbuvir In Vivo
Joseph Rower; Ariel Hodara; Jacob A. Langness; Sarah Tise; Greg Everson; Aimee Truesdale; Fafa Baouchi-Mokrane; Lane Bushman; Peter L. Anderson; Jennifer J. Kiser
1University of Colorado Denver, Anschutz Medical Campus, Aurora, CO, US; 2Denver Health and Hospital Authority, Denver, CO, US; 3University of Colorado Health, Aurora, CO, US; 4University of Colorado Denver, Anschutz Medical Campus, Aurora, CO, US

10:45 82 Drug-Drug Interactions Between Anti-HCV Regimen Ledipasvir/Sofosbuvir and Antiretrovirals
Polina German; Kimberly Garrison; Phillip S. Pang; Luisa M. Stamm; Adrian S. Ray; Gong Shen; Marc Buachareem; Anita Mathias
Gilead Sciences, Inc., Foster City, CA, US

11:00 83 Emtricitabine-Triphosphate in Dried Blood Spots (DBS) as a Marker of Recent Dosing
Jose R. Castillo-Mancilla; Lane R. Bushman; Amie Meditz; Sharon M. Seifert; Jia-Hua Zheng; L Anthony Guida; Edward M. Gardner; David V. Glidden; Robert M. Grant; Peter L. Anderson
1University of Colorado-AMC, Aurora, CO, US; 2Beacon Center for Infectious Diseases, Boulder, CO, US; 3Denver Health and Hospital Authority, Denver, CO, US; 4University of California San Francisco, San Francisco, CA, US

11:15 84 Impact of EFV PK/PG on Neuropsychological Performance in Older HIV+ Patients
Uriel S. Sandkovsky; Anthony T. Podany; Courtney Fletcher; Andrew Owen; Angela Felton-Coleman; Kevin Robertson; Susan Swindells
1University of Nebraska Medical Center, Omaha, NE, US; 2University of Liverpool, Liverpool, United Kingdom; 3University of North Carolina, Chapel Hill, NC, US

11:30 85LB Levornorgestrel Implant + EFV-Based ART: Unintended Pregnancies and Associated PK Data
Kimberly K. Scarsi; Kristin M. Darin; Shadia Nakalama; David Back; Pauline Byakika-Kibwika; Laura Else; Sujan Dilly-Penchala; Susan Cohn; Concepta Merry; Mohammed Lamorde
1University of Nebraska Medical Center, Omaha, NE, US; 2Infectious Diseases Institute, Kampala, Uganda; 3Northwestern University, Feinberg School of Medicine, Chicago, IL, US; 4University of Liverpool, Liverpool, United Kingdom; 5Trinity College Dublin, Dublin, Ireland

11:45 86LB A Phase IV PrEP Study Reveals Limited Ex Vivo Potency of Oral Maraviroc Against HIV-1
Julie Fox; Carolina Herrera; Juan Manuel Tiraboschi; Akil Jackson; Laura Else; Natalia Olejniczak; Saye Khoo; David Back; Robin Shattock; Marta Boffito
On behalf of KCL Infectious Diseases Biobank
1Guys and St Thomas’ NHS Foundation Trust, London, United Kingdom; 2Imperial College London, London, United Kingdom; 3Chelsea and Westminster Hospital, NHS Foundation Trust, London, United Kingdom; 4University of Liverpool, Liverpool, United Kingdom
**Session O-7 Oral Abstracts**  
**10:00 am – 12:15 pm**  
**KS and Cervical/Anal Dysplasia: Tale of 2 Tumors, and TB and Other OIs**  

**Moderators**  
Corey Casper, Fred Hutchinson Cancer Research Center, University of Washington, Seattle, WA, US  
Timothy Sterling, Vanderbilt University, Nashville, TN, US

**10:00**  
**87** Pomalidomide for Kaposi Sarcoma in People With and Without HIV: A Phase I/II Study  
Mark N. Polizzotto; Thomas S. Uldrick; Kathleen M. Wyvill; Karen Aleman; Margaret Bevans; Cody Peer; Douglas Figg; Seth Steinberg; Jerome B. Zeldis; Robert Yarchoan

1National Cancer Institute (NCI), Bethesda, MD, US; 2National Institutes of Health (NIH), Bethesda, MD, US; 3National Cancer Institute (NCI), Bethesda, MD, US; 4National Cancer Institute (NCI), Bethesda, MD, US; 5Celgene Corporation, Summit, NJ, US

**10:15**  
**88** Prognostic Model for Patients With Kaposi Sarcoma Treated With ART Alone in Africa  
Miriam O. Laker-Oketta; David V. Glidden; Victoria Walusansa; Jackson Orem; A. Rain Mocellin; Toby Maurer; Peter W. Hunt; Andrew D. Kambugu; Edward Mbidde  
Jeffrey Martin

1Makerere University College of Health Sciences, Kampala, Uganda; 2University of California San Francisco, San Francisco, CA, US; 3Makerere University College of Health Sciences, Kampala, Uganda; 4University of California San Francisco (UCSF), San Francisco, CA, US; 5University of California San Francisco (UCSF), San Francisco, CA, US

**10:30**  
**89** One-Year Follow-up of HIV+ Women Screened With VIA, Cytology and HPV in South Africa  
Cynthia Finchaber; Bridgette Goeieman; Lu Mao; Mark Faesen; Simon Levin; Sophie Williams; Avril Swarts; Pam Michelov; Tanvier Omar; Jennifer Smith

1University of Witwatersrand, Johannesburg, South Africa; 2University of North Carolina, Raleigh, NC, US; 3Right to Care, Johannesburg, South Africa

**10:45**  
**90** High Rate of HSIL on HRA in HIV+ Women Not Meeting Criteria for Anal Cancer Screening  
Michael M. Gaisa; Fanny Ita-Nagy; Gabriela Rodriguez Caprio; Michael Mullen; Judith Aberg; Michelle Cespedes

1Icahn School of Medicine at Mount Sinai, New York, NY, US

**11:00**  
**91** Xpert MTB/RIF Ultra: A New Near-Patient TB Test With Sensitivity Equal to Culture  
David Alland; Mazhgan Rownek; Laura Smith; Jamie Ryan; Mitchell Chancellor; Ann Marie Simmons; David Persing; Robert Kwiatkowski; Martin Jones; Soumitesh Chakravorty

1Rutgers New Jersey Medical School, Newark, NJ, US; 2Cepheid, Sunnyvale, CA, US

**11:15**  
**92** Majority of XDR TB Cases Are Due to Transmission in a High-HIV-Prevalence Setting  
N. Sarita Shah; James C. Brust; Barun Mathema; Thuli Mthiyane; Nazir Ismail; Pravi Moodley; Koleka Misiana; Salim Allana; Jonathan Smith; Neel R. Gandhi

1US Centers for Disease Control and Prevention, Atlanta, GA, US; 2Montefiore Medical Center & Albert Einstein College of Medicine, Bronx, NY, US; 3Columbia University Mailman School of Public Health, New York, NY, US; 4University of KwaZulu-Natal, Durban, South Africa; 5National Institute for Communicable Diseases, National Health Laboratory Service, Johannesburg, South Africa; 6University of KwaZulu-Natal & National Health Laboratory System, Durban, South Africa; 7Emory University Rollins School of Public Health, Atlanta, GA, US; 8University of KwaZulu-Natal & National Health Laboratory Service, Durban, South Africa

**11:30**  
**93** Linkage to HIV/TB Care in South Africa: A Randomized Trial of Health Navigators  
Ingrid V. Bassett; Sharon M. Coleman; Janet Giddy; Laura M. Bogart; Christine E. Chaisson; Douglas Ross; Tessa Govender; Kenneth A. Freedberg; Rochelle P. Walensky; Elena Losina

1Boston University School of Public Health, Boston, MA, US; 2Massachusetts General Hospital, Harvard Medical School, Boston, MA, US; 3Boston Children’s Hospital, Harvard Medical School, Boston, MA, US; 4McGovern Hospital, Durban, South Africa; 5St. Mary’s Hospital, Marniethill, South Africa

**11:45**  
**94** Is It Safe to Stop Cotrimoxazole in Adults on ART: COSTOP, a Noninferiority RCT  
Paula Munderi; Jonathan B. Levin; Zachaeus Anywaine; Ronnie Kasiye; Anatoli Kamali; Andrew J. Nunn; Heiner Grosskurth

On behalf of the COSTOP Research Team

1MRC/UVRI Uganda Research Unit on AIDS, Entebbe, Uganda; 2University College London, London, United Kingdom; 3London School of Hygiene and Tropical Medicine, London, United Kingdom

**12:00**  
**95LB** High-Dose Rifampin, SQ109 and Moxifloxacin for Treating TB: The PanACEA MAMS-TB Trials  
Martin J. Boeree  
On behalf of the PanACEA consortium

1Radboudumc, Nijmegen, Netherlands; 2University of Munich, Munich, Germany

---

**Session O-8 Special Presentation and Oral Abstracts**  
**Room 6E**  
**10:00 am – 12:30 pm**  
**Factors Affecting HIV Care and Outcome: Global Perspective**  

**Moderators**  
Ruane V. Barnaba, University of California San Francisco, San Francisco, CA, US  
Elizabeth Bukusi, University of California San Francisco, San Francisco, CA, US

**10:00**  
**96** Special Presentation: PEPFAR 3.0: Controlling the Epidemic and Delivering on the Promise of an AIDS-Free Generation  
Ambassador Deborah L. Birx, MD  
US Department of State, Washington, DC, US
10:30  97  Joint Estimation of HIV Progression and Survival: A Pooled Analysis of 25 Countries
Tara D. Mangal
On behalf of the UNAIDS Working Group on CD4 Progression and Mortality Among HIV Serocounters including the CASCADE Collaboration in EuroCoord
Imperial College London, London, United Kingdom

10:45  98  Impact of Emergency Department HIV Testing and Linkage to Care: 25 Years’ Experience
Gabor Kelen1; Eshan U. Patel1; Yu-Hsiang Hsieh1; Oliver B. Laeyendecker2; Judy Shahin3; William Clarke4; Jordyn L. Manucci5; Richard Rothman6; Thomas C. Quinn7
1Johns Hopkins University School of Medicine, Baltimore, MD, US; 2National Institute of Allergy and Infectious Diseases (NIAID), Baltimore, MD, US; 3Johns Hopkins University School of Medicine, Baltimore, MD, US

11:00  99  Linkage to Care and Viral Suppression Among New HIV Diagnoses, New York City, 2006-13
Ellen W. Wievel; Lucia V. Torian; Qiang Xia; Sarah L. Braunstein
New York City Department of Health and Mental Hygiene, Long Island City, NY, US

11:15  100  Care and Viral Suppression Among Women, 18 US Jurisdictions
Ndidi Ike; Angela L. Hernandez; Qian An; Taoying Huang; H. Irene Hall
US Centers for Disease Control and Prevention (CDC), Atlanta, GA, US

11:30  101  Time Above 1500 Copies/ml: A Viral-Load Measure for Assessing Transmission Risk of HIV-Positive Patients in Care
Lytt I. Gardner1; Gary Marks1; Charles Rose2; Meg Sullivan2; Susan Holman3; Jeanne Keruly4; Anne Zinski4; Allan Rodriguez5; Thomas Giordano6
1Centers for Disease Control and Prevention, Atlanta, GA, US; 2Boston University School of Medicine, Boston, MA, US; 3Colleges of Medicine and Nursing, SUNY Downstate Medical Center, Brooklyn, NY, US; 4Johns Hopkins University School of Medicine, Baltimore, MD, US; 5University of Alabama at Birmingham, Birmingham, AL, US; 6Miller School of Medicine, University of Miami, Miami, FL, US; 7Baylor College of Medicine, Houston, TX, US

11:45  102  Incidence and Risk Factors for Sexual Assault Among MSM and Young Women in Coastal Kenya
Adrian D. Smith1; Sam Rogers1; Elizabeth Wahome1; Marianne Darwinkel2; Susan M. Graham3; Eduard J. Sanders1
1Nuffield Department of Population Health, Oxford, United Kingdom; 2Centre for Geographic Medicine Research – Coast, Kilifi, Kenya; 3University of Washington, Seattle, WA, US

12:00  103LB  Impact of the Ebola Epidemic on HIV Care in Macenta, Forest Guinea, 2014
David Leuvenberger1; Jean Hébélamou2; Stefan Strahm1; Gilles Wandelier3; Nathalie de Rekeneire4; François Dabis5
On behalf of International Epidemiological Databases to Evaluate AIDS - West Africa
1Mission Philétaire, Conakry, Guinea; 2Department of Infectious Diseases, University Hospital Bern, Bern, Switzerland; 3Univérsité Bordeaux, ISSEP, Centre Inserm U987-Epidemiologie-Biostatistique, Bordeaux, France

12:15  103-ALB  Favipiravir in Patients with Ebola Virus Disease: Early Results of the JIKI trial in Guinea
Daouda Sissoko1; Elin Folkesson1; M’lebing Abdoul1; Abdoul Habib Beavogui2; Stephen Gunther1; Susan Shepherd1; Christine Danel1; France Mentre1; Xavier Anglaret1; Denis Malvy1
1Inserm U987, Université de Bordeaux, Bordeaux, France; 2Médecins Sans Frontières, Bruxelles, Belgium; 3ALIMA, Montreuil, France; 4Centre de Formation et de Recherche en Santé Rurale de Maférynhay, Conakry, Guinea; 5Inserm U738, Université Paris Diderot, Paris, France; 6Bernhard-Nocht-Institut für Tropenmedizin, Hamburg, Germany

Session 0-9 Oral Abstracts
Room 6D
10:00 am – 12:15 pm
New Insights Into HIV Persistence, Latency Reversal, and Viremia Rebound

Moderators
Françoise Barré-Sinoussi, Institut Pasteur, Paris, France
Celsa A. Spina, University of California San Diego, La Jolla, CA, US

10:00  104LB  Durable Control of Viral Rebound in Humanized Mice by ABX464 Targeting Rev Functions
Noelie Campos1; Renier Myburgh1; Aude Garcel2; Audrey Vautrin1; Laure Lapasset3; Katjana Tantale4; Mark Wainberg5; Roberto Speck6; Didier Scherrer7; Jamal Tazi7
1ABVAX, Montpellier, France; 2University of Montpellier, Montpellier, France; 3University of Zurich, Zurich, Switzerland; 4McGill AIDS Center, Montréal, Canada

10:15  105  Residual Viremia Caused by Clonally Expanded Tumor-Infiltrating CD4+ Cells
Francesco R. Simonetti1; Michele D. Sobolowski2; Shawn Hill3; Wei Shao4; Elizabeth Finne5; Xiaolun Wu6; John M. Coffin7; Stephen H. Hughes7; John W. Mellors7; Frank Malarelli1
1National Cancer Institute (NCI), Frederick, MD, US; 2University of Pittsburgh, Pittsburgh, PA, US; 3Frederick National Laboratory for Cancer Research, Frederick, MD, US; 4Tufts University, Boston, MA, US; 5National Cancer Institute (NCI), Frederick, MD, US

Oral Sessions • Wednesday, February 25, 2015
10:30 106 Analysis of HIV RNA in Single Cells Reveals Clonal Expansions and Defective Genomes
Ann Wieand1; Jonathan Spindler2; Wei Shao3; Feiyu Hong1; Anthony R. Cillo1; Elias Halvas1; Elizabeth Fye1; John M. Coffin1; John W. Mellors2; Mary F. Kearney1
1National Cancer Institute, Frederick, MD, MD, US; 2Leidos, Frederick, MD, US; 3University of Pittsburgh, Pittsburgh, PA, US; 4Tufts University, Boston, MA, US

10:45 107 Low-Level HIV Viremias Originate in Part From Infected Proliferating Cells
Marta E. Bull1; Sherry McLaughlin1; Hannah Huang1; Sheila Stryckak1; Jaime Soria1; Eduardo Ticona1; Alberto La Rosa1; Caroline Mitchell1; James Mullins1; Lisa Frenkel1
1University of Washington, Seattle, WA, US; 2University Children’s Research Institute, Seattle, WA, US; 3Hospital Nacional dos de Mayo, Lima, Peru; 4Investigaciones Médicas en Salud (INMENSA), Lima, Peru; 5Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, US; 6University of Washington, Seattle, WA, US

11:00 108 Treatment With a TLR7 Agonist Induces Transient Viremia in SIV-Infected ART-Suppressed Monkeys
James B. Whitney1; So-Yon Lim1; Christa E. Osuna1; Srisowmya Sanisetty1; Jaime Soria1; Eduardo Ticona1; Alberto La Rosa1; Caroline Mitchell1; James Mullins1; Lisa Frenkel1

11:15 109 Panobinostat Broadly Activates Latent HIV-1 Proviruses in Patients
Kirsten M. Barton1; Thomas A. Rasmussen1; Martin Tolstrup1; Wei Shao2; Bonnie Hiener2; Ajantha Solomon2; Lars Østergaard3; Sharon R. Lewin4; Ole Søgaard1; Sarah E. Palmer1
1Westmead Millennium Institute and University of Sydney, Westmead, Australia; 2Aarhus University Hospital, Aarhus, Denmark; 3Oehmyr Institute for Infection and Immunity, Melbourne, Australia; 4National Cancer Institute, Rockville, MD, US

11:30 110LB The Size of the Active HIV Reservoir Predicts Timing of Viral Rebound
Behzad Etemad1; Hayat Ahmed1; Evgenia Aga2; Ronald Bosch2; John W. Mellors3; Daniel Kuritzkes4; Michael Para5; Rajesh T. Gandhi1; Jonathan Li5
1Brigham and Women’s Hospital, Harvard Medical School, Cambridge, MA, US; 2Harvard School of Public Health, Center for Biostatistics in AIDS Research, Boston, MA, US; 3University of Pittsburgh, Pittsburgh, PA, US; 4Ohio State University, Columbus, OH, US; 5Massachusetts General Hospital, Harvard Medical School, Boston, MA, US

11:45 111LB Biomarkers to Predict Viral Rebound at Antiretroviral Therapy Interruption in SPARC
Jacob Hurst1; James Williams1; John P. Thornhill2; Matthew Pace2; Chris Willberg3; Elizabeth Hamlyn4; Abdel Babiker4; Rodney Phillips4; Sarah Fidler3; John Frater1
1On behalf of the SPARC Trial Investigators; 2University of Oxford, Oxford, United Kingdom; 3St Mary’s Hospital–Imperial College Healthcare NHS Trust, London, United Kingdom; 4King’s College London, London, United Kingdom; 5Medical Research Council Clinical Trials Unit, London, United Kingdom

Session TD-A Themed Discussion Room 615
1:30 pm – 2:30 pm
Interferon: Triggers and Effectors

Themed Discussion Leader
Martin R. Jakobsen, Aarhus University, Aarhus C, Denmark

188 HIV-1 Exploits CD169 to Evade IFNα-Induced Antiviral State in Myeloid Cells
Hisashi Akiyama1; Nora Ramirez2; Gregory Gibson3; Simon Watkins3; Zandreia Ambrose1; Rahim Gummulu1
1Boston University School of Medicine, Boston, MA, US; 2University of Pittsburgh School of Medicine, Pittsburgh, PA, US; 3University of Pittsburgh School of Medicine, Pittsburgh, PA, US

192 HIV and SIV Inhibition by RNA-Associated Early Stage Antiviral Factor (REAF)
Aine McKnight
Queen Mary University of London, London, United Kingdom

203 Mapping Vpx and Vpr Specificity in Antagonism of SAMHD1
Chelsea Spragg; Michael Emerman
Fred Hutchinson Cancer Research Center, Seattle, WA, US

202 A Surprising New Function of SAMHD1 as a Pro-Pathogenic Factor in HIV Infection
Gilad Doitsh; Nicole Galloway; Xin Geng; Isa Monus Arias; Zhiyuan Yang; Warner C. Greene
The J. David Gladstone Institute, University of California San Francisco, San Francisco, CA, US
**Program and Agenda**

**Session TD-H Themed Discussion**

**Room 613**
1:30 pm – 2:30 pm

**New Technologies in Assessing Drug Interactions and Systemic and Intracellular Pharmacology**

**Themed Discussion Leader**

Tim R. Cressey, Harvard School of Public Health / Chiang Mai University, Chiang Mai, Thailand

**531 Pharmacokinetic Interactions Between Antidiabetics and Efavirenz Using PBPK Modeling**

Catia Marzolini1; Rajith Rajoli2; Luigia Elzi1; Manuel Battegay1; David Back1; Marco Siccardi2

1University Hospital Basel, Basel, Switzerland; 2Institute of Translational Medicine, University of Liverpool, Liverpool, United Kingdom

**532 In Silico Simulation of Interaction Between Rifampicin and Boosted Darunavir**

Marco Siccardi; Owain Roberts; Rajith Rajoli; Laura Dickinson; Saye Khoo; Andrew Owen; David Back

University of Liverpool, Liverpool, United Kingdom

**533 Pharmacogenetics of Pregnancy-Induced Changes in Efavirenz Pharmacokinetics**

Adeniyi Olagunju1; Oluseye Bolajii1; Alieu Amara1; Laura Else1; Ogechi Okafor1; Ebnuloluwa Adejoyigbe2; Oyigboja Johnson1; David Back1; Saye Khoo1; Andrew Owen1

1University of Liverpool, Liverpool, United Kingdom; 2Obafemi Awolowo University, Ile-Ife, Nigeria

**534 Antiretroviral Drug Transporters and Metabolic Enzymes in Human Testicular Tissue**

Billy Huang1; Md. Tozammel Hoque1; Mohammad-Ali Jenabian1; Kishanda Vybohi1; Nancy Sheehan1; Pierre Brassard2; Maud Bélanger2; Nicolas Chomont1; Jean-Pierre Routy1; Reina Bendayan1

1University of Toronto, Toronto, Canada; 2McGill University, Montréal, Canada

**535 Imaging the Spatial Distribution of Efavirenz in Intact HIV Tissue Reservoirs**

Elias P. Rosen1; Corbin G. Thompson1; Mark T. Bokhart1; Craig Sykes1; Yuri Fedorov1; Paul Luciw1; David C. Muddiman1; Angela D.M. Kashuba1

1North Carolina State University, Raleigh, NC, US; 2University of North Carolina, Chapel Hill, NC, US; 3University of California Davis, Davis, CA, US

**Session TD-O Themed Discussion**

**Room 6D**
1:30 pm – 2:30 pm

**Cancers in Young and Old, and Lung Cancer in HIV**

**Themed Discussion Leader**

Eric A. Engels, National Cancer Institute, Bethesda, MD, US

724 Cancer in HIV-Infected Children: Record Linkage Study in South Africa

Julia Bohlius1; Nicky Maxwell2; Brian Eley3; Hans Prozesky4; Shobna Sawry1; Karl-Günter Technau1; Alan Davidson1; Cristina Stefan5; Matthias Egger6

On behalf of the IeDEA Southern Africa

1University of the Witwatersrand, Johannesburg, South Africa; 2University of Cape Town, Cape Town, South Africa; 3Red Cross War Memorial Children's Hospital, Cape Town, South Africa; 4University of Stellenbosch and Tygerberg Academic Hospital, Cape Town, South Africa; 5Stellenbosch University and Tygerberg Hospital, Cape Town, South Africa; 6University of Bern, Bern, Switzerland

725 High Risk Among the HIV-Infected Elderly in the United States

Elizabeth L. Yanik; Hornuzd A. Katki; Eric A. Engels

National Cancer Institute (NCI), Rockville, MD, US

726 Smoking Outweighs HIV-Related Risk Factors for Non-AIDS-Defining Cancers

Keri N. Althoff1; Stephen J. Gange1; Chad Achenbach2; Lisa P. Jacobson1; Angel M. Mayor2; Michael J. Silverberg3; Amy Justice3; Richard Moore3; Yuezhou Jing4; Kelly Gebo4

On behalf of the North American AIDS Cohort Collaboration on Research and Design

1Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, US; 2Northwestern University, Feinberg School of Medicine, Chicago, IL, US; 3Universidad Central del Caribe, Bayamon, US; 4Kaiser Permanente Northern California, Oakland, CA, US; 5Veterans Affairs Connecticut Healthcare System and Yale Schools of Medicine and Public Health, New Haven, CT, US; 6Johns Hopkins University School of Medicine, Baltimore, MD, US

727 High Frequency of Early Lung Cancer Diagnosis With Chest CT in HIV-Infected Smokers

Alain Makinson; Sabrina Eymard-Duverney; François Raffi; Fabrice Bonnet1; Laurence Thirard1; Pierre Tattevin1; Sophie Abgrall1; Jacques Reynes1; Vincent Le Moing1

On behalf of the ANRS EP48 HIV CHEST Study Team

1University Hospital Montpellier, UMI233, Montpellier, France; 2UMI 233, IIRD, University Montpellier 1, Montpellier, France; 3Nantes University Hospital, Nantes, France; 4University Hospital Bordeaux, Inserm U987, Bordeaux, France; 5Tourocoing University Hospital, Tourocoing, France; 6Pontchaillou University Hospital, Rennes, France; 7University Hospital Avicennes, Bobigny, France; 8ANRS, Paris, France
728 CD4 Measures as Predictors of Lung Cancer Risk and Prognosis in HIV Infection
Keith Sigel1; Kristina Crothers2; Kirsha Gordon3; Sheldon Brown4; David Rimland5; Maria Rodriguez-Barradas6; Cynthia Gibert7; Matthew B. Goetz2; Roger Bedimo8; Robert Dubrow9
1Icahn School of Medicine at Mount Sinai, New York, NY, US; 2University of Minnesota, Minneapolis, MN, US; 3University of New South Wales, Sydney, NSW, Australia; 4Veterans Affairs Medical Center, Houston, TX, US; 5Los Angeles VA Medical Center, Los Angeles, CA, US; 6Veterans Affairs North Texas Health Care System, Dallas, TX, US; 7Yale University School of Public Health, New Haven, CT, US

Session TD-R Themed Discussion Room 6E
1:30 pm – 2:30 pm
Cryptococcal Meningitis: Host Response, Treatment, and Outcomes

Themed Discussion Leader
Judith A. Aberg, Icahn School of Medicine at Mount Sinai, New York, NY, US

834 Local and Systemic Humoral Responses to Cryptococcal Meningitis in Patients With AIDS
Erin E. Finn1; Jordan Janoff1; Jeremy Rahkola1; David B. Meyea2; Samuel Okurut3; Andrew D. Kambugu4; Paul Bohjanen5; Kirsten Nielsen6; David R. Boulware7; Edward N. Janoff8
1Mucosal and Vaccine Research Colorado, Aurora, CO, US; 2Makerere University College of Health Sciences, Kampala, Uganda; 3University of Minnesota, Minneapolis, MN, US

835 Antiretroviral Therapy Alters the CSF Immune Response in Cryptococcal Meningitis
James E. Scriven1; Britta Urban1; Lisa Graham1; Charlotte Schutz2; Robert J. Wilkinson3; David R. Boulware4; David Laloo5; Graeme Meintjes6
1Liverpool School of Tropical Medicine, Liverpool, United Kingdom; 2University of Cape Town, Cape Town, South Africa; 3Imperial College London, London, United Kingdom; 4University of Minnesota, Minneapolis, MN, US

836 Detrimental Outcomes of Unmasking Cryptococcal Meningitis With Recent ART Initiation
Joshua Rhein1; Katherine H. Hullsiek2; Nathan C. Bahr3; Reuben Kiggundu4; Darlisha Williams5; Henry W. Nabet6; Abdu Musubire7; David B. Meyea8; David R. Boulware9
1University of Minnesota, Minneapolis, MN, US; 2University of Minnesota, Minneapolis, MN, US; 3Makerere University College of Health Sciences, Kampala, Uganda

887 Impact of ART on Mortality in Cryptococcal Meningitis Patients: High-Income Settings
Suzanne M. Ingle1; Jose M. Mira2; Hansjakob Furrer5; Amy Justice6; Michael S. Saag7; Christian Manzardo8; Anna Esteve9; Lauren E. Cain10; Jonathan A. Sterne1; Margaret T. May1
1University of Bristol, Bristol, United Kingdom; 2Hospital Clinic—L’Institut D’Investigacions Biomédiques August Pi i Sunyer, University of Barcelona, Barcelona, Spain; 3Harvard School of Public Health, Boston, MA, US; 4Bern University Hospital and University of Bern, Bern, Switzerland; 5Yale University School of Medicine, VA Connecticut Healthcare System, New Haven, CT, US; 6University of Alabama at Birmingham, Birmingham, AL, US; 7Centre d’Estudis Epidemiològics Sobre ITS/VIH/SIDA de Catalunya, Barcelona, Spain

888 Adjunctive Sertraline for the Treatment of HIV-Associated Cryptococcal Meningitis
Joshua Rhein1; Katherine H. Hullsiek3; Bozena Morawski4; Kyle Smith5; Ali Al-Hadab6; Abdu Musubire7; Darlisha Williams8; Kirsten Nielsen1; David B. Meyea2; David R. Boulware9
1University of Minnesota, Minneapolis, MN, US; 2Makerere University College of Health Sciences, Kampala, Uganda

Session TD-W Themed Discussion Room 6AB
1:30 pm – 2:30 pm
Serosorting and Seroadaptive Behavior: What’s Your Position?

Themed Discussion Leader
Andrew E. Grulich, University of New South Wales, Sydney, NSW, Australia

1060 Trends in Sexual Behaviors Among Men Who Have Sex With Men in the United States, the Role of Antiretroviral Therapy and Seroadaptive Strategies
Gabriela Paz-Bailey1; Maria Mendoza2; Binh Le3; Charles E. Rose4; Teresa Finlayson5; Cyprian Wejnert6; Charles E. Rose3; Henry F. Raymond1; Joseph Prejean7
1US Centers for Disease Control and Prevention (CDC), Atlanta, GA, US; 2San Francisco Department of Public Health, San Francisco, CA, US

1061 Changes in Condomless Sex and Serosorting Among MSM After HIV Diagnosis
Christine M. Khosropour1; Julia C. Dombrowski2; David A. Katz2; Matthew R. Golden3
1University of Washington, Seattle, WA, US; 2University of Washington, Seattle, WA, US

1062 Serosorting and Sexual Risk Behavior Influenced by Perceived HIV Serostatus Among MSM
Kathleen A. Brady1; Jennifer Shinfield; Catherine Mezzacappa
1Philadelphia Department of Public Health, Philadelphia, PA, US
1063 Use of the Seroadaptive Strategies of Sexual Positioning and Serosorting by MSM in Nigeria

Cristina M. Rodriguez-Hart¹; Hongjie Liu²; Iheanyi K. Orazulike³; Sam Zorowitz²; Sylvia Adeba³; Lindsay Hughes¹; Stefan Baral¹; Merlin L. Robb¹; William Blattner¹; Manhattan Charurat¹

¹University of Maryland School of Medicine, Baltimore, MD, US; ²University of Maryland School of Public Health, College Park, MD, US; ³International Center on Advocacy and Rights to Health, Abuja, Nigeria;

1119 Survival Benefits Attributable to the Brazilian National ART Policy

Paula M. Luz¹; Michael P. Girouard¹; Beatriz Grinsztejn¹; Kenneth Freedberg¹; Valdivia Veloso¹; Elena Losina¹; Claudio Struchiner¹; Robert Parker¹; David Patiño¹; Rochelle Walensky¹

¹Weill Cornell Medical College, New York, NY, US; ²Massachusetts General Hospital, Harvard Medical School, Boston, MA, US; ³Yale School of Public Health, New Haven, CT, US; ⁴Harvard School of Public Health, Boston, MA, US; ⁵Johns Hopkins University School of Medicine, Baltimore, MD, US;

1114 Global Fund Cost Projections for Implementing WHO 2013 Guidelines

Obinna Onyekwena; Ade Fakoya; Michael Johnson; Michael Olszak-Olszewski; Mark Dybul

The Global Fund to Fight AIDS, Tuberculosis and Malaria, Geneva, Switzerland

Session 0-10 Oral Abstracts Room 6C

4:00 – 6:15 pm

New Antiretroviral Agents, Strategies, and HIV Drug Resistance

Moderators

Constance Delaugerre, Hôpital Saint-Louis, APHP, Université Paris Diderot, Paris, France

Richard Harrigan, BC Centre for Excellence in HIV/AIDS, Vancouver, BC, Canada

113B Tenofovir Alafenamide (TAF) in a Single-Tablet Regimen in Initial HIV-1 Therapy

David Wohl¹; Anton Pozniak²; Melanie Thompson¹; Edwin DeJesus¹; Daniel Podzamczzer¹; Jean-Michel Molina³; Gordon Crofoot¹; Christian Callebaut¹; Hal Martin³; Scott McCallister³

¹University of North Carolina, Chapel Hill, NC, US; ²Chelsea and Westminster Hospital, NHS Foundation Trust, London, United Kingdom; ³AIDS Research Consortium of Atlanta, Atlanta, GA, US; ⁴Orlando Immunology Center, Orlando, FL, US; ⁵Hospital Universitari de Bellvitge, Barcelona, Spain; ⁶Hospital Saint Louis, Paris, France; ⁷Gordon Crofoot Research, Houston, TX, US; ⁸Gilead Sciences, Inc, Foster City, CA, US; ⁹Gilead Sciences, Inc, Foster City, CA, US

114LB Antiviral Activity/Safety of a Second-Generation HIV-1 Maturation Inhibitor

Carey Hwang¹; Dirk Schürmann⁵; Christian Sobotta⁴; Heather Sivinsky³; Palanikumar Ravindran³; Hong Xiao³; Neelanjana Ray³; Mark Krystal⁴; Ira B. Dicker³; Max Latifa³

¹University of California, San Francisco, CA, US; ²University of Cambridge, Cambridge, UK; ³University of Maryland School of Medicine, Baltimore, MD, US; ⁴Charité Research Organisation Gmbh, Berlin, Germany; ⁵Bristol-Myers Squibb, Wallingford, CT, US

4:15 – 5:30 pm

115LB Early ART and IPT in HIV-Infected African Adults With High CD4 Count (Temprano Trial)

Christine Daniel¹; Raoul Mohi¹; Delphine Gabillard¹; Anani Badjie¹; Jerome Le Carrou¹; Gerard M. Kouame¹; Jean Baptiste Ntakpe¹; Hervé Ménan⁴; Serge Eholie⁴; Xavier Anglaret⁴

On behalf of the Temprano Study Group

¹Inserm, Bordeaux, France; ²Université Felix Houphouet-Boigny, Abidjan, Côte d’Ivoire; ³CHU de Treichville, Abidjan, Côte d’Ivoire; ⁴Programme PCC, Abidjan, Côte d’Ivoire
4:45 116 Antiretroviral Drug Screening Provides Key Insights Into HIV Drug Resistance
Iris Chen; Matthew B. Connor; William Clarke; Mark A. Marzinke; Vanessa Cummings; Sheldon D. Fields; Darrell P. Wheeler; Kenneth H. Mayer; Beryl A. Koblin; Susan H. Eshleman
1Johns Hopkins University School of Medicine, Baltimore, MD, US; 2Fred Hutchinson Cancer Research Center, University of Washington, Seattle, WA, US; 3Florida International University, Miami, FL, US; 4Loyola University Chicago, Chicago, IL, US; 5Fenway Health, Boston, MA, US; 6New York Blood Center, New York, NY, US

5:00 117 Untimed Drug Levels and Resistance in Patients Experiencing Low-Level HIV Viremia
Alejandro Gonzalez-Serna; Luke C. Swenson; Adriana Nohpai; Birgit Watson; Kate Auyeung; Julio Montaner; Richard Harrigan
BC Centre for Excellence in HIV/AIDS, Vancouver, Canada

5:15 118 Pretreatment HIV Drug Resistance Increases Regimen Switch in Sub-Saharan Africa
Tamara Sonia Boender; Bernice M. Hoenderboom; Kim C. Sigaloff; Maureen Wellington; Margaret Sivale; Cissy M. Kityo; Alani Sulaimon Akanmu; Mariette E. Botes; Tobias F. Rinke de Wit
On behalf of the PASER Study Group
1Amsterdam Institute for Global Health and Development, Amsterdam, Netherlands; 2Newlands Clinic, Harare, Zimbabwe; 3Lusaka Trust Hospital, Lusaka, Zambia; 4Joint Clinical Research Centre, Kampala, Uganda; 5Lagos University Teaching Hospital, Lagos, Nigeria; 6Muelmed Hospital, Pretoria, South Africa

5:30 119 Impact of NRTI Cross-Resistance on Second-Line PI + NRTI Therapy Outcomes in Africa
Nicholas Paton; Cissy Kityo; Jennifer Thompson; Leonard Bagenda; James Hakim; Joep van Oosterhout; Andrew D. Kambuugi; Anne Hoppe; Sarah Walker
On behalf of the EARNEST Trial Team
1National University of Singapore, Singapore, Singapore; 2Joint Clinical Research Centre, Kampala, Uganda; 3Infectious Diseases Institute, Kampala, Uganda; 4University of Malawi, Blantyre, Malawi; 5MRC Clinical Trials Unit at University College London, London, United Kingdom; 6University of Zimbabwe Clinical Research Centre, Harare, Zimbabwe

5:45 120 Fitness Effects of Drug-Resistant Strains Across the United States HIV-1 Transmission Network
Joel O. Wertheim; Alexandra M. Oster; Neeraja Saduvala; Walid Heneine; Jeffery A. Johnson; William M. Switzer; Angela L. Hernandez; H. Irene Hall
1University of California San Diego, San Diego, CA, US; 2US Centers for Disease Control and Prevention (CDC), Atlanta, GA, US

6:00 121 Dolutegravir Resistance Requires Multiple Primary Mutations in HIV-1 Integrase
Arne Frantzell; Christos J Petropoulos; Wei Huang
Monogram Biosciences, South San Francisco, CA, US
Session S-5 Symposium
4:00 pm – 6:00 pm
Advancing HIV Prevention: Lessons from Biology, Medicine, and Public Health Law

Target audience: This session is directed to clinicians, scientists, and policy makers who are interested in developing or implementing HIV prevention programs for maximal benefit.

Level of knowledge: It is assumed that participants are familiar with basic HIV epidemiology and transmission, and the effect of antiretroviral drugs for preexposure prophylaxis and treatment as prevention.

Objectives: At the completion of the session, participants will be able to:
  • Determine how new insights into HIV transmission can assist prevention programs.
  • Describe the barriers to scale up of test-and-treat approaches and how the law can help (or inhibit) prevention efforts.

Symposium Conveners
Meg C. Doherty, World Health Organization, Geneva, Switzerland
Jeanne M. Marrazzo, University of Washington, Seattle, WA, US

4:00 126 The Biology of HIV Transmission: What We Think Know and How We Know It
Julie M. Overbaugh
Fred Hutchinson Cancer Research Center, Seattle, WA, US

4:30 127 HIV Phylogenetics: Lessons for HIV Prevention
Christophe Fraser
Imperial College London, London, United Kingdom

5:00 128 Optimizing ART: Treatment as Prevention in the US: Will It Be Enough?
Richard A. Elion
Whitman-Walker Health, Washington, DC, US

5:30 129 Criminalizing HIV: Recent Experience in the United States and Africa to Update Laws and Policies to Promote the Public Health
Jeffrey Crowley
Georgetown University, Washington, DC, US

Session S-6 Symposium
4:00 pm – 6:00 pm
Tuberculosis: Magic Bullets and Moving Targets

Target audience: This session is directed to clinicians and scientists interested in the pathogenesis, clinical manifestations, treatment, and prevention of tuberculosis (TB).

Level of knowledge: It is assumed that participants are familiar with basic TB epidemiology, clinical features, and treatment.

Objectives: At the completion of the session, participants will be able to:
  • List new techniques for TB diagnosis.
  • Describe new investigational TB treatment options and strategies.
  • Describe the unique situation of children and pregnant women infected with TB.

Symposium Conveners
Alison Grant, London School of Hygiene and Tropical Medicine, London, United Kingdom
Ilesh V. Jani, Instituto Nacional de Saúde, Maputo, Mozambique

4:00 130 Advances in Mycobacterial Diagnostics
Mark P. Nicol
University of Cape Town, Cape Town, South Africa

4:30 131 New Medications, Innovative Approaches: Accelerate the TB Regimen Development Pipeline
Michael Hoelscher
University of Munich, Munich, Germany

5:00 132 Tuberculosis in Pregnancy
Amita Gupta
Johns Hopkins University School of Medicine, Baltimore, MD, US

5:30 133 Tuberculosis in Children
Anneke C. Hesseling
Stellenbosch University, Cape Town, South Africa
10:00 136 Statin Therapy Reduces Coronary Noncalcified Plaque Volume in HIV Patients: A Randomized Controlled Trial
Janet Lo1; Michael Lu1; Ezinne Ihenacho2; Jeffrey Wei3; Sara Looby3; Kathleen Fitch4; Suhyr Abbara4; Gregory Robbins5; Udo Hoffmann6; Steven Grinspoon7
1Massachusetts General Hospital, Harvard Medical School, Boston, MA, US; 2Massachusetts General Hospital, Boston, MA, US

10:15 137 Rosuvastatin Arrests Progression of Carotid Intima-Media Thickness in Treated HIV
Chris T. Longenecker1; Ying Jiang1; Sara M. Debanne1; Danielle Labbate2; Bruce Kinley2; Norma Storer2; Grace A. McComsey3
1Case Western Reserve University, Cleveland, OH, US; 2University Hospitals of Cleveland, Cleveland, OH, US

10:30 138 Calcified Plaque Burden Is Associated With Serum Gut Microbiota-Generated TMA in HIV
Suman Srivinasa1; Kathleen V. Fitch1; Janet Lo1; Hanane Kadar2; Kimberly Wong2; Suhyr Abbara3; Dominique Gauguer4; Jacqueline Capeau5; Franck Boccaزا; Steven K. Grinspoon1
1Massachusetts General Hospital, Harvard Medical School, Boston, MA, US; 2University Pierre & Marie Curie, Paris, France; 3University of Texas Southwestern Medical Center, Dallas, TX, US

10:45 139 Varenicline vs Placebo for Smoking Cessation: ANRS 144 Inter-ACTIV Randomized Trial
Patrick Mercie1; Caroline Roussillon2; Christine Katlama3; Aurélie Beuscart; Samuel Ferret3; Nathalie Wirth3; David Zucman3; Xavier Duval4; Genevieve Chene5
On behalf of the ANRS 144 inter-ACTIV study group
1Inserm U897, Bordeaux, France; 2Hosp. Saint-Louis, Paris, France; 3Hosp. Saint-André, Bordeaux, France; 4Hosp. La Pitié-Salpêtrière, Paris, France; 5Hosp. De Brabois, Vandoeuvre les Nancy, France; 6Hosp. Foch, Suresnes, France; 7CIC 1425, Paris, France

11:00 140 Body Composition Changes After Initiation of Raltegravir or Protease Inhibitors
Grace A. McComsey1; Carlee Moser2; Judith S. Currier3; Heather Ribaudo4; Pawel Paczuski5; Michael P. Dube5; Robert L. Murphy5; Jennifer Rothenberg6; James H. Stein7; Todd T. Brown1
1Case Western Reserve University, Cleveland, OH, US; 2Harvard School of Public Health, Center for Biotistics in AIDS Research, Boston, MA, US; 3Johns Hopkins University School of Medicine, Baltimore, MD, US; 4University of Wisconsin School of Medicine and Public Health, Madison, WI, US; 5University of Southern California, Los Angeles, CA, US; 6Northwestern University, Chicago, IL, US; 7Social & Scientific Systems, Inc., Silver Spring, MD, US; 8University of California Los Angeles, Los Angeles, CA, US

11:15 141 Fracture Prediction With Modified FRAX in Older HIV+ and HIV- Men
Michael T. Yin1; Melissa Skanderson2; Stephanie Shiau3; Katherine Harwood4; Josh Aschheim5; David Rimland5; Cynthia Gilbert5; Maria Rodriguez-Barradas6; Roger Bedimo7; Julie Womack6
1Columbia University Medical Center, New York, NY, US; 2VAMC and Emory School of Medicine, Atlanta, GA, US; 3Arcadia Healthcare Solutions, New York, NY, US; 4Baylor College of Medicine, Houston, TX, US; 5VA Medical Center, George Washington University, Washington, DC, US; 6University of Texas, Dallas, TX, US; 7VA Connecticut Healthcare System, West Haven, CT, US

11:30 142 Exposure to Antiretrovirals (ARVs) and Development of Chronic Kidney Disease (CKD)
Amanda Mocroft1; Jens D. Lundgren2; Michael Ross3; Christoph Fux4; Peter Reis5; Olivier Moranne6; Philippe Morlat7; Antonella d’Amminio Monforte8; Ole Kirk9; Lene Ryom10
On behalf of the the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) Study Group
1University College London, London, United Kingdom; 2Copenhagen HIV Programme, Centre for Health and Infectious Diseases Network, University of Copenhagen, Denmark, Denmark; 3Division of Nephrology, Mount Sinai School of Medicine, New York, NY, US; 4Clinic for Infectious Diseases and Hospital Hygiene, Kantonsspital Aarau, Aarau, Switzerland; 5Academic Medical Center, Div. of Infectious Diseases and Dept. of Global Health, University of Amsterdam, Amsterdam, Netherlands; 6Université de Bordeaux, Inserm U897, Bordeaux, France; 7Public Health Department, Nice, France; 8Istituto Di Clinica Malattie Infettive e Tropicale, Milan, Italy
Program and Agenda

11:45 143LB Renal and Bone Safety of Tenofovir Alafenamide vs Tenofovir Disoproxil Fumarate
Paul E. Sax1; Michael S. Saag2; Michael T. Yin3; Frank A. Post4; Shinichi Oka5; Ellen Koenig5; Benoit Trottier6; Jaime Andrade-Villanueva7; Huyen Cao8; Marshall W. Fordye1
1Gilead Sciences Inc, Foster City, CA, US; 2University of Alabama at Birmingham, Birmingham, AL, US; 3College of Physicians and Surgeons, Columbia University, New York, NY, US; 4King’s College Hospital, London, United Kingdom; 5Dominican Institute for Virologic Studies, Santo Domingo, Dominican Republic; 6Unidad de VIH del Hospital Civil de Guadalajara, Guadalajara, Mexico; 7Bingham and Women’s Hospital and Harvard Medical School, Boston, MA, US; 8National Center for Global Health and Medicine, Japan, Tokyo, Japan; 9Clinique Medicale l’Actuel, Montreal, Canada

10:45 148 The Paradox of Highly Effective Sofosbuvir Combo Therapy Despite Slow Viral Decline
Thi Huyen Tram Nguyen1; Jérémie Gujed2; Laetitia Cañini3; Anu Osinusi4; Phillip S. Pang5; John M. Hutchison6; Henry Masur7; Aniha Kohli8; Shyam Kottillil9; Alan S. Persen10

12:00 144 Special Presentation: Update on National Heart, Lung, and Blood Institute High-Impact AIDS Research
Monica Shah
National Heart, Lung, and Blood Institute, Bethesda, MD, US

Session 0-12 Oral Abstracts  Room 6AB
10:00 am – 12:00 pm
Curing HCV: Mission Accomplished
Moderators
Karine Lacombe, Saint Antoine Hospital, AP-HP, Paris, France
John W. Ward, Centers for Disease Control and Prevention, Atlanta, GA, US

10:00 145 The Burden of Liver Disease Among Persons With Hepatitis C in the United States
Monina Klevens1; Xiaohua Huang2; Anthony E. Yeo2; Mouneer Odeh3; Rick L. Pesano3; John W. Ward1
1US Centers for Disease Control and Prevention, Atlanta, GA, US; 2Quest Diagnostics, Madison, NJ, US

10:15 146 High Efficacy of Daclatasvir/Asunaprevir/PR in HIV/HCV1-4 Null Responders (ANRS HC30)
Lionel Piroth1; Hubert Paniez2; Corine Vincent2; Karine Lacombe1; David Rey3; Didier Neau4; Jacques Izopet5; Alpha Diallo6; Laurence Meyer7; Jean-Michel Molina1
1CHU Dijon, Dijon, France; 2Inserm, Paris, France; 3Hôpital Saint-Antoine, Paris, France; 4Strasbourg University Hospital, Strasbourg, France; 5CHU, Bordeaux, France; 6CHU, Toulouse, France; 7Inserm-ANRS, Paris, France; 8CHU Saint Louis, Paris, France

10:30 147 High SVR Regardless of Time to Suppression With ABT-450/o/ombitasvir and simeprevir+RBV
David Wyles1; Peter Ruane2; Mark Sulkowski3; Douglas Dieterich4; Anne Luetkemeyer5; Timothy Morgan6; Kenneth E. Sherman7; Zhaozhi Liu8; Stephanie Noviello9; Peter Ackerman10
1University of California San Diego, La Jolla, CA, US; 2Ruane Medical and Liver Health Institute, Los Angeles, CA, US; 3Johns Hopkins University School of Medicine, Baltimore, MD, US; 4Icahn School of Medicine at Mount Sinai, New York, NY, US; 5University of California and San Francisco General Hospital, San Francisco, CA, US; 6VA Long Beach Healthcare System, Long Beach, CA, US; 7University of Cincinnati College of Medicine, Cincinnati, OH, US; 8Bristol-Myers Squibb Co, Princeton, NJ, US

10:45 151LB Daclatasvir in Combination With Sofosbuvir for HCV/HIV Coinfection: ALY-2 Study
David Wyles1; Peter Ruane2; Mark Sulkowski3; Douglas Dieterich4; Anne Luetkemeyer5; Timothy Morgan6; Kenneth E. Sherman7; Zhaozhi Liu8; Stephanie Noviello9; Peter Ackerman10
1University of California San Diego, La Jolla, CA, US; 2Ruane Medical and Liver Health Institute, Los Angeles, CA, US; 3Johns Hopkins University School of Medicine, Baltimore, MD, US; 4Icahn School of Medicine at Mount Sinai, New York, NY, US; 5University of California and San Francisco General Hospital, San Francisco, CA, US; 6VA Long Beach Healthcare System, Long Beach, CA, US; 7University of Cincinnati College of Medicine, Cincinnati, OH, US; 8Bristol-Myers Squibb Co, Princeton, NJ, US

11:00 149 Real-World Pharmaceutical Costs in the Simeprevir/Sofosbuvir Era: $164,485 per SVR4
Kian Bichoupan1; Neeta Tandon1; Rachana Valamanchi2; Neil M. Patel1; Sweta Chekuri3; Alyson Harty3; Thomas Schiano3; Pooni V. Perumalswami4; Douglas Dieterich1; Andrea D. Branch1
1Mount Sinai School of Medicine, New York, NY, US; 2Janssen Scientific Affairs, Titusville, NJ, US

11:15 150 Impact of Deferring HCV Treatment on Liver-Related Events in HIV+ Patients
Cindy Zahnd1; Luisa P. Salazar-Vizcaya2; Jean-François Dufour2; Beat Mühlbauer3; Gilles Wandelier3; Roger Koyos3; Barbara Bertsch1; André Rauch1; Olivia Keiser1
1On behalf of the Swiss HIV and Hepatitis C Cohort Studies; 2Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland; 3University Hospital Bern, Bern, Switzerland; 4University Hospital Zurich, Zurich, Switzerland

11:30 151LB Daclatasvir in Combination With Sofosbuvir for HCV/HIV Coinfection: ALY-2 Study
David Wyles1; Peter Ruane2; Mark Sulkowski3; Douglas Dieterich4; Anne Luetkemeyer5; Timothy Morgan6; Kenneth E. Sherman7; Zhaozhi Liu8; Stephanie Noviello9; Peter Ackerman10
1University of California San Diego, La Jolla, CA, US; 2Ruane Medical and Liver Health Institute, Los Angeles, CA, US; 3Johns Hopkins University School of Medicine, Baltimore, MD, US; 4Icahn School of Medicine at Mount Sinai, New York, NY, US; 5University of California and San Francisco General Hospital, San Francisco, CA, US; 6VA Long Beach Healthcare System, Long Beach, CA, US; 7University of Cincinnati College of Medicine, Cincinnati, OH, US; 8Bristol-Myers Squibb Co, Princeton, NJ, US

11:45 152LB Ledipasvir/Sofosbuvir for 12 Weeks in Patients Coinfected With HCV and HIV-1
Susanna Naggie1; Curtis Cooper2; Michael S. Saag3; Jenny C. Yang4; Luisa M. Stamm5; Phillip S. Pang6; John M. Hutchison6; Douglas Dieterich7; Mark Sulkowski8
1Duke Clinical Research Institute, Durham, NC, US; 2University of Ottawa, Ottawa, Canada; 3University of Alabama at Birmingham, Birmingham, AL, US; 4Gilead Sciences, Inc, Foster City, CA, US; 5Mount Sinai Health System, New York, NY, US; 6Johns Hopkins University School of Medicine, Baltimore, MD, US
Session 0-13 Oral Abstracts
10:00 am – 12:15 pm
Reaching Populations: Demonstrating Impact

Moderators
Sarah Fidler, Imperial College and Imperial College NHS Trust, London, United Kingdom
Jessica E. Justman, Columbia University Medical Center, New York, NY, US

10:00 153 Population Viral Load in Three High HIV Prevalence Settings in Sub-Saharan Africa
David Maman; Helena Huerga; Gilles Van Cutsem; Irene Mukui; Benson Chilima; Beatrice Kirubi; Ruggero G. Giuliani; Elisabeth Szumilin; Charles Masiku; Jean-François Etard
Epicentre/Médecins Sans Frontières, Paris, France; Médecins Sans Frontières, Cape Town, South Africa; National AIDs and STD Control Program, Nairobi, Kenya; Ministry of Health, Lilongwe, Malawi; Médécins Sans Frontières, Nairobi, Kenya; Médécins Sans Frontières, Paris, France; Médécins Sans Frontières, Lilongwe, Malawi

10:15 154 Disparities in Engagement Within HIV Care in South Africa
Simbarashe Takuva; Alison Brown; William Macleod; Yogan Pillay; Valerie Delpech; Adrian J. Puren
National Institute for Communicable Diseases, NHLS, Johannesburg, South Africa; Centre for Infectious Diseases Surveillance, Public Health England, London, United Kingdom; Boston University, Boston, MA, US; National Department of Health, Pretoria, South Africa

10:30 155 Decentralizing Access to Antiretroviral Therapy Services for Adults in Swaziland
Andrew F. Auld; Harrison Kamiru; Charles Azih; Andrew L. Baughman; Harriet Nwagaba-Biribonwah; Peter Ehrenkranz; Simon Agolory; Tedd V. Ellerbrock; Velephi Okello; George Bicego
US Centers for Disease Control and Prevention, Atlanta, GA, US; ICAP, Columbia University, New York, NY, US; Ministry of Health, Mbabane, Swaziland

10:45 156 Who Are the 10-Year AIDS Survivors on Antiretroviral Therapy in Haiti?
Samuel Pierre; Ashita Batavia; Patrice Severe; Vanessa Rouzier; Benedict Charles; Jean Pape; Warren Johnson; Daniel Fitzgerald; Margaret L. McNairy
On behalf of Les Centres GESKIO CTU; Les Centres GESKIO, Port-au-Prince, Haiti; Weill Cornell Medical College, New York, NY, US

11:00 157 Nationwide Evaluation of Antiretroviral Therapy Coverage on Prevention in Rwanda: A Multisectioonal Time-Trend Analysis
Sabin Nsanzimana; Eric Remera; Steve Kanters; Eric Dusabe; Adeline Dukuzze; Till Barnighausen; Eran Bendavid; Julio Montaner; Edward Mills
On behalf of the Rwanda Treatment as Prevention Working Group
Stanford University, Vancouver, Canada; Rwanda Biomedical Centre, Kigali, Rwanda; Harvard School of Public Health, Boston, MA, US; BC Centre for Excellence in HIV/AIDS, Vancouver, Canada

11:15 158 Impact of Male Circumcision Scale-Up on Community-Level HIV Incidence in Rakai, Uganda
Xiangrong Kong; Godfrey Kigozi; Fred Nalugoda; David Serwadda; Maria J. Wawer; Ronald H. Gray
On behalf of the Rakai Health Sciences Program
Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, US; Rakai Health Sciences Program, Entebbe, Uganda; Makerere University College of Health Sciences, Kampala, Uganda

11:30 159 Effects of Antiretroviral Treatment on Health Care Utilization in Rural South Africa
Jan A. Hontelez; Frank Tanser; Saie J. de Vlas; Kevindra K. Naidu; Rob Baltussen; Deenan Pillay; Till Barnighausen
Erasmus University Medical Center, Nijmegen, Netherlands; Africa Centre for Health and Population Studies, Somkhele, South Africa; Radboud University Medical Centre, Nijmegen, Netherlands

11:45 160 The Impact of PEPFAR Abstinence and Faithfulness Funding Upon HIV Risk Behaviors in Sub-Saharan Africa
Nathan C. Lo; Anita Lowe; Eran Bendavid
Stanford University School of Medicine, Stanford, CA, US

12:00 161 The Impact of Antiretroviral Therapy on Adult Life Expectancy in Sub-Saharan Africa
Georges Reniers; Jeffrey Eaton; Jessica Nakiyung-Liimo; Amelia C. Crampin; Chodziwadziwa Kabudula; Koubob Herbst; Mark Urassa; Amek Nyaguara; Emma Slaymaker
On behalf of the ALPHA Network
Imperial College London, London, United Kingdom; MRC/UVRI Uganda Research Unit on AIDS, Entebbe, Uganda; Africa Centre for Health and Population Studies, Mbuyatuba, South Africa; Karonga Prevention Study, Chiulumba, Malawi; University of the Witwatersrand, Johannesburg, South Africa; National Institute for Medical Research, Mwanza, United Republic of Tanzania; Kenya Medical Research Institute-Centers for Disease Control, Kisumu, Kenya; London School of Hygiene and Tropical Medicine, London, United Kingdom

Thursday, February 26, 2015 • Oral Sessions
CROI 2015
**Session 0-14 Oral Abstracts**

**Program and Agenda**

**Session O-14 Oral Abstracts**

**Room 613**

**10:00 am – 12:15 pm**

**Immune Mechanisms: The Road to Protection**

**Moderators**

Katharine J. Bar, University of Pennsylvania, Philadelphia, PA, US
Bruce Walker, Ragon Institute of MIT, MGH and Harvard, Cambridge, MA, US

**10:00 162**

**Passively Acquired ADCC Activity in HIV-Infected Infants Correlates With Survival**

Caitlin Milligan; Barbra A. Richardson; Grace John-Stewart; Ruth W. Ndubu; Julie M. Overbaugh

1 Fred Hutchinson Cancer Research Center, University of Washington, Seattle, WA, US; 2 University of Washington, Seattle, WA, US; 3 University of Nairobi, Nairobi, Kenya

**10:15 163**

**AAV-Expressed eCD4-Ig Protects Rhesus Macaques From Multiple SHIV-AD8 Challenges**

Michael Farzan

The Scripps Research Institute, Jupiter, FL, US

**10:30 164LB**

**HIV Neutralizing Antibodies Induced by Native-Like Envelope Trimers**

Rogier Sanders

The WCMC/Scripps/AMC HIVRAD team

Academic Medical Center University of Amsterdam, Amsterdam, Netherlands

**10:45 165**

**Efficacy Loss of BnAbs During HIV-1 Cell-Cell Spread Is Strain- and Epitope-Dependent**

Lucia Rhee; Carsten Magnus; Merle Schanz; Jacqueline Weber; Therese Uhr; Peter Rutz; Alexandra Trkola

University of Zurich, Zurich, Switzerland

**11:00 166**

**Peripheral T Follicular Helper Cells With Universal Helper Activity in HIV Infection**

Bruce Schultz; Alexander Oster; Franco Pissani; Jeffrey E. Teijler; Michael A. Eller; Merlin L. Robb; Jerome H. Kim; Nelson L. Michael; Diane Bolton; Hendrik Streeck

US Military HIV Research Program, Silver Spring, MD, US

**11:15 167**

**Redirected Killing of HIV-Infected T Cells by Germinal Center CD8 T Cells**

Constantinos Petrovas; Sara Ferrando-Martinez; Michael Gerner; Amarender Pegu; Perla Del Rio-Estrada; Kristin Boswell; Manuel Leal; Gustavo Reyes-Teran; Ronald Germain; Richard A. Koup

1 Vaccine Research Center, National Institute of Allergy and Infectious Diseases, Bethesda, MD, US; 2 NIAID-NIH, Bethesda, MD, US; 3 Instituto Nacional de Enfermedades Respiratorias, Mexico City, Mexico; 4 Instituto de Biomedicina de Sevilla, Sevilla, Spain

**11:30 168**

**IL-21 Reduces Inflammation and Virus Persistence in ART-Treated SIV-Infected Macaques**

Luca Micci; Emily Ryan; Colleen McGary; Sara Paganimi; Guido Silvestri; Mike Piatak; Jeffery Lifson; Francois Villinger; Jason M. Brenchley; Mirko Paiardini

1 Yerkes National Primate Research Center, Emory University, Atlanta, GA, US; 2 Leidos Biomedical Research, Inc, Frederick, MD, US; 3 National Institute of Allergy and Infectious Diseases (NIAID), Bethesda, MD, US

**11:45 169**

**Discovery of CD8+ T Cell Epitopes Encoded by the HIV 5’ Leader Sequence**

Edward Kreider; Katja J. Pfafferott; Thomas Partridge; Hui Li; Ranjit Warrier; Benedict M. Kessler; Andrew J. McMichael; Persephone Borrow; Beatrice H. Hahn; George M. Shaw

1 University of Pennsylvania, Philadelphia, PA, US; 2 University of Oxford, Headington, United Kingdom

**12:00 170LB**

**Neutralizing Antibodies Differ Between HIV-1–Infected RV144 Vaccines and Placebos**

Shelly J. Krebs; Moragne Rolland; Sodsai Tovanabutra; Ivelin Georgiev; Agnes-Laurence Chenine; Victoria R. Polonis; Supachai Reks-Ngam; Peter D. Kwong; Nelson L. Michael; Jerome H. Kim

On behalf of the RV152 Study Group

1 US Military HIV Research Program, Silver Spring, MD, US; 2 Vaccine Research Center, NIAID, NIH, Bethesda, MD, US; 3 Ministry of Public Health, Bangkok, Thailand

**Session TD-M Themed Discussion**

**Room 615**

**1:30 pm – 2:30 pm**

**Identifying Recent Infections: Issues of False Recency**

**Themed Discussion Leader**

Michael Busch, Blood Systems Research Institute, San Francisco, CA, US

**612**

**A Generalized Entropy Measure of Viral Diversity for Identifying Recent HIV-1 Infections**

Julia W. Wu; Oscar Patterson-Lomba; Marcello Pagano

Harvard School of Public Health, Boston, MA, US

**626**

**Viral Load is Critical in Limiting False-Recent Results From HIV Incidence Assays**

Reshma Kassanjee; Shelley Facente; Sheila Keating; Elaine McKinney; Kara Marson; Christopher D. Pilcher; Michael Busch; Gary Murphy; Alex Welte

On behalf of the Consortium for the Evaluation and Performance of HIV Incidence Assays (CEPHIA)

646 German Cohort on Sofosbuvir-Based Therapy for HIV/HCV and HCV Infection (GECOSO)
Stefan Christensen1; Ingiliz Patrick1; Dietrich Hueppe1; Thomas Lutz1; Karl Georg Simon1; Knud Schewe1; Heiner Busch1; Axel Baumgarten1; Guenther Schmutz1; Stefan Mauss1
1Center for HIV and Hepatogastroenterology, Düsseldorf, Germany; 2CIM Infectious Diseases, Muenster, Germany; 3Medizinisches Infektionszentrum Berlin, Berlin, Germany; 4Infektiologikum Frankfurt, Frankfurt, Germany; 5Infektionsmedizinisches Zentrum Hamburg, Hamburg, Germany; 6Practice for Gastroenterology Leverkusen, Leverkusen, Germany; 7Practice for Gastroenterology Herne, Herne, Germany

649 Successful HCV Treatment With Direct Acting Antivirals in HIV/HCV Patients
Jennifer L. Grant1; Valentina Stosor1; Frank J. Palella1; Richard M. Green1; Guajira Thomas1; Donna V. McGregor1; Milena M. McLaughlin1; Sudhir Penugonda1; Michael Angarano1; Claudia Hawkins1
1Northwestern University, Feinberg School of Medicine, Chicago, IL, US; 2Midwestern University, Chicago, IL, US

645 Effectiveness of Sofosbuvir/Simeprevir for HIV/HCV Patients in Clinical Practice
Jody Gilmore1; Kenneth Lynn1; Delisha Breen1; Stacey Trooskin1; Jihad Slim1; Nancy Scangarello1; Alvin Kingcade1; Katie Hunyh1; Vincent Lo Re1; Jay R. Kostman1
1Perelman School of Medicine, Philadelphia, PA, US; 2Drexel University College of Medicine, Philadelphia, PA, US; 3St Michael’s Medical Center, Newark, NJ, US; 4Philadelphia Health Management Corporation, Philadelphia, PA, US

648 Simeprevir and Sofosbuvir Regimens for Hepatitis C: Decompensation and Serious AEs
Ponni V. Perumalswami1; Kian Bichoupan1; Lawrence Ku1; Neal M. Patel1; Rachana Yalamanchili1; Thomas Schiano1; Mark Woodward1; Douglas Dieterich1; Andrea D. Branch1
1Icahn School of Medicine at Mount Sinai, New York, NY, US; 2George Institute for Health at the University of Oxford, Oxford, United Kingdom

651 Majority of HIV/HCV Patients Need to Switch ART to Accommodate Simeprevir
Rebecca Cope1; Aaron Pickering2; Thomas Glowa1; Samantha Faulds1; Peter Veldkamp1; Ramakrishna Prasad1
1University of Pittsburgh, Pittsburgh, PA, US; 2University of Maryland, Glen Burnie, MD, US

644 Sofosbuvir, Simeprevir, +/- Ribavirin in HCV Protease Inhibitor-Experienced Patients
Kristen M. Marks1; Ethan M. Weinberg1; Sonal Kumar1; Carrie Down1; Ype P. de Jong1; Leah A. Burke1; Mary C. Olson1; Ira M. Jacobson1
Weill Cornell Medical College, New York, NY, US

Session TD-N Themed Discussion
1:30 pm – 2:30 pm
Next-Generation HCV Therapeutics: From Clinical Trials to the Clinic
Themed Discussion Leader
Debika Bhattacharya, University of California Los Angeles CARE Center, Los Angeles, CA, US

Session TD-P Themed Discussion
1:30 pm – 2:30 pm
Cardiovascular Risk Prediction: Can We Do Better?
Themed Discussion Leader
Nina Friis-Moller, Odense University Hospital, Odense, Denmark

746 Cumulative HIV Care Measures Highly Associated With Acute Myocardial Infarction
Jorge L. Salinas1; Christopher T. Rentsch1; Vincent C. Marconi1; Janet Tate1; Adeel A. Butt1; Matthew S. Freiberg1; Matthew B. Goetz1; Maria Rodriguez-Barradas1; Amy Justice1; David Rimland1
1Emory University, Atlanta, GA, US; 2Atlanta VA Hospital, Decatur, GA, US; 3Yale University, New Haven, CT, US; 4University of Pittsburgh, Pittsburgh, PA, US; 5David Geffen School of Medicine at University of California Los Angeles, Los Angeles, CA, US; 6Baylor College of Medicine, Houston, TX, US

747 Cardiovascular Disease Risk Prediction in the HIV Outpatient Study (HOPS)
Angela M. Thompson-Paul1; Kenneth A. Lichtenstein1; Carl Armon1; Kate Buchacz1; Rachel Debes1; Joan S. Chmiel1; Frank J. Palella1; Stanley C. Wei1; Jacek Skarbinski1; John T. Brooks1
1US Centers for Disease Control and Prevention, Atlanta, GA, US; 2National Jewish Health, Denver, CO, US; 3Cerner Corporation, Vienna, VA, US; 4Northwestern University, Feinberg School of Medicine, Chicago, IL, US

748 Incidence and Risk of Myocardial Infarction (MI) by Type in the NA-ACCORD
Daniel R. Drozd1; Mari A. Kitabata1; Keri N. Althoff1; Jinbing Zhang1; Susan R. Heckbert1; Matthew J. Budoff1; Frank J. Palella1; Daniel B. Klein1; Richard D. Moore1; Heidi M. Crane1
1University of Washington, Seattle, WA, US; 2Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, US; 3University of California Los Angeles, Los Angeles, CA, US; 4Northwestern University, Chicago, IL, US; 5Kaiser Permanente Northern California, Hayward, CA, US; 6Johns Hopkins University, Baltimore, MD, US
750 HIV-Infected Veterans and the New ACC/AHA Cholesterol Guidelines: Got Statins?

Meredith E. Clement; Lawrence Park; Ann Marie Navar-Boggan; Nwora L. Okeke; Michael Pencina; Pamela Douglas; Susanna Naggie

1Duke University, Durham, NC, US; 2Duke University, Durham, NC, US

751 Evaluation of the ACC/AHA CVD Risk Prediction Algorithm Among HIV-Infected Patients

Susan Regan; James B. Meigs; Joseph Massaro; Ralph B. D’Agostino; Steven Grinspoon; Virginia A. Triant

1Massachusetts General Hospital, Harvard Medical School, Boston, MA, US; 2Massachusetts General Hospital, Harvard Medical School, Boston, MA, US; 3Boston University, Boston, MA, US; 4Massachusetts General Hospital, Harvard Medical School, Boston, MA, US

Session TD-T Themed Discussion
Room 6D
1:30 pm – 2:30 pm
Keys to the Kingdom: Viral Suppression in Pregnant and Postpartum Women

Themed Discussion Leader
Laurent Mandelbrot, Hospital Louis Mourier, Colombes, France

863 Specific Effects of ZDV, 3TC and LPV/r on HIV-1 RNA Viral Load During Pregnancy

Patumnrat Sripan; Sophie Le Coeur; Lily Ingrisawang; Tim R. Cressey; Jean-Marc Treluyer; Naim Bouazza; Frantz Foissac; Gonzague Jourdain; Marc G. Lallemand; Saik Urien

1ED420, University of Paris Sud 11, Paris Descartes, Paris, France; 2PHPT-IRD UMI 174, Paris, France/Institut de Etudes Demographiques, Institut de Recherche Pour le Developpement (UMR 196 CEPED), Paris, France/Institut de Recherche Pour le Developpement (UMR 196 CEPED), Paris, France/Institut de Etudes Demographiques, Institut de Recherche Pour le Developpement (UMR 196 CEPED), Paris, France/Institut de Etudes Demographiques, Institut de Recherche Pour le Developpement (UMR 196 CEPED), Paris, France

864 Viral Suppression After Antiretroviral Therapy Initiation in Pregnancy in South Africa

Landon Myer; Tasmin Phillips; Nei-Yuan Hisao; Allison Zerbe; Jo Ramjith; Linda-Gail Bekker; James A. McIntyre; Elaine J. Abrams

1University of Cape Town, Cape Town, South Africa; 2National Health Laboratory Services/University of Cape Town, Cape Town, South Africa; 3ICAP at Columbia University, New York, NY, US; 4Anova Health Institute, Johannesburg, South Africa

865 Maternal Viral Load in the Context of PMTCT B+ Within the Kabeho Study in Kigali

Emily A. Bobrow; Placidie Mugwaneza; Gilles F. Ndayisaba; Dieudonne Ndatimana; Michelle Gill; Heather J. Hoffman; Cyprien Baribwira; Laura Guay; Anita Asimwe

On behalf of the Kabeho Study Team

1Elizabeth Glaser Pediatric AIDS Foundation, Washington, DC, US; 2Ministry of Health, Kigali, Rwanda; 3Elizabeth Glaser Pediatric AIDS Foundation, Kigali, Rwanda; 4George Washington University Milken Institute School of Public Health, Washington, DC, US; 5University of Maryland, School of Medicine, Kigali, Rwanda; 6University of Nairobi, Nairobi, Kenya; 7Fred Hutchinson Cancer Research Center, Seattle, WA, US

Session TD-V Themed Discussion
Room 6C
1:30 pm – 2:30 pm
PEP: Remember Me?

Themed Discussion Leader
Kenneth H. Mayer, Fenway Health, Boston, MA, US

959 Tenofivir/Emtricitabine Plus LPV/r vs MVC or Raltegravir for PEP: 2 Randomized Trials

Lorna Leal; Agathe Leon; Berta Torres; Alexy Inciarte; Constanza Lucero; Josep Mallolas; Maria Martinez-Rebollar; Ana Gonzalez-Cordon; Jose M. Gatell; Felipe Garcia

Hospital Clinic Barcelona, Barcelona, Spain

958 Rilpivirine-Emtricitabine-Tenofovir for HIV Nonoccupational Postexposure Prophylaxis

Rosalind Foster; John McAllister; Tim R. Read; Anna Pierce; Robyn Richardson; Anna McNulty; Andrew Carr

On behalf of the EPEP Study Researchers

1Sydney Sexual Health Centre, Sydney, Australia; 2St Vincent’s Centre for Applied Medical Research, Sydney, Australia; 3Melbourne Sexual Health Centre, Melbourne, Australia; 4The Alfred Hospital, Melbourne, Australia

957 Significant Intolerability of Efavirenz in HIV Occupational Postexposure Prophylaxis

Surasak Wiboontchutikul; Varaporn Thientong; Patama Sutha; Boonchai Roidwidaiburan; Weerawat Manosuthi

1Bamrasnaradura Infectious Diseases Institute, Nonthaburi, Thailand; 2Bangkok Hospital, Bangkok, Thailand
Session S-7 Symposium Room 613
4:00 pm – 6:00 pm
From Pathways to Paradigms: Applications of Systems Biology to HIV/Host Interactions

Target audience: This session is directed to scientists and clinicians who are interested in recent advances in the use of RNA profiling, transcriptomic analyses, microarrays, and other state-of-the-art methodologies in an integrated approach (i.e., systems biology) to probe new insights and hypotheses in HIV pathogenesis, prevention, and treatment.

Level of knowledge: It is assumed that participants are familiar with the basic concepts and challenges in the fields of HIV pathogenesis, prevention, and treatment and have some familiarity with the cellular processes that underlie the molecular biology of viral-host interactions.

Objectives: At the completion of the session, participants will be able to:

- Recognize how integrative approaches to profiling RNA transcription can be applied to provide new interpretations of relevant problems in HIV pathogenesis research.
- Appreciate how a systems-biology approach can generate new hypotheses for developing novel interventions for HIV prevention and therapy.
- Discuss emerging technologies and bioinformatic analyses that have enabled molecular signatures and networks to be identified and applied to relevant questions for HIV and other infectious pathogens.

Symposium Conveners
Steven Bosinger, Emory University, Yerkes National Primate Research Center, Atlanta, GA, US
Raphael Gottardo, Fred Hutchinson Cancer Research Center, University of Washington, Seattle, WA, US

4:00 171 Using Systems Approaches to Study Pathogenesis: Bridging Networks and Mechanisms
Nevan Krogan, University of California San Francisco, San Francisco, CA, US

4:30 172 Molecular Basis of T-Cell Exhaustion
E. John Wherry, University of Pennsylvania, Philadelphia, PA, US

5:00 173 A Systems Biology Approach to Identify Targets and Mechanisms of HIV Latency and HIV Eradication
Rafick P. Sekaly, Case Western Reserve University, Cleveland, OH, US

5:30 174 Translating Anti–HIV-1 Immune Mechanisms Into Clinical Interventions
Sallie R. Permar, Duke University, Durham, NC, US

Session S-8 Symposium Room 6D
4:00 pm – 6:00 pm
Scale-Up of Interventions

Target audience: This session is directed to researchers and programmers interested in the scale-up of HIV programs around the world.

Level of knowledge: It is assumed that participants are familiar with HIV prevention methods, the impact of HIV on key populations, HIV testing approaches, laboratory assays in support of HIV prevention, and HIV care and treatment.

Objectives: At the completion of the session, participants will be able to:

- Describe scientific evidence relating to male circumcision and its programmatic scale-up for HIV prevention.
- Describe scientific bases for interventions for people who inject drugs.
- Describe recent evidence and trends concerning scale-up of HIV testing.
- Describe the role of laboratory infrastructure and systems required to support HIV/AIDS program scale-up.

Symposium Conveners
Linda-Gail Bekker, Desmond Tutu HIV Foundation, Cape Town, South Africa
Kevin M. De Cock, Centers for Disease Control and Prevention, Nairobi, Kenya

4:00 175 From Equipoise to Efficacy to Millions Reached With Voluntary Medical Male Circumcision for HIV Prevention
4:30  176  Scale-Up of HIV Interventions for People Who Inject Drugs: Quality and Coverage
Anna Deryabina
ICAP at Columbia University, Almaty, Kazakhstan

5:00  177  HIV Testing and Counseling: Emerging Issues, New Directions
Rachel C. Baggaley
World Health Organization, Geneva, Switzerland

5:30  178  Ten Years of Strengthening Laboratory Services and Systems: Then, Now, and the Future
John Nkengasong
US Centers for Disease Control and Prevention, Atlanta, GA, US

Session S-9 Symposium  Room 6E
4:00 pm – 6:00 pm
HCV: New Frontiers and Controversies

Target audience: This session is directed to persons who are interested in the basic science, public health impact, and management of hepatitis C virus (HCV) infections.

Level of knowledge: It is assumed that participants are familiar with general concepts of virology and medicine.

Objectives: At the completion of the session, participants will be able to:
• Describe the mechanisms by which HCV affects the liver.
• Recognize the cells that HIV infects within the liver.
• Describe the impact of HCV eradication on HCV transmission, and the pitfalls.

Symposium Conveners
Chloe M. Orkin, Barts Health NHS Trust, London, United Kingdom
David L. Wyles, University of California San Diego, La Jolla, CA, US

4:00  179  Pathogenesis of Acute HCV Infection
Ashwin Balagopal
Johns Hopkins University School of Medicine, Baltimore, MD, US

4:30  180  HCV Treatment as Prevention: Challenges and Opportunities
Gregory Dore
University of New South Wales, Sydney, Australia

5:00  181  HCV Therapeutics: It’s the Virus, Stupid
Mark S. Sulkowski
Johns Hopkins University School of Medicine, Baltimore, MD, US

5:30  182  HCV Therapeutics: Big Sticks With Big Stickers
Marion G. Peters
University of California San Francisco, San Francisco, CA, US
POSTER SESSIONS, BY CATEGORY

All poster sessions will be held in the Poster Hall from 2:30 PM to 4:00 PM on the scheduled day.

A: Virology
P-A1: Cellular Innate Immunity: Tuesday, 2/24/2015
P-A2: Nucleus Entry, Integration, and Export: Wednesday, 2/25/2015
P-A3: SAMHD1: Tuesday, 2/24/2015
P-A4: Enhancers and Inhibitors of Viral Infectivity and Entry: Thursday, 2/26/2015
P-A5: Envelopes, Receptors, and Tropism: Wednesday, 2/25/2015
P-A6: Nef Functions: Thursday, 2/26/2015

B: Molecular Epidemiology and HIV/SIV Evolution
P-B1: Viral Origins and Recombinant Forms: Thursday, 2/26/2015
P-B2: Defining Epidemiologically Linked Transmission: Tuesday, 2/24/2015
P-B3: Transmission Clusters: Wednesday, 2/25/2015
P-B4: Transmission Networks: MSM: Tuesday, 2/24/2015
P-B5: Next Generation of Next-Generation Sequencing: Thursday, 2/26/2015

C: Pathogenesis—Human Studies and Animal Models
P-C1: The Gut Microbiome: Tuesday, 2/24/2015
P-C2: The Mucosa in HIV/SIV Pathogenesis: Tuesday, 2/24/2015
P-C3: Innate and Unconventional T-Cell Responses: Wednesday, 2/25/2015
P-C4: Monocytes, Dendritic Cells, and Neutrophils: Wednesday, 2/25/2015
P-C5: Studies of HIV-Exposed Uninfected Individuals: Tuesday, 2/24/2015
P-C6: Host Factors in HIV Pathogenesis: Tuesday, 2/24/2015
P-C7: HIV/CMV Interactions in Transmission and Pathogenesis: Thursday, 2/26/2015
P-C8: Aging and Immune Senescence: Thursday, 2/26/2015
P-C9: Immune Pathogenesis of IRIS: Tuesday, 2/24/2015
P-C10: Immune Activation and HIV Pathogenesis: Wednesday, 2/25/2015
P-C11: Manipulating Immune Activation: Wednesday, 2/25/2015
P-C12: Pathogenesis in Lymph Nodes: Thursday, 2/26/2015
P-C13: Dissecting Pathogenesis Through In Vitro Studies: Thursday, 2/26/2015
P-C14: Dissecting Pathogenesis Through In Vivo Studies: Thursday, 2/26/2015

E: Host immune responses to infection, vaccines, and immunotherapy
P-E1: The Effect of HIV Infection on B Cells: Tuesday, 2/24/2015
P-E2: The Envelope/Antibody Dynamic: Tuesday, 2/24/2015
P-E3: New Approaches to Immunostimulation: Wednesday, 2/25/2015
P-E4: Cellular Immune Response to HIV: Thursday, 2/26/2015

F: HIV Persistence, Reservoirs, Latency, Eradication, including Gene Therapy
P-F1: Immune-Based Strategies in Latency: Tuesday, 2/24/2015
P-F2: Viral Reservoir Dynamics During ART: Thursday, 2/26/2015
P-F3: Cellular Factors of Latency: Thursday, 2/26/2015
P-F4: Dynamics of Latency and Reactivation: Wednesday, 2/25/2015
P-F5: Gene Editing: Wednesday, 2/25/2015
P-F6: HDAC Inhibitors: Tuesday, 2/24/2015
P-F7: Pharmacologic Latency-Reactivation Agents: Tuesday, 2/24/2015
P-F8: Latency Models and Assays: Wednesday, 2/25/2015
P-F9: Stem Cell Transplantation: Wednesday, 2/25/2015

G: Neuropathogenesis
P-G1: CNS Reservoirs: Tuesday, 2/24/2015
P-G2: Optimizing ART for HAND Treatment and Prevention: Tuesday, 2/24/2015
P-G3: Neurologic Disorders in Resource-Limited Settings: Wednesday, 2/25/2015
P-G4: HAND Genetics: Thursday, 2/26/2015
P-G5: HAND Diagnosis and Predictors: Tuesday, 2/24/2015
P-G6: Inflammation and Markers of Brain Injury in HAND: Thursday, 2/26/2015
P-G7: Aging and Cognitive Decline: Wednesday, 2/25/2015
P-G8: Mitochondrial Dysfunction in HAND and Depression: Thursday, 2/26/2015
P-G9: Neuropathogenesis Mechanisms: Thursday, 2/26/2015

H: Clinical pharmacology
P-H1: Pharmacokinetics, Pharmacodynamics, and Adherence: Tuesday, 2/24/2015
P-H2: Pharmacogenomics: Tuesday, 2/24/2015
P-H3: Drug-Drug Interactions: Tuesday, 2/24/2015
P-H4: Pharmacokinetics in Compartments and Reservoirs and of Novel Formulations: Thursday, 2/26/2015

I: Antiretroviral therapy: preclinical studies
P-I1: Drug development: Wednesday, 2/25/2015

J: Antiretroviral therapy: randomized clinical trials
P-J1: ART: Recent Perspectives: Tuesday, 2/24/2015

K: Antiretroviral therapy: observational studies
P-K1: ART: Adherence, Adherence, Adherence: Tuesday, 2/24/2015
P-K2: ART: Monitoring and Biomarkers: Tuesday, 2/24/2015
P-K4: ART: Mortality: Wednesday, 2/25/2015
L: HIV Drug Resistance
P-L1: HIV Drug Resistance: Mechanisms and Mutations: Thursday, 2/26/2015
P-L2: HIV Subtypes and Resistance: Thursday, 2/26/2015
P-L4: HIV Drug Resistance: Global Perspective and Clinical Implications: Thursday, 2/26/2015

M: HIV Diagnostics
P-M1: Nucleic-Acid–Based Detection of HIV: Tuesday, 2/24/2015
P-M2: Comparison of HIV Incidence Assays: Wednesday, 2/25/2015

N: Hepatitis Viruses
P-N1: Natural History and Prognosis of HCV Infection: Tuesday, 2/24/2015
P-N2: HCV Therapy: Observations From Cohort Studies: Tuesday, 2/24/2015
P-N3: Treatment of HCV with DAAs: Short-Term Costs and Long-Term Benefits: Tuesday, 2/24/2015
P-N4: HCV: Getting the Drugs to Those Who Need Them: Tuesday, 2/24/2015
P-N5: HCV: Epidemiology and Case Detection: Wednesday, 2/25/2015
P-N6: Acute HCV Infection: Wednesday, 2/25/2015
P-N7: Immunopathogenesis of HCV Infection: Wednesday, 2/25/2015
P-N8: HCV Therapeutics: Preclinical Observations and Clinical Trials of DAAs: Thursday, 2/26/2015
P-N9: Mental Health and Treatment Adherence with Direct-Acting Antivirals: Thursday, 2/26/2015
P-N10: HCV: Resistance to Antiviral Agents: Thursday, 2/26/2015
P-N11: Other Hepatitis Viruses: HBV, HDV, HEV: Thursday, 2/26/2015

O: HIV-Related and Non–HIV-Related Malignancies
P-O1: HPV Infections and Cancers: Tuesday, 2/24/2015
P-O2: AIDS-Related Cancers: Lymphoma and KS: Wednesday, 2/25/2015
P-O3: Cancer and Cancer Risk in HIV Subpopulations and Lung Cancer: Thursday, 2/26/2015

P: Cardiovascular Complications of HIV Infection and Antiretroviral Therapy
P-P1: Cardiovascular Disease Outcomes: Tuesday, 2/24/2015
P-P2: Dyslipidemia: Mediators and Treatment: Wednesday, 2/25/2015
P-P3: ART: Cardiovascular Risk and Hypertension: Wednesday, 2/25/2015
P-P4: What Predicts Risk for CVD in HIV? Tuesday, 2/24/2015
P-P5: Cardiovascular Risk Prediction: Wednesday, 2/25/2015
P-P6: Biomarkers and Atherosclerosis: Tuesday, 2/24/2015
P-P7: Endothelial Functions and Cerebral Vasoreactivity: Tuesday, 2/24/2015

Q: Other Complications of HIV Infection and Antiretroviral Therapy
P-Q1: Inflammation: Biomarkers and Relationship to Outcomes: Tuesday, 2/24/2015
P-Q2: Bone Metabolism and ART: Mechanisms and Outcomes: Tuesday, 2/24/2015
P-Q3: Bone Disease: Mechanisms of Bone Loss and Fracture Risk: Tuesday, 2/24/2015
P-Q4: Measuring Bone Density: Tuesday, 2/24/2015
P-Q6: Aging: Frailty, Telomeres, and mtDNA: Tuesday, 2/24/2015
P-Q7: Diabetes and Other Endocrine Disorders: Tuesday, 2/24/2015
P-Q8: Renal Dysfunction: ART and Biomarkers: Thursday, 2/26/2015
P-Q9: Renal Transplantation: Long-Term Outcomes: Thursday, 2/26/2015
P-Q10: Pulmonary Disease: Thursday, 2/26/2015
P-Q11: Body Composition and Risk Factors for Abnormalities: Thursday, 2/26/2015
P-Q12: Complications: Liver Disease Without Viral Hepatitis: Thursday, 2/26/2015
P-Q13: Depression and Alcohol Use Disorders: Thursday, 2/26/2015

R: Tuberculosis and Other Opportunistic Infections
P-R1: Immune Reconstitution Inflammatory Syndrome in Opportunistic Infections: Tuesday, 2/24/2015
P-R2: T-Cell Responses to Tuberculosis Infection: Tuesday, 2/24/2015
P-R3: TB Diagnostic Challenges: Tuesday, 2/24/2015
P-R4: TB Adverse Events, Recurrence, and Mortality: Tuesday, 2/24/2015
P-R5: Cryptococcal Meningitis: Host Response, Treatment, and Outcomes: Thursday, 2/26/2015
P-R6: Syphilis and HIV Coinfection: Tuesday, 2/24/2015
P-R7: Opportunistic Infections: Odds and End Organs: Tuesday, 2/24/2015

S: HIV in Women and Women’s Health
P-S1: Access and Engagement: Thursday, 2/26/2015
P-S2: Cervical Sampling, Shedding, and Outcomes: Tuesday, 2/24/2015
P-S3: Hormonal Contraception: Thursday, 2/26/2015

T: Maternal/Fetal HIV
P-T2: Rates and Risks of MTCT and HIV-Free Survival: Tuesday, 2/24/2015
P-T3: Option B+: Retention and Transmission: Tuesday, 2/24/2015
P-T4: Health Outcomes of HIV- and ARV-Exposed Infants, Children, and Youth: Thursday, 2/26/2015
P-T5: Coinfections Among HIV-Exposed Infants and Children: Thursday, 2/26/2015
P-T6: ART Adherence, Adverse Effects, and Retention Among Pregnant Women and Infants: Tuesday, 2/24/2015
P-T7: Pharmacokinetics and Safety of ART During Pregnancy: Tuesday, 2/24/2015
P-T8: Planning and Preventing Pregnancy: Tuesday, 2/24/2015
P-T9: Mechanisms of MTCT and Maternal/Infant Health: Thursday, 2/26/2015
P-T10: Immune Mechanisms in MTCT: Tuesday, 2/24/2015
P-T11: PMTCT-Associated Drug Resistance in Women and Infants: Tuesday, 2/24/2015

U: Pediatrics and Adolescents
P-U1: HIV Diagnosis in Infants and Children: Tuesday, 2/24/2015
P-U2: Early ART and HIV Persistence: Tuesday, 2/24/2015
P-U3: Treatment Outcomes Among Children and Youth With HIV: Wednesday, 2/25/2015
P-U4: Treatment and Monitoring Strategies in Children: Wednesday, 2/25/2015
P-U5: Determinants of Disease Progression in Children: Tuesday, 2/24/2015
P-U6: Complications of HIV and ART: Pulmonary and Cardiovascular Outcomes: Thursday, 2/26/2015
P-U7: Complications of HIV and ART: Bones, Brains, and Kidneys: Thursday, 2/26/2015
P-U8: Tuberculosis and Other Coinfections in Children With HIV: Wednesday, 2/25/2015
P-U9: Responses to Vaccines in Children: Tuesday, 2/24/2015
P-U10: Pharmacokinetics, Safety, and Efficacy of ART in Children and Youth: Tuesday, 2/24/2015

V: Prevention and Intervention Studies
P-V1: Postexposure Prophylaxis (PEP): Wednesday, 2/25/2015
P-V2: PrEP and Microbicide Challenge: Thursday, 2/26/2015
P-V3: PrEP: Uptake: Tuesday, 2/24/2015
P-V4: PrEP: Measures and Correlates of Adherence: Tuesday, 2/24/2015
P-V6: HIV Prevention, Miscellaneous: Thursday, 2/26/2015

W: Epidemiology
P-W1: HIV Testing and the Continuum of Care in the Industrialized World: Tuesday, 2/24/2015
P-W2: HIV Testing and the Continuum of Care in the Developing World: Tuesday, 2/24/2015
P-W3: Risk Factors for Transmission in MSM: Wednesday, 2/25/2015
P-W4: Transmission Through Needles and Heterosexual Contact: Wednesday, 2/25/2015
P-W5: Incidence and Prevalence of HIV Infection, Including Acute HIV: Thursday, 2/26/2015
P-W6: Disease Progression, Morbidity, and Mortality: Thursday, 2/26/2015
P-W7: HIV Stigma: Thursday, 2/26/2015

X: Health Care Delivery and Health Systems
P-X1: Paying for Care: Tuesday, 2/24/2015
P-X2: Linkage to and Retention in Care: Wednesday, 2/25/2015
P-X3: Guidelines and Their Implementation: Thursday, 2/26/2015

Y: Implementation Science
P-Y1: Male Circumcision: Risk, Innovation, and Scale-Up: Thursday, 2/26/2015
P-Y2: Linkage to Care and ART Initiation: Wednesday, 2/25/2015

Z: Population and Economic Modeling
P-Z1: Costs and Cost Effectiveness: Tuesday, 2/24/2015
P-Z2: Modeling HIV Epidemiology: Wednesday, 2/25/2015
P-Z3: Modeling the Impact of HIV Interventions: Thursday, 2/26/2015
Program and Agenda

Poster Listings

**TUESDAY, FEBRUARY 24, 2015**

**Session P-A1 Poster Session**

2:30 pm – 4:00 pm

**Cellular Innate Immunity**

183  **STAT5 Inhibition Reduces HIV-1 Infection and TLR7/8 Responses in Human Macrophages**
    Sofia Appelberg; Carla N. Mavian; Julie C. Williams; Philip Lichlyter; John Sleasman; Maureen M. Goodenow
    University of Florida, Gainesville, FL, US; Duke University, Durham, NC, US

184  **Regulation of the Innate Immune Sensing of HIV by the Viral Capsid and the Cytosolic DNA Sensor cGAS**
    Nicolas Manel
    Institut Curie, Paris, France

185  **cGAS Induced Type I IFN Responses in Dendritic Cells From HIV Elite Controllers**
    Enrique Martin-Gayo; Jacqueline Cronin; Zhengyu Ouyang; Taylor Hickman; John Trombetta; Florecia Pereyra; Bruce Walker; Alex Shailek; Mathias Lichterfeld; Xu Yu
    Ragon Institute of MIT, MGH and Harvard, Boston, MA, US; MIT Institute for Medical Engineering & Science, Boston, MA, US; Massachusetts General Hospital, Boston, MA, US

186  **Characterization of Interferon-α Subtypes in the LPAC Model**
    Michael Harper; Kathrin Gibbert; Eric Lee; Kejun Guo; Stephanie Dillon; Martin McCarter; Ulf Dittmer; Cara C. Wilson; Mario Santiago
    University of Colorado Anschutz Medical Campus, Denver, CO, US; University of Duisburg-Essen, Essen, Germany; University of Colorado Anschutz Medical Campus, Aurora, CO, US

187  **HIV Vpu Inhibits NF-κB Activity but Does Not Interfere With Interferon Regulatory Factor 3**
    Lara Manganaro; Elisa de Castro; Ana Maestre; Adolfo García-Sastre; Ana Fernandez-Sesma; Viviana A. Simon
    Icahn School of Medicine at Mount Sinai, New York, NY, US

188  **HIV-1 Exploits CD169 to Evade IFNα-Induced Antiviral State in Myeloid Cells**
    Hisashi Akiyama; Nora Ramirez; Gregory Gibson; Simon Watkins; Zandrea Ambrose; Rahm Gummuluru
    Boston University School of Medicine, Boston, MA, US; University of Pittsburgh School of Medicine, Pittsburgh, PA, US; University of Pittsburgh School of Medicine, Pittsburgh, PA, US

189  **Interferon-Induced Transmembrane Proteins (IFITMs) Antagonize Postintegration Replication of HIV but Are Overcome by Viral Membrane Accessory Proteins**
    Wingyiue Liu; Ifran Omar; Richard D. Sloan
    Queen Mary University of London, London, United Kingdom

**190**  **HSV-1-Induced Enhancement of HIV-1 Replication Is Dependent on Decrease in IFITM3 Levels**
    Viviane Andrade; Milene Miranda; Mario Stevenson; Thiago M. Souza
    University of Miami, Miami, FL, US; Oswaldo Cruz Foundation, Rio de Janeiro, Brazil

**191**  **Characterization of the Activity of an Innate Immunity Protein, the Apolipoprotein L6**
    Nitisha Pyndiah; Angela Ciuffi; Amalio Telenti
    Institute of Microbiology, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland; J Craig Venter Institute, San Diego, CA, US

**192**  **HIV and SIV Infection by RNA-Associated Early Stage Antiviral Factor (REAF)**
    Aine McKnight
    Queen Mary University of London, London, United Kingdom

**193**  **Translational Control of APOBEC3G/F Restriction Factors by the HIV-1 Vif Protein**
    Camille Libre; Santiago X. Guererro; Julien Batisse; Roland Marquet; Jean-Christophe Paillart
    IBMC CNRS, Strasbourg, France; Centre for Genomic Regulation, Barcelona, Spain

**194**  **Evidence for Lentivirus-Driven Evolution of APOBEC3C Factors by the HIV-1 Vif Protein**
    Sara Rodriguez-Mora; Mayte Coiras; Mercedes Bermejo; Elena Mateos; Ramon Marti; Juan Jesus Vilchez; Antonio Luis Andreu; Jose Alcami
    On behalf of the AIDS Immunopathogenesis Unit
    Instituto de Salud Carlos III, Madrid, Spain; Vall d’Hebron Institut de Recerca, Barcelona, Spain; Hospital Universitari i Politècnic La Fe, Valencia, Spain

**WEDNESDAY, FEBRUARY 25, 2015**

**Session P-A2 Poster Session**

2:30 pm – 4:00 pm

**Nucleus Entry, Integration, and Export**

196  **The Mutated Form of Transportin 3 From Patients With Limb-Girdle Muscular Dystrophy 1F Hijacks Wild-Type Transportin 3 and Interferes With CPSF6 Subcellular Localization, Impairing HIV-1 Nuclear Entry**
    Sara Rodriguez-Mora; Mayte Coiras; Mercedes Bermejo; Elena Mateos; Ramon Marti; Juan Jesus Vilchez; Antonio Luis Andreu; Jose Alcami
    On behalf of the AIDS Immunopathogenesis Unit
    Instituto de Salud Carlos III, Madrid, Spain; Vall d’Hebron Institut de Recerca, Barcelona, Spain; Hospital Universitari i Politècnic La Fe, Valencia, Spain
TUESDAY, FEBRUARY 24, 2015

Session P-A3 Poster Session
2:30 pm – 4:00 pm
SAMHD1

202 A Surprising New Function of SAMHD1 as a Pro-Pathogenic Factor in HIV Infection
Glad Doitsh; Nicole Galloway; Xin Geng; Isa Monus Arias; Zhiyuan Yang; Warner C. Greene
The J. David Gladstone Institute, University of California San Francisco, San Francisco, CA, US

203 Mapping Vpx and Vpr Specificity in Antagonism of SAMHD1
Chelsea Spragg; Michael Emerman
Fred Hutchinson Cancer Research Center, Seattle, WA, US

204 Differentiation Stimuli Strongly Impact the Ability of Macrophages to Support HIV-1 Replication Due to SAMHD1 Restriction
Ester Ballana; Roger Badia; Eva Riveira-Muñoz; Alba Ruiz; Javier Torres-Torronteras; Bonaventura Clotet; Eduardo Paus; Ramon Martí; José Esté
HIV Pathogenesis Research Group
IrsiCaixa Institute for AIDS Research, Badalona, Spain; Instituto de Recerca Hospital Universitari Vall d’Hebron, Badalona, Spain

205 Essential Role of Cyclin D3 in dNTP Pool Control and HIV-1 Replication in Macrophages
Ester Ballana; Alba Ruiz; Eduardo Paus; Javier Torres-Torronteras; Roger Badia; Eva Riveira-Muñoz; Bonaventura Clotet; Ramon Martí; José Esté
HIV Pathogenesis Research Group
IrsiCaixa Institute for AIDS Research, Badalona, Spain; Instituto de Recerca Hospital Universitari Vall d’Hebron, Badalona, Spain

206 Low SAMHD1 Expression Renders Activated and Proliferated CD4+ T Cells Susceptible to HIV-1
Nabila Seddiki; Nicolas Ruffin; Vedran Brezar; Diana Ayinde; Julian Schulze zur Wiesch; Jan van Lunzen; Olivier Schwartz; Jean-Daniel Lelièvre; Jacques Banchereau; Yves Lévy
Inserm U955 Eq16/UPMC, Créteil, France; Institut Pasteur, Paris, France; University Medical Center, Hamburg-Eppendorf and Heinrich-Pette-Institute, Hamburg, Germany

207 SAMHD1 Partially Blocks Lentiviral Gene Transfer Into Hematopoietic Stem Cells
Duo Li; Erika Schlaepfer; Annette Audige; Baek Kim; Roberto Speck
University Hospital Zurich, Zurich, Switzerland; Department of Pediatrics Emory School of Medicine, Atlanta, GA, US

THURSDAY, FEBRUARY 26, 2015

Session P-A4 Poster Session
2:30 pm – 4:00 pm
Enhancers and Inhibitors of Viral Infectivity and Entry

208 Fresh Semen Harbors HIV-Enhancing Amyloids and Decreases the Efficacy of Microbicides
Jan Munch; Onofrio Zirafi; Shariq Usmani; Kyeong-Ae Kim; Frank Kirchhoff; Christopher D. Pilcher; Haichuan Liu; H. Ewa Witkowska; Warner C. Greene; Nadia R. Roan
University of California San Francisco, San Francisco, CA, US; The J. David Gladstone Institutes, San Francisco, CA, US; Ulm University Medical Center, Ulm, Germany

209 Semen’s HIV Enhancing Activity Is an Individual Characteristic Independent of VL
Christopher D. Pilcher; Teri Liegler; Jason Neidleman; H. Ewa Witkowska; Wendy Hartogensis; Karin Marson; Peter Bacchetti; Frederick M. Hecht; Warner C. Greene; Nadia R. Roan
University of California San Francisco, San Francisco, CA, US
WEDNESDAY, FEBRUARY 25, 2015

Session P-A5 Poster Session Poster Hall
2:30 pm – 4:00 pm
Envelopes, Receptors, and Tropism

215 Evaluation of HIV-1 Clones for Unique Properties Associated With Transmission
Katja Klein; Annette Ratcliff; Gabrielle Nickel; Immaculate Nankya; Mike Lobritz; Yong Gao; Robin Shattock; Eric J. Arts
1University of Western Ontario, London, Canada; 2Case Western Reserve University, Cleveland, OH, US; 3Imperial College London, London, United Kingdom

216 Selection of HIV Env Mutants With Altered Trimeric Properties by EMPIRIC Saturation Mutagenesis
Maria Duenas-Decamp; Li Jiang; Dan Bolon; Paul R. Clapham
University of Massachusetts Medical School, Worcester, MA, US

217 Characterization of HIV-1 Envelopes in Acutely and Chronically Infected Injection Drug Users
Behzad Etemad; Oscar A. Gonzalez; Laura F. White; Oliver B. Laeyendecker; Greg D. Kirk; Shrutika Mehta; Manish Sagar
1Boston University School of Medicine, Boston, MA, US; 2Boston University, Boston, MA, US; 3Johns Hopkins University, Baltimore, MD, US

218 Phenotypic Characterization of Transmitted/Founder Virus in HIV-1 Transmission Pairs
Corinna S. Oberle; Beda Joos; Nottania K. Campbell; David Beauparlant; Herbert Kuster; Corinne Schenkel; Peter Ruset; Alexandra Trkola; Karin J. Metzner; Huldrych F. Günthard
1University Hospital Zürich, Zürich, Switzerland; 2Institute of Medical Virology, Zürich, Switzerland

219 HIV Coreceptor Tropism Switching Is Correlated With Binding Affinity to CXCR4
Homero Vazquez; Antoine Chaillon; Douglas D. Richman; Sara Gianella Weibel; Gabriel Wagner; David M. Smith
1University of California San Diego, San Diego, CA, US; 2Inserm UMR US66, Tours, France; 3Veterans Affairs Medical Center, San Diego, CA, US

220 Selective Cell-Free or Cell-to-Cell HIV-1 Infection by gp41 Cytoplasmic Tail Mutants
Natasha D. Durham; Benjamin K. Chen
1Icahn School of Medicine at Mount Sinai, New York, NY, US; 2Icahn School of Medicine at Mount Sinai, New York, NY, US

221 Analysis of Viral Evolution in the Blood Reveals Potential Insight Into the Evolution of Macrophage Tropism
Maria M. Bednar; LiHua Ping; Kathryn Arrildt; Christa Sturdevant; Sarah B. Joseph; Laura Kincher; Celia LaBranche; David Montefiori; Myron Cohen; Ronald Swanstrom
1University of North Carolina, Durham, NC, US; 2Duke University, Durham, NC, US; 3University of North Carolina, Chapel Hill, NC, US

222 Mechanistic Differences in Interactions of HIV-1 and HIV-2 With Dendritic Cells
Suzanne D. Kijewski; Hisashi Akiyama; Caitlin Miller; Nora P. Ramirez; Rahm Gummuluru
Boston University School of Medicine, Boston, MA, US

223 Identification of the First Nonhuman Primate CD4 Receptor for T/F HIV-1 Isolates
Nicholas Meyerson; Amit Sharma; Gregory Wilkerson; Julie M. Overbaugh; Sara Sawyer
1Fred Hutchinson Cancer Research Center, Seattle, WA, US; 2The University of Texas at Austin, Austin, TX, US; 3University of Texas, MD Anderson Cancer Center, Bastrop, TX, US

224LB Vpr Increases Env Spikes on Virions to Enhance HIV-1 Replication in Nondividing Myeloid Cells
Tao Zhou; Xianfeng Zhang; Yonghui Zheng
1Michigan State University, East Lansing, MI, US; 2Harbin Veterinary Research Institute, Harbin, China
225 Env and Nef Cooperatively Contribute to HIV-1—Induced pDC Activation via CD4-Dependent Mechanisms  
Natalia J. Reszka-Blanco; Vijay Sivaraman; Liguo Zhang; Lishan Su  
1University of North Carolina, Chapel Hill, NC, US; 2Key Lab of Infection and Immunity, Institute of Biophysics, Chinese Academy of Science, Beijing, China

226 Naturally Occurring Polymorphisms in HIV-1 Nef Impair Its Functions and Decrease Viral Replication Capacity  
Thomas Vollbrecht; Lorelei Bornfleth; Patricia Frohnen; Martha J. Lewis  
1David Geffen School of Medicine at University of California Los Angeles, Los Angeles, CA, US; 2University of California San Diego (UCSD), La Jolla, CA, US

227 Dynamic Range of Down-Regulation of HIV-1 Entry Receptors by Primary Nef Isolates  
Mako Toyoda; Yoko Ogata; Macdonald Mahiti; Florencia Pereyra; Toshiyuki Miura; Bruce Walker; zabrina L. Brumme; Mark A. Brockman; Takamasa Ueno  
1Kumamoto University, Kumamoto, Japan; 2University of Tokyo, Tokyo, Japan; 3Ragon Institute of MGH, MIT and Harvard University, Cambridge, MA, US; 4Simon Fraser University, Burnaby, Canada

228 Differential Down-Regulation of HLA Class I Allotypes by HIV-1 Nef Primary Isolates  
Macdonald Mahiti; Xiaofei Jia; Mako Toyoda; Francis Mwimanz; Bruce Walker; zabrina L. Brumme; Mark Brockman; Yong Xiong; Takamasa Ueno  
1Kumamoto University, Kumamoto, Japan; 2Yale University, New Haven, CT, US; 3Ragon Institute of MGH, MIT and Harvard University, Boston, MA, US; 4Simon Fraser University, Burnaby, Canada

230 The 2 Phases of HIV-1 Group O Diversification  
Marie Leoz; Felix Feyertag; Anfumbom Kfutwah; Philippe Maucleure; Guillaume Lachenal; Florence Damond; Veronique Lemee; Francois Simon; David Roberton; Jean-Christophe Plantier  
1University Hospital Rouen, Rouen, France; 2Manchester University, Manchester, United Kingdom; 3Centre Pasteur du Cameroun, Yaounde, Cameroon; 4Direction Interarmees du Service de Santé, Noumea, New Caledonia; 5Universite Paris Diderot, Paris, France; 6APHP CHU Bichat Claude Bernard, Paris, France; 7APHP CHU Saint Louis, Paris, France

231 Evidence for More Major HIV-1M Lineages From the Early Stages of the HIV-1 Epidemic  
Marcel Tongo  
232 HIV-1/M+O Dual Infections and HIV-MO Recombinants in France From 2004 to 2014  
Pierre Cappy; Fabienne De Oliveira; Veronique Lemee; Jean-Louis Gaillard; Laurence Bouquet; Jean-Dominique Poveda; Magali Bouvier; Anne Maillaud; Thomas Mourez; Jean-Christophe Plantier  
1Rouen University Hospital, Rouen, France; 2Ambroise Pare Hospital, Paris, France; 3Lille University Hospital, Lille, France; 4CERBA Laboratory, Saint-Ouen L’Hamonne, France; 5Henri Mondor Hospital, Creteil, France; 6Pontchaillou Hospital, Rennes, France

233 Evidence of Intra-Familial Transmission of an HIV-1 M/O Intergroup Recombinant Virus  
Paul Alain T. Ngooppo; Serge Alain Sadeuh-Mba; Fabienne De Oliveira; Valerie Ngoon; Laure Ngoon; Patrice Thendjou; Veronique Penlap Mbeng; Richard Njouom; Anfumbom Kfutwah; Jean-Christophe Plantier  
1Centre Pasteur of Cameroon, Yaounde, Cameroon; 2Virology, CHU Rouen, Rouen, France; 3University of Yaounde I, Yaounde, Cameroon; 4Epidemiology, Centre Pasteur of Cameroon, Yaounde, Cameroon

Ansa. Vallari; Carole McArthur; Larry Stshleshley; Catherine Brennen  
1Abbott Laboratories, Chicago, IL, US; 2University of Missouri–Kansas City, Kansas City, MO, US; 3IMA World Health, Kinshasa, Congo (the Democratic Republic of the)

235 Clinical and Virological Characterization of CRF07_BC infection  
Szu-Wei Huang; Sheng-Fan Wang; Chih-Hao Lee; Wing-Wai Wong; Hung-Chin Tsai; Chia-Jui Yang; Chien-Tien Wang; Jaang-Jian Wang; Daniel Kuritzkes; Yi-Ming A. Chen  
1Koahsiung Medical University, Kaohsiung City, Taiwan; 2Taipei Veterans’ General Hospital, Taipei, Taiwan; 3Koahsiung Veterans’ General Hospital, Koahsiung City, Taiwan; 4Far Eastern Memorial Hospital, New Taipei City, Taiwan; 5National Yang-Ming University, Taipei, Taiwan; 6Children’s Healthcare of Atlanta and Emory University School of Medicine, Atlanta, GA, US; 7Brigham and Women’s Hospital and Harvard Medical School, Boston, MA, US
236 Reconstructing the HIV-1 Epidemics in Burkina Faso Using Early Samples
Gonzalo Yebra¹; Marcia L. Kalish²; Andrew J. Leigh Brown¹
¹University of Edinburgh, Edinburgh, United Kingdom;²Vanderbilt University, Nashville, TN, US

237 Neutralizing Antibodies in Humans Infected With Zoonotic Simian Foamy Viruses
Caroline Lambert¹; Julie Gouzi²; Réjane Rua¹; Edouard Betsem²; Antoine Gessain¹
¹Institut Pasteur, Paris, France;²École Vétérinaire, Maison-Alfort, France;²University of Yaoundé, Yaoundé, Cameroon

TUESDAY, FEBRUARY 24, 2015

Session P-B2 Poster Session
Poster Hall
2:30 pm – 4:00 pm

Defining Epidemiologically Linked Transmission

238 Large Phylogenetically Linked HIV Cluster in King County, Washington, 2008 to 2014
Susan E. Buskin¹; Joshua T. Herbeck¹; Katelynne M. Gardner Toren¹; Michelle R. Perry¹; Amy Bennett¹; Matthew R. Golden¹
¹Public Health—Seattle & King County, Seattle, WA, US;²University of Washington, Seattle, WA, US

239 Reconciling Named Partner and Genetic Partner HIV-1 Transmission Networks in New York City
Joel O. Wertheim¹; Sergei L. Kosakovsky Pond²; Konrad Scheffler²; Davey M. Smith²; Sanjay Mehta¹; Sharmila Shah¹; Lisa Forgione¹; Lucia V. Torian¹
¹The Swiss HIV Cohort Study, Zurich, Switzerland;²Sanford-Burnham Preclinical Research Institute, La Jolla, CA, US

240 Efforts to Characterize Community HIV Transmission Dynamics May Be Critically Dependent on Provision of Both Partner Services and Genetic Sequence Analysis
Nella L. Green¹; Christy Anderson¹; Sergei L. Kosakovsky Pond¹; Martin Hoenigl¹; David M. Smith¹; Sanjay Mehta¹; Susan Little¹
¹University of California San Diego, San Diego, CA, US

WEDNESDAY, FEBRUARY 25, 2015

Session P-B3 Poster Session
Poster Hall
2:30 pm – 4:00 pm

Transmission Clusters

241 Growth and Geographic Spread of HIV Transmission Clusters, United States, 2007–2012
Alexandra M. Oster¹; Joel Wertheim¹; Ellsworth Campbell¹; Angela L. Hernandez¹; Neeraja Sudavala¹; William M. Switzer¹; M. Cheryl Ocfemia¹; Anupama Shankar¹; H. Irene Hall¹
¹US Centers for Disease Control and Prevention (CDC), Decatur, GA, US;²ICF International, Atlanta, GA, US

242 HIV Transmission Networks Among the USA, Mexico, and Central America
Santiago Avila-Rios¹; Joel O. Wertheim¹; Ann M. Dennis¹; Gustavo Reyes-Terán¹; Carlos Mejia-Villalobos¹; Elsa Y. Palou¹; Guillermo Porras-Cortes²; Juan M. Pascale³; Huldrych F. Günthard⁴; Elsa Y. Palou¹; Sanjay Mehta¹
¹National Institute of Respiratory Diseases, Mexico City, Mexico;²University of California San Diego (UCSD), San Diego, CA, US;³Roosevelt Hospital, Guatemala City, Guatemala;⁴Hospital Escuela Universidad, Tegucigalpa, Honduras;⁵Gorgas Memorial Institute for Health Studies, Panama, Panama;⁶Vivian Pellas Metropolitan Hospital, Managua, Nicaragua;⁷Ministry of Health, Belmopan, Belize;⁸University of North Carolina, Chapel Hill, NC, US

243 Sexual Networks Across Risk Groups Persistently Contribute to Local Spread of HIV
Marije Hofstra¹; Tania Mudrikova¹; Marieke Pingen¹; Kristine Koekkoek¹; Anvar Jan Vaarbohoven¹; Rob Schuurman¹; Andy I. Hoepelman¹; Annemie M. Wensing¹
¹University Medical Center Utrecht, Utrecht, Netherlands;²University Medical Center Utrecht, Utrecht, Netherlands

244 Estimation of HIV-1 Transmission During Recent Infection in Switzerland
Alex Marzel¹; Mohamed Shilaih¹; Wan-Lin Yang¹; Jürg Böni¹; Sabine Yerly¹; Thomas Klimkait¹; Vincent Aubert¹; Huldrych F. Günthard¹; Roger Koury¹
On behalf of the Swiss HIV Cohort Study (SHCS)
¹Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, Zurich, Switzerland;²Swiss National Center for Retroviruses, Zurich, Switzerland;³Laboratory of Virology, Geneva, Switzerland;⁴Department of Biomedicine—Petersplatz, Basel, Switzerland;⁵Division of Immunology and Allergy, Lausanne, Switzerland;⁶The Swiss HIV Cohort Study, Zurich, Switzerland

245 Clustering of Swiss HIV Patients Not Enrolled in the Swiss HIV Cohort Study (SHCS)
Mohamed Shilaih¹; Alex Marzel¹; Jürg Schüpbach¹; Jürg Böni¹; Sabine Yerly¹; Thomas Klimkait¹; Vincent Aubert¹; Huldrych F. Günthard¹; Roger Koury¹
On behalf of the Swiss HIV Cohort Study (SHCS)
¹University Hospital Zurich, Zurich, Switzerland;²Geneva University Hospital, Geneva, Switzerland;³University Hospital Lausanne, Lausanne, Switzerland;⁴University of Basel, Basel, Switzerland;⁵University of Zurich, Zurich, Switzerland

246 HIV Transmission Network Structure Reveals Characteristics of Bridging Individuals
Sanjay Mehta; Joel O. Wertheim; Konrad Scheffler; Susan Little; Richard R. Garfein; Sergei L. Kosakovsky Pond; David M. Smith University of California San Diego, La Jolla, CA, US

247 Phylodynamic Analysis of HIV Sub-Epidemics in Mochudi, Botswana
Vladimir Novitsky¹; Denise Kuhenh²; Sikhulile Moyo³; Erik van Widenfeld³; Lillian Okui³; Max Essex³
¹Harvard School of Public Health, Boston, MA, US;²ETH Zürich, Zürich, Switzerland;³Botswana-Harvard AIDS Institute Partnership, Gaborone, Botswana
248 Exploring Transmission Dynamics of HIV in Rural KwaZulu-Natal, Using Phylogenetics
Eduan Wilkinson1; Siva Danaviah1; Justen Manasa1; Frank Tanser2; Kobus Herbst1; Deenan Pillay1; Tulio de Oliveira1
On behalf of the PANGEA_HIV Consortium
1University of KwaZulu-Natal, Durban, South Africa; 2University College London, London, United Kingdom

249 Detecting Changes in Incidence Using Phylogenetic Tools: Simulation-Based Studies Within the PANGEA_HIV Initiative
Emma B. Hodcroft1; Oliver Ratmann2; Anne Cori3; Mike Pickles2; Samantha Lycett3; Manon L. Ragonnet-Cronin4; Matthew Hall1; Andrew J. Leigh Brown1; Christophe Fraser2
On behalf of the Pangea HIV Consortium
1University of Edinburgh, Edinburgh, United Kingdom; 2Imperial College London, London, United Kingdom; 3University of Glasgow, Glasgow, United Kingdom

TUESDAY, FEBRUARY 24, 2015

Session P-B4 Poster Session Poster Hall
2:30 pm – 4:00 pm
Transmission Networks: MSM

250 HIV Transmission Among Seattle Adolescents
Joshua Herbeck1; Elizabeth Wolf2; Stephen van Rompaey3; Mari M. Kitahata4; Lisa Frenkel1
1University of Washington, Seattle, WA, US; 2Center for AIDS Research, Seattle, WA, US

251 Characterization of Large Cluster Viral Networks Sustaining the Montreal MSM Epidemic
Bluma Brenner1; Ruxandra-Ilinca Ibanescu2; Daniela Moisi1; Isabelle Hardy1; Jean-Pierre Routy1; Joanne Otis1; Mark Wainberg2; Michel Roger1
1McGill University, Montreal, Canada; 2Lady Davis Institute, Montreal, Canada; 3Université de Montréal, Montreal, Canada; 4UQAM, Montreal, Canada

252 Sources of HIV-1 Transmission in the Ongoing, Concentrated HIV Epidemic Among Men Having Sex With Men in the Netherlands Between July 1996 and December 2010
Oliver Ratmann1; Ard van Sighem2; Daniela Bezemer3; Alexandra Gavryushkina4; Peter Reiss5; Frank de Wolf6; Christophe Fraser1
1Imperial College London, London, United Kingdom; 2Stichting HIV Monitoring Foundation, Amsterdam, Netherlands; 3University of Auckland, Auckland, New Zealand

253 A Direct Comparison of Two Densely Sampled Western European HIV Epidemics: The UK and Switzerland
Manon L. Ragonnet-Cronin1; Mohamed Shilaiah2; Huldrych F. Günthardt2; Jung Boni3; Sabine Yerly4; Valerie Delpech5; David Dunn6; Roger Koup7; Andrew J. Leigh Brown1
Swiss HIV Cohort Study/UK HIV Drug Resistance Database
1University of Edinburgh, Edinburgh, United Kingdom; 2University Hospital Zurich, Zurich, Switzerland; 3University Hospital Geneva, Geneva, Switzerland; 4Public Health England, London, United Kingdom; 5IMRC CTU at UCL, London, United Kingdom

THURSDAY, FEBRUARY 26, 2015

Session P-B5 Poster Session Poster Hall
2:30 pm – 4:00 pm
Next Generation of Next-Generation Sequencing

254 Present Applications of a High-Throughput, Single Measure HIV Genomic Incidence Assay
Sung Yong Park1; Tanzy Love1; Nolan Goeken2; Robert Bolan3; Alan S Perelson4; Michael Dube1; Ha Youn Lee1
1Keck School of Medicine at University of Southern California, Los Angeles, CA, US; 2University of Rochester School of Medicine and Dentistry, Rochester, CA, US; 3Los Angeles Gay and Lesbian Center, Los Angeles, CA, US; 4Los Alamos National Laboratory, Los Alamos, CA, US

255 A Comprehensive Analysis of Primer IDs to Study Heterogenous HIV-1 Populations
David Seifert1; Armin Tüper1; Francesca Di Giallonardo3; Stefan Schmutz1; Huldrych F. Günthard1; Volker Roth3; Niko Beerenswinkel1; Karin J. Metzner1
1ETH Zurich, Basel, Switzerland; 2University Hospital Zurich, Zurich, Switzerland; 3University of Basel, Basel, Switzerland

256 Near Full Length HIV-1 Sequencing to Understand HIV Phylogenetics in Africa in Real Time
Siva Danaviah1; Justen Manasa1; Eduan Wilkinson1; Sureshnee Pillay2; Zandile Sibisi2; Shembiso Msweli2; Deenan Pillay1; Tulio de Oliveira1
1University of KwaZulu-Natal, Durban, South Africa

257 Pan-HIV Next-Gen Sequencing Strategy for Viral Surveillance
Michael G. Berg1; Julie Yamaguchi1; Elodie Alessandri-Gradt1; Jean-Christophe Plantier1; Catherine Brennan1
1Abbott Laboratories, Abbott Park, IL, US; 2Virology Unit, National Reference for HIV, Rouen, France

258 PCR-Free Full Genome Characterization of Diverse HIV-1 Strains by Nextgen Sequencing
Viswanath Ragupathy1; Feng Gao2; Ana Sanchez3; Marco Schito4; Thomas Denny3; Michael Busch4; Jiangjin Zhao3; Christelle Mbonjzi1; SaiVikram Vemula1; Indira Hewlett1
1US Food and Drug Administration, Silver Spring, MD, US; 2HIV Vaccine Institute and Departments of Medicine, Duke University Medical Center, Durham, NC, US; 3Henry Jackson Foundation, DAIDS, NIAID, Bethesda, MD, US; 4Blood Systems Research Institute/University of California San Francisco, San Francisco, CA, US

259 Full-Length Env Deep Sequencing in a Donor With Broadly Neutralizing V1/V2 Antibodies
Ben Murrell1; Melissa Laird1; Elise Landais2; Caroline Ignacio3; Ellen Paxinos2; Pham Phung2; Sergei L. Kosakovsky Pond4; Douglas D. Richman1; Pascal Poignard2; Dawey M. Smith1
1University of California San Diego, La Jolla, CA, US; 2Pacific Biosciences, Menlo Park, CA, US; 3The International AIDS Vaccine Initiative, New York, NY, US; 4LabCorp, South San Francisco, CA, US

Program and Agenda
Poster Listings

CROI 2015
**Session P-C1 Poster Session**

**Poster Hall**

**2:30 pm – 4:00 pm**

**The Gut Microbiome**

### 260 Functional Profiling of the Gut Microbiome in HIV Infection

Yolanda Guíllen; Marc Noguera-Julian; Muntsa Rocafort; Mariona Parera; Maria Casadellà; Isabel Bravo; Josep Coll; Julià Blanco; Bonaventura Clotet; Roger Paredes

MetalinHIV Study Group

IrsiCaixa AIDS Res Inst, Hosp Univ Germans Trias i Pujol, Univ Autònoma de Barcelona, Badalona, Spain

### 261 Gut Microbiota Correlates with HIV-1 Control and Immune Status

Muntsa Rocafort; Marc Noguera-Julian; Yolanda Guillén; Mariona Parera; Maria Casadellà; Isabel Bravo; Josep Coll; Julià Blanco; Bonaventura Clotet; Roger Paredes

MetalinHIV-Pheno Study Group

IrsiCaixa AIDS Res Inst, Hosp Univ Germans Trias i Pujol, Univ Autònoma de Barcelona, Badalona, Spain

### 262 Butyrate Reduces Pathobiont-Associated HIV-1 Infection and Activation of Gut T Cell

Jon Kibbie; Stephanie Dillon; Eric Lee; Charles Robertson; Daniel N. Frank; Martin McCarter; Cara C. Wilson

University of Colorado Anschutz Medical Campus, Aurora, CO, US

### 263 Maraviroc Does Not Induce Changes in the Gut Microbiome of HIV-Infected Individuals

Andrey Vitomirov; David M. Smith; Susanna R. Var; Maile Karris; Parris Jordan; Douglas D. Richman; Susan Little; Josué Pérez-Santiago

University of California San Diego, La Jolla, CA, US

### 264 Fecal Microbiota of HIV Controllers Is Similar to That of Non–HIV-Infected Individuals

Selma N. Alva Hernández; Sandra M. Pinto Cardoso; Norma Téllez; Akio Murakami-Ogasawara; Gustavo Reyes-Terán

National Institute of Respiratory Diseases, Research Center in Infectious Diseases, Mexico City, Mexico

### 265 Impact of 2 Antiretroviral Regimens on Fecal Microbiota Diversity and Composition

Sandra M. Pinto Cardoso; Selma N. Alva Hernández; Norma Téllez; Akio Murakami-Ogasawara; Gustavo Reyes-Terán

National Institute of Respiratory Diseases, Mexico City, Mexico

### 266 Targeting Gut Dysbiosis With Prebiotics and Glutamine in HIV-Infected Subjects

Sergio Serrano-Villar1; Jorge Vázquez-Castellanos2; Alejandro Vallejo1; Sara Ferrando-Martínez1; Talía Sainz1; Mar Vera1; Santiago Moreno1; Andrés Moya1; María José Gosalbes2; Vicente Estrada1

1University Hospital Ramón y Cajal, Madrid, Spain; 2FISABIO-Salud Pública, Valencia, Spain; 3University Hospital La Paz, Madrid, Spain; 4University Hospital Virgen del Rocío, Seville, Spain; 5Centro Sandoval, Madrid, Spain; 6University Hospital Clínico San Carlos, Madrid, Spain

---

**Session P-C2 Poster Session**

**Poster Hall**

**2:30 pm – 4:00 pm**

**The Mucosa in HIV/SIV Pathogenesis**

### 267 Impact of Mucosal Immunity and HIV Persistence on CD4/CD8 Ratio After ART Initiation

Sergio Serrano-Villar1; Talía Sainz2; Tae Wook-Chun3; Netanya S. Utay4; Zhong-Min Ma5; Basile Siewe5; Steven Deeks1; Richard Pollard6; Christopher Miller4; David Asmuth4

1University Hospital Ramón y Cajal, Madrid, Spain; 2University Hospital La Paz, Madrid, Spain; 3National Institute of Allergy and Infectious Diseases (NIAID), Bethesda, MD, US; 4University of California Davis, Davis, CA, US; 5University of Texas, Galveston, TX, US; 6Rush University Medical Center, Chicago, IL, US; 7University of California San Francisco, San Francisco, CA, US

### 268 Monocyte/Macrophage Activation and Recruitment to Mucosal Sites in SIV Pathogenesis

Jan Kristoff1; Jenny Stock2; Tianyu He3; Bruno Andrade4; Benjamin Policicchio5; Alan Landay6; Ivo Francischetti5; Cristian Apetrei7; Irini Sereti7; Ivona Pandrea1

1University of Pittsburgh, Pittsburgh, PA, US; 2National Institute of Allergy and Infectious Diseases (NIAID), Bethesda, MD, US; 3Rush University, Chicago, IL, US

### 269 Rectal Tenofovir Gel Usage Is Associated With Changes in the Mucosal Proteome

Adam Burgener1; Laura Romas1; Kenzie Birse1; Kenneth H. Mayer2; Irma Febo3; Ross Cranston4; Alex Carbarballo-Díezquez4; Ian McGowan2

1University of Minnesota, Winnepeg, Canada; 2University of Pittsburgh, Pittsburgh, PA, US; 3Harvard Medical School, Boston, MA, US; 4Columbia University, New York, NY, US; 5University of Puerto Rico, San Juan, US

### 270 Links Between Systemic and Mucosal Immunity in Treated HIV Infection

Talía Sainz1; Sergio Serrano-Villar1; Gregory Melcher2; Zhong-Min Ma3; Christopher Miller4; Netanya S. Utay4; Basile Siewe5; Paolo Troia-Cancio1; Elizabeth Sinclair2; David Asmuth1

1Hospital Universitario Gregorio Marañón, Madrid, Spain; 2Hospital Ramón y Cajal, Madrid, Spain; 3University of California Davis, Davis, CA, US; 4University of Texas Medical Branch, Galveston, TX, US; 5Rush University Medical Center, Chicago, IL, US; 6University of California San Francisco (UCSF), San Francisco, CA, US

### 271 No Impact of Early Intensified Antiretroviral Therapy on Gut Immune Reconstitution

Connie J. Kim1; Rodney Rousseau2; Colin Kovacs3; Sanja Huibner4; Gabor Kandel5; Erika Benko6; Kamnosh Shahabi5; Tae Wook Chun5; Mario Ostrowski5; Rupert Kaul6

1Toronto General Hospital, Toronto, Canada; 2University of Toronto, Toronto, Canada; 3Maple Leaf Medical Clinic, Toronto, Canada; 4St. Michael’s Hospital, Toronto, Canada; 5National Institute of Allergy and Infectious Diseases (NIAID), Bethesda, MD, US
In KIR3DL1/S1 Heterozygotes Are KIR3DL1 and KIR3DS1 Co-Dominantly Expressed?
Zahra Kiani1; Yuwadee Phuang-Ngern2; Eugene Kroon1; Rungsun Rerknimit3; Nittyia Chomrue1; Nittyaya Phanaphak1; Merlin L. Robb4; Jerome H. Kim5; Mark de Souza5; Jintanat Ananworanich6
1Army Forces Research Institute of Medical Sciences, Bangkok, Thailand; 2Thai Red Cross AIDS Research Center, Bangkok, Thailand; 3Chulalongkorn University, Bangkok, Thailand; 4US Military HIV Research Program, Silver Spring, MD, US

WEDNESDAY, FEBRUARY 25, 2015

Session P-C3 Poster Session
2:30 pm – 4:00 pm
Innate and Unconventional T-Cell Responses

Effect of KIR2D-Mediated Immunity on Clinical Outcome Among CRF01_AE-Infected Thais
Masahiko Mori1; Nuanjun Wichukchinda1; Reiko Miyahara1; Archawin Rojanawiwat2; Panita Pathipvanich3; Toshiyuki Miura1; Michio Yasunami1; Koya Aiyoshi1; Pathom Sawanpanyalert1
1Institute of Tropical Medicine, Nagasaki University, Nagasaki City, Japan; 2Ministry of Public Health, Nonthaburi, Thailand; 3Day Care Centre, Lampang Hospital, Lampang, Thailand

HLA-KIR-Associated Sites in Gag and Their Effects on Clinical Outcome in Thailand
Masahiko Mori1; Nuanjun Wichukchinda1; Reiko Miyahara1; Archawin Rojanawiwat2; Panita Pathipvanich3; Toshiyuki Miura1; Michio Yasunami1; Koya Aiyoshi1; Pathom Sawanpanyalert1
1Institute of Tropical Medicine, Nagasaki University, Nagasaki City, Japan; 2Ministry of Public Health, Nonthaburi, Thailand; 3Day Care Centre, Lampang Hospital, Lampang, Thailand

In KIR3DL1/S1 Heterozygotes Are KIR3DL1 and KIR3DS1 Co-Dominantly Expressed?
Zahra Kiani1; Nicole F. Bernard2; Julie Bruneau2
1McGill University, Montreal, Canada; 2Centre de Recherche du Centre Hospitalier de l’Universite de Montreal, Montreal, Canada

Disruption of Innate-Like Unconventional T-Cell Subsets in HIV-Infected Children
Alka Khaitan1; Adam Kravietz2; Ilmet Tiina3; Mussa Mwamzuka1; Fatma Marshed4; Cihan Tastan5; Aabid Ahmed6; Bill Borkowsky7; Derya Unutmaz8
1New York University School of Medicine, New York, NY, US; 2Bomu Hospital, Mombasa, Kenya; 3New York University School of Medicine, New York, NY, US

HIV-1 Alters Innate Immune Response to BCG, Which Differs From SIV Infected Mangabeys
Melanie Gasper; David Sherman; Donald Sodora
Seattle Biomed, Seattle, WA, US

High-Level Replication Allows SHIVs to Overcome the Macaque Interferon Response
David F. Boyd; Amit Sharma; Julie M. Overbaugh
Fred Hutchinson Cancer Research Center, University of Washington, Seattle, WA, US

Elevated IFN-γ in HIV Patients Using a Novel Assay for Adaptive and Innate Immunity
Michelle K. Yong1; Paul Cameron1; Tim Spelman2; Julian Elliott3; Christopher Fairley4; Jeffrey Boyle5; Misato Miyamasa6; Sharon R. Lewin1
1Monash University/Alfred Hospital, Melbourne, Australia; 2Burnet Institute, Melbourne, Australia; 3Qaigen, Melbourne, Australia; 4Melbourne Sexual Health Centre, Melbourne, Australia

TLR8 Regulation of LILRA3 Is Abrogated in HIV Infection and Correlates to CD4 Counts and Virus Loads
Hui Zhi Low1; Gerrit Ahrenstorff; Torsten Witte
Hannover Medical School, Hannover, Germany
286 Dysfunctional Neutrophil Responses to SIV Infection
Tiffany Hensley-McBain1; Laura E. Richert-Spuhler1; Jillian Gile1; Melon T. Nega1; Thomas H. Vanderford1; Jacob D. Estes1; Brandon F. Keele1; Nichole R. Klatt1
1University of Washington, Seattle, WA, US; 2Emory University, Atlanta, GA, US; 3Frederick National Laboratory for Cancer Research, Frederick, MD, US

287 Studies of HIV-Exposed Uninfected Individuals
HIV-Exposed Seronegative MSM Have Increased Novel Antiviral Factors in Rectal Mucosa
Laura Romas1; Klara Hasselrot1; Kristina Broliden1; Carolina Herrera1; Garrett Westmacott1; Francis Plummer1; Terry B. Ball1; Adam Burgener1
1University of Manitoba, Winnipeg, Canada; 2Karolinska Institutet, Stockholm, Sweden; 3Imperial College London, London, United Kingdom; 4Public Health Agency of Canada, Winnipeg, Canada

288 PBMC From Highly Exposed Seronegative Individuals Inhibit Transmitted Founder HIV
Kevin C. Olivier1; Eunyoung Kim1; Susan Little1; Michael Turchin1; Vanessa Serrano1; Amna Rasheed1; Quy Nguyen1; Paul Dejesus1; Steven Wolinsky1; Sumit Chanda1
1Sanford-Burnham Medical Research Institute, San Diego, CA, US; 2University of California Los Angeles (UCLA), Los Angeles, CA, US; 3Northwestern University, Feinberg School of Medicine, Chicago, IL, US; 4University of Chicago, Chicago, IL, US; 5University of California San Diego (UCSD), San Diego, CA, US

289 HIV-1-Exposed Seronegative Persons Have Lower Mucosal Innate Reactivity
Jennifer A. Fulcher1; Jennifer C. Hoffman1; Laura M. Romas1; Karen Tanner1; Terry Saunders1; Julie Elliott1; Adam D. Burgener1; Peter A. Anton1; Otto O. Yang1
1David Geffen School of Medicine at University of California Los Angeles, Los Angeles, CA, US; 2University of Manitoba, Winnipeg, Canada

290 Increased Levels of Regulatory T-cells Correlate With Protection From HIV Infection
Lauria Pattacini1; Jared Baeten1; Katherine Thomas1; Tayler Fluharty1; Pamela Murmane1; Deborah Donnell1; Nelly Mugo1; Jairam R. Lingappa1; Connie Celumi1; Jennifer Lund1
1Fred Hutchinson Cancer Research Center, University of Washington, Seattle, WA, US; 2University of Washington, Seattle, WA, US

Session P-C6 Poster Session
2:30 pm – 4:00 pm
Poster Hall
Host Factors in HIV Pathogenesis

291 Estimating the Respective Contributions of Human and Viral Genetic Variation to HIV Control
István Bartha1; Paul J. McLaren1; Chanson J. Brumme1; Richard Harrigan2; Amalio Telenti1; Jacques Fellay1
1École Polytechnique Fédérale de Lausanne, Lausanne, Switzerland; 2BC Centre for Excellence in HIV/AIDS, Vancouver, Canada; 3J. Craig Venter Institute, La Jolla, CA, US

292 Refinement of Association Signals Assessment of Residual Heritability in Host Control of HIV Viral Load
Paul J. McLaren1; Istvan Bartha1; Jacques Fellay1
École Polytechnique Fédérale de Lausanne, Lausanne, Switzerland

293 Genetic and Clinical Predictors of CD4 Recovery During Suppressive cART: WHIS
Ruth M. Greenblatt1; Kord Kobet1; Peter Bacchetti1; Ross Boylan1; Kathryn Anastos1; Margde Cohen1; Mary A. Young1; Deborah Gustafson1; Bradley Aouizerat1
On behalf of the WHIS
1University of California San Francisco, San Francisco, CA, US; 2Montefiore Medical Center, University Hospital for Albert Einstein College of Medicine, New York, NY, US; 3Georgetown University, Washington, DC, US; 4State University of New York, Downstate, Brooklyn, NY, US; 5CORE Center, Chicago, IL, US; 6National Institutes of Health (NIH), Bethesda, MD, US

294 Host Genetic Predictors of Plasma Kynurenine/Tryptophan Among Treated HIV+ Ugandans
Sulggii A. Lee1; Joel Mefford1; Yong Huang1; John S. Witte1; Jeffrey Martin1; David R. Bangsberg1; Taisei Mushiroda1; Michiaki Kubo1; Deanna Kroetz1; Peter W. Hunt1
1University of California San Francisco, San Francisco, CA, US; 2Massachusetts General Hospital and Harvard University, Boston, MA, US; 3RIKEN Center for Genomic Medicine, Wako, Japan

295 Regulation of IL-32 Expression by a Promoter Polymorphism and MicroRNA29b in HIV-1 Patients
Carolina Scagnolari1; Giulia Cacciotti1; Carla Selvaggi1; Noemi Giustini1; Ivano Mezzaroma1; Massimo Gentile1; Gabriella D’Ettorre1; Ombretta Turrziani1; Vincenzo Vollo1; Guido Antonelli1
Sapienza University of Rome, Rome, Italy

297 LILRA3 Deletion Is a Genetic Risk Factor of HIV Infection
Gerrit Ahrenstor1; Hui Zhi Low1; Katja kniesch1; Matthias Stoll1; Dirk Meyer-Olson1; Torsten Matthias2; Reinhold E. Schmidt1; Torsten Witte1
1Hannover Medical School, Hannover, Germany; 2AESKU Diagnostics, Wendelsheim, Germany
298LB SIV Infection Triggers Endothelial Dysfunction and Diminished Expression of Kruppel-Like Factor 2 (KLF2) in Nonhuman Primates
Soumya Panigrahi1; Michael L. Freeman1; Joseph C. mudd4; Nicholas Funderburg2; Scott Seig1; David A. Zidar1; Mirko Paiardini2; Francois Villinger1; Mukek K. Jain1; michael lederman1
1Case Western Reserve University/University Hospitals Medical Center, Cleveland, OH, US; 2Ohio State University School of Health and Rehabilitation Sciences, Columbus, OH, US; 3Emory University, Atlanta, GA, US; 4Lab of Molecular Microbiology, Bethesda, MD, US

299LB A Novel Method Using H2O to Measure Collagen Turnover in HIV-Infected Individuals
Leslie R. Cockerham1; Claire Emson1; Ma Sommouk2; Kera Harvill1; Kevin Li1; Scott M. Turner1; Martin L. Decaris2; Marc K. Hellerstein1; Steven G. Deeks1; Hiroyu Hatano1

THURSDAY, FEBRUARY 26, 2015
Session P-C7 Poster Session Poster Hall
2:30 pm – 4:00 pm
HIV/CMV Interactions in Transmission and Pathogenesis

300 Effect of CMV and HIV Replication on T-Cell Exhaustion and Senescence During ART
Jennifer M. Dan1; Marta Massanella1; David M. Smith1; Eric S. Daar1; Michael P. Dube1; Richard Hauberich2; Sheldon Morris3; Sara Gianella Weibel4
1University of California San Diego, La Jolla, CA, US; 2Harbor–University of California Los Angeles Medical Center, Torrance, CA, US; 3University of Southern California Keck School of Medicine, Los Angeles, CA, US; 4University of California San Diego, La Jolla, CA, US

301 HIV Myeloid Derived Suppressor Cells Control Cytomegalovirus Inflammation by IL-27
Ankita Garg1; Stephen Spector1
1University of California San Diego, La Jolla, CA, US

302 Persistent Elevation of Inflammation Markers in HIV+ Persons with CMV Disease
Melissa Schechter1; Bruno Andrade2; Eleanor M. Wilson1; Virginia Sheikh1; Sonya Krishnan1; Margaret Caplan1; Gregg Roby1; Adam Rupert1; Peter Burbelo1; Irini Sereti1
1NIH, Leidos Biomedical Inc., Frederick, MD, US; 2National Institute of Allergy and Infectious Diseases, Bethesda, MD, US; 3NIH, Leidos Biomedical Inc., Frederick, MD, US; 4National Institute of Dental and Craniofacial Research, Bethesda, MD, US

303 sCD163 Increase in HIV/CMV-Coinfected Subjects Included in ICONA Cohort
Serena Vita1; Miriam Lichtner1; Giulia Marchetti1; Claudia Mascia1; Esther Merlino1; Paola Cicconi1; Vincenzo Vullo1; Pier Luigi Viale1; Alberto Costantini1; Antonella d’Arminio Monforte1

For the ICONA Foundation Study
1University of Rome La Sapienza, Polo Pontina, Latina, Italy; 2University of Rome La Sapienza, Rome, Italy; 3University of Ancona, Ancona, Italy; 4University of Bologna, Bologna, Italy

304 Genital CMV Shedding Predicts Syphilis Acquisition in HIV-Infected MSM on ART
Sara Gianella Weibel1; David M. Smith1; Eric Daar2; Michael Dube1; Andrea Lisco3; Christophe Vanpouille4; Richard Hauberich1; Sheldon Morris1
1University of California San Diego, La Jolla, CA, US; 2Los Angeles Biomedical Research Institute at Harbor–UCLA Medical Center, Torrance, CA, US; 3University of Southern California Keck School of Medicine, Los Angeles, CA, US; 4National Institute of Allergy and Infectious Diseases, Bethesda, MD, US; 5National Institute of Child Health and Human Development, Bethesda, MD, US

Session P-C8 Poster Session Poster Hall
2:30 pm – 4:00 pm
Aging and Immune Senescence

305 Early Start of ART Affects Late Markers of Immune Senescence
Sharon L. Karmon1; Teresa H. evening; Melissa La Mar; Martin Markowitz1
1Aaron Diamond AIDS Research Center, an Affiliate of the Rockefeller University, New York, NY, US

306 Chronic HIV Infection Exacerbates Cellular Aging Markers in Isolated T-Cell Subsets
Anthony Hsieh1; Beherose Sattha2; Hélène Côté3
1CIHR Team in Cellular Aging and HIV Comorbidities in Women and Children (CARMA cohort)
2University of British Columbia, Vancouver, Canada

307 Age Associated Increases in Markers of Microbial Translocation and Inflammation in HIV-1 Infection
Eileen Scully1; Ainsley Lockhart1; Lisa Huang1; Marisol Romero-Tejeda1; Mary Albrecht1; Christine D. Palmer1; Ronald Bosch1; Marcus Altfield1; Daniel Kurtzkes1; Nina Lin1
1Ragon Institute of MGH, MIT and Harvard, Jamaica Plain, MA, US; 2Brigham and Women’s Hospital, Boston, MA, Boston, MA, US; 3Harvard School of Public Health, Center for Biostatistics in AIDS Research, Boston, MA, US; 4Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, US; 5Boston University School of Medicine, Boston, MA, US

Session P-C9 Poster Session Poster Hall
2:30 pm – 4:00 pm
Immune Pathogenesis of IRIS

308 Vitamin D, D-Dimer, IFNγ and sCD14 Predict IRIS in a Prospective Multicenter Study
Laura W. Musselwhite1; Ann Tierney1; Susan Ellenberg1; Pablo F. Belanzarráz- Zamudio1; Adam Rupert1; Ian Sanne1; Michael D Lederman1; Juan Sierra-Madero1; Irini Sereti1
1Duke University, Durham, NC, US; 2University of Pennsylvania, Philadelphia, PA, US; 3Leidos Biomedical Inc., Reston, VA, US; 4University of the Witwatersrand, Johannesburg, South Africa; 5Instituto Nacional de Ciencias Medicas y Nutricion, Mexico City, Mexico; 6Case Western Reserve University, Cleveland, OH, US; 7National Institutes of Health (NIH), Bethesda, MD, US
309 LC-MS Analysis of Metabolites Differentiating IRIS From Non-IRIS in ACTG Study A5221
Mary A. De Groot1; Laura Ashton1; Marisa Harton1; Sam Bokatizen1; Kristofer Webb1; Carlos Adriano Matos de Silva1; Reem Al-Mubarak1; Sebahatra Mahapatra1; Diane Hlavir1; John Belisle1

310 Associations Between Plasma Cytokine and Microbial Translocation Biomarkers and IRIS
Margaret A. Fisch1; Linda J. Harrison1; Varghese George1; Margaret Roach1; Xiao-Dong Li1; David Asmuth1; Pablo Tebas1; Camlin Tierney1; Catherine Godfrey1; Savita Pahwa1
1Center for Biostatistics in AIDS Research, Harvard School of Public Health, Boston, MA, US; 2University of Miami Miller School of Medicine, Miami, FL, US; 3University of California Davis, Sacramento, CA, US; 4University of Pennsylvania, Philadelphia, PA, US; 5National Institute of Allergy and Infectious Diseases (NIAID), Bethesda, MD, US

311 Potential Role of IL-1 and IL-10 Pathways in IRIS Pathogenesis
Ainhoa Perez-Diez1; Elizabeth Richards1; Stig Jensen1; Eleanor M. Wilson1; Virginia Sheikh1; Maura M. Manion1; Bruno Andrade1; Timothy Myers1; Irini Sereti1
National Institute of Allergy and Infectious Diseases (NIAID), Rockville, MD, US

WEDNESDAY, FEBRUARY 25, 2015

Session P-C10 Poster Session
2:30 pm – 4:00 pm
Immunodulatory and HIV Pathogenesis

312 Inflammatory Biomarkers Decline but Do Not Normalize After 10 Years of cART
Kenneth A. Lichtenstein1; Carl Armon1; Vijaya Knight1; Rafaeul Alam1
1National Jewish Health, Denver, CO, US; 2Children’s Hospital Colorado, Aurora, CO, US

313 Persistently High IL-18 and sCD14 Are Independently Associated With Clinical Failure
Ashwin Balagopal1; Nikhil Gupta1; James Hakim1; Mina C. Hosseinpour1; Nagalingeswaran Kumarsamy1; Andrea Cox1; Ian Sanne1; David Asmuth3; Thomas Campbell3; Amita Gupta1
On behalf of the ACTG
1Johns Hopkins University School of Medicine, Baltimore, MD, US; 2University of Zimbabwe, College of Health Sciences, Harare, Zimbabwe; 3University of North Carolina, Chapel Hill, NC, US; 4K.R.G. Care, Chennai, India; 5University of California San Diego, San Diego, CA, US; 6University of Colorado, Denver, CO, US; 7ACTG, Washington, DC, US

314 Impact of Partner HIV Status on Immune Activation and Inflammation During Chronic HIV
Shameen Z. Jaumdally1; Pamela Gumbe1; Hoyam Gamieldien1; Anabela Picton1; Caroline Tiemessen1; Linda Masson1; Lenine Liebenberg1; David Coetzee1; Anna-Lise Williamson1; Jo-An Passmore1
1University of Cape Town, Cape Town, South Africa; 2National Institute for Communicable Diseases, National Health Laboratory Service, Johannesburg, South Africa; 3Centre for AIDS Programme Research in South Africa, Durban, South Africa; 4University of Cape Town, Cape Town, South Africa

315 Pretherapy Inflammation and Long-Term CD4 Response to Antiretroviral Therapy
Amit C. Achhra1; Andrew N. Phillips2; Sean Emery1; Rodger D. MacArthur1; Hansjakob Furrer1; Stéphane De Wit1; Marcelo H. Losso3; Matthew G. Law4
On behalf of the INSIGHT SMART and FIRST Study groups
1Kirby Institute, University of New South Wales, Sydney, Australia; 2University College London, London, United Kingdom; 3Wayne State University, Detroit, MI, US; 4University Hospital Bern, Bern, Switzerland; 5Saint-Pierre University Hospital, Brussels, Belgium; 6Hospital J.M. Mejia, Buenos Aires, Argentina

316 Plasma Levels of sCD163 Predict All-Cause Mortality From HIV Infection
Troels Bygum Knudsen1; Janne Petersen2; Holger Jon Møller2; Søren Møestrup1; Jesper Eugen-Olsen1; Gitte Kronborg3; Thomas Benfield1
1Copenhagen University Hospitals, Hvidovre, Copenhagen, Denmark; 2Copenhagen University Hospitals, Hvidovre, Copenhagen, Denmark; 3Aarhus University Hospital, Aarhus, Denmark; 4Aarhus University, Aarhus, Denmark

317 Immunologic Pathways That Predict Mortality in HIV+ Ugandans Initiating ART
Suligi A. Lee1; Helen Byakwaga1; Yap Boum1; Tricia Burdo1; Yong Huang1; Jessica Haberer1; Annet Kembabazi2; David R. Bangsberg3; Jeffrey Martin1; Peter W. Hunt1
1University of California San Francisco, San Francisco, CA, US; 2Mbarara University of Science and Technology, Mbarara, Uganda; 3Boston College, Boston, MA, US; 4University of California San Francisco, San Francisco, CA, US; 5Massachusetts General Hospital and Harvard University, Boston, MA, US

318 Immune Activation Impairs Yellow Fever Vaccine Efficacy in HIV-Infected Patients
Vivian I. Avelino-Silva1; Karina T. Miyaji1; Marisol Simoes1; Marcos Freire1; Ana Sartori1; Peter W. Hunt1; Karine Milani1; Augusto Mathias1; Ana Paula Batista1; Espre G. Kallas1
1University of Sao Paulo Medical School, Sao Paulo, Brazil; 2Fundação Oswaldo Cruz, Rio de Janeiro, Brazil; 3University of California San Francisco, San Francisco, CA, US; 4University of Sao Paulo Medical School, Sao Paulo, Brazil

319 Association Between sCD163 and CMV IgG in Virologically Suppressed HIV+ Patients
Aimee Hodowniec1; Brett Williams1; Barbara Hanson1; Britt Livak2; Sheila Keating1; Nell Lurain1; Oluwatoyin M. Adeyemi4
1Rush University Medical Center, Chicago, IL, US; 2University of Chicago, Chicago, IL, US; 3Blood Systems Research Institute/University of California San Francisco, San Francisco, CA, US; 4Ruth M Rothstein CORE Center, Chicago, IL, US
**Session P-C11 Poster Session**  
*Manipulating Immune Activation*

320  
The mTORC1 Inhibitors, Temsirolimus and Everolimus, Suppress HIV Patient-Derived CD4+ T-Cell Death and Activation In Vitro  
Clovis S. Palmer; Matias Ostrowski; Jingling Zhou; Linda Lam; Alan Landay; Anthony Jaworowski; Joseph M. McCune; Suzanne M. Crowe

321  
Decreased Monocyte Activation With Daily Acyclovir Use in HIV-1/HSV-2 Coinfected Women  
Andrew D. Redd; Kevin Newell; Eshan U. Patel; Fred Nalugoda; Paschal Ssebowa; Sarah Kaliballa; Ronald H. Gray; Thomas C. Quinn; David Serwadda; Steven J. Reynolds

322  
Atorvastatin Reduced T-Cell Activation and Exhaustion Among Suboptimal Immune Responders: A Randomized Crossover Placebo Controlled Trial  
Damalie Nakanjako

**THURSDAY, FEBRUARY 26, 2015**

**Session P-CT2 Poster Session**  
*Pathogenesis in Lymph Nodi*

324  
CD4+ T cell death mediated by pyroptosis in early SIV infected lymphatic tissues  
Wuxun Lu; Guobin Kang; Fangrui Ma; Yanmin Wan; Yue Li; Mark Lewis; Qingzheng Li

325  
Fibrosis in Lymphoid Tissue Is Associated With Peripheral Blood Regulatory T Cells  
Julie C. Gaardbo; Patricia S. Niels; Lise Mette R. Gjerdrum; Karoline Springborg; Elisabeth Ralfkiaer; Henrik Ullum; Åse Andersen

326  
Decreased T\(_{FM}/T\(_{FN}\) Ratio in SIV-Infected Rhesus Macaques  
Ankita Chowdhury; Perla Del Rio-Estrada; Steven Bosing; Guido Silvestri

**Session P-C13 Poster Session**  
*Dissecting Pathogenesis Through In Vitro Studies*

327  
A Dual-Tropic HIV-1 Env Interacts With CCR5 to Deplete Bystander CD4 T Cells In Vitro and In Vivo  
Li-Chung Tsao; Hailao Guo; Jerry Jeffrey; James A. Hoxie; Lishan Su

328  
Investigation of the Association of Gag-Protease Dependent Replication Capacities With Clinical Outcomes of HIV-1 Infection  
Keiko Sakai; Takayuki Chikata; Hiroyuki Gatanaga; Shinichi Oka; Masafumi Takiguchi

329  
Association of Bacteria-Induced IL-23 and Th17 Frequencies in HIV-1 Individuals  
Jennifer Manuzak; Sonia Amraoui; Nipa Decroix; Pierre Loulergue; Odile Launay; Marco Iannetta; Jean-Baptiste Guillerme; Lene Vimeux; Anne Hosmalin

330  
Effect of Methamphetamine Use on T-Cell Proliferation In Vivo and Ex Vivo  
Marta Massanella; Sara Gianella; Jennifer M. Dan; Eric Daar; Michael P. Dube; Richard H. Haubrich; Douglas D. Richman; Davey M. Smith; Sheldon Morris; Rachel D. Schrier

**Poster Listings**
Session P-C14 Poster Session
2:30 pm – 4:00 pm
Dissecting Pathogenesis Through In Vivo Studies

331  A Random Forest Approach to Detect Immunological Thresholds for CD4 Recovery in HIV-Treated Individuals
Josué Pérez-Santiago1; Marta Massanella1; Dan Ouchi1; Elisabet Gómez1; Cecilia Cabrera1; Bonaventura Clotet1; Eugenia Negredo1; Julià Blanco2
1University of California San Diego, La Jolla, CA, US; 2FresCaixa Institute for AIDS Research, Badalona, Spain; 3Lluïta Contra la Sida Foundation, Germans Trias i Pujol University Hospital, Badalona, Spain

332  Disease Progression in HIV Controllers; Uptake and Outcome of Antiretroviral Therapy
Jane R. Deayton1; Katherine C. Groves2; David F. Bibby2; Duncan A. Clark2; Iain Reeves2; Jane Anderson2; Chloe M. Orkin3; Eithne O’Sullivan1; Aine McNiktith1
1Barts and the London, Que, London, United Kingdom; 2Barts Health NHS Trust, London, United Kingdom; 3Homerton University Hospital NHS Foundation Trust, London, United Kingdom; 4Barts Health NHS Trust, London, United Kingdom

333  Immunological and Virological Progression in HIV Controllers
Nicolas Noel1; Nathalie Lerolle1; Camille Lecuroux1; Cécile Goujard1; Alain Venet1; Asier Sáez-Cirión2; Laurence Meyer1; Farouzy Boufassa1; Olivier Labbe1; Anne-Mieke Vandamme1
1ANRS CO21/CODEX Study Group; 2APHP Service de Médecine Interne et Immunologie Clinique, Hôpital Bicêtre, Le Kremlin-Bicêtre, France; 3University of Miami, Miami, FL, US; 4Inserm U1012, Unité d’Immunologie Moléculaire et Cellulaire, Inserm U1018, Centre de Recherche en Épidémiologie et Santé des Populations, Université Paris Sud, Le Kremlin-Bicêtre, France

334  HIV Replication History Is Associated With Plasma IL-7 Levels in Aviremic Youths
Daniel Scott-Algera1; Jerome Chenadec2; Josiane Warszawski2; Thomas Montange1; Jean-Paul Ward1; Catherine Dolflis2; Véronique Avettand-Fenoel2; Christine Rouzioux3; Stéphane Blanchet1; Florence Buseyne1
1Institut Pasteur, Paris, France; 2Inserm, Le Kremlin-Bicêtre, France; 3AP-H, Paris, France; 4Université Paris Descartes, Paris, France

335  Enhanced Immunological Reconstitution With Initiation of ART at HIV-1 Seroconversion (PHI)
Sabine I. Kinloch1; Colette Smith2; Kwong Tsz-Shan3; Jayne Ellis3; Margaret Johnson2
1University College London, London, London, United Kingdom; 2Royal Free London NHS Foundation Trust, London, United Kingdom

336  cART-Driven Recovery of Immune Function Preferentially Targeting CCR4-Tropic HIV-1
Joëlle Bader1; Martin Dürmer2; Jürg Böni3; Meri Gorgievski3; Thomas Klmitka1
1The Swiss HIV Cohort Study; 2University of Basel, Basel, Switzerland; 3Institute for Immunogenetics, Kaiserslautern, Germany; 4University of Berne, Berne, Switzerland; 5Swiss National Center for Retroviruses, Zürich, Switzerland

337  Repeated injections of rhIL-7 in HIV Patients receiving ART in INSPIRE 2 & 3 trials
Rodolphe Theibaut1; Ana Jame1; Jean-Pierre Routy1; Irini Sereti1; Margaret A. Fischl1; Prudence Iwe1; Roberto Speck2; Giuseppe Tambussi1; Yves Lévy1; Michael M Lederman1
1on behalf of Inspire 2 and Inspire 3 study groups; 2Bordeaux University, Bordeaux, France; 3McGill University, Montreal, Canada; 4National Institute of Allergy and Infectious Diseases (NIAID), Bethesda, MD, US; 5University of Miami, Miami, FL, US; 6Wits Health consortium, Johannesburg, South Africa; 7University Hospital Zurich, Zurich, Switzerland; 8San Raffaele Scientific Institute, Milano, Italy; 9INSERM, Paris, France; 10Case Western Reserve University, Cleveland, OH, US

338  CRF19_cpx Is an Evolutionary Fit HIV-1 Variant Exclusively Associated With Rapid Progression to AIDS in Cuba
Vivian Kour1; Ricardo Khouri1; Yoan Alemán2; Yeisell Abrahantes2; Nico Pfeifer2; Andrea-Clemencia Pineda-Peña3; Jorge Pérez3; Lissette Pérez2; Kristel Van Laethem4; Anne-Mieke Vandamme1
1Fundação Oswalco Cruz, Salvador, Brazil; 2Instituto Pedro Kouri, Havana, Cuba; 3Max Planck Institute for Informatics, Saarbrucken, Germany; 4Katholieke Universiteit Leuven, Leuven, Belgium

TUESDAY, FEBRUARY 24, 2015

Session P-E1 Poster Session
2:30 pm – 4:00 pm
The Effect of HIV Infection on B Cells

339  Acute HIV-1 Infection Is Associated With Rapid Changes in B-Cell Subsets and Levels of CXCL13
Jennifer K. Maroa1; Anne-Sophie Dugust2; Zelda Euler1; Yathisha Ramakhan1; Krista Dong1; Bruce Walker1; Thumbi Ndungu1; Galit Alter1
1University of KwaZulu-Natal, Durban, South Africa; 2Ragon Institute of MIT, MGH and Harvard, Boston, MA, US; 3Massachusetts General Hospital, Harvard Medical School, Boston, MA, US; 4HIV Pathogenesis Programme, Durban, South Africa

340  Bone Marrow Plasma Cells Dictate Serum HIV-Specific Antibodies in Chronic Viremia
Jairo Mauricio Montezuma-Rusca1; Olivia R. Fankuchen1; Lela Kardava1; Clarisa M. Buckner2; Aaron Louie1; Yuxing Li3; Tae Wook Chun1; Katherine R. Calvo1; Susan Moir1; Anthony S. Fauci1
1NIAD/NIAID, Bethesda, MD, US; 2University of Maryland, Rockville, MD, US; 3NIH Clinical Center, Bethesda, MD, US

341  Reduced Expression of Blimp-1 on Memory B Cells in Patients with HIV-1 Infection
Claudia Beisel1; Ilona Toth1; Jan van Lunzen1; Julian Schulze zur Wiesch1
1University Hospital Hamburg-Eppendorf, Hamburg, Germany

342  Similar or Higher Memory Responses to Influenza Vaccination in Aviremic HIV-infected Patients on Antiretroviral Therapy
Zhenwu Luo1; Lisa Martin1; J. Michael Kilby1; Wei Jiang1
1Medical University of South Carolina, Charleston, SC, US
WEDNESDAY, FEBRUARY 25, 2015

Session P-E3 Poster Session  
2:30 pm – 4:00 pm  
New Approaches to Immunostimulation

352 Use of Pre-ART-Adjusted Endpoints in the Analysis of an HIV Therapeutic Vaccine Trial  
Yunda Huang; Lily Zhang; Darren Jolliffe; Arnt-Ove Hovden; Mats Okvist; Pantaleo; Mauro Ruocco; John Robinson; Harry Schroeder

353 Decreased HIV-Specific T-Regulatory Responses Mark Effective Vaccine-Induced Immunity  
Vedran Bresar; Nicolas Ruffin; Laura Riehert; Mathieu Surenaud; Christine Lacabaratzi; Karolina Palucka; Rodolphe Thiebaut; Jacques Banchereau; Yves Lévy; Nabilah Seddiki

354 Viral Reservoir Dynamics After Therapeutic Vaccination and cART Interruption  
Cristina Andres; Carmen Alvarez-Fernandez; Nuria Climent; Teresa Gallant; Montserrat Planas; Agathe Leon; Nicolas Chomont; Jose M. Okvist; Felipe Garcia; Sonsoles Sanchez-Palomino

355 HIV-1 Envelope Epitope Recognition Is Influenced by Immunoglobulin D, Gene Segment Repertoire  
Yuge Wang; Aaron Sanchez-Silva; Barton Haynes; Harry Schroeder

356 Human Rhinovirus Displaying HIV-1 4E10 Epitope Elicits Broad Neutralization in iHAC-1 Tg Mice  
Guohua Yi; Xiongying Tu; Preeti Bharaj; Premila Shankar; Manjunath Swamy

Session P-E2 Poster Session  
2:30 pm – 4:00 pm  
The Envelope/Antibody Dynamic

343 Estimating and Visualizing HIV-1 Susceptibility to Broadly Neutralizing Antibodies  
Anna Feldmann; Nico Pfeifer  
Max Planck Institute for Informatics, Saarbrücken, Germany

344 Sequential SHIV-Env Clones With Neutralization Sensitivity for Breadth Development  
Manxue Jia; Cecilia Cheng-Mayer; Xueling Wu  
Aaron Diamond AIDS Research Center, New York, NY, US

345 V1V2 Neutralizing Epitopes Are Conserved Within Divergent Groups of HIV-1  
Marion Morgand; Mélanie Bouvin-Pley; Craig S Pace; David Ho; Pascal Poignard; Marie Pancera; Jean-Christophe Plantier; Francois Simon; Martine Brabant; Francis Barin

1 Université de Tours, Inserm U966, Tours, France; 2 Aaron Diamond AIDS Research Center, The Rockefeller University, New York, NY, US; 3 Department of Immunology and Microbial Science, The Scripps Research Institute, La Jolla, CA, US; 4 Vaccine Research Center, NIAID, NIH, Bethesda, WA, US; 7 Université de Rouen, CHU Charles Nicolle, Rouen, France; 8 Laboratoire de Virologie, Hôpital St Louis, Paris, France; 9 Université de Tours, Inserm U966, Laboratoire de Bactériologie-Virologie, CNR du VIH, CHU Bretonneau, Tours, France

346 Improving Neutralization Potency and Breadth by Combining Broadly Reactive HIV-1 Antibodies Targeting Major Neutralization Epitopes  
Rui Kong; Mark Louder; Kshitij Wagh; Robert Bailer; Kelli Greene; Hongmei Gao; Michel Nussenzweig; Bette Korber; David Montefiori; John Mascola

1 Vaccine Research Center, NIAID, NIH, Bethesda, MD, US; 2 Los Alamos National Laboratory, Los Alamos, NM, US; 3 Duke University Medical Center, Durham, NC, US; 4 The Rockefeller University, New York, NY, US

347 Improved Antibody Cross-Neutralizing Activity in HIV-1 Dual-Infected LTNP Patients  
Maria Pernas; Concepción Casado; Víctor Sanchez-Merino; Alberto Sanchez-Merino; Isabel Olivares; eloisa Yuste; Cecilio Lopez-Galindez

1 Instituto de Salud Carlos III, Majadahonda, Spain; 2 Institut d’Investigacions Biomediques, Barcelona, Spain

348 Characterization of CD4 Independent HIV-1 Envelope As Potential Immunogens  
Lifei Yang; Bradley Cleveland; Andrea P. Jordan; Patricia Polacino; James A. Hoxie; Shiou-Lok Hu

1 University of Washington, Seattle, WA, US; 2 University of Pennsylvania, Philadelphia, PA, US

349 Phenotypic Neutralization Sieve Analysis of an SIV Nonhuman Primate Vaccine Challenge Study  
Fang-Hua Lee; Brandon F. Keele; Robert Doms; George M. Shaw; Mario Roederer; Katharine J. Bar

1 University of Pennsylvania, Philadelphia, PA, US; 2 Vaccine Research Center, NIAID, NIH, Bethesda, MD, US; 3 National Cancer Institute, Frederick, MD, US

350 AvFc, a Novel Fc Fusion Protein Targeting Env High-Mannose Glycans  
Nobuyuki Matoba; Adam Husk; J. Calvin Koukam; Krystal Hamorsky; Tiffany Grooms-Williams; Garima Mahajan  
University of Louisville James Graham Brown Cancer Center, Owensboro, KY, US

351 DARPin as Entry Inhibitor Alternative to HIV-1 Broadly Neutralizing Antibodies  
Emanuel Stiegeler; Nikolae Friedrich; Thomas Reinberg; Mylene Morin; Yufan Wu; Jonas V. Schaefer; Peter Rusert; John Robinson; Andreas Glückthun; Alexandra Trkola  
University of Zurich, Zurich, Switzerland
A New Mucosal Vaccine With Inactivated Bacteria Linked to Adjuvanted Nanoparticles

Georg Stary; Andrew Olive; Aleksandar F. Radovic-Moren; David Alvarez; Mario Perro; Vladimir Ubranac; Omid Farokhzad; Robert Langer; Stambach Michael; Ulrich H. von Andrian

1Harvard Medical School, Boston, MA, US; 2Department of Chemical Engineering, Massachusetts Institute of Technology, Cambridge, MA, US; 3Laboratory of Nanomedicine and Biomaterials, Department of Anesthesiology, Boston, MA, US; 4The Center for Immunology and Inflammatory Diseases, Massachusetts General Hospital, Harvard Medical School, Boston, MA, US

A Superagonist Antibody to Human Interleukin-21 Increases HIV-Specific T-Cell Function

Yew Ann Leong; Yanfang Cui; Zhian Chen; Fiona Wightman; Pellegrini Marc; Jamie Rossjohn; Sharon R. Lewin; Alan Landay; Charles Mackay; Di Yu

1Monash University/Alfred Hospital, Melbourne, Australia; 2Walter and Eliza Hall Institution, Melbourne, Australia; 3University of Melbourne, Melbourne, Australia; 4Rush University Medical Center, Chicago, IL, US; 5Monash University/Alfred Hospital, Melbourne, Australia

THURSDAY, FEBRUARY 26, 2015

Evolution of HIV-Specific CD8 + T-Cell Responses in Hyperacute HIV Infection

Zaza M. Ndhlovu; Nikoshia Mewala; Philomena Kamya; Thandeka Nkosi; Karyn Pretorius; Nasreen Ismail; Amber Moodley; Krista Dong; Thumbi Nduung’u; Bruce Walker

1University of KwaZulu-Natal, Durban, South Africa; 2Ragon Institute of MGH, MIT and Harvard, Cambridge, MA, US

Nonclassical Regulatory HIV-1–Specific CD8 T Cells in HIV-1 Disease Progression

Selena Viganò; Chun Li; Jordi J. Negroni; Bruce D. Walker; Mathias Lichterfeld; Xu G. Yu

1Massachusetts General Hospital, Boston, MA, US; 2The Ragon Institute of MGH, MIT and Harvard, Cambridge, MA, US

Nef Plays a Role in the Resistance of SIV-Infected Macrophages to CDB8 T-Cell Suppression

Jennifer N. Rainbo; Mauricio A. Martins; Francesc Cunyat; David I. Watkins; Mario Stevenson

University of Miami, Miami, FL, US

Defining Efficacious HIV-Specific CTL Responses Using Sapopin-Conjugated Tetramers

Ellen M. Leitman; Stuart Sims; Rebecca P. Payne; Fabian Chen; Lynn Riddell; Soren Buus; Steven Deeks; Bruce Walker; Philippa C. Matthews; Philip J.oulder

1University of Oxford, Oxford, United Kingdom; 2ETH Zurich, Basel, Switzerland; 3Royal Berkshire Hospital, Reading, United Kingdom; 4Northamptonshire Healthcare NHS Trust, Northampton, United Kingdom; 5University of Copenhagen, Copenhagen, Denmark; 6University of California San Francisco, San Francisco, CA, US; 7Ragon Institute of MGH, MIT and Harvard, Charlestown, MA, US

Linking Pig-Tailed Macaque Major Histocompatibility Complex Class I Haplotypes and Cytotoxic T Lymphocyte Escape Mutations in SIV Infection

Shayaraa Goonertatne; Hamid Alinejad-Rokny; Diako Ebrahimi Mohammadi; Patrick Bohn; Roger Wiseman; David O’Connor; Miles Davenport; Stephen Kent

1University of Melbourne, Melbourne, Australia; 2University of New South Wales, Kensington, Australia; 3University of Wisconsin Madison, Madison, WI, US

THURSDAY, FEBRUARY 26, 2015

Session P-E4 Poster Session

Poster Hall

2:30 pm – 4:00 pm

Cellular Immune Response to HIV

Evolution of HIV-Specific CD8+ T-Cell Responses in Hyperacute HIV Infection

Zaza M. Ndhlovu; Nikoshia Mewala; Philomena Kamya; Thandeka Nkosi; Karyn Pretorius; Nasreen Ismail; Amber Moodley; Krista Dong; Thumbi Nduung’u; Bruce Walker

1University of KwaZulu-Natal, Durban, South Africa; 2Ragon Institute of MGH, MIT and Harvard, Cambridge, MA, US

Nonclassical Regulatory HIV-1–Specific CD8 T Cells in HIV-1 Disease Progression

Selena Viganò; Chun Li; Jordi J. Negroni; Bruce D. Walker; Mathias Lichterfeld; Xu G. Yu

1Massachusetts General Hospital, Boston, MA, US; 2The Ragon Institute of MGH, MIT and Harvard, Cambridge, MA, US

Nef Plays a Role in the Resistance of SIV-Infected Macrophages to CDB8 T-Cell Suppression

Jennifer N. Rainbo; Mauricio A. Martins; Francesc Cunyat; David I. Watkins; Mario Stevenson

University of Miami, Miami, FL, US

Defining Efficacious HIV-Specific CTL Responses Using Sapopin-Conjugated Tetramers

Ellen M. Leitman; Stuart Sims; Rebecca P. Payne; Fabian Chen; Lynn Riddell; Soren Buus; Steven Deeks; Bruce Walker; Philippa C. Matthews; Philip J.oulder

1University of Oxford, Oxford, United Kingdom; 2ETH Zurich, Basel, Switzerland; 3Royal Berkshire Hospital, Reading, United Kingdom; 4Northamptonshire Healthcare NHS Trust, Northampton, United Kingdom; 5University of Copenhagen, Copenhagen, Denmark; 6University of California San Francisco, San Francisco, CA, US; 7Ragon Institute of MGH, MIT and Harvard, Charlestown, MA, US

Session P-F1 Poster Session

Poster Hall

2:30 pm – 4:00 pm

IFN-alpha Stimulated NK Lysis of HIV-Infected CD4+ T Cells Requires NKp46 and NKG2D

Costin Tomescu; Domenico Mavilio; Luis J. Montaner

1The Wistar Institute, Philadelphia, PA, US; 2Humanitas Clinical and Research Center, Milan, Italy

TUESDAY, FEBRUARY 24, 2015

Session P-F1 Poster Session

Poster Hall

2:30 pm – 4:00 pm

Stimulation of Broad CTL Response Is Required to Clear Latent HIV-1 in Humanized Mice

Liang Shan; Kai Deng; Richard Flavell; Robert F. Siliciano

1Yale University, New Haven, CT, US; 2Johns Hopkins University School of Medicine, Baltimore, MD, US

Stimulation of Broad CTL Response Is Required to Clear Latent HIV-1 in Humanized Mice

Liang Shan; Kai Deng; Richard Flavell; Robert F. Siliciano

1Yale University, New Haven, CT, US; 2Johns Hopkins University School of Medicine, Baltimore, MD, US

In vivo effects of Panobinostat and Romidepsin on HIV-1-specific CD8 T Cell Immunity

Rikke Olesen; Thomas A. Rasmussen; Mathias Lichterfeld; Mette E. Graversen; Steffen Leth; Lars Østergaard; Ole S. Søgaard; Martin Tolstrup

1Aarhus University Hospital, Aarhus, Denmark; 2Ragon Institute of MIT, MGH and Harvard, Boston, MA, US
370 Vaccine Induced Follicular CD8 T Cells Enhance Control of Pathogenic SIV Infection
Geetha H. Mylvaganam; Daniel Rios; Gregory Tharp; Steven Bosinger; Vijayakumar Velu; Rama R. Amara
Emory University, Atlanta, GA, US

371 Blockade of PD-L1 Does Not Reverse HIV Latency in CD4+ T Cells Ex Vivo
Elizabeth Fyne1; Shalyn Campellone1; Huilin Qi1; Amy Sheaffer2; Stephen Mason1; John W. Mellors1
1University of Pittsburgh, Pittsburgh, PA, US; 2Bristol-Myers Squibb Co., Wallingford, CT, US

372 Impact of HIV Latency Reversing Agents on Natural Killer Cells
Carolina Garrido; Julia Sung; Swati Gupta; Katherine Sholtis; Nancie Arcin; David Margolis
Medicine, University of North Carolina
University of North Carolina, Chapel Hill, NC, US

THURSDAY, FEBRUARY 26, 2015
Session P-F2 Poster Session
2:30 pm – 4:00 pm
Poster Hall

373 The Earlier cART Is Initiated During PHI, the More Intracellular HIV-DNA Decreases
Moussa Laanani1; Jade Ghosn1; Asma Essat2; Adeline Méland3; Rémonie Seng4; Emmanuel Mortier5; Cécile Goujard6; Laurence Meyer6; Christine Rouzioux1
On behalf of the ANRS PRIMO Cohort Study Group
1APHP, Hôtel Dieu University Hospital, Paris, France; 2APHP, Bicêtre Hospital, Le Kremlin-Bicêtre, France; 3APHP, Necker Hospital, Paris, France; 4APHP, Louis Mourier Hospital, Colombes, France

374 Decay Rate and HIV-1 DNA Reservoir Size Following Early Infant Antiretroviral Therapy
Priyanka Upetry1; Kaitlin Rainwater-Lovett1; Ellen G. Chadwick1; Edmund Gapparelli1; Carrie Ziemnick1; Katherine Luzuriaga1; Larry Moulton1; Deborah Persaud1
International Maternal Pediatric Adolescent AIDS Clinical Trial Network (IMPAACT) P1030 trial group
1Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, US; 2Johns Hopkins University School of Medicine, Baltimore, MD, US; 3Northwestern University, Feinberg School of Medicine, Chicago, IL, US; 4University of California San Diego, San Diego, CA, US; 5University of Massachusetts Medical School, Boston, MA, US

375 Detectable CMV in PBMC Is Associated With Slower HIV DNA Decay During Suppressive ART
Sara Gianella Weibel; Christy Anderson; Susanna R. Var; Michelle Faria de Oliveira; Marta Massanella; Susan J. Little; Douglas D. Richman; Matt Strain; Josue Pérez-Santiago; David M. Smith
University of California San Diego, La Jolla, CA, US

376 Stable Total HIV-1 DNA Levels Prior and Post ART Interruption in Chronic HIV
Emmanouil Papasavvas1; Matthew Strain1; Steven Lada2; Jocelyn Joseph1; Livio Azzone1; Karam Mounzer1; Jay R. Kostman1; Douglas D. Richman1; Luis J. Montaner1

377 Aviremia 10-Year Post-ART Discontinuation Initiated at Serocconversion
Sabine I. Kinloch1; Lucy Dorrell1; Hongbing Yang1; Linos Vandekerckhove1; Ward de Spieghelaere1; Eva Malatinkova1; Sabine Yuri1; Daniel Webster1; Margaret Johnson1
1University College London, London, United Kingdom; 2University of Oxford, Oxford, United Kingdom; 3Universiteit Ziekenhuis Gent, Gent, Belgium; 4Geneva University Hospital, Geneva, Switzerland; 5Royal Free London NHS Foundation Trust, London, United Kingdom

378 Identifying HIV Variants that Rebound after Treatment Interruption
Mary F. Kearney1; Wei Shao1; Rajesh T. Gandhi2; Brandon F. Keele3; Jonathan Z. Li4
1Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, US; 2National Cancer Institute (NCI), Frederick, MD, US; 3Frederick National Laboratories for Cancer Research, Frederick, MD, US; 4Massachusetts General Hospital, Harvard Medical School, Boston, MA, US

379 Characterizing the Active HIV Reservoir on ART: Cell-Associated HIV RNA and Viremia
Feiyu Hong; Elizabeth Fyne; Anthony R. Cillo; Margaret A. Bedison; Dianna Koontz; John W. Mellors
University of Pittsburgh, Pittsburgh, PA, US

380 Liver Macrophages and HIV-1 Persistence
Abraham J. Kandathil1; Christine M. Durand; Jeffrey Quinn; Andrew Cameron; David L. Thomas; Ashwin Balagopal
Johns Hopkins School of Medicine, Baltimore, MD, US

381 Large-Scale Analysis of HIV-1 Integration Sites in Untreated and Treated Patients
Stephanie Lauf1; Diana Schenkwein; Neeltje Kootstra; Frank A. Giordano1; Christoph Stephan1; Hans-Georg Kraeusslich1; Winfried Kern1; Susanne Usadel1; Manfred Schmidt1; Christof von Kalle1
1National Center for Tumor Diseases; German Cancer Research Center, Heidelberg, Germany; 2Sanquin Research, Landsteiner Laboratory, and Center for Infectious Diseases and Immunity Amsterdam, Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands; 3University Hospital Frankfurt, Frankfurt, Germany; 4Department of Infectious Diseases, Virolgy, University Hospital Heidelberg, Heidelberg, Germany; 5Heidelberg University, Heidelberg, Germany; 6Division of Infectious Diseases, Department of Medicine, Albert-Ludwigs-University Center for Infectious Diseases & Travel Medicine, and IFB-Center for Chronic Immunodeficiency, University Hospital, Freiburg, Germany
Session P-F3 Poster Session
2:30 pm – 4:00 pm
Cellular Factors of Latency

384 Minor Contribution of Host-HIV Readthrough Transcripts to the Level of HIV-1 gag RNA
Alexander Pasternak; Una O’Doherty; Ben Berkhout
1 Academic Medical Center University of Amsterdam, Amsterdam, Netherlands; 2 Academic Medical Center University of Amsterdam, Amsterdam, Netherlands

385 MicroRNA-155 Reinforces HIV Latency by Downregulating the TRIM32 Viral Activator
Debbie S. Ruelas; Jonathan Chan; Eugene Oh; Amy Heidersbach; Andrew Hebble; Leonard Chavez; Eric Verdin; Warner C. Greene
1 University of California San Francisco (UCSF), San Francisco, CA, US; 2 University of California Berkeley, Berkeley, CA, US

386 Select Host Restriction Factors Are Associated With HIV Persistence During Therapy
Mohamed Abdel-Mohsen; Leonard Chavez; Charlene Wang; Matt Strain; Xutao Deng; Christopher D. Pilcher; Teri Liegler; Douglas D. Richman; Steven Deeks; Satish Pillai
1 Blood Systems Research Institute, San Francisco, CA, US; 2 University of California San Diego, La Jolla, CA, US; 3 University of California San Francisco, San Francisco, CA, US

387 Selectively Eliminating HIV Latently Infected Cells Without Viral Reactivation
Grant R. Campbell; Rachel S. Bruckman; Yen-Lin Chu; Stephen A. Spector
University of California San Diego, La Jolla, CA, US

388 PD1 Identifies Latently HIV-Infected Nonproliferating and Proliferating CD4+ T Cells
Renee M. van der Sluis; Nitasha A. Kumar; Vanessa A. Evans; Rafick P. Sekaly; Remi Fromentin; Nicolas Chomont; Paul U. Cameron; Sharon R. Lewis
1 Doherty Institute, Melbourne University, Melbourne, Australia; 2 VGTI-Vaccine and Gene Therapy Institute Florida, Port St. Lucie, FL, US

389LB 2B4+PD1+ Naïve and Memory CD4+ T Cells Are Associated With Residual Viremia on ART
Cynthia Klamar; Feiyu Hong; John Bui; Anthony R. Cillo; Arcadio Aguadelo-Hernandez; Deborah A. McMahon; Charles R. Rinaldo; John W. Mellors; Bernard J. Macatangay
University of Pittsburgh, Pittsburgh, PA, US

Program and Agenda

Poster Listings

WEDNESDAY, FEBRUARY 25, 2015

Session P-F4 Poster Session
2:30 pm – 4:00 pm
Dynamics of Latency and Reactivation

391 Influenza Vaccination Increases HIV-1 Transcription During Antiretroviral Therapy
Christina C. Yek; Sara Gianella; Montserrat Plana; Pedro Castro; Felipe Garcia; Marta Massanella; David M. Smith
1 University of California San Diego, San Diego, CA, US; 2 University of Barcelona, Barcelona, Spain

392 Defective HIV-1 Proviruses Can Be Transcribed Upon Activation
Ya-Chi Ho; Ross Pollack; Patrick Yong; Robert F. Siliciano
Johns Hopkins University School of Medicine, Baltimore, MD, US

393 Kinetics of HIV-1 Gene Expression Following Reactivation in a Primary Cell Model of Latency
Victoria Walker-Sperling; Joel Blankson
Johns Hopkins University School of Medicine, Baltimore, MD, US

394 Variable HIV Replication Competency Following Latency Disruption in CD4+ T Cells
Jason M. Hataye; Joseph Casazza; David Ambrozak; Eli Boritz; Takuya Yamamoto; Daniel Douek; Richard A. Koup
National Institute of Allergy and Infectious Diseases, Bethesda, MD, US

395 Latent HIV-1 Reactivation and Lysosomal Destabilization Synergize to Host Cell Death
Metodi Stankov; Christina Suhr; Hazel Lin; Diana Panayotova-Dimitrova; Christine Goffinet; Georg Behrens
1 Hannover Medical School, Hannover, Germany; 2 Mannheim Clinic of University of Heidelberg, Mannheim, Germany

396 Noninduced Proviral Genome Characterization in Perinatal HIV Infection
Kaitlin Rainwater-Lovett; Carrie Ziemniak; Douglas Watson; Katherine Luzuriaga; Priyanka Upreti; Yahui Chen; Ya-Chi Ho; Deborah Persaud
1 Johns Hopkins University School of Medicine, Baltimore, MD, US; 2 University of Maryland, Baltimore, MD, US; 3 University of Massachusetts Medical School, Worcester, MA, US; 4 Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, US; 5 Johns Hopkins University School of Medicine, Baltimore, MD, US
397 Multiple Rounds of T-Cell Activation Induce Additional HIV-1 From the Latent Reservoir
Nina N. Hosmane; Adam A. Capoferri; Robert F. Siliciano
Johns Hopkins University School of Medicine, Baltimore, MD, US

398 The Inducible HIV-1 Reservoir Predicted by Combinations of pre- and post-ART Parameters
Anthony R. Gillo; Michele Sobolowsk; Elizabeth Lynne; Dianna Koontz; Feiyu Hong; John W. Mellors
University of Pittsburgh, Pittsburgh, PA, US

399 Effects of Antineoplastic Chemotherapy on Dynamics of HIV Population Genetics In Vivo
Sarah A. Watters; Wei Shao; Kieron Dunleavy; Margaret Shovlin; Mark N. Polizzotto; Thomas S. Ulrick; Robert Yarchoon; Wyndham Wilson; Frank Maldarelli
1National Cancer Institute (NCI), Frederick, MD, US; 2National Cancer Institute (NCI), Frederick, MD, US; 3National Cancer Institute (NCI), Bethesda, MD, US; 4National Cancer Institute (NCI), Bethesda, MD, US; 5National Cancer Institute (NCI), Bethesda, MD, US; 6National Cancer Institute (NCI), Bethesda, MD, US

Session P-F5 Poster Session
2:30 pm – 4:00 pm
Gene Editing

400 Targeted Disruption of Essential HIV-1 Proviral Genes by Rare-Cutting Endonucleases
Harshana S. De Silva Feeble; Nioon Niyzonime; Harlan L. Pietz; Martine Aubert; Dan Stone; Keith R. Jerome
Fred Hutchinson Cancer Research Center, University of Washington, Seattle, WA, US

401 Enhancing Anti-HIV Gene Therapy: Combining MegaTAL Nuclease Gene Editing With Selection Cassettes
Biswaajit Paul; Alexander Astrakhan; Patrick Youman; Blythe D. Sather; Jordan Jarjour; Guillermo Roman; John F. Kowalski; Iram Khan; David J. Rawlings; Hans-Peter Kiem

402 A Phase I Clinical Trial of Autologous CD4+ T Cells Modified With a Retroviral Vector Expressing the MazF Endonuclease In Patient With HIV-1
Jeffrey M. Jacobson; Hideo Chono; Megan Metz; Gabriela Plesa; Julie Jadlosky; Simon Lacey; Bruce Levine; Hirofumi Yoshioka; Junichi Minemo; Carl H. June
1Drexel University College of Medicine, Philadelphia, PA, US; 2Takara Bio Inc., Shiga, Japan; 3University of Pennsylvania, Philadelphia, PA, US

403 CRISPR Are able to Efficiently Target Latent HIV and Halt New Infections
Robert Jan Lebink; Dorien de Jong; Femke Wolters; Emmanuel J. Wiertz; Monique Nijhuis
University Medical Center Utrecht, Utrecht, Netherlands

TUESDAY, FEBRUARY 24, 2015

Session P-F6 Poster Session
2:30 pm – 4:00 pm
Poster Hall

404 Histone Deacetylase (HDAC) and Histone Acetyltransferase (HAT) Inhibitors Have Opposing Effects on Cellular Susceptibility to HIV Infection
Mark B. Lucera; Curtis Dobrowolski; Jonathan Karn; John C. Tilton
Case Western Reserve University, Cleveland Heights, OH, US; Case Western Reserve University, Cleveland, OH, US

405 Panobinostat Dosing Has Broad but Transient Immunomodulatory Effects in HIV Patients
Martin Tolstrup; Christel R. Brinkmann; Thomas A. Rasmussen; Rikke Olesen; Anne Sofie Kjaer; Mathias Lichterfeld; Charles Dinarello; Lars Østergaard; Ole S. Sgaard
1Aarhus University Hospital, Aarhus, Denmark; 2Ragon Institute of MIT, MDI and Harvard, Boston, MA, US; 3University of Colorado, Denver, CO, US

406 Multi-Dose Romidepsin in SIV-Infected RMs Reactivates Latent Virus in Absence of ART
Benjamin Policicchio; Egidio Brocca-Cofano; Guiling Xu; Dongzhu Ma; Hui Li; George Richer-Hare; Tammy Dunsmore; George M. Shaw; Ivona Pandrea; Cristian Apetrei
1University of Pittsburgh, Pittsburgh, PA, US; 2University of Pennsylvania, Philadelphia, PA, US

407 Suberanilohydroxamic Acid (SAHA)-Induced Histone Modifications in the HIV Promoter in a Human, Primary CD4 T Cell Model of Latency
Brian Reardon; Amey Mukim; Savitha Deshmukh; Christopher H. Woelk; Douglas D. Richman; Celsa A. Spina
1University of California San Diego, La Jolla, CA, US; 2VA San Diego Healthcare System, La Jolla, CA, US; 3University of Southampton, Southampton, United Kingdom

408 Donor-to-Donor Variation in the Host Gene Expression Response to SAHA
bastiaan Moesker; Brian Reardon; Nadejda Beliakova-Bethell; Akul Singhania; Michael S. Breen; Christopher H. Woelk
1University of California San Diego, La Jolla, CA, US; 2University of Southampton, Southampton, United Kingdom; 3University of California San Diego, La Jolla, CA, US

409 Off-Target Effects of SAHA May Inhibit HIV Activation
Cory H. White; Harvey E. Johnston; Antigoni Manousopoulou; Celsa A. Spina; Douglas D. Richman; Spiros D. Garbis; Christopher H. Woelk; Nadejda Beliakova-Bethell
1University of California San Diego, La Jolla, CA, US; 2University of Southampton, Southampton, United Kingdom

410 Bystander Effect of Histone Deacetylase Inhibitors on HIV-1 Infection
Grant R. Campbell; Rachel S. Bruckman; Yan-Lin Chu; Stephen A. Spector
University of California San Diego, La Jolla, CA, US
411 HIV-1 Reactivation Increases Mitochondrial Priming of the Latent Reservoir
Jeremy A. Ryan; Allison L. Schure; Zelda Euler; Anthony Letai; Atha Tsibris
1Brigham and Women’s Hospital, Harvard Medical School, Cambridge, MA, US; 2Dana-Farber Cancer Institute, Boston, MA, US; 3Ragon Institute of MIT, MGH and Harvard, Cambridge, MA, US

412 Reactivation of HIV Latently Infected T Cells by Targeting Tat IRES Translation
Georges Khoury; Sri Ramaratnam; Charlene Mackenzie; David Yuirk; Con Sonza; Tony Purcell; Damian F. Purcell
1University of Melbourne At the Peter Doherty Institute for Infection and Immunity, Melbourne, Australia; 2Monash University/Alfred Hospital, Melbourne, Australia

413 Targeting HIV-1 Latency With a Potent Tat Inhibitor
Guillaume Mousseau; Remi Fromentin; Karis Kesing; Lydie Trautmann; Nicolas Chomont; Susana T. Valente
1The Scripps Research Institute, Jupiter, FL, US; 2The Vaccine and Gene Therapy Institute, Port Saint Lucie, FL, US

414 Impact of IFN-γ-2a on the Replication-Competent HIV-1 Reservoir in CD4+ T Cells
Sara Morón-López; Maria Salgado; Dan Ouchi; Mari Carmen Puertas; Toni Jou; Cristina Tural; Jordi Navarro; Mercedes Perez-Bernal; Manel Crespo; Javier Martinez-Picado
1Hospital Universitari Vall d’Hebron, Barcelona, Spain; 2AIDS Research Institute irisiCaixa, Barcelona, Spain; 3Fundació Lluïta contra la SIDA, Barcelona, Spain

415 Immune Modulation With Rapamycin as a Potential Strategy for HIV-1 Eradication
Alyssa R. Martin; Robert F. Siliciano
1Johns Hopkins University School of Medicine, Baltimore, MD, US

416 Latency Reversing Agents Activate Latent Reservoirs in the Brain of SIV-Infected Macaques
Lucio Gama; Sarah Price; Erin Shirk; Suzanne E. Queen; Ming Li; Brandon Bullock; Stephen Wietgrefe; Luiz Pianowski; M. Christine Zink; Janice Clements
1Johns Hopkins University School of Medicine, Baltimore, MD, US; 2University of Minnesota, Minneapolis, MN, US; 3Bioqual, Valinhos, Brazil

417 TLR7 Agonist GS-9620 Activates HIV-1 in PBMCs From HIV-Infected Patients on cART
Derek D. Sloan; Alivelu Irrinki; Angela Tsai; Jasmine Kaur; Jay Lalezari; Jeff Murry; Tomás Cihlar
1Gilead Sciences, Inc., Foster City, CA, US; 2Quest Clinical Research, San Francisco, CA, US

418 Baracitinib, Ruxolitinib, Dasatinib Block HIV Replication, Activation, Reactivation
Christina Gavegnano
Emory University, Atlanta, GA, US

419 Ex Vivo Identification of Highly Effective Latency-Reversing Drug Combinations
Gregory M. Laird; C Korin Bullen; Daniel I. Rosenbloom; Alyssa R. Martin; Alison L. Hill; Christine M. Durand; Janet D. Siliciano; Robert F. Siliciano
1Johns Hopkins University School of Medicine, Baltimore, MD, US; 2Columbia University, New York, NY, US; 3Harvard University, Boston, MA, US

WEDNESDAY, FEBRUARY 25, 2015

Session P-F8 Poster Session
2:30 pm – 4:00 pm

420 Investigating Mechanisms of HIV Persistence Using Droplet Digital PCR Approaches
Elizabeth M. Anderson; Robert Gorelick; Shawn Hill; Catherine A. Rhem; Mary Kearney; John W. Mellors; John M. Coffin; Mike Piatak; Frank Maldarelli
1National Cancer Institute at Frederick, Frederick, MD, US; 2Leidos Biomedical Research, Inc, Frederick, MD, US; 3University of Pittsburgh, Pittsburgh, PA, US; 4Tufts University, Boston, MA, US; 5National Institute of Allergy and Infectious Diseases (NIAID), Bethesda, MD, US

421LB High-Throughput Single-Cell Quantification of HAART-Based HIV Reservoir Reactivation
Robert W. Yucha; Emily Hanhauser; Kristen S. Hobbs; Helen Bae; Fatih Inci; Hadi Shafee; Shuqi Wang; Daniel Kuritzkes; Utkan Demirci; Timothy J. Henrich
1Brigham and Women’s Hospital, Harvard Medical School, Cambridge, MA, US; 2Brigham and Women’s Hospital, Cambridge, MA, US; 3Harvard University, Cambridge, MA, US; 4Stanford University, Palo Alto, CA, US

422 Evaluation of HIV-1 Latency-Reversing Agents by a Modified Virus Growth Assay (VOA)
Riddhima Banga; Francesco Procopio; Matthias Cavassini; Alessandra Noto; Song Ding; Giuseppe Pantaleo; Matthieu Perreau
Lausanne University Hospital, Epalinges, Switzerland

423 “Kick and Kill” of Latent HIV-1 Infection in Naïve and Central Memory CD4+ T cells
Jennifer M. Zerba; Nicolas Sluis-Cremer
1University of Pittsburgh, Pittsburgh, PA, US

424 HIV Reactivation in the In Vitro TCM Latency Model – Reasons and Solutions
Pawel Bonczkowski; Laura J. Martins; Ward de Spieghelaere; Alberto Bosque; Eva Malatinkova; Christopher H. Woelk; Cory H. White; Adam M. Spivak; Vicente P lanesles; Linos Vandeckerkvohe
1University Of Utah School of Medicine, Salt Lake City, UT, US; 2Ghent University and University Hospital, Ghent, Belgium; 3University of Southampton, Southampton, United Kingdom; 4University of California San Diego (UCSD), La Jolla, CA, US; 5University of Utah Hospital, Salt Lake City, UT, US

425 CD4+ Tissue-Resident Memory T Cells Are an Important Reservoir for HIV Persistence
Angela R. Wahl; J. Victor Garcia
University of North Carolina, Chapel Hill, NC, US
426  HIV-1 Reprograms Resting CD4 T Cells via Foxo1 and L-Selectin Suppression
Benjamin Triniti; Chi N. Chan; Caroline S. Lee; Joy Folkvord; Elizabeth Connick; David N Levy
1New York University, New York, NY, US; 2University of Colorado Anschutz Medical Campus, Aurora, CO, US

427  Measurements of Viral Transcription in Elite Suppressor CD4+ T Cells
Christopher W. Pohlmeier; C. Korin Bullen; Greg Laird; Alyssa R. Martin; Victoria Walker-Sperling; Stanley U. Chioma; Robert F. Siliciano; Joel Blankson
Johns Hopkins University School of Medicine, Baltimore, MD, US

428LB  Short-Term Disulfiram to Reverse Latent HIV Infection: A Dose Escalation Study
Julian H. Elliott; James H. McMahon; Wendy Hartogensis; Namandje Bumpus; Christina Chang; Sulggi A. Lee; Jeff Lifson; Peter Bacchetti; Steven Deeks; Sharon R. Lewin
on behalf of the Disulfiram Study investigators
1Monash University/Alfred Hospital, Melbourne, Australia; 2University of California San Francisco, San Francisco, CA, US; 3Johns Hopkins University, Baltimore, MD, US; 4University of Melbourne, Melbourne, Australia; 5National Cancer Institute, Frederick, MD, US

430  HIV-1 Reservoirs and Humoral Immunity in Allogeneic Stem Cell Transplantation Patients
Kathryn E. Stephenson; George H. Neubauer; Emily Hanhauser; Marcelo J. Wolff; Cristian Carvallo; Francisco M. Marty; Steven G. Deeks; Daniel R. Kuritzkes; Dan H. Barouch; Timothy J. Henrich
1Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, US; 2Brigham and Women’s Hospital, Boston, MA, US; 3Clínica Santa Maria, Santiago, Chile; 4Dana-Farber Cancer Institute, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, US; 5University of California San Francisco (UCSF), San Francisco, CA, US; 6Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, US

431  Breakthrough of Preexisting X4-Capable HIV After Allogeneic Stem-Cell Transplantation
Jens Verheyen; Alexander Thießen; Miriam Dirks; Nadine Lübbe; Marek Widera; Lambros Kordelas; Martin Däumer; Rolf Kaiser; Stefan Esser
1University Hospital Essen, University Duisburg-Essen, Essen, Germany; 2Institute of Immunology and Genetics, Kaiserslautern, Germany; 3University of Cologne, Cologne, Germany; 4University Hospital Essen, University Duisburg-Essen, Essen, Germany; 5University Hospital Essen, University Duisburg-Essen, Essen, Germany

432  Allogeneic Transplantation With CCR5 Δ32/Δ32 Cord Blood Hematopoietic Cells in an HIV-Infected Patient
Rafael Duarte; Maria Salgado; Isabel Sanchez-Ortega; Sara Morón-López; Maria C. Puertas; Lawrenez D. Petz; Sergi Querol; Bonaventura Clotet; Javier Martinez-Picado
1Institut Català d’Oncologia, L’Hospitalet de Llobregat, Spain; 2IrsiCaixa Institute for AIDS Research, Badalona, Spain; 3Barcelona Cord Blood Bank, Barcelona, Spain; 4StemCyte International Cord Blood Center, Covina, CA, US

433  CCR5 Editing in Hematopoietic Stem Cells in a Nonhuman Primate Model of HIV/AIDS
Christopher W. Peterson; Jiabin Wang; Patricia Polacino; Michael C. Holmes; Shiu-Lok Hu; Philip D. Gregory; Hans-Peter Kiem

434  Cytoxan Enhancement of SB-728-T Engraftment: A Strategy to Improve Anti-HIV Response
Gary Blick; Jay Lalezari; Ricky Hsu; Erin DeJesus; Trevor Hawkins; Ronald T. Mitsuyasu; Shelley Wang; Gary Lee; Winson Tang; Dale Ando
1Sangamo BioSciences, Inc., Richmond, CA, US; 2CIRCLE CARE Center, Norwalk, CT, US; 3Quest Clinical Research, San Francisco, CA, US; 4New York University School of Medicine, New York, NY, US; 5Orlando Immunology Center, Orlando, FL, US; 6Southwest Care Center, Santa Fe, NM, US; 7University of California Los Angeles CARE Center, Los Angeles, CA, US

Session P-F9 Poster Session
2:30 pm – 4:00 pm
Poster Hall

429  Impact of Combination of Chemotherapy and Autologous Hematopoietic Stem-Cell Transplantation for Lymphoma on HIV Reservoir Persistence
Heloise Delagreverie; Laurence Gerard; Marie Laure Chaix; Marie Laure Nere; Lionel Galcier; Francois Simon; Eric Oksendenhedler; Constance Delagrevere
Hôpital Saint-Louis, APHP, Université Paris Diderot, Paris, France

435  Highly Precise Measurements of HIV DNA in CSF and Blood by Droplet Digital PCR
Michelli Faria de Oliveira; Sara Gianella; Scott Letendre; Konrad Scheffler; Sergei L. Kosakovsky Pond; Davey M. Smith; Matt Strain; Ronald J. Ellis
1University of California San Diego, La Jolla, CA, US; 2HIV Neurobehavioral Research Center, San Diego, CA, US

436  Antiretroviral Concentrations in Brain Tissue Are Similar to or Exceed Those in CSF.
Namandjé Bumpus; Qing Ma; David J. Moore; Brooke M. Best; Ronald J. Ellis; Cristian L. Achim; Melanie Crescini; Courtney Fletcher; Igor Grant; Scott Letendre
The CNTN Group
1University of California San Diego, San Diego, CA, US; 2Johns Hopkins University School of Medicine, Baltimore, MD, US; 3University of Nebraska Medical Center, Omaha, NE, US; 4University at Buffalo, Buffalo, NY, US
437 HIV DNA Peripheral Reservoirs Have a Nonlinear Impact on Brain Pathology
William Hey-Cunningham1; Nadene Dermody1; Phillip Chan1; Bruce Brew1; Kersten Koelsch1; Lucette A. Cysique1
1NeuRA, University of New South Wales, Randwick, Australia; 2Kirby Institute, University of New South Wales, Sydney, Australia; 3Macquarie University, Sydney, Australia; 4Queen Elizabeth Hospital, HKSOR, Hong Kong, China; 5St. Vincent's Hospital, University of New South Wales, Sydney, Australia

438 Acute HIV CSF/Plasma RNA Ratios Are Variable and Greater Than in Chronic HIV
Joanna Hellmuth1; Serena Spudich2; Eugene Kroon3; Naponpon Sailsutad2; Somprarthana Rattanamanee3; Sukalaya Lerdlim2; Linda L. Jagodzinski4; Shelly J. Krebs4; Jintanat Ananworanich3; Victor G. Valcour2
The RV254/SEARCH010 Study Group
1University of California San Francisco, San Francisco, CA, US; 2Yale University School of Medicine, New Haven, CT, US; 3Thai Red Cross AIDS Research Centre, Bangkok, Thailand; 4University of Hawaii, Honolulu, HI, US; 5Chulalongkorn University, Bangkok, Thailand; 6Walter Reed Army Institute of Research, Silver Spring, MD, US; 7Henry M. Jackson Foundation for the Advancement of Military Medicine, Silver Spring, MD, US; 8US Military HIV Research Program, Bethesda, MD, US

439 Greater CSF HIV Reduction and CSF Rapid Decay Associated with Improved Neurocognition
Kevin R. Robertson1; Natalie M. Bowman1; Sarah B. Joseph3; Prema Menezes1; Nisha Bhatia2; Christopher Lippincott3; Michael Vinikoor3; Joseph Eron3; Ronald Swanstrom1; Richard Price1
THINC UNC
1University of North Carolina, Chapel Hill, Chapel Hill, NC, US; 2University of California San Francisco, San Francisco, CA, US

440 HIV-1 Replication in the CNS Is Associated With Increased Neurocognitive Impairment
Sarah B. Joseph1; Laura Kincer1; Natalie M. Bowman1; Prema Menezes3; Kevin Robertson1; Albert M. Anderson2; David W. Loring2; Joseph J. Eron3; Richard W. Price3; Ronald Swanstrom1
1University of North Carolina, Chapel Hill, Chapel Hill, NC, US; 2Emory University, Atlanta, GA, US; 3Emory University, Atlanta, GA, US; 4University of California San Francisco, San Francisco, CA, US; 5University of North Carolina, Chapel Hill, Chapel Hill, NC, US

441 Maraviroc-Enhanced CART Improves Cognition in Virally Suppressed HAND: A Pilot Study
Thomas M. Gates1; Lucette A. Cysique1; Joga Chaganti1; Krista J. Siefried1; Bruce J. Brew1
1St Vincent’s Hospital, Sydney, Sydney, Australia; 2Neuroscience Research Australia (NeuRA), Sydney, Australia

442 Similar Neurocognitive Performance in Patients on ATV/r Monotherapy vs Triple Therapy
Giada Caramatti1; Francesca Ferretti1; Antonio Di Biagio1; Amedeo Capetti1; Andrea Antinori1; Fiorella Di Sori1; Roberta Gagliardini6; Concetta Vinci1; Adriano Lazzarin1; Laura Galli1
1San Raffaele Scientific Institute, Milan, Italy; 2Azienda Ospedaliera San Martino, Genoa, Italy; 3L. Sacco University Hospital, Milan, Italy; 4National Institute for Infectious Diseases IRCCS Lazzaro Spallanzani, Rome, Italy; 5Ospedale San Giovanni, Rome, Italy; 6Catholic University of the Sacred Heart, Rome, Italy

443 Cerebrospinal Fluid Markers in Long-Term Atazanavir/Ritonavir Monotherapy
Francesca Ferretti; Alba Bigoloni; Valeria Longo; Laura Galli; Laura Passeri; Simonetta Gerevini; Vincenzo Spagnuolo; Adriano Lazzarin; Paola Cinque; Antonella Castagna
San Raffaele Scientific Institute, Milan, Italy

444 Neurocognitive Decline Is Associated With Antiretroviral Concentrations in Plasma and Cerebrospinal Fluid (CSF)
Qing Ma1; Xia Lui2; Robert Heaton1; Fujie Zhang3; Hua Jin4; Hao Wu5; Melanie Crescini6; Hongxiong Zhao7; Hui Zeng8; Scott Letendre1
1University of California San Diego, San Diego, CA, US; 2Chinese Center for Disease Control and Prevention, Beijing, China

445 Viral Decay Rate in the Cerebrospinal Fluid After Initiating Antiretroviral Therapy
Natalie M. Bowman1; Sarah B. Joseph3; Prema Menezes3; Jessica Margolis3; Christopher Lippincott3; Michael J. Vinikoor3; Kevin R. Robertson3; Richard Price3; Ronald Swanstrom1; Joseph Eron1
1University of North Carolina, Chapel Hill, NC, US; 2University of California San Francisco (UCSF), San Francisco, CA, US

446 Rates of Nonconfounded HIV-Associated Neurocognitive Disorder After Early cART
Teresa H. Evering1; Allison Applebaum1; Melissa La Mar1; Donald Garmon2; David Dorfman2; Martin Markowitz2
1Aaron Diamond AIDS Research Center, an Affiliate of the Rockefeller University, New York, NY, US; 2Memorial Sloan-Kettering Cancer Center, New York, NY, US; 3Mount Sinai School of Medicine, New York, NY, US

447 The Impact of HAART CNS Penetration Effectiveness on Brain Integrity in HIV+ Adults
Laurie Baker1; Robert H. Paul1; Jodi M. Heaps2; Mario Ortega2; Christin Usher2; Jee Yoon Chang2; Beau Ancs3
1University of Missouri St Louis, St Louis, MO, US; 2Washington University School of Medicine, St Louis, MO, US

448 Efavirenz Use Is Not Associated With Increased Risk of Neuropsychological Impairment
Sean B. Rourke1; John Gill2; Anita Rachlis1; Colin Kovacs4; Gordon Arbess1; Jason Brunetta1; Adriana Carvalhal1; Chris Power1; Ann N. Burchell1; Tsegaye Bekele1
1University of Toronto, Toronto, Canada; 2University of Alberta, Calgary, Canada; 3The Ontario HIV Treatment Network, Toronto, Canada; 4Maple Leaf Medical Clinic, Toronto, Canada; 5St. Michael’s Hospital, Toronto, Canada
449 Quantitative Electroencephalogram as a Translational Biomarker for NNRTI CNS AEs
Pamela Tannenbaum; Jacqullyn Binns; Spencer Tye; Alan Savitz; Steven Fox; Christopher Burgey; Ming-tain Lai; Arthur Simen; Daria Hazuda; Michael D. Miller
Merck and Co, Inc, West Point, PA, US

450 Neurocognition Following Antiretroviral Initiation in Behaviorally HIV-Infected Youth
Sharon Nichols; Patricia Garvie; Tiaadong Li; Wei jia Ren; Bill Kapogiannis; Bret Rudy; John Sleasman; Steven Woods; Ana Puga
The Adolescent Medicine Trials Network for HIV/AIDS Interventions

451 Neurocognitive Impairment in Diverse Resource-Limited Settings: The International Neurological Study ACTG AS199 and AS271
Kevin R. Robertson; Hongyu Jiang; Scott Evans; Christina Marra; Baiba Berzins; James Hakim; Ned Sacktor; Thomas Campbell; Ann Walawander; Jeff Schouten
On behalf of ACTG 5199 and 5271
1University of North Carolina Chapel Hill, Chapel Hill, NC, US; 2Harvard University, Boston, MA, US; 3Northwestern University, Chicago, IL, US; 4University of Washington, Seattle, WA, US; 5University of Zimbabwe, College of Health Sciences, Harare, Zimbabwe; 6Johns Hopkins University, Baltimore, MD, US; 7University of Colorado, Denver, CO, US; 8Frontier Science, Amherst, NY, US; 9University of Washington, Seattle, WA, US

452 High Frequency of Dementia in Antiretroviral-Naive HIV + Individuals in Rural Uganda
Ned Sacktor; Deanna R. Saylor; Gertrude Nakigozi; Noeline Nakasujja; Xiangrong Kong; Kevin Robertson; Ronald H. Gray; Maria J. Wawer
1Johns Hopkins University School of Medicine, Baltimore, MD, US; 2Rakai Health Sciences Program, Entebbe, Uganda; 3Makerere University College of Health Sciences, Kampala, Uganda; 4Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, US; 5University of North Carolina, Chapel Hill, NC, US

453 Validation of the International HIV Dementia Scale Screening Tool for HAND in Uganda
Megan M. Hosein; Deanna Saylor; Gertrude Nakigozi; Noeline Nakasujja; Xiangrong Kong; Kevin Robertson; Ronald H. Gray; Maria J. Wawer; Ned Sacktor
1Johns Hopkins University School of Medicine, Baltimore, MD, US; 2Rakai Health Sciences Program, Entebbe, Uganda; 3Makerere University College of Health Sciences, Kampala, Uganda; 4Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, US; 5University of North Carolina Chapel Hill, Chapel Hill, NC, US

454 Cerebrospinal Fluid Cytokines and HIV-Associated Neurocognitive Disorders in Uganda
Mahsa Abassi; Gertrude Nakigozi; Noeline Nakasujja; Xiangrong Kong; David B. Meya; Kevin Robertson; Ronald H. Gray; Maria J. Wawer; Ned Sacktor; David R. Bouwens
1University of Minnesota, Minneapolis, MN, US; 2Infectious Disease Institute, Kampala, Uganda; 3Rakai Health Sciences Program, Entebbe, Uganda; 4Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, US; 5Johns Hopkins University School of Medicine, Baltimore, MD, US

455 A Comparison of 5 Brief Screening Tools for HAND in the USA and South Africa
John A. Joska; Jade Witten; Kevin Thomas; Come Robertson; Martine Casson-Cook; Heidi Roosa; Jason Creighton; Jennifer Lyons; Justin McArthur; Ned Sacktor
1University of Cape Town, Cape Town, South Africa; 2Johns Hopkins University School of Medicine, Baltimore, MD, US; 3Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, US

456 Subtype Associations With HIV-Associated Neurocognitive Dysfunction
Tyler R. Day; Davey M. Smith; Robert Heaton; Donald Franklin; Myres W. Tilghman; Josué Pérez-Santiago
University of California San Diego, San Diego, CA, US

457 Peripheral Neuropathy at First-Line Failure and on Second Line in Sub-Saharan Africa
Alejandro Arenas-Pinto; Jennifer Thompson; Goddess Musoro; Helen Mussana; Abbas Lugemwa; Andrew D. Kambugu; Aggrey Mweemba; Sarah Walker; Paton Nicholas
On behalf of the EARNEST Trial Team
1University College London, London, United Kingdom; 2Makerere University, Kampala, Uganda; 3Joint Clinical Research Centre, Mbarara, Uganda; 4University of Zimbabwe, Harare, Zimbabwe; 5Joint Clinical Research Centre, Kampala, Uganda; 6University Teaching Hospital, Lusaka, Zambia

458 Prevalence of and Risk Factors for Peripheral Neuropathy in Rakai, Uganda
Deanna R. Saylor; Gertrude Nakigozi; Noeline Nakasujja; Xiangrong Kong; Kevin Robertson; Ronald H. Gray; Maria J. Wawer; Ned Sacktor
1Johns Hopkins University School of Medicine, Baltimore, MD, US; 2Rakai Health Sciences Program, Entebbe, Uganda; 3Makerere University College of Health Sciences, Kampala, Uganda; 4Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, US; 5University of North Carolina, Chapel Hill, NC, US

459 Predictors of Cognitive Performance Among HIV-Infected Patients in East Africa
Victor G. Valcour; Francis Kiwewa; Rosemary Namagembe; Rither Langat; Samoeil Khamadi; Kyra Hansson; Christina S. Polak; Julie Ake
On behalf of the RV329 AFRICOS Study Team
1University of California San Francisco, San Francisco, CA, US; 2Walter Reed Project, Kampala, Uganda; 3Walter Reed Project, Kericho, Kenya; 4Walter Reed Project – Tanzania, Mbeya, United Republic of Tanzania; 5Walter Reed Army Institute of Research, Silver Spring, MD, US
THURSDAY, FEBRUARY 26, 2015

Session P-G4 Poster Session
2:30 pm – 4:00 pm

HAND Genetics

460 Mitochondrial DNA Haplogroups and CSF Neuroinflammation in the CHARTER Cohort
   Todd Hulgan1; David Samuels2; Ronald J. Ellis3; William Bush2; Scott Letendre4; Donald Franklin1; Igor Grant1; Asha R. Kallianpur1
   CHARTER Group
   1University of California San Diego, San Diego, CA, US; 2Case Western Reserve University, Cleveland, OH, US; 3Cleveland Clinic Foundation, Lerner Research Institute, Cleveland, OH, US; 4Vanderbilt University, Nashville, TN, US

461 Iron-Regulatory Genes Are Associated With Neuroimaging Traits in HIV Infection
   Tricia A. Thornton-Willis1; Christine Fennema-Notestine1; Todd Hulgan1; Scott Letendre4; Ronald J. Ellis3; Asha R. Kallianpur1; for the CHARTER Group
   1Cleveland Clinic/Lerner Research Institute, Cleveland, OH, US; 2Vanderbilt University School of Medicine, Nashville, TN, US; 3University of California San Diego, San Diego, CA, US; 4Vanderbilt University School of Medicine, Nashville, TN, US; 5University of California San Diego, San Diego, CA, US; 6University of California San Diego, San Diego, CA, US; 7University of California San Diego, La Jolla, CA, US

462 Synergistic Effects of MBL2/APP Polymorphisms on Neuroimaging Impairment in CHARTER
   Kumud Singh1; Qianqian Deng; Christine Fennema-Notestine; Florin Vaida; Ronald Ellis; Scott Letendre; Donald Franklin; Debralee Rosario; Robert Heaton; Igor Grant
   CHARTER
   University of California San Diego, La Jolla, CA, US

463 No Association Between ApoE4, HIV Infection, Age, Cognitive Outcome or Death
   James T. Becker1; Jeremy J. Martinson1; Sudhir Penugonda2; Lawrence Kingsley1; Samantha A. Molsberry1; Sandra Reynolds1; Andrew Levine1; Eileen Martin1; Cynthia A. Munro1; Ted Sacktor1
   1University of Pittsburgh, Pittsburgh, PA, US; 2Northwestern University, Feinberg School of Medicine, Chicago, IL, US; 3Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, US; 4David Geffen School of Medicine at University of California Los Angeles, Los Angeles, CA, US; 5Rush University Medical Center, Chicago, IL, US; 6Johns Hopkins University School of Medicine, Baltimore, MD, US

464 Bridging Genetics, Histopathology, and Neurocognition in the Context of HAND
   Andrew Levine1; Virawudh Soontornmiyormkij1; Cristian L. Achim1; Ben Gouaux1; Eleizer Masliah1; Janet Sinsheimer1; Elyse Singer1; David J. Moore2
   1University of California Los Angeles, Long Beach, CA, US; 2University of California San Diego, San Diego, CA, US; 3University of California Los Angeles, Los Angeles, CA, US

TUESDAY, FEBRUARY 24, 2015

Session P-G5 Poster Session
2:30 pm – 4:00 pm

HAND Diagnosis and Predictors

465 Relative Risk and Factors Associated With Progression to Symptomatic HAND
   Sean B. Rourke1; John Gill2; Anita Rachlis1; Colin Kovacs3; Gordon Arbeas2; Jason Brunetta5; Adriana Carvalhal4; Chris Power4; Ann N. Burchell4; Tegeye Bekele1
   1University of Toronto, Toronto, Canada; 2University of Alberta, Calgary, Canada; 3Maple Leaf Medical Clinic, Toronto, Canada; 4The Ontario HIV Treatment Network, Toronto, Canada; 5St. Michael's Hospital, Toronto, Canada

466 Monocytes Activation Characterizes Immune Failure but Not Cognitive Impairment on ART
   Antonio Muscatello1; Davide Mangioni1; Paolo Perseghin1; Arianna Incontri1; Alessandro Soria1; Nicola Squillace1; Giuseppe Lapadula1; Sebastiano Leone1; Andrea Gori1; Alessandra Bandera1
   1S. Gerardo Hospital, Monza, Italy; 2San Gerardo Hospital—UOS Aferesi e Nuove Tecnologie Trasfusionali—SIMT, Monza, Italy

467 The VACS Index Predicts Change in Neurocognitive Functions in People With HIV
   Sean B. Rourke1; John Gill2; Anita Rachlis1; Amy Justice1; Colin Kovacs3; Gordon Arbeas2; Jason Brunetta5; Adriana Carvalhal4; Chris Power4; Ann N. Burchell4
   1University of Toronto, Toronto, Canada; 2University of Alberta, Calgary, Canada; 3Maple Leaf Medical Clinic, Toronto, Canada; 4The Ontario HIV Treatment Network, Toronto, Canada; 5University of Alberta, Edmonton, Canada; 6Yale University School of Medicine, New Haven, CT, US

468 When Diagnosing HAND, Should Visuospatial Functioning be Evaluated?
   Talia Shirazi1; Angela Summers1; Sally Steinbach1; Suad Kapetanovick1; Avindra Nath1; Bryan Smith2; Joseph Snow1
   1National Institute of Mental Health (NIMH), Bethesda, MD, US; 2National Institute of Neurological Disorders and Stroke, Bethesda, MD, US

469 Predictors of Neurocognitive Decline Among Aviremic Individuals in the CHARTER Cohort
   Marie-Josée Brouillette1; Tracy Yuen1; Susan C. Scott1; Lesley K. Fellows2; Robert Heaton3; Scott Letendre4; Ronald J. Ellis4; Nancy Mayo5 the CHARTER group
   1McGill University Health Centre, Montreal, Canada; 2McGill University Health Centre, Montreal, Canada; 3Montreal Neurological Hospital, Montreal, Canada; 4University of California San Diego, San Diego, CA, US

470 Association Between Plasma Homocysteine Levels and Neuronal Injury in Untreated HIV
   Erika Ahlgren1; Lars Hagberg1; Lars-Magnus Andersson1; Staffan Nilsson1; Dietmar Fuchs1; Henrik Zetterberg1; Magnus Gisslen1
   1University of Gothenburg, Gothenburg, Sweden; 2Chalmers University of Technology, Gothenburg, Sweden; 3Innsbruck Medical University, Innsbruck, Austria
471 Plasma MicroRNA Profiling Predicts HIV-Associated Neurocognitive Disorder  
Eugene L. Ashchop; William G. Branton; Segun M. Akwunwi; Noshin Koenig; Esther Fujiwara; John Gill; Christopher Power; 
1University of Alberta, Edmonton, Canada; 2University of Alberta, Edmonton, Canada; 3Southern Alberta Clinic, Calgary, Canada

472 Performance of 4 Tools to Screen for HIV-Associated Cognitive Impairment  
Judith Schouten; Tanja Su; Rosan A. van Zoest; Ferdinand W. Wit; Inke G. Stolte; Alan Winston; Peter Reiss; Peter Portegies; Gert J. Geurtsen; Ben A. Schmand; 
1Amsterdam Institute for Global Health and Development, Amsterdam, Netherlands; 2Academic Medical Center University of Amsterdam, Amsterdam, Netherlands; 3Imperial College London, London, Netherlands; 4Onze Lieve Vrouwe Gasthuis, Amsterdam, Netherlands; 5Public Health Service of Amsterdam, Amsterdam, Netherlands

THURSDAY, FEBRUARY 26, 2015

Session P-G6 Poster Session  
Poster Hall  
2:30 pm – 4:00 pm  
Inflammation and Markers of Brain Injury in HAND

473 Astrocyte and Microglial Activation in Acute and Chronic HIV Pre- and Post-cART  
Michael Peluso; Victor G. Valcour; Jintanat Ananworanich; James L. Fletcher; Somporn Tipsuk; Bonnie Sliker; Nittaya Phanuphak; Magnus Gisslen; Henrik Zetterberg; Serena Spudich; 
RV524/SEARCH 010 & SEARCH 011 Study Teams; 1Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, US; 2University of California San Francisco, San Francisco, CA, US; 3Walter Reed Army Institute of Research, Bethesda, MD, US; 4Thai Red Cross AIDS Research Centre, Bangkok, Thailand; 5University of Gothenburg, Gothenburg, Sweden; 6Yale University, New Haven, CT, US

474 CNS Immunoactivation and Neuronal Damage in Patients With Progressive Neurocognitive Impairment  
Arvid Edén; Donald Franklin; Henrik Zetterberg; Dietmar Fuchs; Robert Heaton; Scott Letendre; Thomas Marcotte; Richard Price; Igor Grant; Magnus Gisslen; 
1University of Gothenburg, Gothenburg, Sweden; 2University of California San Diego, San Diego, CA, US; 3Innsbruck Medical University, Innsbruck, Austria; 4University of California San Francisco, San Francisco, CA, US

475 Endothelial Function and CNS Measures in Primary HIV Infection Pre and Post Early ART  
Sebastian Urday; Zaina Zayyad; Julia Peterson; Felicia C. Chow; Kevin R. Robertson; Richard Price; Priscilla Hsue; Serena Spudich; 
1Yale University, New Haven, CT, US; 2University of California San Francisco, San Francisco, CA, US; 3University of North Carolina, Chapel Hill, NC, US

476 Platelet-Endothelial Interactions in SIV-Associated CNS Disease  
Claire E. Lyons; Hannah Schneider; Liz Engle; Suzanne E. Queen; Craig N. Morrell; Joseph L. Mankowski; Kelly A. Pate; 
1Johns Hopkins University School of Medicine, Baltimore, MD, US; 2Tufts University, North Grafton, MA, US; 3Colorado State University, Fort Collins, CO, US; 4University of Rochester, Rochester, NY, US

477 Microbial Translocation Is Associated With Neuroinflammation in HIV Subjects on ART  
Jaime H. Vera; Qi Guo; Adriano Boasso; Louise Greathhead; James Cole; Courtney Bishop; Rabiner Ilan; Roger Gunn; Paul Matthews; Alan Winston; 
1Imperial College London, London, United Kingdom; 2Imanova Centre for Imaging Sciences, London, United Kingdom

478 DKK1 Is Associated With HIV-Associated Neurocognitive Impairment  
Chunjiang Yu; Melanie Seaton; Scott Letendre; Robert Heaton; Lena Al-Harthi; 
1Rush University Medical Center, Chicago, IL, US; 2University of California at San Diego, San Diego, CA, US

479 Markers of HIV-Associated Cognitive Impairment Are Elevated in HIV-Infected Patients With Neurosyphilis  
Emily Ho; Lauren Tantalo; Sharon Sahi; Trudy Jones; Shelia Dunaway; Christina Marra; 
University of Washington, Seattle, WA, US

480 CD14+ PMBC Secrete Cytokines Linked to HIV-Associated Neurocognitive Disorders  
Melissa A. Agsalda-Garcia; Victor G. Valcour; Pasiri Sithinamsuwan; Guangxiang G. Zhang; Cecilia M. Shikuma; James L. Fletcher; Nicholas Hutchings; Alexandra Schuetz; Jintanat Ananworanich; Bruce Shiramizu; 
1University of California San Francisco, San Francisco, CA, US; 2Phramongkutkla Hospital, Bangkok, Thailand; 3The Thai Red Cross AIDS Research Centre, Bangkok, Thailand; 4University of Hawaii, John A. Burns School of Medicine, Honolulu, HI, US; 5Armed Forces Research Institute of Medical Sciences, Bangkok, Thailand

481 MBL-HIVgp120 Immunoreactivity Is Associated With Markers of Neuronal Injury  
Carmen Teodorof; Damhnien Nguyen; Nishi Kadakia; Ricky Maung; Benchawanna Soontornniyomki; Cristian Achim; David Moore; Eliezer Masliah; Marcus Kaul; Kumud Singh; 
1University of California San Diego, San Diego, CA, US; 2The Sanford Burnham Medical Research Institute, La Jolla, CA, US

WEDNESDAY, FEBRUARY 25, 2015

Session P-G7 Poster Session  
Poster Hall  
2:30 pm – 4:00 pm  
Aging and Cognitive Decline

482 Amyloid Uptake by PET Imaging in Older HIV+ Individuals With Cognitive Impairment  
Ned Sacktor; Richard Skolasky; Heidi Roosa; Yun Zhou; Weiguo Ye; Noble George; Dean Wong; Mona Mohamed; 
Johns Hopkins University School of Medicine, Baltimore, MD, US
483  Lower CSF Amyloid-β Levels Are Associated With Worse Neurocognitive Functioning in HIV-Infected Adults With a Family History of Dementia  
Parinya L. Fazeli; David J. Moore; Donald Franklin; Robert Heaton; Christina Marra; Benjamin B. Gelman; Allen McCutchan; Igor Grant; Scott Letendre  
1University of California San Diego, San Diego, CA, US; 2University of Washington Seattle, Seattle, WA, US; 3University of Texas Medical Branch, Galveston, TX, US

484  Cystatin C Is Associated With Neurocognitive Impairment in Older HIV+ Adults  
Marissa Sakoda; Parinya L. Fazeli; Scott Letendre; Dilip Jeste; Igor Grant; David J. Moore  
1John A. Burns School of Medicine at the University of Hawaii, Honolulu, HI, US; 2University of California San Diego, San Diego, CA, US

485  Leptomeningeal Enhancement on MRI in the Aging HIV-Positive Population  
Bryan R. Smith; Sally Steinbach; Govind Nair; Caryn Morse; Joseph Snow; Suad Kapetanovich; Henry Masur; Avindra Nath; Daniel S. Reich  
1National Institutes of Health, Bethesda, MD, US; 2National Institute of Mental Health, Bethesda, MD, US; 3National Institutes of Health, Clinical Center, Bethesda, MD, US

486  Hepatitis C Infection and Cognition in Older HIV+ Adults: Data From the Center of Excellence on Disparities in HIV and Aging (CEDHA)  
Oluwayooyin M. Adeyemi; Sue Leurgans; Alan Landay; David Bennett; Lisa Barnes  
2Ruth M Rothstein CORE Center, Cook County Health and Hospitals System, Chicago, IL, US; 3Rush University Medical Center, Chicago, IL, US

487  Neurocognitive Screening Tests Are Associated With Cardiovascular Risk and VACS Scores  
Andrea Calcagni; Marielisabetta Scaravaglioni; Daniela Vai; Alessandro Livelli; Letizia Marinaro; Giancarlo Ortolino; Nicole Pagani; Daniele Imperiale; Giovanni Di Perri; Stefano Bonora  
1University of Torino, Torino, Italy; 2ASL TO2, Torino, Italy; 3ASL TO2, Torino, Italy

488  Aerobic Exercise Attenuates Cognitive Decline and Brain Volume Loss Associated With HIV  
Brian Basco; Mario Ortega; Jodi M. Heaps; Laurie Baker; Florin Vaida; Bea Anes  
1Washington University School of Medicine, St. Louis, MO, US; 2University of Missouri St. Louis, St. Louis, MO, US; 3Missouri Institute of Mental Health, St. Louis, MO, US; 4University of California San Diego, San Diego, CA, US

489  The Impact of Physical Activity on Cognition in Men With and Without HIV  
Anne Monroe; Long Zhang; Lisa P. Jacobson; Todd T. Brown; Michael Plankey; Eric Miller; James T. Becker; Eileen Martin; Ned Sacktor  
On behalf of the Multicenter AIDS Cohort Study  
1Johns Hopkins University School of Medicine, Baltimore, MD, US; 2Johns Hopkins University School of Medicine, Baltimore, MD, US; 3University of California Los Angeles, Los Angeles, CA, US; 4Georgetown University, Washington, DC, US; 5University of Pittsburgh, Pittsburgh, PA, US; 6Rush University Medical Center, Chicago, IL, US; 7Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, US

490  Abnormal Lung Function Associated With Abnormal Brain Structure and Function in HIV  
Alison Morris; Lawrence Kingsley; Matthew Gingo; Meghan Fitzpatrick; Roger Detels; Oto Martinez; Eric Miller; Jeffrey Alger; Eric Kleerup; James T. Becker  
1University of Pittsburgh, Pittsburgh, PA, US; 2University of Pittsburgh, Pittsburgh, PA, US; 3David Geffen School of Medicine at University of California Los Angeles, Los Angeles, CA, US

491  HIV DNA and Neurocognitive Impairment in Older Subjects on Suppressive ART  
Michelli Faria de Oliveira; Ben Murrell; Jessué Perez-Santiago; Milenka Vargas; Ronald J. Ellis; Scott Letendre; Igor Grant; Davey M. Smith; Steven P. Woods; Sara Gianella  
1University of California San Diego, La Jolla, CA, US; 2HIV Neurobehavioral Research Center, San Diego, CA, US

492  Suppressive ART Is Key to Reduce Neurocognitive Impairment in Aging HIV+ Individuals  
Christina C. Yek; David M. Smith; Gabriel Wagner; Susan Morgello; Scott Letendre; Igor Grant; Sergei L. Kosakovsky Pond; Sara Gianella  
On behalf of the CHARTER group  
1University of California San Diego, San Diego, CA, US; 2Icahn School of Medicine at Mount Sinai, New York, NY, US

493  Mixed Membership Trajectory Model of Cognitive Impairment in the MACS  
Samantha A. Molsberry; Fabrizio Lecci; Brian Junker; Sandra Reynolds; Andrew Levine; Eileen Martin; Cynthia A. Munro; Ned Sacktor; James T. Becker; Neuropsychology Working Group O. Multicenter AIDS Cohort Study  
1University of Pittsburgh, Boston, MA, US; 2Carnegie Mellon University, Pittsburgh, PA, US; 3Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, US; 4University of California Los Angeles, Los Angeles, CA, US; 5Rush University Medical Center, Chicago, IL, US; 6Johns Hopkins University School of Medicine, Baltimore, MD, US; 7National Institutes of Health (NIH), Bethesda, MD, US

494  Brain Structural Correlates of Trajectories to Cognitive Impairment in HIV Disease  
James T. Becker; Mikhail Popov; Samantha A. Molsberry; Fabrizio Lecci; Brian Junker; Sandra Reynolds; Eric Miller; Cynthia A. Munro; Ann Ragin; Ned Sacktor  
1University of Pittsburgh, Pittsburgh, PA, US; 2Carnegie Mellon University, Pittsburgh, PA, US; 3Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, US; 4David Geffen School of Medicine at University of California Los Angeles, Los Angeles, CA, US; 5Johns Hopkins University School of Medicine, Baltimore, MD, US; 6Northwestern University, Feinberg School of Medicine, Chicago, IL, US
495 Cognitive Reserve and Neuropsychological Functioning in Older HIV-Infected People
Beneditta Milanini1; Nicoletta Ciccarelli2; Silio Limiti1; Pierfrancesco Grima1; Massimiliano Fabiani3; Barbara Rossetti1; Elena Visconti1; Enrica Tamburini1; Roberto Cauda1; Simona Di Giambenedetto1
1Institute of Infectious Diseases, Catholic University of Sacred Heart, Rome, Italy; 2Division of Infectious Diseases, “S. Cattarina Novella” Hospital, Galatina, Italy; 3Division of Infectious Diseases, University of Siena, Italy

THURSDAY, FEBRUARY 26, 2015

Session P-G8 Poster Session Poster Hall 2:30 pm – 4:00 pm
Mitochondrial Dysfunction in HAND and Depression

496 Mitochondrial DNA, Neurologic and Systemic Inflammation, and Immune Dysregulation
Josué Pérez-Santiago: Michelli Faria de Oliveira; Susanna R. Var; Steven P. Woods; Sara Gianella Weibel; Sanjay Mehta; Ben Murrell; Tyler R. Day; Ronald J. Ellis
University of California San Diego, La Jolla, CA, US

497 CSF Metabolomics Implicate Bioenergetic Adaptation as a Neural Mechanism Regulating Shifts in the Cognitive States of HIV-Infected Subjects
Norman J. Haughey1; Alex Dickens1; Reena Deutsch2; Michelle Mielke3; Timothy Claridge4; Igor Grant1; Thomas Marcotte5; Scott Letendre6; Justin McArthur1
1Johns Hopkins University School of Medicine, Baltimore, MD, US; 2University of California San Diego, San Diego, CA, US; 3Mayo Clinic Rochester, MN, US; 4University of Oxford, Oxford, United Kingdom

498 Altered Monoamine and Acylcarnitine Metabolites in HIV Patients with Depression
Edana Cassol1; Vikas Misra2; Susan Morgello3; Gregory D. Kirk4; Shruti H. Mehta5; Dana H. Gabuzda6
1York Univeristy, Toronto, ON, Canada; 2Brown University, Providence, RI, US; 3University of Toronto, Toronto, ON, Canada; 4University of Michigan, Ann Arbor, MI, US; 5University of Nebraska Medical Center, Omaha, NE, US; 6University of Pennsylvania, Philadelphia, PA, US

Program and Agenda
TUESDAY, FEBRUARY 24, 2015

Session P-H1 Poster Session
2:30 pm – 4:00 pm
Pharmacokinetics, Pharmacodynamics, and Adherence

509 HIV-1 Attachment Inhibitor Prodrug BMS-663068: Model-Based Dose Selection
Ishani Savant Landry1; Li Zhu2; Malaz Abutarif2; Matthew Hruska1; Brian M. Sadler2; Maria Pitsiu2; George J. Hanna1; David W. Boulton1; Richard Bertz3
1Bristol-Myers Squibb, Princeton, NJ, US; 2ICON plc, Cary, NC, US; 3ICON plc, Manchester, United Kingdom

510 Pharmacokinetic and Pharmacodynamic Evaluation of NNRTI IQP-0528 Duogel™ in Macaques
Lara E. Pereira1; Pedro Mesquita1; Anthony Ham1; Tyana Singleton4; Janet McNicholl1; Karen W. Buckheit4; Robert Buckheit4; James M. Smith1
1LifeSource Biomedical LLC, Moffett Field, CA, US; 2Albert Einstein College of Medicine, Bronx, NY, US; 3Emory University School of Medicine, Atlanta, GA, US; 4University of California San Francisco, San Francisco, CA, US

511 Tenofovir PK in Adults With Renal Dysfunction on LPV/r and NNRTI-Based ART
Tim R. Cresse1; Anchalee Avihingsanon1; Guttiga Halve1; Prattana Leenarisrinakul2; Pra-orn-suda Sukrakanchana2; Anthony T. Podany1; Courtney Fletcher2; Gonzague Jourdain3; Vinat Kiranbuayaeni1; Chureeratana Bowonwatanuwong1
1PHP-IRD UMI 174 Chiang Mai University/ Harvard School of Public Health, Chiang Mai, Thailand; 2HIV Netherlands Australia Thailand Research Collaboration, Bangkok, Thailand; 3Phaya Hospital, Phaya, Thailand; 4Nakorn Lampang Hospital, Phayao, Thailand; 5Chiang Mai University, Chiang Mai, Thailand; 6University of Nebraska Medical Center, Omaha, NE, US; 7Sanpatong Hospital, Sanpatong, Thailand; 8Chonburi Hospital, Chonburi, Thailand

512 Population Pharmacokinetics of Cotrimoxazole West African HIV-Infected Children
Claire Pressiat1; Sihem Benaboud1; Jean-Marc Treluyer1; Véronique Méa-Assande2; Caroline Tonaba3; Sophie Dattez1; Diana Ye1; Yi ZHENG2; Valeriane Leroy1; Deborah HIRT1
1MONOD ANRS 12206; 2Paris Descartes University, EA 08, Paris, France; 3Clinical Pharmacology Department, AP-HP, Paris Centre Hospital Group, Paris, France; 4Avocatier Health Center, Abidjan, Côte d’Ivoire; 5Department of Paediatrics, CHU Yaounde Université, Yaounde, Cameroon; 6Institute of Public Health, Epidemiology and Development (ISPED), University of Bordeaux, Bordeaux, France; 7Department of Paediatrics, CHU Charles de Gaulle, Université de Ouagadougou, Ouagadougou, Burkina Faso

513 ART Choice Impacts Antimalarial Exposure and Treatment Outcomes in Ugandan Children
Sumil Parikh1; Norah Mwaba1; Richard Kajubi1; Joshua Ssebuliba1; Sylvia Kiconco1; Lusheung Huang2; Qin Gao3; Abiel Kakuru1; Jane Achau4; Francesca T. Aweke1
1University of California, San Francisco, San Francisco, CA, US; 2Yale University, New Haven, CT, US; 3Makerere University College of Health Sciences, Kampala, Uganda

514 Exploring Long-Term Adherence Markers Using Hair and Dried Blood Spots in iPrEx OLE
Monica Gandhi1; David V. Glidden2; Albert Liu1; Peter L. Anderson1; Howard Homg3; Juan Guanira4; Beatriz Grinsztejn4; Suwat Charityalertsak2; Linda-Gail Bekker6; Robert M. Grant1
1University of California San Francisco, San Francisco, CA, US; 2San Francisco Department of Public Health, San Francisco, CA, US; 3Investigaciones Medicas en Salud, Lima, Peru; 4Instituto de Pesquisa Clinica Evandro Chagas, Rio de Janeiro, Brazil; 5Chiang Mai University, Chiang Mai, Thailand; 6University of Cape Town, Cape Town, South Africa; 7University of Colorado, Denver, CO, US

Session P-H2 Poster Session
2:30 pm – 4:00 pm
Pharmacogenomics

515 UGT1A1 Genotype Predicts Bilirubin-Related Discontinuation of Atazanavir/Ritonavir
Saran Vardhanabhatti1; Heather J. Ribaudo1; Raphael J. Landovitz2; Igbo Ofotokun1; Jeffrey L. Lennox1; Judith S. Currier1; Lana M. Olson2; David W. Haas3
1Harvard School of Public Health, Center for Biostatistics in AIDS Research, Boston, MA, US; 2UCLA Center for Clinical AIDS Research Education, Los Angeles, CA, US; 3Emory University School of Medicine, Atlanta, GA, US; 4Vanderbilt University School of Medicine, Nashville, TN, US

516 ABCB1 Polymorphism Affects Tenofovir Exposure as Determined by Areas-Under-the-Time-Concentration-Curve With 24-hour Intensive Pharmacokinetic Monitoring
Sanjiv M. Barx1; Peter Bacchetti1; Mardge Cohen1; Jack A. Dehovitz1; Kathryn Anastor1; Stephen J. Gange1; Mary A. Young1; Monica Gandhi1; Bradley Aouizerat1
1University of California San Francisco, San Francisco, CA, US; 2John Stroger (formerly Cook County) Hospital, Chicago, IL, US; 3State University of New York Downstate Medical Center, Brooklyn, NY, US; 4Montefiore Medical Center, University Hospital for Albert Einstein College of Medicine, Bronx, NY, US; 5Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, US; 6Georgetown University, Washington, DC, US

517 Pharmacogenomics of Plasma Tenofovir Clearance and Change in Creatinine Clearance
Valentine Wanga1; Charles Venuto1; Gene D. Morse1; Edward A. Acosta1; Eric Daar1; David W. Haas1; Chuen Li1; Bryan E. Shepherd1
1Vanderbilt University School of Medicine, Nashville, TN, US; 2University of Rochester Medical Center, Rochester, NY, US; 3State University of New York at Buffalo, Buffalo, NY, US; 4Los Angeles Biomedical Research Institute at Harbor–UCLA Medical Center, Torrance, CA, US; 5University of Alabama at Birmingham, Birmingham, AL, US

518 Variant ITPA Phenotypes Are Associated With Increased Ribavirin Triphosphate Levels
Leah C. Jimmerson1; Thomas J. Urban1; Eric Meissner1; Ariel Hodara1; Jacob A. Langness1; Christina Aquilante1; Aimée Truesdale1; Fafa Baouchi-Mokrane1; Michelle Ray1; Jennifer K. Kiser1
1University of Colorado, Aurora, CO, US; 2University of North Carolina, Chapel Hill, NC, US; 3NIADDK, NIH, Bethesda, MD, US; 4University of Colorado Health, Aurora, CO, US; 5Denver Health and Hospital Authority, Denver, CO, US
Session P-H3 Poster Session Poster Hall
2:30 pm – 4:00 pm
Drug-Drug Interactions

519 Interactions of Antiretroviral Drugs With the SLC22A1 (OCT1) Drug Transporter
Darren M. Moss; Neill Liptrott; Marco Siccardi; Andrew Owen
University of Liverpool, Liverpool, United Kingdom

520 EFV but Not ATV/r Significantly Reduces Atovaquone Concentrations in HIV+ Subjects
Monica M. Calderon1; Joseph A. Kovacs2; Alice K. Pau2; Maryellen McManus2; Raul Alfaro2; Parag Kumar2; Scott R. Prenzak1
1National Institutes of Health (NIH), Bethesda, MD, US; 2National Institute of Allergy and Infectious Diseases (NIAID), Bethesda, MD, US;

521 The Effect of Single and Multiple Dose Rifampin on the Pharmacokinetics of Doravirine
Ka Lai Yee1; Sauzanne G. Khalilieh2; Rachael Liu3; Rosa Sanchez2; Matt S. Anderson3; Candice Smith-Bradley3; Joann Butterton3; Timothy Judge1; Helen Manthos1; John Brejda1

522 Drug-Drug Interaction Between HCV Inhibitors Grazoprevir/Elbasvir With Dolutegravir
Wendy W. Yeh1; Ted Marreno2; Hwa-Ping Feng3; Zifang Guo3; Daria Stypinski3; Lisa Ross4; Ivy H. Song5; Patricia Jumes3; Barbara Cook2; Joan R. Butterton3

523 HIV-1 Attachment Inhibitor Prodrug BMS-663068: Interactions with DRV/r and/or ETR
Ishani Savant Landry1; Xiaolu Tao; Jeffrey Anderson; Michael Hesney; Michele Stonier; Susan Lubin; Jian Wang; George J. Hanna; David W. Boulton
Bristol-Myers Squibb, Princeton, NJ, US

THURSDAY, FEBRUARY 26, 2015

Session P-H4 Poster Session Poster Hall
2:30 pm – 4:00 pm
Pharmacokinetics in Compartments and Reservoirs and of Novel Formulations

524 Local and Systemic Pharmacokinetic Profile of Dapivirine Vaginal Ring-004 When Used Continuously Over Various Periods up to Twelve Weeks
Annalene M. Nel1; Wouter Haazen2; Marisa Russell3; Jeremy P. Nuttall1; Neliette Van Niekerk1; Nicole Treijtel1
1International Partnership for Microbicides, Paarl, South Africa; 2SGS Life Science Services, Antwerp, Belgium; 3International Partnership for Microbicides, Silver Spring, MD, US; 4Kinessa Pharma BV, Breda, Netherlands

525 Steady-state TDF/FTC in Genital, Rectal, and Blood Compartments in Males vs Females
Sharon M. Seifert1; Amie L. Meditz2; Jose R. Castillo-Mancilla3; Edward M. Gardner1; Brandon Klein4; Becky Kerr1; L. Anthony Guida1; Jia-Hua Zheng5; Lane R. Bushman6; Peter L. Anderson1
1University of Colorado, Aurora, CO, US; 2Boulder Community Hospital, Boulder, CO, US; 3University of Colorado School of Medicine, Aurora, CO, US;

526 Effects of Tenofovir/Emtricitabine on Endogenous Deoxyribonucleotide Pools In Vivo
Xinhui Chen1; Kevin McAllister2; Jia-Hua Zheng; Jose R. Castillo-Mancilla; Amie Meditz; Brandon Klein; Sharon M. Seifert; Lane Bushman; Peter L. Anderson1
1University of Colorado Anschutz Medical Campus, Aurora, CO, US; 2Beacon Center of Infectious Diseases, Boulder, CO, US;

527 Higher Cell Accumulation and Antiviral Activity of Lopinavir/Ritonavir Nanoparticles
Philip Martin1; Tom O. McDonald2; Marco Giardiello3; Steven P. Rannard4; Andrew Owen5
1University of Liverpool, Liverpool, United Kingdom; 2University of Liverpool, Liverpool, United Kingdom

528 HIV reservoir targeted antiretroviral nanofabrication facilitates viral clearance
Pavan Puliguruka; JoEllyn McMillan; Shantanu Balkundi; Prasanta K. Dash; James Hilaire; Santhi Gorantla; Larisa Poluektova; Xin-Ming Liu; Howard Gendelman
1University of Nebraska Medical Center, Omaha, NE, US; 2Kansas University Innovation and Collaboration, Lawrence, KS, US

529 The Macrophage Proteome Defines the Long Acting Antiretroviral Therapy Cell Depot
Dongwei Guo; Mariluz Araingga; Jayme Horning; Pawel Ciborowski; Xin-Ming Liu; JoEllyn McMillan; Howard Gendelman
University of Nebraska Medical Center, Omaha, NE, US

530 Primary CD4 Subsets Are Similarly Loaded by Tenofovir Alafenamide (TAF)
Christian R. Frey; Yang Liu; Darius Babus; Adam Palazzo; Adrian S. Ray; Michael D. Miller; Kathryn M. Kitirinos; Christian Callebaut
Gilead Sciences, Inc., Foster City, CA, US
533 Pharmacogenetics of Pregnancy-Induced Changes in Efavirenz Pharmacokinetics

Adeniyi Olagunju1; Oluseye Bolaji; Alleu Amara; Laura Else; Ogechi Okafor; Ebunoluwa Adejuyigbe; Oyigboja Johnson; David Back; Saye Khoo; Andrew Owen1

1University of Liverpool, Liverpool, United Kingdom; 2Obafemi Awolowo University, Ile-Ife, Nigeria; 3Bishop Murray Medical Centre, Makurdi, Nigeria; 4Catholic Caritas Foundation of Nigeria, Makurdi, Nigeria

534 Antiretroviral Drug Transporters and Metabolic Enzymes in Human Testicular Tissue

Billy Huang1; Md. Tozammel Hoque1; Mohammad-Ali Jenabian1; Kishanda Vobo1; Nancy Sheehan1; Pierre Brassard1; Maud Bélander1; Nicolas Chomont1; Jean-Pierre Routy1; Reina Bendayan1

1University of Toronto, Toronto, Canada; 2McGill University, Montreal, Canada; 3Université du Québec à Montréal, Montréal, Canada; 4Metropolitan Centre of Plastic Surgery, Montréal, Canada; 5Vaccine and Gene Therapy Institute of Florida, Port St Lucie, FL, US

535 Imaging the Spatial Distribution of Efavirenz in Intact HIV Tissue Reservoirs

Elias P. Rosen1; Corbin G. Thompson1; Mark T. Bokhart1; Craig Sykes1; Yuri Fedorivi1; Paul Lucivi1; David C. Muddiman1; Angela D.M. Kashuba1

1North Carolina State University, Raleigh, NC, US; 2University of North Carolina, Chapel Hill, NC, US; 3University of California Davis, Davis, CA, US

WEDNESDAY, FEBRUARY 25, 2015

Session P-11 Poster Session Poster Hall
2:30 pm – 4:00 pm
Drug Development

536 Inhibition of HIV-1 Replication by a Novel Acylguanidine-Based Molecule

Philip Mwimanzi1; Ian Tietjen1; Aniqa Shahid1; Scott C. Miller1; David Fedida1; Zabrina L. Brumme1; Mark Brockman1

1Simon Fraser University, Burnaby, Canada; 2University of British Columbia, Vancouver, Canada

537 4’-Ethynyl-2-Fluoro-2’-Deoxyadenosine (Efda) Has an Extremely High Genetic Barrier, Persistently Exerting Highly Potent Activity Against a Variety of HIV-1 Isolates Including Efda-Selected HIV-1 Variants

Kenji Maeda1; Yuki Takamatsu1; Satoru Kohgo1; Nicole S. Delino1; Simon B. Chang1; Kazuhiro Haraguchi1; Hiroaki Mitsuva1

1National Institutes of Health (NIH), Bethesda, MD, US; 2National Center for Global Health and Medicine, Tokyo, Japan; 3Nihon Pharmaceutical University, Saitama, Japan

538 GS2838232, a Second Generation HIV-1 Maturation Inhibitor With an Optimized Virology Profile

Jerry Jeffrey1; Ping Wang1; Charlene McDana1; Pauline J. Shipper1; Kevin Brown1; Cristin Galardi1; Jun Tang1; Monique Nijhuis1; Brian Johns1

1GlaxoSmithKline, Research Triangle Park, NC, US; 2University of Utrecht, Utrecht, Netherlands

539 Maturation Inhibitor Mechanistic Studies - Differential Inhibition of Gag Polymorphs

Zeyu Lin1; Joseph Cantone1; Tricia Protack1; Dieter Drexler1; Befa Nowicka-Sans1; Yuan Tian1; Zheng Liu1; Mark Krystal1; Alicia Regueiro-Ren1; Ira B. Dicker1


540 Late-Stage Integrate-LEDGF Initiators Mode of Action and Acquisition of Resistance

Richard Benarous1; Erwann Le Rouzic1; Nikki van Bel1; Yme van der Velden1; Damien Bonnard1; Atze Das1; Celine Amadori1; Alessia Zamborlini1; Stephane Emiliani1; Ben Berkhourt1

1Biodim Mutabilis, Romainville, France; 2Academic Medical centre, Amsterdam, Netherlands; 3Inserm CNRS, Paris, France; 4U944 UMR7212, Inserm CNRS, Paris, France

541 BMS-986001: A Promising Candidate for HIV-2 Treatment

Robert A. Smith1; Dana Raugi1; Kate Parker1; Mariah Oakes1; Papa Salif Sow1; Selly Ba1; Moussa Seydi1; Geoffrey S. Gottlieb1

On behalf of the University of Washington-Dakar HIV-2 Study Group

1University of Washington, Seattle, WA, US; 2CHU de Fann, Dakar, Senegal

542 Dual Loaded Sustained Release Core-Shell Nanoparticles for Anti-HIV Therapy

Hilliard L. Kutscher1; Jessica L. Reynolds1; Faithful Makita1; Sara DiTursi1; Jacob Milling1; Jesse Hanchett1; Charles C. Maponga1; Paras N. Prasad1; Gene D. Morse1

1University at Buffalo, Buffalo, NY, US; 2University of Zimbabwe, College of Health Sciences, Harare, Zimbabwe

543 Chemical Facilitated Endosomal Storage of Long-Acting Antiretroviral Nanoparticles

Dongwei Guo1; Prasanta K. Dash1; Gang Zhang1; Marliz Arainga1; Jaclyn Knibbe1; Joffilyn McMillan1; Larisa Poluektova1; Harris Gelbard1; Santhi Gorantla1; Howard Gendelman1

University of Nebraska Medical Center, Omaha, NE, US

TUESDAY, FEBRUARY 24, 2015

Session P-J1 Poster Session Poster Hall
2:30 pm – 4:00 pm
ART: Recent Perspectives

544 24-Weeks Virologic Efficacy of Fozivudine in ART-Naive Patients From Africa

Arne Kroidl1; Tessa Lennemann1; Frederic Ello1; Jimson Mgaya1; Raoul Mohi1; Lucas Maganga1; Serge P. Eholié1; Pierre-Marie Girard1; Friedrich von Massow1; Christine Danel1

1Medical Center of the University of Munich (LMU), Munich, Germany; 2CHU de Treichville, Abidjan, Côte d’Ivoire; 3NIMR–Mbeya Medical Research Center, Mbeya, United Republic of Tanzania; 4University Hospital Saint-Antoine, Paris, France; 5Institute for Life Sciences and Environment GmbH, Heidelberg, Germany; 6Programme PAC-CI, ANRS, Abidjan, Côte d’Ivoire
545 Attachment Inhibitor Prodrug BMS—663068 in ARV-Experienced Subjects: Week 48 Analysis
Melanie Thompson; Jay Lalezari; Richard Kaplan; Yvette Pinedo; Otto Sussman Pena; Pedro Cahn; David A. Stock; Samit R. Joshi; George J. Hanna; Max Latella

546 Delay in Antiretroviral Therapy Is Not Associated With Increased Virologic Failure
Ashita S. Batavia; Patrice Severi; Marc Antoine Jean Juste; Rode Secours; Daphné C. Bernard; William J. Pape; Daniel Fitzgerald
1Weill Cornell Medical College, New York, NY, US; 2GIESKO Center, Port-au-Prince, Haiti

547 Effects of Quadruple First-Line ART on Mucosal Immunity
Sergio Serrano-Villar; Tatia Sainz; Surinder Mann; Zhong-Min Ma; Christopher Miller; Netanya S. Utaba; Basile Siewe; Tae Wook-Chun; Paolo Troia-Cancio; David Asmuth
1University Hospital Ramón y Cajal, Madrid, Spain; 2University Hospital Gregorio Marañón, Madrid, Spain; 3University of California Davis, Sacramento, CA, US; 4University of Texas, Galveston, TX, US; 5Rush University Medical Center, Chicago, IL, US; 6National Institute of Allergy and Infectious Diseases (NIAID), Bethesda, MD, US

548 Maraviroc-Dependent Pharmacologic Effects on Viral Decay and Immune Recovery in GALT
Corbin Thompson; Tae Wook Chun; Craig Sykes; Zhing-Min Ma; Christopher Miller; Surinder Mann; Richard Pollard; Angela Kashuba; David Asmuth
1University of North Carolina at Chapel Hill, Chapel Hill, NC, US; 2Division of AIDS, NIAID, NIH, Bethesda, MD, US; 3University of California Davis Medical Center, Davis, CA, US; 4University of California Davis, Davis, CA, US

549 Maraviroc Induces HIV Production in RCT and In Vitro, Potentially via the NFkB Pathway
Jori Symons; Ward de Spieglaelere; Annemarie Wensing; Julia Drylevich; Anania Middel; Andy I. Hoepelman; Kiki Tessaara; Lino Vandekerckhove; Steven F. van Lelyveld; Monique Nijhuis
1University Medical Center Utrecht, Utrecht, Netherlands; 2Ghent University, Ghent, Belgium; 3University Medical Center Utrecht, Utrecht, Netherlands; 4University Medical Center Utrecht, Utrecht, Netherlands

550 Consistency of Douleugreavir Treatment Difference in HIV+ Treatment Naives at Week 96
Catherine M. Granier; Robert Cuffe; Louise Martin-Carpenter; Kimberly Y. Smith; Clare Brennan; Keith Pappa; Brian Wynne; Steve Almond; Naomi Givens; Michael Abouit
1GlaaxSmithKline, Uxbridge, United Kingdom; 2GIV Healthcare, London, United Kingdom; 3GIV Healthcare, Research Triangle Park, NC, US; 4GlaaxSmithKline, Research Triangle Park, NC, US; 5GlaaxSmithKline, Mississauga, Canada

551 Predictors of HIV RNA Suppression on Darunavir/Ritonavir Monotherapy in the MONET and PROTEA Trials
Diego Ripamonti; Ralph DeMasi; Andrew M. Hill; Ceyyun Bicer; Christiane Moecklinghoff
1Chelsea and Westminster Hospital, London, United Kingdom; 2O. Papa Giovanni XXIII, Bergamo, Italy; 3Janssen Pharmaceuticals, Inc., Titusville, NJ, US; 4Janssen Pharmaceuticals, Inc., Beerse, Belgium; 5Janssen Pharmaceuticals, Inc., Neuss, Germany

552 Second-Line Treatment in Sub-Saharan Africa: Week 144 Follow-up of the EARNEST Trial
James G. Hakim; Jennifer Thompson; Cissy M. Kityo; Sarah Walker; Joep van Oosterhout; Anne Hoppe; Andrew D. Kambu; Peter Mugenyi; Nicholas Paton
1On behalf of the EARNEST Trial Team
2University of Zimbabwe, College of Health Sciences, Harare, Zimbabwe; 3University College London, London, United Kingdom; 4Joint Clinical Research Centre, Kampala, Uganda; 5Dignitas, Zomba, Malawi; 6Infectious Disease Institute, Kampala, Uganda; 7National University of Singapore, Singapore, Singapore; 8MRC Clinical Trials Unit at University College London, London, United Kingdom

553 Withdrawing Inactive NRTIs in Subjects With Suppressed Viremia: A Randomized Trial
Josep M. Llibre; Hortensia Alvarez; Antonio Antela; Jessica Toro; Juan González-Moreno; M Jesus Perez-Elias; Arkaitz Imaz; Mar Masía; Manel Crespo; Bonaventura Clotet
1Univ Hosp Germans Trias, Badalona, Spain; 2Hospital Clínico Universitario, Santiago de Compostela, Spain; 3Hospital Son Llátzer, Mallorca, Spain; 4Hospital Ramón y Cajal, IRYCIS, Madrid, Spain; 5Hospital Universitari del Bellvitge, L’Hospitalet de Llobregat, Spain; 6Hospital Universitario de Elche, Elche, Spain; 7Hospital Universitari Vell d’Hebrón, Barcelona, Spain; 8Complejo Universitario de Ferrol, A Coruña, Spain

554LB Cabotegravir and Rilpivirine As 2-Drug Oral Maintenance Therapy: LATTE W96 Results
David A. Margolis; Cynthia C. Brinson; Graham H. Smith; Jerome de Vente; Debbie P. Hagnis; Sandy K. Griffith; Marty H. St. Clair; Kimberly Y. Smith; Peter E. Williams; William R. Spreen
1GlaaxSmithKline, Durham, NC, US; 2Central Texas Clinical Research, Austin, TX, US; 3Maple Leaf Medical Clinic, Toronto, Canada; 4Living Hope Foundation, Long Beach, CA, US; 5Chatham County Health Department, Savannah, GA, US; 6VII Healthcare, Durham, NC, US; 7Janssen Pharmaceuticals, Inc, Beerse, Belgium

Session P-K1 Poster Session
2:30 pm – 4:00 pm
ART: Adherence, Adherence, Adherence

555 Self-Reported Versus Blood-Tested ART Intake to Estimate ART Coverage in South Africa
Helena Huerga; Gilles Van Cutsem; Lubbe Wiesner; Malika Bouhennia; Jihane Ben Farhat; Emmanuel Fajadot; Ruggero G. Giuliani; David Mambo; Thomas Ellman; Jean-François Etabl
1Epicentre, Paris, France; 2Département des Frontières, Cape Town, South Africa; 3University of Cape Town, Cape Town, South Africa
Real-Time Electronic Adherence Monitoring and Risk of Viral Rebound
Jessica E. Haberer; Nicholas Musinguzi; Mark Siedner; Yap Boum; Peter W. Hunt; Jeffrey Martin; David R. Bangsberg
1Massachusetts General Hospital, Harvard Medical School, Boston, MA, US; 2Mbarara University of Science and Technology, Mbarara, Uganda; 3Université Paris-Est Créteil Université Paris 12, Créteil, France; 4University of California, San Francisco, San Francisco, CA, US

Determinants of Adherence to Antiretroviral Therapy Differ Between Africa and Asia
Rimke Bijker; Awachana Jiamsakul; Margaret Siwale; Sasisopin Kiertiburanakul; Cissy M. Kityo; Praphan Phanuphak; Tobias F. Rinke de Wit; Oon Tek Ng; Raph L. Hamers; PATER-TASER Cohort Collaboration
PASER-TASER Cohort Collaboration
1Amsterdam Institute for Global Health and Development, Amsterdam, Netherlands; 2The Kirby Institute, Sydney, Australia; 3Lusaka Trust Hospital, Lusaka, Zambia; 4Ramathibodi Hospital, Mahidol University, Bangkok, Thailand; 5Joint Clinical Research Centre, Kampala, Uganda; 6HIV-NAT/Thai Red Cross AIDS Research Centre, Bangkok, Thailand; 7Tan Tock Seng Hospital, Novena, Singapore

Retention on Antiretroviral Therapy by Sex and Pregnancy Status in a Large Cohort of HIV-Infected Patients in Rural Nigeria
Usman I. Gebi; Meredith Blevins; Mukhtar Y. Muhammad; C. William Wester; Muktar H. Ailiy
1Vanderbilt University, Nashville, TN, US; 2Friends for Global Health Initiative Nigeria, Abuja, Nigeria

Randomised Controlled Trial of Text-Message Dosing Reminders in Patients Starting ART
Catherine Orrell; Karen Cohen; Katya Mauff; David R. Bangsberg; Gary Maartens; Robin Wood
1University of Cape Town, Cape Town, South Africa; 2Harvard Medical School, Boston, MA, US

Socioeconomic Factors and Virological Rebound: A Prospective UK Cohort Study
Lisa S. Burch; Colette Smith; Jane Anderson; Lorraine Sherr; Alison Rodger; Richard Gilson; Jonathan Elford; Andrew N. Phillips; Margaret Johnson; Alison Rodger; Lisa S. Burch
1University College London, London, United Kingdom; 2City University London, London, United Kingdom; 3Homerton University Hospital NHS Foundation Trust, London, United Kingdom; 4Royal Free London NHS Foundation Trust, London, United Kingdom

New Marker of Standard-of-ART Care: Percentage of Time on cART With Suppressed HIV-RNA
Kamilla G. Laut; Leah C. Shepherd; Court Pedersen; Jürgen Rockstroh; Helen Sambatakou; Dzmitry Paduta; Jens D. Lundgren; Amanda Mocroft; Ole Kirk; EuroSIDA in EuroCoord
on behalf of EuroSIDA in EuroCoord
1Righospitalet, University of Copenhagen, Copenhagen, Denmark; 2Odense University Hospital, Odense, Denmark; 3University Hospital Bonn, Bonn, Germany; 4University College London, London, United Kingdom; 5Hippokration General Hospital, University of Athens, Athens, Greece; 6Gomel Regional Centre for Hygiene, Gomel, Belarus

Viremia Copy Years and Its Impact on Risk of Clinical Progression According to Shape
Alessandro Cozzi-Leppri; Antonella Cingolani; Andrea Antinori; Andrea De Luca; Cristina Mussini; Stefano Rusconi; Carmela Pinetti; Massimo Galli; Antonella Castagna; Antonella d’Arminio Monforte
1University College London, London, United Kingdom; 2Sacro Cuore University, Roma, Italy; 3NIMI Spallanzani, Roma, Italy; 4University of Siena, Siena, Italy; 5University of Modena, Modena, Italy; 6Luigi Sacco University Hospital, Milano, Italy; 7S. Paolo Hospital, Milano, Italy; 8San Raffaele Scientific Institute, Milano, Italy

Monitoring and Switching of Antiretroviral Therapy in Sub-Saharan Africa
Andreas D. Haas; Olivia Keeser; François Dabis; Mary-Ann Davies; Rosalind M. Parkes-Ratanshi; Steven J. Reynolds; Kara Wools-Kaloustian; Gilles Wandeler; Matthias Egger
1IeDEA East, West and Southern Africa; 2Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland; 3Université Bordeaux, Bordeaux, France; 4University of Cape Town, Cape Town, South Africa; 5Makere University College of Health Sciences, Makerere, Uganda; 6National Institute of Allergy and Infectious Diseases (NIAID), Bethesda, MD, US; 7Indiana University, Indianapolis, IN, US

Virological Factors Associated With Outcome of Dual MVC/RAL Therapy (ANRS-157 Trial)
Cathia Soulie; Lambert Assoumou; Melanie Darty; Christophe Rodriguez; Gilles Peytavin; Marc-Antoine Valantin; Dominique Costagliola; Christine Katlama; Vincent Calvez; Anne-Genevieve Marcelin
1Hôpital Pitié Salpêtrière, Paris, France; 2INSERM/UPMC, Paris, France; 3APHP Mondor, Creteil, France; 4APHP Bieth, Paris, France; 5Hôpital Saint-Louis, APHP, Université Paris Diderot, Paris, France

D-dimer Doesn’t Return to Pre-HIV Levels After Therapy and Is Linked With HANA Events
Matthew S. Freibberg; Ionut Bebu; Russell Tracy; Jason F. Okulicz; Anuradha Ganesan; Adam Armstrong; Thomas O’Bryan; Brian K. Agan
1IDCRP HIV Working Group; 2Uniformed Services University of the Health Sciences, North Bethesda, MD, US; 3Vanderbilt University Medical Center, Nashville, TN, US; 4University of Vermont College of Medicine, Burlington, VT, US; 5George Washington University, Rockville, MD, US; 6US Naval Medical Research Unit No. 6, Peru, Lima, Peru
566 Virological Responses to Lamivudine and Emtricitabine in the Nationwide ATHENA Cohort
Casper Rolks\(^1\); Azzania Fibriani\(^2\); David A. van de Vijver\(^2\); Annelies Verbon\(^1\); Martin Schutten\(^1\); Luuk Gras\(^1\); Bart J. Rijnders\(^1\)
On behalf of the Dutch HIV Monitoring Foundation
\(^1\)Erasmus University Medical Center, Rotterdam, Netherlands; \(^2\)Academic Medical Center University of Amsterdam, Amsterdam, Netherlands

567 Prevalence and Risk Factors of Multiple Micronutrient Deficiencies Pre- and Post-ART
Rupak Shikakoti\(^1\); Parul Christian\(^2\); Nikhil Gupta\(^1\); Cecilia Kanyama\(^3\); Sima Berendes\(^4\); Javier Luna\(^5\); Richard Semba\(^1\); Thomas Campbell\(^6\); Anita Gupta\(^1\)
NWCS 319 and PEARLS Study Team
\(^1\)Johns Hopkins University School of Medicine, Baltimore, MD, US; \(^2\)Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, US; \(^3\)University of North Carolina Project—Malawi, Lilongwe, Malawi; \(^4\)Malawi College of Medicine—Johns Hopkins University Research Project, Blantyre, Malawi; \(^5\)Association Civil Impacta Salud y Educacion, Lima, Peru; \(^6\)University of Colorado School of Medicine, Aurora, CO, US

568 Detection of HIV RNA and DNA in Anal Swabs of HIV Infected Men Having Sex With Men
Julian Storm\(^1\); Jens Verheyen\(^2\); Eva Wolff\(^2\); Lewin Eisele\(^1\); Meriam Wohlschläger\(^1\); Peter-Michael Rath\(^2\); Evelyn Heintschel von Heinegg\(^1\); Casper Rokx\(^1\); Stefan Esser\(^1\)
\(^1\)University Hospital Essen, Germany; \(^2\)University Hospital Essen, University Duisburg-Essen, Essen, Germany; \(^3\)University Hospital Essen, University Duisburg-Essen, Essen, Germany; \(^4\)University Hospital Essen, University Duisburg-Essen, Essen, Germany

WEDNESDAY, FEBRUARY 25, 2015

569 Reference Curves for CD4 Response to Antiretroviral Treatment in HIV-1—Infected Naïve Patients
Rodolphe Thiebaut
On behalf of the Standard Reference Distribution of CD4 Working Group in COHERE in EuroCoord
Bordeaux University, Bordeaux, France

570 Comparing Immunological Failure Definitions, Using Tanzanian National HIV Data
Fiona Vanobberghen\(^1\); Bonita K. Kilama\(^2\); Alison Wringe\(^1\); Angela Ramadhan\(^1\); Basia Zaba\(^1\); Donan Mmbando\(^2\); Jim Todd\(^1\)
\(^1\)London School of Hygiene and Tropical Medicine, London, United Kingdom; \(^2\)National AIDS Control Program, Dar es Salaam, United Republic of Tanzania; \(^3\)Ministry of Health & Social Welfare, Dar es Salaam, United Republic of Tanzania

571 Delaying Second-Line Therapy After First-Line Failure: Moderating Effect of CD4 Count
Julia K. Rohr\(^1\); Prudence Iwe\(^1\); Rebecca H. Berhanu\(^1\); Kate Shearer\(^1\); Mhaini Maskew\(^1\); Lawrence Long\(^2\); Ian Sannie\(^1\); Matthew P. Fox\(^1\)
\(^1\)Boston University School of Public Health, Boston, MA, US; \(^2\)University of Witswatersrand, Johannesburg, South Africa; \(^3\)Right to Care, Johannesburg, South Africa

572 Rapid Progression Hinders the Recovery of CD4 + T Cells Following Initiation of cART
Inma Jarrin
On behalf of the CASCADE Collaboration within EUROCORDER
Instituto de Salud Carlos III, Madrid, Spain

573 Increase in CD4 Counts at Presentation to ART Care Among Urban HIV Clinics in Uganda
ELIZABETH K. NALINTYA\(^1\); Agnes N. Kiragga\(^1\); Edison Katunguka\(^2\); Henry W. Nabeta\(^3\); Joanita Kigozi\(^4\); Yukari Manabe\(^1\); David R. Boulware\(^1\); Jon Kaplan\(^1\); David B. Meya\(^5\)
\(^1\)Infectious Diseases Institute, Kampala Uganda, Kampala, Uganda; \(^2\)University of Minnesota, Minneapolis, MN, US; \(^3\)CDC Center for Global Health, Division of Global AIDS/HIV, Atlanta, GA, US; \(^4\)Johns Hopkins University, Baltimore, MD, US

574 Implications of Poor CD4 Recovery During HIV Suppressive ART in Sub-Saharan Africa
Marieke E. de pondert\(^1\); Tamara Sonia Boender\(^1\); Raph L. Hamers\(^1\); Kim Sigaloff\(^2\); Cissy M. Kityo\(^3\); Alani S. Akanmu\(^4\); Maureen Wellington\(^1\); Tobias F. Runke de WIT\(^5\); Pascale Ondoa\(^6\)
Pan African Studies to Evaluate Resistance (PASER) studygroup
\(^1\)Amsterdam Institute for Global Health and Development, Brasschaat, Belgium; \(^2\)Joint Clinical Research Centre Kampala, Kampala, Uganda; \(^3\)Lagos University Teaching Hospital, Lagos, Nigeria; \(^4\)Newlands Clinic, Harare, Zimbabwe

575 Better CD4/CD8 Restoration in First-Line HIV-Infected CMV-Seronegative Patients
Isabelle Poizot-Martin\(^1\); Clotilde Allavena\(^1\); Claudine Duvivier\(^1\); Carla E. Cano\(^3\); Francine Guillouet de Salvador\(^1\); David Rey\(^1\); Lise Cuzin\(^1\); Antoine Cheret\(^1\); Bruno Hoen\(^1\)
On behalf of the Dat’AIDS Group
\(^1\)Aix-Marseille Univ, APHM Hôpital Sainte-Marguerite, Marseille, France; \(^2\)CHU Hotel Dieu, Nantes, France; \(^3\)APHP—Hôpital Necker—Université Paris Descartes—IHU Imagine, Paris, France; \(^4\)CHU Archet 1, Nice, France; \(^5\)Hôpitaux Universitaires Strasbourg, Strasbourg, France; \(^6\)Regional Coordination for HIV, Toulouse, France; \(^7\)Hospital Tourocoing, Tourocoing, France; \(^8\)University Medical Center of Guadeloupe, Guadeloupe, France; \(^9\)The Dat’AIDS Group, Nice, France

576 CD4 Response in Treatment-Naïve HIV-2—Infected Patients: The IeDEA West Africa Cohort
Eric Balestre\(^1\); Koumavi K. Ekouevi\(^2\); Boris Tchounga\(^3\); Serge P. Eholie\(^4\); Eugène Messou\(^5\); Adrien Savadogo\(^6\); Rodolphe Thiebaut\(^1\); Margaret T. May\(^1\); Jonathan A. Sterne\(^1\); François Dabis\(^1\)
\(^1\)Univ Bordeaux, ISPED, Centre Inserm U897-Epidemiologie-Biostatistique, Bordeaux, France; \(^2\)Programme PAM-CI, Centre Hospitalier Universitaire de Treichville, Abidjan, Côte d’Ivoire; \(^3\)Service de Maladies Infectieuses et Tropicales, Centre Hospitalier Universitaire de Treichville, Abidjan, Côte d’Ivoire; \(^4\)Centre de Prise en Charge de Recherche et de Formation, Hôpital Yopougon Atlé, Abidjan, Côte d’Ivoire; \(^5\)Institut Supérieur des Sciences de la Santé, Université Polytechnique de Bobo-Dioulasso, Bobo-Dioulasso, Burkina Faso; \(^6\)School of Social and Community Medicine, Bristol University, Bristol, United Kingdom
**Session P-K4 Poster Session**  
**2:30 pm – 4:00 pm**  
**ART: Mortality**

577  
**Mortality and Retention After 12 Months in a Cohort of Patients Initiated With the New WHO Recommendations in Uganda**  
John Ssali; Juan Gonzalez Perez; Jonathan Ikapule; Lydia Buzzaahirwa; Kate Ssamula; Augustine Lubanga; Sulaiman Kawogoya; Monday Busulwa; Penninah Lutung Amor; Michael Wohlfeiler  
AIDS Healthcare Foundation, Kampala, Uganda

578  
**Effect of ART on Mortality Generalized to Newly HIV-Diagnosed Persons in the USA**  
Catherine R. Lesko1; Stephen R. Cole1; H. Irene Hall2; Michael J. Mugavero1  
1University of North Carolina, Chapel Hill, NC, US; 2University of Alabama at Birmingham, Birmingham, AL, US  
On behalf of the Antiretroviral Therapy Cohort Collaboration (ART-CC)

579  
**Association of CD4:CD8 With Cause-Specific Mortality in Patients on Long-Term ART**  
Margaret T. May1; Adam Trickey1; Dominique Costagliola1; Peter Reiss1; Santiago Moreno2; John Gill3; Colette Smith1; Suzanne M. Ingle1; Jonathan A. Sterne1  
1University of Bristol, Bristol, United Kingdom; 2University of California, Berkeley, CA, US; 3Academic Medical Center University of Amsterdam, Amsterdam, Netherlands  
On behalf of the Antiretroviral Therapy Cohort Collaboration (ART-CC)

580  
**Outcomes of First ART in Latino Populations in North America and Latin America**  
Carina T. Cesar1; Mark J. Giganti2; Bryan E. Shepherd1; Richard Moore1; Keri N. Althoff1; Sonia Napravnik1; Angel M. Mayor1; Catherine Mc Govan1; Pedro E. Cahn1  
1Fundacion Huesped, Buenos Aires, Argentina; 2Vanderbilt University, Nashville, TN, US  
On behalf of the Antiretroviral Therapy Cohort Collaboration (ART-CC)

581  
**Gender Disparity in cART Initiation/Outcome: The South African Military Phidisa Cohort**  
Ming-Han Motsoung1; Linda Mesani1; Selloane Pula1; Jing Wang1; Michael Proshansky1; Matthew Dolan1  
1On behalf of the Phidisa Gender Disparity Group  
2Henry Jackson Foundation, San Antonio, TX, US; 3Project Phidisa, Bloemfontein, South Africa; 4National Institute of Allergy and Infectious Diseases (NIAID), Bethesda, MD, US

---

**Session P-L1 Poster Session**  
**2:30 pm – 4:00 pm**  
**HIV Drug Resistance: Mechanisms and Mutations**

585  
**Structural Basis of Inhibition and Resistance Mechanism to EfdA, a Highly Potent NRTI**  
Zhe Li1; Karen Kirby1; Bruno Marchand1; Michalidis Eleftherios1; Eiichi Kodama1; Hisao Mitsuya2; Michael Parriott3; Stefan Sarafianos3  
1University of Missouri, Columbia, MO, US; 2Tohoku University, Sendai, Japan; 3National Institutes of Health, Division of AIDS, Bethesda, MD, US; 4University of Pittsburgh, Pittsburgh, PA, US

586  
**Structural Basis and Distal Effects of Gag Substrate Coevolution in Drug Resistance to HIV-1 Protease**  
Kuan-Hung Lin; Celia A. Schiffer  
University of Massachusetts Medical School, Worcester, MA, US

587  
**Influence of Codon Pair Usage in the Evolvability of HIV-1**  
Maria Nevot1; Cristina Andries1; Mariona Parera1; Glòria Martrus1; Miguel Ángel Martinez1  
1IrsiCaixa Institute for AIDS Research, Badalona, Spain
Four Amino Acid Changes in HIV-2 Protease Confer Class-Wide PI Susceptibility  
Dana N. Raugi; Robert A. Smith; Matthew Coyne; Julie Olson; Kara Parker; Selly Ba; Papa Salif Sow; Moussa Seydi; Geoffrey S. Gottlieb  
University of Washington-Dakar HIV-2 Study Group  
1University of Washington School of Medicine, Seattle, WA, US; 2Centre Hospitalier National Universitaire de Fann, Universite Cheikh Anta Diop de Dakar, Dakar, Senegal

Enhanced Neutralization of HIV-1 With Fusion Inhibitor Resistant Mutations  
Muntasir Alam; Takeo Kuwata; Kristel P. Ramirez; Yasuhiro Maruta; Kazuki Tanaka; Kazuya Shimura; Shinya Oishi; Nobutaka Fujii; Masao Matsuoka; Shuzo Matsushita  
1Kumamoto University, Kumamoto, Japan; 2Kyoto University, Kyoto, Japan

Mutations at the Bottom of the Phe43 Cavity Are Responsible for Cross-Resistance to NBD Analogue  
Shigeoishi Harada; Yu Iraha; Samatchaya Boonchawalit; Mai Goryo; Hirokazu Tamamura; Tetsuro Matano; Shuzo Matsushita; Kazuhsia Yoshimura  
1National Institute of Infectious Diseases, Shinjuku, Japan; 2Tokyo Medical and Dental University, Chiyoda, Japan; 3Kumamoto University, Kumamoto, Japan

SIV S derived Integrase as a Model of HIV Drug Resistance Against Integrase Inhibitors  
Said Hassounah; Thibault Mesplede; Maureen Oliveira; Peter K. Quashe; Daniela Moisi; Paul A. Sandstrom; Mark A. Wainberg; Bluma Brenner  
1McGill University, Montreal, Canada; 2National HIV and Retrovirology Laboratory, National Microbiology Laboratory, Public Health Agency of Canada, Ottawa, Canada

Within-Run Cross-Contamination in Deep Sequencing Applications on the Illumina MiSeq  
Chanson J. Brunme; Winnie Dong; Celia K. Chui; Richard Liang; Art F. Poon; Richard Harrigan  
BC Centre for Excellence in HIV/AIDS, Vancouver, Canada

Analysis of Resistance Haplotypes Using Primer IDs and Next Gen Sequencing of HIV RNA  
Valerie F. Boltz; Jason Rauch; Wei Shao; Charles Coomer; John W. Mellors; Mary Kearney; John M. Coffin  
1National Institutes of Health (NIH), Frederick, MD, US; 2Leidos, Frederick, MD, US; 3University of Pittsburgh, Pittsburgh, PA, US; 4Tufts University, Boston, MA, US

Session P-L2 Poster Session  
2:30 pm – 4:00 pm  
Poster Hall  
HIV Subtypes and Resistance

HIV-1 Subtype Influences the Pathways of Genotypic Resistance to Integrase Inhibitors  
Tomas J. Doyle; David Dunn; Rolf Kaiser; Erasmus Smit; Anne-Genevieve Marcellin; Carmen de Mendoza; Javier Martinez-Picado; Federico Garcia; Francesca Ceccherini-Silberstein; Anna Maria Geretti  
CORONET study group  
1King’s College London, London, United Kingdom; 2University of Liverpool, Liverpool, United Kingdom; 3University of Cologne, Cologne, Germany; 4University College London, London, United Kingdom; 5Hopital Pitié Salpetriere, APHM, Paris, France; 6Hospital Carlos III, Madrid, Spain; 7University Hospital San Cecilio, Granada, Spain; 8University of Rome Tor Vergata, Rome, Italy; 9Institut de Recerca de la Sida, Barcelona, Spain; 10Birmingham Heartlands Hospital, Birmingham, United Kingdom

Differences in Resistance Mutations in Non-B Subtypes at First-Line Failure in Africa  
Cissy M. Kityo; Sarah Walker; Immaculate Nankywa; Anne Hoppe; Jennifer Thompson; Silvia Bertagnolio; Philippa Easterbrook; Peter Muyengyi; Nicholas Paton  
On behalf of the EARNEST Trial Team  
1Joint Clinical Research Centre, Kampala, Uganda; 2MRC Clinical Trials Unit at University College London, London, United Kingdom; 3World Health Organization, Geneva, Switzerland; 4Yong Loo Lin School of Medicine, Singapore, Singapore

K65R Detected More Frequently in HIV-1 Subtype C Viruses at Virological Failure  
Erasmus Smit; Ellen White; Duncan Clark; Duncan Churchill; Hongyi Zhang; Simon Collins; Deenan Pillay; Anna Tostevin; David Dunn  
UKHD RD and UKCHIC  
1Public Health England, Birmingham, United Kingdom; 2Brighton and Sussex Hospitals NHS Trust, Brighton, United Kingdom; 3University of KwaZulu-Natal and University College London, London, United Kingdom; 4St Bartholomew’s and the London NHS Trust, London, United Kingdom; 5HIV-1 Base, London, United Kingdom; 6Addenbrooke’s Hospital, Cambridge, United Kingdom; 7University College London, London, United Kingdom

Viral Failure and High K65R in Kenyan Patients on Tenofovir-Based First-Line Therapy  
Katherine C. Brooks; Lameck Diero; Allison Delong; Maya Balamane; Marissa Reitsma; Emmanuel Kemboi; Millicent Orido; Mia Coetzer; Joseph Hogan; Rami Kantor  
1Moi University, Eldoret, Kenya; 2Brown University, Providence, RI, US; 3Academic Model Providing Access to Healthcare, Eldoret, Kenya

Session P-L3 Poster Session  
2:30 pm – 4:00 pm  
Transmitted HIV Drug Resistance: Assessing the Threat

Large NNRTI-Resistant Transmission Cluster in Injection Drug Users From Saskatchewan  
Alexander Wong; Jaspret Kambo; Richard Harrigan; Art F. Poon; Jeffrey B. Joy  
1University of Saskatchewan, Regina, Canada; 2BC Centre for Excellence in HIV/AIDS, Vancouver, Canada
599 Transmitted Drug Resistance and Time of HIV Infection, New York State, 2006-2013
Zhengyan Wang; Emily Walits; Daniel E. Gordon; Bridget J. Anderson; Deepa Rajulu; Ling Wang; Lou C. Smith
1New York State Department of Health, Albany, NY, US; 2University at Albany, School of Public Health, Albany, NY, US

600 Transmitted HIV Drug Resistance Among Early Infected Persons in San Diego, California
Theppharit Panichsillapakit; David M. Smith; Joel Wertheim; Douglas D. Richmond; Susan Little; Sanjay Mehta
1Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand; 2University of California San Diego (UCSD), La Jolla, CA, US

601 HIV Molecular Epidemiology and Transmitted Drug Resistance in the Mesoamerican Region
Claudia Garcia-Morales; Santiago Avila-Rios; Daniela Tapia-Trejo; Carlos Mejia-Villatoro; Juan M Pascale; Guillermo Porras-Cortes; Ivette Lorenzana; Elsa Palou; Marvin Manzanero; Gustavo Reyes-Terán
1National Institute of Respiratory Disease, Mexico City, Mexico; 2Roosevelt Hospital, Guatemala City, Guatemala; 3Gargas Memorial Institute for Health Studies, Panama City, Panama; 4Universidad Nacional Autónoma de Honduras, Tegucigalpa, Honduras; 5Vivian Pellias Metropolitan Hospital, Managua, Nicaragua; 6Ministry of Health, Belize City, Belize

602 Temporal Trends of Transmitted HIV Drug Resistance Following Seroconversion
Ashley Olson; Claudia Kuchere; Anders Sönnerborg; Carmen de Mendoza; Robert Zangerle; Maria Prins; John Gill; Anne-Marie Bakken Kran; Dimitrios Paraskevis; Kholoud Porter
for CASCADE collaboration in EuroCoord
1University College London, London, United Kingdom; 2University of Calgary, Alberta Health Services, Calgary, Canada; 3Robert Koch Institute, Berlin, Germany; 4Karolinska Institutet, Stockholm, Sweden; 5Puerta de Hierro Research Institute and University Hospital, Madrid, Spain; 6Insbruck Medical University, Innsbruck, Austria; 7Oulu University Hospital, Oulu, Norway; 8University of Athens, Athens, Greece; 9Public Health Service of Amsterdam, Amsterdam, Netherlands;

603 Increase in HIV Primary Drug Resistance in a Demographic Surveillance Area in Rural KwaZulu-Natal South Africa
Justen Manasa; Siva Danaviah; Frank Tanser; Sureshnee Pillay; Tholiphile Mthiyane; Eduan Wilkinson; Deenan Pillay; Tulio de Oliveira
University of KwaZulu-Natal, Durban, South Africa

604 A Clinical Prediction Rule for PI Resistance in Resource-Limited Settings
Karen Cohen; Annemie Stewert; Andre P. Kengne; Rory F. Leisegang; Marla Coetse; Shavani Maharaj; Liezl Dunn; Graeme Meintjes; Gert U. van Zyl; Gary Maartens
1University of Cape Town, Cape Town, South Africa; 2Aid for AIDS Management Pty Ltd, Cape Town, South Africa; 3University of Stellenbosch, Cape Town, South Africa

605 Baseline Low-Frequency HIV-1 Variants Do Not Predict Virologic Failure to RPV/FTC/TDF
Danielle P. Porter; Martin Däumer; Alexander Thielens; Michael D. Miller; Kirsten L. White
1Gilead Sciences, Inc., Foster City, CA, US; 2Seq-IT GmbH & Co KG, Kaiserslautern, Germany

606 High Rates of Early Virologic Failure in a Cohort of Tanzanian HIV-Infected Adults
Claudia A. Hawkins; Nzovu Ulenga; Enju Liu; Said Aboud; Ferdinand Mugusi; Guerino Chalamilla; David Sando; Eric Aris; Wafaei Fawzi
1Northwestern University, Feinberg School of Medicine, Chicago, IL, US; 2Management and Development for Health, Dar es Salaam, United Republic of Tanzania; 3Harvard School of Public Health, Boston, MA, US; 4Muhimbili University of Health and Allied Sciences, Dar es Salaam, United Republic of Tanzania

607 HIV Drug Resistance Surveillance in Honduras After 10 Years of Widespread ART
Claudia Garcia-Morales; Santiago Avila-Rios; Daniela Tapia-Trejo; Rita Meza; Sandra Nuñez-Rubio; Norma Flores; Wendy Murillo; Ivette Lorenzana; Elsa Palou; Gustavo Reyes-Terán
1National Institute of Respiratory Diseases, Mexico City, Mexico; 2Honduran HIV National Program and National Laboratory, Tegucigalpa, Honduras; 3Universidad Nacional Autónoma de Honduras, Tegucigalpa, Honduras; 4Hospital Escuela Universitaria, Tegucigalpa, Honduras; 5Instituto Nacional Cardiopulmonar, Tegucigalpa, Honduras

608 High Prevalence of Genotypic Resistance to Integrase inhibitors of HIV-1 Strains in Taiwan
Sui-Yuan Chang; Chien-Ching Huang
1National Taiwan University, Taipei, Taiwan; 2National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan

609 Integrase Resistance Correlates of Response to Dolutegravir (DTG) Through 48 Weeks
Cindy L. Vavro; Jenny Huang; Mounir Ait-Khaled
Gilead Sciences, Inc., Foster City, CA, US; 2Seq-IT GmbH & Co KG, Kaiserslautern, Germany

610 Discordant Predictions Could Impact Dolutegravir Use Upon Raltegravir Failure
Kristof Theys; Ana B. Abecasis; Pieter Libin; Perpétua Gomes; Joaquim Cabanas; Ricardo J. Camacho; Kristel Van Laethem
1The Portuguese HIV-1 Resistance Study Group
2University of Leuven, Leuven, Belgium; 3Universidade Nova de Lisboa, Lisbon, Portugal; 4Hospital Egas Moniz, Lisbon, Portugal

611 Integrase S119P Mutation Correlates With Disease Progression in HIV-1 Naïve Patients
Daniele Armenia; Maria Mercedes Santoro; Caterina Gori; Emanuele Nicastri; Antonio Cristaudo; Massimo Andreoni; Andrea Antinori; Zeger Depuyt; Carlo-Federico Perno; Francesca Ceccherini-Silberstein
1University of Rome Tor Vergata, Rome, Italy; 2L. Spallanzani Hospital, Rome, Italy; 3San Gallicano Dermatological Institute, Rome, Italy; 4University Hospital Tor Vergata, Rome, Italy; 5Katholieke Universiteit Leuven, Leuven, Belgium
TUESDAY, FEBRUARY 24, 2015

Session P-M1 Poster Session
2:30 pm – 4:00 pm
Poster Hall

Nucleic-Acid–Based Detection of HIV

612 A Generalized Entropy Measure of Viral Diversity for Identifying Recent HIV-1 Infections
Julia W. Wu; Oscar Patterson-Lomba; Marcello Pagano
Harvard School of Public Health, Boston, MA, US

613 Acute Infections, Cost and Time to Reporting of HIV Test Results in US State Public Health Laboratories
Muazam Nasrullah1; Laura G. Wesolowski1; Steven F. Ethridge1; Kevin Cranston1; Robert A. Myers1; James T. Rudrik1; Angela B. Hutchinson1; Barbara G. Werner2

614 The POC Alere q HIV-1/2 Detect Test for Detection and Quantification of HIV-2
Ming Chang1; Katja Weimar1; Dana N. Raugi1; Robert A. Smith1; Selly Ba2; Moussa Seydi2; Katrin Steinmetzer3; Robert W. Coombs4; Geoffrey S. Gottlieb2
1Department of Health and Mental Hygiene, Baltimore, MD, US; 2POC Technologies, Jena, Germany; 3Service des Maladies Infectieuses, CHU de Fann, Dakar, Senegal

615 Performance of HIV Viral Load with Dried Blood Spots in Children on ART in Mozambique
Amina M. de Sousa Muhate1; James C. Houston1; Mariam Assane1; Joy Chang1; Emilia Koumans1; Ilesh V. Jani1; Jennifer Sabatier1; Paula M. Vaz1; Chunfu Yang2; Emilia Rivadeneira2
1Ministry of Health, Mozambique, Mozambique; 2Centers for Disease Control and Prevention, Atlanta, GA, US; 3Fundação Ariel Glaser Contra o SIDA Pediátrico, Maputo, Mozambique

616 Cost-Effectiveness of Pooled PCR Testing of Dried Blood Spots for Infant HIV Diagnosis
Cari van Schalkwyk1; Jean Maritz1; Alex Welte1; Gert U. van Zyl1; Wolfgang Preiser1
1University of Stellenbosch, Tygerberg, South Africa; 2University of Stellenbosch, Stellenbosch, South Africa; 3University of Stellenbosch, Tygerberg, South Africa

617 Evaluating Dried Blood Spot Performance in Assessing HIV Treatment Failure in Uganda
Allen Roberts; Herbert C. Duber; Ming Chang; Anne Gasasira; Gloria Iklezi; Jane Achau; Joan Dragavon; Glenda Daza; Emmanuela Gakidou; Robert W. Coombs
Makerere University College of Health Sciences, Kampala, Uganda

618 Comparison of Pooled RNA and 4th Gen Ag/Ab Testing to Identify Acute HIV Infection
Gary Murphy; Simon Carne; Bharati Patel; Elaine Mckinney; Samuel Moses; Noel Gill; John Parry; Jennifer Tosswill
Public Health England, London, United Kingdom

WEDNESDAY, FEBRUARY 25, 2015

Session P-M2 Poster Session
2:30 pm – 4:00 pm
Poster Hall

Comparison of HIV Incidence Assays

620 Evaluation of Determine2 HIV-1/2 Ag/Ab Combo in the Context of Acute HIV Screening
Silvina Masciota1; S. Michele Owen1; Wei Luo1; Emily Westheimer1; Stephanie Cohen1; Laura Hall1; Cindy L. Gay1; Philip J. Peters1

621 Performance of the Geenius HIV-1/HIV-2 Assay in the CDC HIV Testing Algorithm
Kevin P. Delaney; Steven Ethridge; Laura G. Wesolowski; Michele Owen; Bernard M. Branson
US Centers for Disease Control and Prevention (CDC), Atlanta, GA, US

622 The Effect of HIV-1 Subtype A, C and D on Cross-Sectional Incidence Assay Performance
Andrew F. Longosz1; Mary Grabowski1; Charles S. Morrison1; Ronald H. Gray2; Connie Celum3; Quarraisha Abdool Karim4; Hilmarie Brand5; Thomas C. Quinn; Susan H. Eshleman; Oliver B. Laeyendecker6
1National Institute of Allergy and Infectious Diseases, Baltimore, MD, US; 2Johns Hopkins University, Baltimore, MD, US; 3FFH 360, Durham, NC, US; 4University of Washington, Seattle, WA, US; 5CAPRISA, University of KwaZulu-Natal, Congella, South Africa; 6SAEMTA, Stellenbosch University, Stellenbosch, South Africa

623 Avidity Assay for Cross-Sectional Incidence Based on a 4th-Generation Combo Ag/Ab EIA
Allison R. Kirkpatrick1; Eshan U. Patel1; Connie L. Celum1; Richard D. Moore2; Joel N. Blankson2; Shruti H. Mehta3; Gregory D. Kirk4; Thomas C. Quinn5; Susan H. Eshleman6; Oliver B. Laeyendecker7
1National Institutes of Health, Bethesda, MD, US; 2University of Washington, Seattle, WA, US; 3Johns Hopkins University School of Medicine, Baltimore, MD, US; 4Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, US; 5Johns Hopkins University School of Medicine, Baltimore, MD, US; 6Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, US; 7Johns Hopkins University School of Medicine, Baltimore, MD, US
624  
Andrea A. Kim¹; David Maman²; Harrison Fredrick Omondi²; Alex Morwabe³; Irene Mukui⁴; Valerie Opollo⁴; Beatrice Kirubi²; Jean-François Etard⁵; Martinus W. Borgdorff⁶; Clement Zeh⁷
¹US Centers for Disease Control and Prevention, Dpa, AE, US; ²Médecins Sans Frontières, Paris, France; ³Kenya Medical Research Institute (KEMRI)/CDC Research and Public Health Collaboration, Kisumu, Kenya; ⁴Kenya Ministry of Health, Nairobi, Kenya; ⁵Médecins Sans Frontières, Nairobi, Kenya; ⁶US Centers for Disease Control and Prevention (CDC), Kisumu, Kenya; ⁷US Centers for Disease Control and Prevention (CDC), Kisumu, Kenya

625  
False Recent Rates for Two Recent Infection Testing Algorithms, South Nyanza, Kenya
Clement Zeh¹; David Maman²; Harrison Omondi²; Alex Morwabe³; Collins Odhiambo²; Beatrice Kirubi³; Irene Mukui⁴; Martinus W. Borgdorff⁵; Jean-François Etard⁶; Andrea A. Kim⁷
¹US Centers for Disease Control and Prevention, Kisumu, Kenya; ²Kenya Medical Research Institute, Kisumu, Kenya; ³National AIDS and STI Control and Prevention, Nairobi, Kenya; ⁴Médecins Sans Frontières, Paris, France

626  
Viral Load is Critical in Limiting False-Recent Results From HIV Incidence Assays
Reshma Kassanjee¹; Shelley Facente²; Sheila Keating³; Elaine McKinney⁴; Kara Marson⁵; Christopher D. Pilcher⁵; Michael Busch⁶; Gary Murphy⁷; Alex Welte⁸

627  
Use of the Sample-to-Cutoff Ratio (S/CO) to Identify Recency of HIV-1 Infection
Eric M. Ramos; José Ortega; Glenda Daza; Yuree Namkung; Socorro Harb; Joan Dragavon; Robert W. Coombs
University of Washington, Seattle, WA, US

628  
An Abbott Architect Combo Signal to Cut-Off Ratio With Adequate PPV to Confirm HIV
Tomas O. Jensen¹; Peter Robertson²; Jeffrey J. Post³
¹Prince of Wales Hospital, Randwick, Australia; ²South Eastern Area Laboratory Services, Prince of Wales Hospital, Sydney, Australia

629  
Determining HIV Status of African Adults With Discordant HIV Rapid Tests
Jessica M. Fogel¹; Estelle Piwowar-Manning¹; Mark A. Marzinke¹; William Clarke¹; Michal Kulich⁴; Jessie K. Mbwamba⁴; Linda Richter⁴; Glenda Gray²; Thomas J. Coates³; Susan H. Eshleman¹
¹Johns Hopkins University School of Medicine, Baltimore, MD, US; ²Charles University, Prague, Czech Republic; ³Muhimbili University Teaching Hospital, Dar es Salaam, United Republic of Tanzania; ⁴Universities of the Witwatersrand and KwaZulu-Natal, Durban, South Africa; ⁵South African Medical Research Council, Cape Town, South Africa; ⁶David Geffen School of Medicine and University of California Los Angeles Health, Los Angeles, CA, US

Session P-M3 Poster Session  
2:30 pm – 4:00 pm

HIV Detection, Tropism, and CD4 Measurement

630  
Accuracy of POC CD4 testing using microtube capillary sampling in Botswana households
Sikhulile Moyo¹; Lillian Okui²; Hermann Bussmann³; Simani Gasetteiswe⁴; Erik van Widenfeld⁴; Molly P. Holme⁵; Joseph Makhema⁶; Shahin Lockman⁷; Vladimir Novitsky⁸; Max Essex⁹
¹Botswana Harvard AIDS Institute Partnership, Gaborone, Botswana; ²Harvard School of Public Health, Boston, MA, US

631  
Zymomyx MyT4 and BD FACSPresto Comparison to the Pima CD4 Assay
Katie Tucker; Sehin Birhana; Larry Westerman
US Centers for Disease Control and Prevention (CDC), Atlanta, GA, US

632LB  
Point-of-Care CD4 (Pima) Impact on Linkage to Care With Home-Based HIV Testing, Kenya
Mitesh A. Desai¹; Duncan Okal²; Robert T. Chen³; Richard Nduvo³; Charles Lebaron¹; Tiffany Williams¹; Fred Otieno¹; Charles Rose¹; Taraz Samandari¹; Clement Zeh²
¹US Centers for Disease Control and Prevention, Atlanta, GA, US; ²Kenya Medical Research Institute, Kisumu, Kenya

633  
Reliable Genotypic Tropism Tests for the Major HIV-1 Subtypes
Kieran Cashin¹; Lachlan R. Gray²; Katherine L. Harvey³; Danielle Perez-Bercoff⁴; Guinevere Q. Lee⁵; Jasmina Stejnovski⁶; James F. Demarest⁷; Fraser Drummond⁸; Melissa J. Churchill⁹; Paul R. Gorry¹⁰
¹Burnet Institute, Melbourne, Australia; ²Centre Recherche Public de la Santé, Strassen, Luxembourg; ³UC Centre for Excellence in HIV/AIDS, Vancouver, Canada; ⁴ViiV Healthcare, Durham, NC, US

634  
Accuracy of Re-Reading HIV Rapid Tests and the Effect of Prolonged High Temperature
Augustine T. Choko¹; Deus Thindwa¹; Peter MacPherson²; Rodrick Sambakunsi³; Aaron Moldo⁴; Kondwani Chiyumya⁵; Owen Malema⁶; Simon Makombe⁷; Emily L. Webb⁸; Elizabeth L. Corbett⁹
¹Malawi Liverpool Wellcome Trust Clinical Research Programme, Blantyre, Malawi; ²University of Liverpool, Liverpool, United Kingdom; ³Ministry of Health, Blantyre, Malawi; ⁴Ministry of Health, Lilongwe, Malawi; ⁵London School of Hygiene and Tropical Medicine, London, United Kingdom; ⁶London School of Hygiene and Tropical Medicine, London, United Kingdom

635  
Analysis of False Negative HIV Tests Based on Oral Fluid in 3 Clinical Trials
Marcel E. Curlin¹; Michael T. Martin¹; Wanna Leelawiwat¹; Roman Gvetadze²; Charles Rose³; Sarika Pattanasin³; Richard Niska³; Timothy Holtz³; Kachit Choopanya⁴; Janet Michieli⁵¹
¹US Centers for Disease Control and Prevention, Apo, US; ²Thailand Ministry of Public Health—Centers for Disease Control and Prevention Collaboration, Nonthaburi, Thailand; ³Bangkok Tenofovir Study Group, Bangkok, Thailand
**TUESDAY, FEBRUARY 24, 2015**

**Session P-N1 Poster Session**  
*2:30 pm – 4:00 pm*

**Natural History and Prognosis of HCV Infection**

636 **Progression of Liver Disease in LHI/HCV Coinfected People According to Gender in Icona Cohort: Role of Age as Potential Different Exposure to Estrogens**  
Antonella Cingolani1; Paola Cicconi2; Gloria Taliani1; Alessandro D. Cozzi-Lepri1; Massimo Puoti3; Carmela Pinnetti6; Pier Luigi Viale2; Antonella d’Arminio Monforte2  
for Icona Foundation Study Group  
1Catholic University, Roma, Italy; 2University of Milano, Milano, Italy; 3University La Sapienza, Roma, Italy; 4University College London Medical School, Royal Free Campus, London, United Kingdom; 5Niguarda Hospital, Milano, Italy; 6National Institute for Infectious Diseases L. Spallanzani, Roma, Italy; 7University of Bologna, Bologna, Italy

637 **A Prognostic Score Estimating the Risk of Liver-Related Death Among HIV/HCV Coinfected Subjects**  
Daniel Grint1; Lars Peters2; Jürgen Rockstroh3; Karine Lacombe4; Andrzej Horban5; Irina Khromova5; Jose Gatell5; Antonella d’Arminio Monforte5; Jens D. Lundgren5; Amanda Mocroft1  
on behalf of EuroSIDA in EuroCoord  
1University College London, London, United Kingdom; 2University of Copenhagen, Copenhagen, Denmark; 3University Hospital Bonn, Bonn, Germany; 4Hospital Saint Antoine, Paris, France; 5Wojewodzki Szpital Zakazny, Warsaw, Poland; 6University of Barcelona, Barcelona, Spain; 7Clinica delle Malattie Infettive e Tropicali, Milan, Italy; 8Centre for HIV/AIDS & Infectious Diseases Prevention & Control, Kaliningrad, Russian Federation

638 **Has Modern ART Reduced Endstage Liver Disease Risk in HIV-Hepatitis Coinfection?**  
Marina B. Klein1; Keri N. Althoff1; Yuezhou Jing2; Greg D. Kirk1; Vincent Lo Re3; Nina Kim4; Mari Kitahata2; Chloé Thio5; Michael J. Silverberg6; Richard Moore7  
North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD)  

639 **Marijuana Use Does Not Accelerate Liver Fibrosis in HCV/HIV-Coinfected Women**  
Erin M. Kelly1; Jennifer L. Dodge1; Monika Sarkar1; Audrey French2; Phyllis Tien3; Marshall Glesby4; Elizabeth Golub; Michael Augenbraun5; Michael Plankney5; Marion G. Peters1  

640 **HIV Infection Does Not Worsen Prognosis of Liver Transplantation for Hepatocellular Carcinoma**  
Fernando H. Aguiar1; Alejandro Forner2; Christian Manzano3; Andres Valdivieso4; Marino Blanes1; Rafael Barcena1; Antoni Rafecas1; Lluis Castells1; Antonio Rimola2; Jose M Miro2  
1University of Barcelona, Barcelona, Barcelona, Spain; 2Hospital Clinic, IDIBAPS and El Centro de Investigación Biomédica en Red en el Área Temática de Enfermedades Hepáticas y Digestivas (CIBERehd), Barcelona, Spain; 3University Hospital Universitario de Cruces, Bilbao, Spain, Bilbao, Spain; 4Hospital Universitario La Fe, Valencia, Spain, Valencia, Spain; 5Hospital Universitario Ramón y Cajal, Madrid, Spain, Madrid, Spain; 6Hospital Universitari Vall d’Hebron, Barcelona, Spain, Barcelona, Spain

641 **Rapid Progression to Cirrhosis and Death Among HCV-Infected Persons Who Inject Drugs in India**  
Shruti H. Mehta1; Suniti Solomon2; Allison M. McFall1; Aylur K. Srikrishnan3; Pachamuthu Balakrishnan4; Nadagopal P5; David L. Thomas1; Mark Sulkowski1; Sunil S. Solomon3  
1Johns Hopkins University, Baltimore, MD, US; 2YR Gaitonde Centre for AIDS Research and Education, Chennai, India

642 **Chronic Kidney Disease Progression After HCV Serocconversion**  
Adeel A. Butt  
University of Pittsburgh/VA Pittsburgh Healthcare System, Pittsburgh, PA, US

**Session P-N2 Poster Session**  
*2:30 pm – 4:00 pm*

**HCV Therapy: Observations From Cohort Studies**

643 **Statins Improve SVR, Reduce Fibrosis Progression and HCC Among HCV+ Persons**  
Adeel A. Butt1; Peng Yan1; Obaid Shaikh2; Shari Rogal1  

644 **Sofosbuvir, Simeprevir, +/- Ribavirin in HCV Protease Inhibitor-Experienced Patients**  
Kristen M. Marks1; Ethan M. Weinberg1; Sonal Kumar1; Carrie Down1; Yee P. de jong1; Leah A. Burke1; Mary C. Olson1; Ira M. Jacobson1; Jay R. Kostman1  
1Reperelman School of Medicine, Philadelphia, PA, US; 2Drexel University College of Medicine, Philadelphia, PA, US; 3St Michael’s Medical Center, Newark, NJ, US; 4Philadelphia Health Management Corporation, Philadelphia, PA, US

645 **Effectiveness of Sofosbuvir/Simeprevir for HIV/HCV Patients in Clinical Practice**  
Jody Gilmore1; Kenneth Lynn1; Delisha Breen1; Stacey Trooskin1; Jihad Slim1; Nancy Scangarelo2; Alvin Kingcade1; Carrie Down1; Vincent Lo Re1; Jay R. Kostman1  
1Reperelman School of Medicine, Philadelphia, PA, US; 2Drexel University College of Medicine, Philadelphia, PA, US; 3St Michael’s Medical Center, Newark, NJ, US; 4Philadelphia Health Management Corporation, Philadelphia, PA, US
646 German Cohort on Sofosbuvir-Based Therapy for HIV/HCV and HCV Infection (GECOSO)
Stefan Christensen; Ingiliz Patrick; Dietrich Hueppe; Thomas Lutz; Karl Georg Simon; Knud Schewe; Heiner Busch; Axel Baumgarten; Guenther Schmutz; Stefan Mauss

1Center for HIV and Hepatogastroenterology, Duesseldorf, Germany; 2Center for Infectious Diseases, Muenster, Germany; 3Medizinisches Infektionszentrum Frankfurt, Germany; 4Infektiologisches Zentrum Berlin, Berlin, Germany; 5Institut für Infektiologie, Hamburg, Hamburg, Germany; 6Practice for Gastroenterology Leverkusen, Leverkusen, Germany; 7Practice for Gastroenterology Herne, Herne, Germany

647 Real-World Data on HIV-Positive Patients With HCV Treated With Sofosbuvir and/or Simeprevir
David Del Bello; Kian Bichoupan; Calley Levine; Agnes Cha; David Perlman; Nadim H. Salomon; Donald Kotler; Daniel Fierer; Douglas Dieterich; Andrea Branch

1Mount Sinai Health System, New York City, NY, US; 2Brooklyn Medical Center, New York City, NY, US

648 Simeprevir and Sofosbuvir Regimens for Hepatitis C: Decompensation and Serious AEs
Ponni V. Perumalswami; Kian Bichoupan; Lawrence Ku; Neal M. Patel; Rachana Valamanchili; Thomas Schiano; Mark Woodward; Douglas Dieterich; Andrea Branch

1Lamb Hospital of Medicine at Mount Sinai, New York, NY, US; 2George Institute for Health at the University of Oxford, Oxford, United Kingdom

649 Successful HCV Treatment With Direct Acting Antivirals in HIV/HCV Patients
Jennifer L. Grant; Valentina Stosor; Frank J. Palella; Richard M. Green; Guijira Thomas; Donna V. McGregor; Milena M. McLaughlin; Sudhir Penugonda; Michael Angarone; Claudia Hawkins

1Northwestern University, Feinberg School of Medicine, Chicago, IL, US; 2Midwestern University, Chicago, IL, US

650 Sofosbuvir/Daclatasvir in HIV/HCV Co-infected Patients With Extensive Liver Fibrosis
Alissa Naqui; Francine Guillouet de Salvador; Isabelle Perbost; Brigitte Dunais; Aline Joulié; Rodolphe Garraffo; Pascal Pugliese; Jacques Durant; Pierre Marie Roger; Eric Rosenthal

Centre Hospitalier Universitaire de Nice, Nice, France

651 Majority of HIV/HCV Patients Need to Switch ART to Accommodate Simeprevir
Rebecca Cope; Aaron Pickering; Thomas Glowa; Samantha Faulds; Peter Veldkamp; Ramakrishna Prasad

1University of Pittsburgh, Pittsburgh, PA, US; 2University of Maryland, Glen Burnie, MD, US

Session P-N3 Poster Session
2:30 pm – 4:00 pm
Treatment of HCV with DAAs: Short-Term Costs and Long-Term Benefits

652 Simeprevir/Sofosbuvir vs Triple Therapy (Telaprevir or Boceprevir) for HCV GT1: A cost analysis
Jacob A. Langness; David Tabano; Sarah Tise; Lindsay Pratt; Lauren Ayres; Amanda Wieland; Sonia Lin; Valahram Ghushchyan; Kavita Nair; Greg Everson

1University of Colorado, Arvada, CO, US; 2Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado, Aurora, CO, US; 3University of Colorado, Aurora, CO, US

653 SVR Durability: HCV Patients Treated With IFN-Free DAA Regimens
Aurielle M. Thomas; Sarah Kattakuzhy; Sarah Jones; Anita Kohli; Wilson Eleanor; Angie Price; Rachel Silk; Zayani Sims; Anu Osinusi; Shyam Kottili

1The National Institutes of Health, Bethesda, MD, US; 2Leidos Biomedical Research, Inc., Bethesda, MD, US; 3Institute of Human Virology, University of Maryland, Baltimore, MD, US

654 Five-Year Risk of Late Relapse or Reinfection With Hepatitis C After Sustained Virological Response: Meta-analysis of 49 Studies in 8534 Patients
Andrew M. Hill; Bryony Simmons; Jawaad Saleem; Graham Cooke

1Chelsea and Westminster Hospital, London, United Kingdom; 2St Mary’s Hospital–Imperial College Healthcare NHS Trust, London, United Kingdom

655 Incidence of Extrahepatic Complications in HIV/HCV Patients Who Achieved SVR
Sebastiano Leone; Mattia Prosperi; Silvia Costarelli; Francesco Castelli; Franco Maggiolo; Simona Di Giambenedetto; Annalisa Saracino; Massimo Di Pietro; Fabio Zach; Andrea Gori

1San Gerardo Hospital, University of Milano-Bicocca, Monza, Italy; 2University of Manchester, Manchester, United Kingdom; 3University of Brescia, Brescia, Italy; 4Ospedale Riuniti, Bergamo, Italy; 5Polichemico Gemelli, Rome, Italy; 6Polichemico of Bari, Bari, Italy; 7S.M Annunziata Hospital, Firenze, Italy; 8Istituti Ospedalieri di Cremona, Cremona, Italy

656 Impact of SVR on Liver Decompensation and Hepatic Fibrosis Markers in HIV/HCV
Janet Tate; E. John Wherry; Jay R. Kostman; Debika Bhattacharya; Guadalupe Garcia-Tsao; Cynthia Gibert; Joseph K. Lim; David Rimland; Amy Justice; Vincent Lo Re

1VA Connecticut Health System, West Haven, CT, US; 2University of Pennsylvania, Philadelphia, PA, US; 3Atlanta VA Health Care System, Atlanta, GA, US; 4VA Greater Los Angeles, Los Angeles, CA, US; 5Yale University School of Medicine, New Haven, CT, US; 6Washington DC VA Medical Center, Washington, DC, US

657 Portal Pressure Changes After HCV Eradication in HIV/HCV+ Patients With Cirrhosis
Matilde Sanchez-Conde; Leire Perez-Latorre; Diego Rincón; Pilar Miralles; Maria Vega Catalina; Juan Carlos Lopez; Rafael Bahena; Juan Berenguer

Hospital General Universitario Gregorio Marañon, Madrid, Spain
Session P-N4 Poster Session  Poster Hall
2:30 pm – 4:00 pm
HCV: Getting the Drugs to Those Who Need Them

658  Assessment of PCP Knowledge of HCV Screening, Recommendations, and Treatment Options
Allison Brodsky; Monique Allen; Gregory Johnson; Lora Magaldi; Carolyn Moy; Nancy Tursi; Stephanie Tzarnas; Stacey Trooskin
Drexel University College of Medicine, Philadelphia, PA, US

659  Majority of HCV/HIV-Infected Patients in the Netherlands Remain in Need of Effective HCV Treatment
Colette Smit; Joop E. Arends; Marc van der Valk; Kees Brinkman; Heidi Ammerlaan; S. Arend; Peter Reiss; Clemens Richter
1Stichting HIV Monitoring, Amsterdam, Netherlands; 2Universitair Medisch Centrum Utrecht, Utrecht, Netherlands; 3Academic Medical Center, Amsterdam, Netherlands; 3Onze Lieve Vrouwe Gasthuis, Amsterdam, Netherlands; 2CZE, Eindhoven, Netherlands; 2Leiden University Medical Center, Leiden, Netherlands; 2Rijnstate Ziekenhuis, Arnhem, Netherlands

660  Identifying and Prioritizing Hepatitis C Treatment for HIV-Related Hepatitis C Co-Infection
Amanda D. Castel; Mariah M. Kalmin; Rachel Hart; Alan Greenberg; 2Henry Masur
1DC Cohort Executive Committee
1The Milken Institute School of Public Health at George Washington University, Washington, DC, US; 2Cerner Corporation, Kansas City, MO, US; 2National Institutes of Health (NIH), Bethesda, MD, US

661  One-Year Results of a Community-Based Hepatitis C Testing and Linkage-to-Care Program
Christian B. Ramers; Robert Lewis; Letty Reyes; Danelle Wallace; Robert Gish; David Wyles; Alex Kuo
1Family Health Centers of San Diego, San Diego, CA, US; 2University of California San Diego, La Jolla, CA, US; 2Stanford University, Palo Alto, CA, US

WEDNESDAY, FEBRUARY 25, 2015

Session P-N5 Poster Session  Poster Hall
2:30 pm – 4:00 pm
HCV: Epidemiology and Case Detection

662  Hepatitis C and B Testing Among HIV-Infected Individuals in England
Sam Lattimore; Sarah Collins; Celia Penman; Lukasz Cieply; Sema Mandal
Sentinel Surveillance of Blood-Borne Virus Testing
Public Health England, London, United Kingdom

663  WITHDRAWN

664  HCV 2k/1b Recombinant Form among Hepatitis C–Infected Genotype 2 Patients in Georgia
Marika Karchava; Jesper Waldenström; Monica M. Parker; Renee Hallack; Lali Sharvadze; Lana Gatserelia; Nikoloz Chkhartishvili; Natia Dvali; Helen Norder; Tengiz Tsertsvadze
1Infectious Diseases, AIDS and Clinical Immunology Research Center, Tbilisi, Georgia; 2Institute of Biomedicine, University of Gothenburg, Gothenburg, Sweden; 2Wadsworth Center, Albany, NY, US

665  High HCV Prevalence Among Baby Boomers in Surveillance-Identified High HIV Risk Areas
Irene Kuo; Meriam Mikre; A. Toni Young; Geoffrey Maughan; Amanda D. Castel
1George Washington University, Washington, DC, US; 2Community Education Group, Washington, DC, US

666  Low HCV Screening Uptake of the Current Birth Cohort Testing Guidelines
Alexander G. Gebo; Hyun A. Cha; Idene E. Perez; Matthew T. Bell; Sandeep Mahajan; Adesbi O. Ayodele; Dawn A. Fishbein
1MedStar Health Research Institute, Hyattsville, MD, US; 1MedStar Washington Hospital Center, Washington, DC, US

667  Evaluation of CDC Recommendations for HCV Testing in an Urban Emergency Department
Yu-Hsiang Hsieh; Richard Rothman; Oliver B. Laeyendecker; Gabor Kelen; Ama Avornu; Eshan U. Patel; Jim Kim; Risha Irvin; David L. Thomas; Thomas C. Quinn
1Johns Hopkins University School of Medicine, Baltimore, MD, US; 2National Institute of Allergy and Infectious Diseases, Baltimore, MD, US; 2Johns Hopkins University School of Medicine, Baltimore, MD, US

668  Impact of Integrating EMR HCV Testing Prompts in a Difficult to Navigate EMR System
Stephanie Tzarnas; Monique Allen; Allison Brodsky; Gregory Johnson; Lora Magaldi; Carolyn Moy; Nancy Tursi; Steven Zivich; Stacey Trooskin
1Drexel University College of Medicine, Philadelphia, PA, US; 2Drexel University College of Medicine, Philadelphia, PA, US; 2Drexel University College of Medicine, Philadelphia, PA, US

669  SVR12 Results After 12w Boceprevir + P/R in the Dutch Acute Hepatitis C in HIV Study
Sebastiaan J. Hullegie; Mark A. Claassen; Guido E. van den Berk; Jan T. van der Meer; Joop E. Arends; Clemens Richter; Dirk Posthouwer; Peter P. Koopmans; Fanny N. Lauw; Bart J. Rijnders
1Academic Medical Center University of Amsterdam, Amsterdam, Netherlands; 2Onze Lieve Vrouwe Gasthuis, Amsterdam, Netherlands; 2Academic Medical Center Utrecht, Utrecht, Netherlands; 2Rijnstate Ziekenhuis, Arnhem, Netherlands; 2Maastricht University Medical Center, Maastricht, Netherlands; 2Radboud University Medical Center, Nijmegen, Netherlands; 2Slotervaart Ziekenhuis, Amsterdam, Netherlands; 2Erasmus University Medical Center, Rotterdam, Netherlands
670 Does the Availability of New DAA’s Influence Treatment Uptake in Acute Hepatitis C in HIV Coinfection?
Christoph Boesecke1; Mark Nelson2; Patrick Ingliz3; Thomas Lutz4; Stefan H. Scholten4; Christoph D. Spinner5; Michael Rausch6; Thomas Reiberger; Stefan Mauss7; Jürgen Rockstroh1
1Bonn University Hospital, Bonn, Germany; 2Chelsea and Westminster Hospital, NHS Foundation Trust, London, United Kingdom; 3Infektiologikum, Frankfurt/Main, Germany; 4Praxis Hohenstaufenerring, Cologne, Germany; 5MUB, Berlin, Germany; 6Interdisciplinary HIV Centre (IZAR), University Hospital Klinikum Rechts der Isar, Munich, Germany; 7Medical University of Vienna, Vienna, Austria; 8Center for HIV and Hepatogastroenterology, Düsseldorf, Germany; 9Aerztezentrum Nollendorfplatz, Berlin, Germany

671 Long-Term Follow-Up of HIV-Positive Men Who Have Sex With Men (MSM) With Acute Hepatitis C Virus (HCV) Infection: High Rates of Treatment and Low Rates of Liver-Related Complications
Patrick Ingliz; Anders C. Boyd; Katharina Steininger; Andreas Carganico; Stephan Duple; Ivanka Krmancic; Marcel Schuetze; Stefan Neifer; Martin J. Obermeier; Axel Baumgarten
1Medical Center for Infectious Diseases, Berlin, Germany; 2Microbiology Laboratory, Berlin, Germany; 3INSEMINUM, S 1136, Paris, France

672 Hepatitis C in Men Who Have Sex With Men With New HIV Diagnoses in Los Angeles
Kara W. Chew1; Marjan Javanbakht2; Laurel Clare1; Lorelei Bornfleth1; Debiika Bhattacharya3; Pamina Gorbach1; Martha L. Blum1
1David Geffen School of Medicine at UCLA, Los Angeles, CA, US; 2UCLA Fielding School of Public Health, Los Angeles, CA, US; 3Community Hospital of the Monterey Peninsula, Monterey, CA, US

673 Development and Comparison of Hepatitis C Cross-Sectional Incidence Testing Methods
Eshan U. Patel1; Andrea Cox2; Shruti H. Mehta3; Caroline E. Mullis4; Jeffrey Quinn5; Gregory D. Kirk6; Thomas C. Quinn7; Oliver B. Laeyendecker9
1National Institute of Allergy and Infectious Diseases (NIAID), Baltimore, MD, US; 2Johns Hopkins University School of Medicine, Baltimore, MD, US; 3Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, US; 4Georgetown University, Washington, IL, US; 5University of California San Francisco, San Francisco, CA, US; 6Northwestern University, Chicago, IL, US; 7Georgetown University Hospital, Washington, IL, US; 8Rush University Medical Center, Chicago, IL, US; 9Aerztezentrum Nollendorfplatz, Berlin, Germany

675 Behavioural and Treatment Interventions to Reduce HCV Transmissions in HIV+ MSM
Luisa Salazar-Vizcaya1; Roger Kouyos2; Cindy Zahnd3; Manuel Battegay1; Katharine Darling4; Alexandra Calmy5; Pietro L. Vernazza6; Olivia Keiser7; Andri Rauch8
1On behalf of the Swiss HIV Cohort Study; 2University of Bern, Bern, Switzerland; 3University Hospital Zürich, Zürich, Switzerland; 4University Hospital Basel, Basel, Switzerland; 5Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland; 6Geneva University Hospitals, Geneva, Switzerland; 7Kantonsspital St Gallen, St Gallen, Switzerland; 8University Hospital Bern, Inselspital, Bern, Switzerland

676 Macrophage Activation and Hepatitis C (HCV) Disease Progression in HIV-Infected Women Participating in the Women’s Interagency HIV Study (WHIS)
Audrey L. French1; Charlesnika Evans2; Marion G. Peters3; Mary A. Young2; Mark Kuniholm1; Michael Augenbraun1; Seema N. Desai8
1CORE Center/Strayer Hospital of Cook County, Chicago, IL, US; 2University of California San Francisco, San Francisco, CA, US; 3Northwestern University, Chicago, IL, US; 4Rush University Medical Center, Chicago, IL, US; 5Montefiore Medical Center, University Hospital for Albert Einstein College of Medicine, Bronx, NY, US; 6State University of New York Downstate, Brooklyn, NY, US

677 HIV/HCV Co-Infection Accelerated Liver Disease is Associated With Induction of M2-Like Macrophages
Moses T. Bility1; Feng Li2; Junichi Nunoya3; Guangming Li4; Eoin Feeney5; Raymond Chung6; Lishan Su1
1University of North Carolina, Chapel Hill, NC, US; 2Massachusetts General Hospital, Harvard Medical School, Boston, MA, US

678 HIV Infection Is Associated With an Impaired Anti-HCV Activity of NK-Like T Cells
Pavlos Kokordelis1; Benjamin Krämer2; Christoph Boesecke3; Esther Voigt4; Patrick Ingliz5; Andreas Glässner6; Franziska Wolter7; Ulrich Spengler7; Jürgen K. Rockstroh8; Jacob Nattermann9
1University of Bonn, Bonn, Germany; 2Praxis am Ebertplatz, Cologne, Germany; 3Medical Center for Infectious Diseases, Berlin, Germany

679 Dys-Regulated Cross Talk Between CD4+ T Cells and NK Cells in HIV/HCV Coinfection
Benjamin Krämer1; Andreas Glässner2; Claudia Zwank3; Felix Goeser1; Christoph Boesecke4; Patrick Ingliz5; Christian P. Strassburg6; Ulrich Spengler7; Jürgen Rockstroh8; Jacob Nattermann9
1University of Bonn, Bonn, Germany; 2Medical Center for Infectious Diseases, Berlin, Germany

680 HIV/HCV Coinfection Is Associated With Significant Alterations of the NK Cell Pool
Dominik J. Kaczmarek1; Pavlos Kokordelis2; Benjamin Krämer3; Andreas Glässner4; Franziska Wolter5; Patrick Ingliz6; Christian P. Strassburg7; Ulrich Spengler8; Jürgen Rockstroh9; Jacob Nattermann10
1University of Bonn, Bonn, Germany; 2Medical Center for Infectious Diseases, Berlin, Germany
681  Dynamic Changes of CXCL10 Isoforms and DPP4 During IFN-Free Treatment for HCV
Eric G. Meissner1; Jeremie Decalf2; Armanda Casrouge3; Henry Masur4; Shyam Kotttili4; Darragh Duffy5; Matthew L. Albert6
1Medical University of South Carolina, Charleston, SC, US; 2Institut Pasteur, Paris, France; 3National Institutes of Health (NIH), Bethesda, MD, US; 4University of Maryland School of Medicine, Baltimore, MD, US

682  Mx1 and OAS1-2 SNPs Are Related With Severity of Liver Disease in HIV/HCV Coinfection
Mónica García-Alvarez1; Juan Berenguer2; Daniel Pineda-Tenor3; María Ángeles Jiménez-Sousa4; María Guzmán-Fuligencio5; Ana Carrero1; Teresa Aldaimiz-Echevarria6; Francisco Tejerina7; Cristina Diez8; Salvador Resino9
1Centro Nacional de Microbiología, Instituto de Salud Carlos III, Madrid, Spain; 2Hospital General Universitario Gregorio Marañón, Madrid, Spain

683  Treatment With DCV Plus ASV Reduces Immune Activation in HIV/HCV Coinfected Patients
Eleanor M. Wilson1; Anita Kohli2; Julia B. Purdy3; Louisa Howard4; Sabrina Mangat5; Gebeeyehu Teferi6; John Hogan7; Henry Masur8; Shyam Kotttili9
1National Institutes of Health (NIH), Bethesda, MD, US; 2Unity Health Care, Washington, DC, US; 3NIH, Bethesda, MD, US; 4Leidos Biomedical Services, Inc, Bethesda, MD, US

684  Innate Immune Activation Pathways Overlap, Yet Are Distinct in HCV and HIV Infection
Lenche Kostadinova1; Benigno Rodriguez; Donald Anthony Case Western Reserve University, Cleveland, OH, US

685  A Novel Mechanism of Resistance to Multiple bNAb Revealed by Natural Variation in Panel of 199 HCVpp
Ramy El-Diwany1; Lisa Wasilewski; Madeleine Mankowski; Stuart C. Ray; Justin R. Bailey
Johns Hopkins University School of Medicine, Baltimore, MD, US

686  Single-Variant Sequencing Revealed Rapid HCV Evolution in HIV Immune Reconstitution
Lin Liu; David Nardo; Eric Li; Gary Wang
University of Florida, Gainesville, FL, US

THURSDAY, FEBRUARY 26, 2015
Session P-N8 Poster Session 2:30 pm – 4:00 pm
Poster Hall
HCV Therapeutics: Preclinical Observations and Clinical Trials of DAAs

687  UNITY-1: Daclatasvir/Asunaprevir/BMS-791325 for HCV Genotype 1 Without Cirrhosis
Fred Poordad1; William Sievert2; Norbert Brau3; Samuel Lee4; Jean-Pierre Bronowicki5; Ira Jacobson6; Eric Hughes7; Eugene S. Swenson8; Philip Yin9
On behalf of the UNITY-1 Study Team
1Texas Liver Institute, San Antonio, TX, US; 2Monash Health and Monash University, Melbourne, Australia; 3Brisbane Veterans Affairs Medical Center, New York, NY, US; 4University of Calgary, Alberta Health Services, Calgary, Canada; 5Centre Hospitalier Universitaire de Nancy, Université de Lorraine, Vandoeuvre les Nancy, France; 6Weill Cornell Medical College, New York, NY, US; 7Bristol-Myers Squibb Co, Princeton, NJ, US; 8Bristol-Myers Squibb Co, Wallingford, CT, US

688  UNITY-2: Daclatasvir/Asunaprevir/BMS-791325 ± RBV for HCV Genotype 1 With Cirrhosis
Andrew Muir1; Fred Poordad2; Jay Lalezari3; Gregory Dore4; Christophe Hezode5; Alnoor Ramji6; Eric Hughes7; Eugene S. Swenson8; Philip Yin9
On behalf of the UNITY-2 Study Team
1Duke University School of Medicine, Durham, NC, US; 2University of Texas Health Science, San Antonio, TX, US; 3Quest Clinical Research, San Francisco, CA, US; 4University of New South Wales Australia, Sydney, Australia; 5Université Paris-Est, Créteil, France; 6University of British Columbia, Vancouver, Canada; 7Bristol-Myers Squibb Co, Princeton, NJ, US; 8Bristol-Myers Squibb Co, Wallingford, CT, US

689  Utility of Hepatitis C Viral-Load Monitoring With Ledipasvir and Sofosbuvir Therapy
Sreetha Sidharthan1; Anita Kohli2; Anu Osinusui3; Amy Nelson1; Zayani Sims1; Kenny S. Townsend4; Lydia Tang5; Michael Polis6; Henry Masur7; Shyam Kotttili8
1Institute of Human Virology, University of Maryland, Baltimore, MD, US; 2NIH Clinical Center, Bethesda, MD, US; 3Leidos Biomedical Research, Inc, Frederick, MD, US; 4National Institute of Allergy and Infectious Diseases (NIAID), Bethesda, MD, US

690  Viral Kinetic Profiles of HCV Response to Telaprevir-Based Therapy in Patients With Hemophilia
Kenneth E. Sherman1; Ruian Ke2; Susan D. Rouswer3; Alan S. Perelson1
1University of Cincinnati, Cincinnati, OH, US; 2Los Alamos National Laboratory, Los Alamos, NM, US

691  Hematological Analysis of ABT-450/r/Ombitasvir and Dasabuvir + RBV in TURQUOISE-I
Robert S. Brown1; David Wyles2; Jihad Slim3; Peter J. Ruane4; Barbara McGovern5; Roger Trinh6; Yiran Hu7; Joseph J. Eron8
1Johns Hopkins University, Baltimore, MD, US; 2University of California San Diego, La Jolla, CA, US; 3St Michael’s Medical Center, Newark, NJ, US; 4Peter J. Ruane MD Inc, Los Angeles, CA, US; 5AbbVie, Inc, North Chicago, IL, US; 6University of North Carolina, Chapel Hill, NC, US
692 Effect of HIV Coinfection on Adherence to a 12-Week Regimen of HCV Therapy With Ledipasvir/Sofosbuvir
Kerry S. Townsend; Tess L. Peterson; Lori A. Gordon; Amy Nelson; Cassie Seamon; Chloé Gross; Anu Osinusi; Michael Apis; Henry Masur; Shyam Kottillil
1National Institute of Allergy and Infectious Diseases, Bethesda, MD, US; 2National Institutes of Health, Bethesda, MD, US; 3Leidos Biomedical Research Inc, Frederick, MD, US

693 Investigation of the Role of Macromodulation in HCV Protease Inhibitor MK-5172
Djaded Soumana; Kristina Prachanaronong; Nese Kurt Yilmaz; Ali Akbar; Cihan Aydin; Celia A. Schiffer
University of Massachusetts Medical School, Worcester, MA, US

694 Impact of Baseline Mental Health on Adherence to Interferon-Free HCV Therapy
Jack Masur; Lydia Tang; Amy Nelson; Anu Osinusi; Anita Kohli; Rachel Silk; Chloé Gross; Sarah Kattakuzhy; Michael Polis; Shyam Kottillil
1University of Maryland, Baltimore, MD, US; 2National Institutes of Health, Bethesda, MD, US; 3National Institutes of Health, Bethesda, MD, US

695 Mental Health Impact of HCV Treatment in HIV/HCV Patients: DAA vs IFN-Based Therapy
Louise Lundgren; Sarah Kattakuzhy; Angie Price; Catherine Seamon; Amy Nelson; Anita Kohli; Rachel Silk; Chloé Gross; Henry Masur; Shyamasundaran Kottillil
1National Institutes of Health Clinical Center, Bethesda, MD, US; 2Leidos Biomedical Research, Inc, Frederick, MD, US; 3Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, US; 4Institute of Human Virology, University of Maryland, Baltimore, MD, US

698 HCVNS3 Variants in HIV/HCV Coinfected Patients Before-After PegIFN/Ribavirin
Enass Abdel-Hameed; Susan D. Rouster; Xiang Zhang; Jing Chen; Mario Medvedovic; Kenneth E. Sherman
1University of Cincinnati, Cincinnati, OH, US; 2University of Cincinnati, Cincinnati, OH, US

699 Compensatory Mutations in HCV NSSA/B Coevolve in Patients Failing NS3 Inhibitors
Velia Chiara Di Maio; Valeria Cento; Daniele Di Paolo; Sergio Babudieri; Gloria Taliani; Giustino Parruti; Giuliano Rizzardini; Mario Angelico; Carlo Federico Perno; Francesca Ceccherini-Silberstein
1University of Rome Tor Vergata, Rome, Italy; 2University of Rome Tor Vergata, Rome, Italy; 3University of Sassari, Sassari, Italy; 4University of Rome La Sapienza, Rome, Italy; 5Pescara General Hospital, Pescara, Italy; 6Hospital Sacco of Milan, Milan, Italy

Session P-N9 Poster Session
2:30 pm – 4:00 pm
Mental Health and Treatment Adherence with Direct-Antiviral Therapy

Session P-N10 Poster Session
2:30 pm – 4:00 pm
HCV: Resistance to Antiviral Agents

Session P-N11 Poster Session
2:30 pm – 4:00 pm
Other Hepatitis Viruses: HBV, HDV, HEV

700 Hepatitis B Vaccine Response in Children Attending Rwanda Military Hospital
Judy T. Onkiiriza; Louis Mjuvwiwa; Elizabeth Karlsson; Vincent Mutabazi; Johan Normark
1Infectious Diseases Institute Makerere College of Health Sciences, Kampala, Uganda; 2University of Rwanda, Kigali, Rwanda; 3Umea Infectious Diseases Institute, Kigali, Sweden; 4Rwanda Biomedical Center, Kigali, Rwanda

701 Revaccinating HIV+ Adults With Double vs Standard HBV Regimen: ANRS B-BOOST Trial
David Rey; Cécile Dufour; Marie-Josée Wendling; Patrick Mialhès; Philippe Sogni; Georges Haour; Marie-Louise Michel; Lionel Pirotti; Odile Launay; Fabrice Carrat
1University Hospital Strasbourg, Strasbourg, France; 2Université Pierre et Marie Curie, Strasbourg, France; 3Hôpitaux Universitaires Strasbourg, Strasbourg, France; 4University Hospital of Lyon, Lyon, France; 5CIC Vaccinologie, Paris, France; 7University Hospital of Dijon, Dijon, France; 8Institut Pasteur, Paris, France; 9Cochin Hospital, Paris, France

702 Complex HBV Quasispecies Affects Immunogenicity in Acute Hepatitis B Infection
Valentina Svicher; Marianna Araogi; Nicola Coppola; Claudia Alteri; Arianna Battisti; Caterina Sagnelli; Mariantonietta Pisaturo; Maria Concetta Bellocchi; Evangelista Sagnelli; Carlo-Federico Perno
1University of Rome Tor Vergata, Rome, Italy; 2Second University of Naples, Naples, Italy

703 Higher Rate of Hepatitis B Antigen and Anti-HBV Antibody Seroconversion Among HIV/Chronic Hepatitis B Coinfection Initiating HBV Active HAART From Thailand
Anchalee Avihingsanon; Opas Putcharoen; Salavut Chittmittrapap; Tanakorn Apompong; Vorapat Sapsirirsavat; Sasiwimol Ubolyam; Stephen J. Kerr; Kiat Ruxrungtham
On behalf of the HIV-NAT 105 Study Team
1HIV Netherlands Australia Thailand Research Collaboration, Thai Red Cross - AIDS Research Centre, Patumwan, Thailand; 2Chulalongkorn University, Bangkok, Thailand
704 Occult HBV/HIV Coinfection and Validation of Cost-Effective NAT Pooling PCR
Shanmugam Saravanan; Janardhanan Mohanakrishnan; Thongadi Ramesh Dinesha; Jayaseelan Boobalan; Pachamuthu Balakrishnan; Kailapuri G Murugavel; Sunit S Solomon; Suniti Solomon; Davey M. Smith1
1YRG Centre for AIDS Research and Education, Chennai, India; 2Johns Hopkins University School of Medicine, Baltimore, MD, US; 3University of California San Diego, San Diego, CA, US

705 Invariant Natural Killer T-Cells in HIV-HBV Coinfection
Matteo Basliassi; Camilla Tincati; Esther Merlini; Elisabetta Sinigaglia; Javier Sanchez-Martinez; Giovanni Carpiani; Antonella d’Arminio Monforte1; Laura Milazzo; Giulia Marchetti
1University of Milan, Milan, Italy; 5San Paolo Hospital, Milan, Italy

706 Effect of Immunosuppression and Antivirals on Intracellular HBV Replication in HIV-HBV Coinfection
Anders C. Boyd; Karine Lacombe; Fabien Lavocat; Sarah Maylin; Patrick Maillehs; Caroline Lascoux-Combe; Constance Delaegerre; Pierre-Marie Girard; Fabien Zoulim
1Inserm UMR_S1136, Paris, France; 2Inserm U1052, Lyon, France; 2Inserm U941, Paris, France; 3Hospices Civils de Lyon, Lyon, France; 4Hôpital Saint-Louis AP-HP, Paris, France

707 Prevalence of HDV in a Midwestern HIV-HBV Coinfected Population
Sanam Razeghi; Susan Rouster; Kenneth E. Sherman
University of Cincinnati, Cincinnati, OH, US

708LB Oral Prenylation Inhibition With Lonafarnib in Chronic Hepatitis D Infection: A Randomized, Double-Blinded, Placebo-Controlled Proof-of-Concept Study
Christopher Koh; Laetitia Canini; Harel Dahari; David Cory; Ingrid Choong; David Kleiner; Stewart Cooper; Mark A. Winters; Jeffrey Glenn; Theo Heller
1National Institute of Diabetes and Digestive and Kidney Diseases, NIH, Fulton, MD, US; 2Loyola University Medical Center, Maywood, IL, US; 3Eiger BioPharmaceuticals, San Carlos, CA, US; 4National Cancer Institute, Bethesda, MD, US; 5Stanford University, Stanford, CA, US; 6California Pacific Medical Center, Palo Alto, CA, US; 7University of Edinburgh, Edinburgh, United Kingdom

709 Incidence of Hepatitis E Virus in HIV-Infected Patients: A Longitudinal Prospective Study
Antonio Rivero-Juarez; Loreto Martinez-Dueñas; Antonio Martinez-Peinado; Angela Camacho; Celia Cifuentes; Ana Gordon; Mario Frias; Julian Torre-Cisneros; Juan A. Pineda; Antonio Rivero1
1Instituto Maimonides de Investigación Biomédica de Córdoba, Córdoba, Spain; 1Instituto Maimonides de Investigación Biomédica de Córdoba, Córdoba, Spain; 1Hospital Universitario de Valme, Seville, Spain

TUESDAY, FEBRUARY 24, 2015
Session P-01 Poster Session Poster Hall
2:30 pm – 4:00 pm
HPV Infections and Cancers

710 Factors Associated With Extensive Cervical Lesions Among HIV-Infected Women Screening for AIDS Clinical Trials Group (ACTG) Protocol A5282
Timothy J. Wilkin; Roy Matining; Vikrant Sahasarabuddhe; Catherine Godfrey; Thandie Lungu; Mulindi Mwanahamuntu; Ramesh Bhosale; Scott Evans; Robert W. Coombs; Cynthia Finnhaber1
1Weill Cornell Medical College, New York, NY, US; 2Harvard School of Public Health, Center for Biostatistics in AIDS Research, Cambridge, MA, US; 3National Cancer Institute (NCI), Bethesda, MD, US; 4Division of AIDS (DAIDS), NIAID, NIH, Bethesda, MD, US; 5University of North Carolina Project—Malawi, Lilongwe, Malawi; 6University Teaching Hospital, Lusaka, Zambia; 7Byramjee Jeejeebhoy Medical College, Pune, India; 8University of Washington, Seattle, WA, US; 9University of Witswatersand, Johannesberg, South Africa

711 HIV Infection and Survival Among Women With Cervical Cancer in Botswana
Scott Dryden-Petersen; Memory Bvocora-Nsingo; Heluf Medhin; Gita Sunega; Aida Asmelash; Malebogo Pusoentsi; Anthony Russell; Jason Efstatiiou; Bruce Chabner; Shahnin Lockman1
1Brigham and Women’s Hospital, Harvard Medical School, Jamaica Plain, MA, US; 2Gaborone Private Hospital, Gaborone, Botswana; 3Botswana Ministry of Health, Gaborone, Botswana; 4University of Utah, Salt Lake City, UT, US; 5Botswana Harvard AIDS Institute, Gaborone, Botswana; 6Massachusetts General Hospital, Harvard Medical School, Boston, MA, US

712 Potential Cost-Effectiveness of Cervical Cancer Screening of HIV-Positive Kenyan Women
Marita Mann; Joseph Babigumira; Louis Garrison; Michael Chung
University of Washington, Seattle, WA, US

713 Anal High-Risk Human Papillomavirus (HPV) Infection Among HIV-Infected MSM in the SUN Study, 2004–2011
Pragna Patel; Tim Bush; Ema Kojic; Lois Conley; Elizabeth Unger; Teresa Darragh; Keith Henry; John Hammer; Nur Onen; Joel Palefsky1
1CDC, Atlanta, GA, US; 2Brown University, Providence, RI, US; 3University of California San Francisco, San Francisco, CA, US; 4University of Minnesota, Minneapolis, MN, US; 5Denver Infectious Diseases Consultants, Denver, CO, US; 6Washington University School of Medicine, St. Louis, MO, US

714 Long-Term Effectiveness of Electrocautery Ablation of HGIN in HIV-Infected MSM
Joaquin Burgos; Adria Curran; Natalia Tallada; Ana Guelar; Jordi Navarro; Stefania Landolfi; Judith Villar; Manel Crespo; Esteve Ribera; Vicenç Falco1
1University Hospital Vall d’Hebron, Barcelona, Spain; 2University Hospital del Mar, Barcelona, Spain

715 Survival and Treatment Trends for Squamous Cell Carcinoma of the Anus in HIV Infection
Robert A. Pitts; Stephen Goldstone; Keith Sigel; Michael M. Gaisa; Carlie Sigel; Juan Wishovsky
Icahn School of Medicine at Mount Sinai, New York, NY, US
716  Oral HPV Shedding and Warts After Starting Antiretroviral Therapy: ACTG Protocol A5272
Caroline H. Shiboski 1; Anthony Lee 1; Jennifer Webster-Cyriaque 1; Huichao Chen 1; Malcolm John 1; Raphael J. Landovitz 1; Mark Jacobson 1
Oral HIV/AIDS Research Alliance and the AIDS Clinical Trial Group

717  Excess Risk of Rectal Squamous Cell Carcinoma in HIV-Infected Persons
Anna E. Coghil; Meredith S. Shieh; Eric A. Engels
National Cancer Institute, Rockville, MD, US

WEDNESDAY, FEBRUARY 25, 2015

Session P-02 Poster Session  Poster Hall
2:30 pm – 4:00 pm
AIDS-Related Cancers: Lymphoma and KS

718  Incidence and Outcomes of HIV-Associated Lymphomas in Botswana
Michael G. Milligan 1; Elizabeth Bigger 1; Musimair Zola 1; Mukendi Kayembe 1; Heluf Medhin 1; Gita Suneja 1; Shahin Lockman 1; Jeremy Abramson 1; Bruce Chaibner 1; Scott Dryden-Peterson 1
1 Harvard Medical School, Brookline, MA, US; 2 Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, US; 3 Massachusetts General Hospital, Harvard Medical School, Boston, MA, US; 4 University of Utah, Salt Lake City, UT, US; 5 Botswana Ministry of Health, Gaborone, Botswana; 6 Botswana National Health Laboratory, Gaborone, Botswana; 7 Princess Marina Hospital, Gaborone, Botswana

719  CHOP Is Feasible for HIV-Associated Lymphoma in the ART Era in Malawi
Satish Gopal 1; Yuri Fedorov 1; Agnes Moses 1; Nathan Montgomery 1; Wongani Kaimila 1; Coixilly Kampani 1; Robert Krysiak 1; Kristy Richards 1; Thomas Shea 1; George Liomba 1
1 University of North Carolina, Chapel Hill, NC, US; 2 University of North Carolina Project–Malawi, Lilongwe, Malawi

720  Chronic Hepatitis B and C Infection and Risk for Non-Hodgkin Lymphoma in HIV-Infected Patients
Heiner C. Bucher
On behalf of the Collaboration of Observational HIV Epidemiological Research Europe (COHERE) in EuroCoord
University Hospital Basel, Basel, Switzerland

721  HIV-Associated Kaposi Sarcoma Treated With Chemotherapy and ART in Rural Malawi
Michael E. Herce 1; Noel Kalanga 1; Jonathan T. Crocker 1; Emily B. Wroe 1; James W. Keck 1; Felix D. Chingoli 1; Satish Gopal 1; Junior Bazile 1; Jason A. Beste 1; Jonas Rigodon 1
1 University of North Carolina, Chapel Hill, NC, US; 2 Partners In Health, Neno, Malawi; 3 Ministry of Health of the Republic of Malawi, Neno, Malawi

722  High Mobility Group Box 1 (HMGB1) and HIV-Associated Kaposi Sarcoma in Africa
Helen Byakwaga 1; Peter W. Hunt 1; Miriam O. Loker-Oketta 1; Albert R. Davalos 1; Conrad Muzoora 1; David V. Glidden 1; A. Rain Moccio 1; David R. Bangsberg 1; Edward Mbidde 1; Jeffrey N. Martin 1
1 Mbarara University of Science and Technology, Mbarara, Uganda; 2 Infectious Diseases Institute, Kampala, Uganda; 3 University of California San Francisco, San Francisco, CA, US; 4 Massachusetts General Hospital, Center for Global Health, Harvard Medical School, Boston, MA, US; 5 Uganda Virus Research Institute, Entebbe, Uganda; 6 Buck Institute for Research on Aging, Novato, CA, US

THURSDAY, FEBRUARY 26, 2015

Session P-03 Poster Session  Poster Hall
2:30 pm – 4:00 pm
Cancer and Cancer Risk in HIV Subpopulations and Lung Cancer

724  Cancer in HIV-Infected Children: Record Linkage Study in South Africa
Julia Bohlius 1; Nicky Maxwell 1; Brian Eley 1; Hans Prozesky 1; Shobna Sawry 1; Karl-Günter Technau 1; Alan Davidson 1; Cristina Stefan 1; Matthias Egger 1
On behalf of the North American AIDS Cohort Collaboration on Research and Design
1 University of the Witwatersrand, Johannesburg, South Africa; 2 University of Cape Town, Cape Town, South Africa; 3 Red Cross War Memorial Children’s Hospital, Cape Town, South Africa; 4 University of Stellenbosch and Tygerberg Academic Hospital, Cape Town, South Africa; 5 Stellenbosch University and Tygerberg Hospital, Cape Town, South Africa; 6 University of Bern, Bern, Switzerland

725  High Cancer Risk Among the HIV-Infected Elderly in the United States
Elizabeth L. Yanik 1; Hormuzd A. Katki 1; Eric A. Engels
National Cancer Institute (NCI), Rockville, MD, US

726  Smoking Outweighs HIV-Related Risk Factors for Non-AIDS-Defining Cancers
Keri N. Althoff 1; Stephen J. Gange 1; Chad Achenbach 1; Lisa P. Jacobson 1; Angela M. Mayor 1; Michael J. Silverberg 1; Amy Justice 1; Richard Moore 1; Yuezhou Jing 1; Kelly Gebo 1
On behalf of the North American AIDS Cohort Collaboration on Research and Design
1 Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, US; 2 Northwestern University, Feinberg School of Medicine, Chicago, IL, US; 3 Universidad Central del Caribe, Bayamón, US; 4 Kaiser Permanente Northern California, Oakland, CA, US; 5 Veterans Affairs Connecticut Healthcare System and Yale Schools of Medicine and Public Health, New Haven, CT, US; 6 Johns Hopkins University School of Medicine, Baltimore, MD, US
277 High Frequency of Early Lung Cancer Diagnosis With Chest CT in HIV-Infected Smokers
Alain Makinson1; Sabrina Eymard-Duvenay2; François Raffi1; Fabrice Bonnet3; Laurence Thirard1; Pierre Tatievin1; Sophie Abgrall1; Jacques Reynes1; Vincent Le Moing1
on behalf of the ANRS EP48 HIV CHEST Study Team
1University Hospital Montpellier, UMI 233, Montpellier, France; 2UMI 233, IRD, University Montpellier 1, Montpellier, France; 3Nantes University Hospital, Nantes, France; 4University Hospital Bordeaux, Inserm U897, Bordeaux, France; 5Toussaint University Hospital, Toussaint, France; 6Ponchtaillou University Hospital, Rennes, France; 7University Hospital Avicenne, Bobigny, France; 8ANRS, Paris, France

278 CD4 Measures as Predictors of Lung Cancer Risk and Prognosis in HIV Infection
Keith Sigel1; Kristina Crothers1; Kirsha Gordon; Sheldon Brown; David Rimland; Maria Rodriguez-Barradas; Cynthia Gibert; Matthew B. Goetz; Roger Bedimo; Robert Dubrow1
1Icahn School of Medicine at Mount Sinai, New York, NY, US; 2University of Washington School of Medicine, Seattle, WA, US; 3VA Connecticut Healthcare System and Yale University Schools of Medicine and Public Health, New Haven, CT, US; 4James J. Peters VA Medical Center, Bronx, NY, US; 5Atlanta VA Medical Center, Atlanta, GA, US; 6Michael E. DeBakey Veterans Affairs Medical Center, Houston, TX, US; 7Washington DC Veterans Affairs Medical Center, Washington, DC, US; 8Los Angeles VA Medical Center, Los Angeles, CA, US; 9Veterans Affairs North Texas Health Care System, Dallas, TX, US; 10Yale University School of Public Health, New Haven, CT, US

TUESDAY, FEBRUARY 24, 2015

Session P-P1 Poster Session
2:30 pm – 4:00 pm
Cardiovascular Disease Outcomes

279 Cardiovascular Disease Mortality Among HIV-Infected Persons, New York City, 2001–2012
David B. Hanna1; Chitra Ramaswamy1; Robert C. Kaplan1; Regina Zimmerman1; Sarah L. Braunstein1
1Albert Einstein College of Medicine, Bronx, NY, US; 2New York City Department of Health and Mental Hygiene, Long Island City, NY, US

270 Angiographic Restenosis After PTA in HIV-Infected Patients: Incidence and Predictors
Dominik Promny1; Christoph D. Spinner1; Salvatore Cassese2; Isabella Bernlochner1; Christian Bradaric2; Karl-Ludwig Laugwitz2; Adnan Kastrati1; Simon Schneider1
1University Hospital Klinikum Rechts der Isar, Munich, Germany; 2Deutsches Herzzentrum Muenchen, Munich, Germany; 3University Hospital Klinikum Rechts der Isar, Munich, Germany

WEDNESDAY, FEBRUARY 25, 2015

Session P-P2 Poster Session
2:30 pm – 4:00 pm
Dyslipidemia: Mediators and Treatment

731 PCSK9 Is Elevated in HIV+ Patients and May Mediate HIV-Associated Dyslipidemia
Payal Kohli1; Peter Ganz2; Yifei Ma3; Rebecca Schezer1; Kristinalisa Maka1; Scott Wasserman1; Rob Scott1; Priscilla Hsu1

732 Enhanced, Not Inhibited Monocyte Cell Efflux Characterises Untreated HIV
Jane A. O’Halloran1; Therese Herlihy2; Alan Macken1; Louise Rainford1; John S. Lambert3; Gerard J. Sheehan1; Nial G. Mahon1; Leo P. Lawler4; Patrick W. Mallon2
1University College Dublin, Dublin, Ireland; 2University College Dublin, Dublin, Ireland; 3University College Dublin, Dublin, Ireland; 4University College Dublin, Dublin, Ireland

733 Rosuvastatin vs Protease Inhibitor Switch for Hypercholesterolemia: Randomised Trial
Frederick J. Lee1; Poliana Monteiro1; David Baker1; Mark Bloch2; Robert Finlayson3; Richard Moore4; Norman Roth4; Jennifer F. Hoy1; Esteban Martinez1; Andrew Carr1
1East Sydney Doctors, Sydney, Australia; 2Holdsworth House Medical Practice, Sydney, Australia; 3Hospital Clinic, University of Barcelona, Barcelona, Spain; 4Monash University/Alfred Hospital, Melbourne, Australia; 5Northside Clinic, Melbourne, Australia; 6Phrahan Market Clinic, Melbourne, Australia; 7St. Vincent’s Hospital, Sydney, Australia; 8Taylor Square Private Clinic, Sydney, Australia

734 Application of New ACC/AHA Cholesterol Guidelines to an HIV Clinical Care Cohort
Mosepele Mosepele1; Susan Regan1; James B. Meigs1; Steven Grinspoon2; Virginia A. Trian1
1Massachusetts General Hospital, Harvard Medical School, Boston, MA, US; 2Massachusetts General Hospital, Harvard Medical School, Boston, MA, US; 3Massachusetts General Hospital, Harvard Medical School, Boston, MA, US; 4Harvard School of Public Health, Boston, MA, US

Session P-P3 Poster Session
2:30 pm – 4:00 pm
ART: Cardiovascular Risk and Hypertension

735 ICAM-1 Overexpression Induced by Abacavir is Mediated by P2X, Receptors
Carmen de Pablo; Victor Collado-Diaz; Samuel Orden; Cesar Rios-Navarro; Juan Esplugues; Angeles Alvarez
University of Valencia, Valencia, Spain

736 Changes in Platelet Function Following Abacavir Administration: A Pilot Study
Janine M. Trevillyan1; Elizabeth E. Gardiner1; Jane F. Arthur2; Jing Jing2; Robert K. Andrews3; Jennifer F. Hoy3
1Monash University, Melbourne, Australia; 2Monash University, Melbourne, Australia
737  An RCT of Rilpivirine vs Efavirenz on Cardiovascular Risk in Healthy Volunteers
Samir K. Gupta1; James E. Slaven1; Ziyue Liu1
1Indiana University School of Medicine, Indianapolis, IN, US; 2Indiana University, School of Medicine, Indianapolis, IN, US

738  Elvitegravir Reduces Monocyte Activation and Vascular Inflammation More Than Efavirenz
Corriynn O. Hileman1; Bruce Kinley1; Valeska Scharen-Guivel1; Kathy Melbourne1; Javier Szwarewicz1; Janet Robinson1; Michael M Lederman1; Grace A. McComsey1
1Case Western Reserve University, Cleveland, OH, US; 2Gilead Sciences, Inc., Foster City, CA, US

739  Impact of Antiretroviral Drugs on Hypertension in HIV-Positive Persons: D:A:D Study
Camilla I. Hatleberg1; Lene Ryom1; Antonella d’Arminio Monforite1; Eric Fontas1; Peter Reiss1; Ole Kirk1; Wafa M. El-Sadr1; Stéphane De Wit1; Jens D. Lundgren1; Caroline Sabin1
On behalf of the D:A:D study group
1Rigshospitalet, University of Copenhagen, Copenhagen, Denmark; 2San Paolo University Hospital, Milan, Italy; 3Netherlands University Hospital, Amsterdam, Netherlands; 4Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands; 5Division of Nephrology, Mount Sinai School of Medicine, New York, New York City, NY, US; 6Clinic for Infectious Diseases and Hospital Hygiene, Kantonsspital Aarau, Aarau, Switzerland; 7Nephropathy department, Public Health department, CHU Nice, Nice, France; 8University College London, London, United Kingdom

740  Population-Based Assessment of Hypertension Among HIV Patients in Rural Uganda
Dalsone Kwarisima1; Prashant Kotwani1; Norton Sanga1; Florence Mwangwa1; Vivek Jain1; Dathan Byonanebye1; James Ayieko1; Laura Balzer1; Diane Havlin1; Moses R. Kamya1
1Makerere University Joint AIDS Program, Kampala, Uganda; 2Infectious Disease Research Collaboration, Kampala, Uganda; 3University of California San Francisco, San Francisco, CA, US; 4Research Care Training Program, Kenya Medical Research Institute, Nairobi, Kenya; 5University of Berkeley, Berkeley, CA, US; 6Makerere University College of Health Sciences, Kampala, Uganda

TUESDAY, FEBRUARY 24, 2015

Session P-P4 Poster Session  Poster Hall
2:30 pm – 4:00 pm
What Predicts Risk for CVD in HIV?

741  CD4/CD8 Ratio, Age, and Serious Noninfectious Outcomes in HIV-Infected Adults
Jessica L. Castilho; Megan Turner; Sally Bebawy; Bryan E. Shepherd; Timothy Sterling
Vanderbilt University School of Medicine, Nashville, TN, US

742  Relationship Between Confirmed eGFR and Cardiovascular Disease in HIV-Positive Persons
Lene Ryom1; Jens D. Lundgren2; Peter Reiss1; Michael Ross1; Christoph Fux2; Philippe Morlat1; Olivier Moranne1; Colette Smith1; Caroline Sabin1; Amanda Mocroft1
On behalf of the D:A:D study group
1CHRP, Department of Infectious Diseases and Rheumatology, Rigshospitalet and University of Copenhagen, Copenhagen, Denmark; 2Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands; 3Division of Nephrology, Mount Sinai School of Medicine, New York, New York City, NY, US; 4Clinic for Infectious Diseases and Hospital Hygiene, Kantonsspital Aarau, Aarau, Switzerland; 5Nephropathy department, Public Health department, CHU Nice, Nice, France; 6University College London, London, United Kingdom; 7University of Bordeaux, INSERM U 897, CHU de Bordeaux, Bordeaux, France

743  Smoking, Other Substance Use and Coronary Atherosclerosis Among HIV-Infected and Uninfected Men
Sean G. Kelly1; Michael Plankeney1; Wendy Post1; Xiuhong Li2; Ron Stall1; Lisa P. Jacobson1; Mallory Witt1; Lawrence Kingsley2; Christopher Cox1; Frank J. Palella1
1Northwestern University, Chicago, IL, US; 2Johns Hopkins University School of Medicine, Baltimore, MD, US; 3Georgetown University, Washington, DC, US; 4University of Pittsburgh, Pittsburgh, PA, US; 5University of California Los Angeles, Los Angeles, CA, US

744  Pericardial Fat Density: A Novel Marker of Cardiometabolic Risk in HIV Infection
Chris T. Longenecker1; Mark Schlucter1; Yiying Liu1; Grace A. McComsey1
Case Western Reserve University, Cleveland, OH, US

745  The Effect of Physical Activity on Cardiometabolic Health and Inflammation in HIV
Saheer Dirajjal-Fargo1; Allison R. Weibel2; Bruce Kinley1; Danielle Labbato1; Ying Jiang1; Sara M. Debanne1; Grace A. McComsey1
1Rainbow Babies and Children’s Hospital, Case Western Reserve University School of Medicine, Cleveland, OH, US; 2Frances Payne Bolton School of Nursing Case Western Reserve University, Cleveland, OH, US; 3University Hospitals Case Medical Center, Cleveland, OH, US; 4Case Western Reserve University, Cleveland, OH, US

WEDNESDAY, FEBRUARY 25, 2015

Session P-P5 Poster Session  Poster Hall
2:30 pm – 4:00 pm
Cardiovascular Risk Prediction

746  Cumulative HIV Care Measures Highly Associated With Acute Myocardial Infarction
Jorge L. Salinas1; Christopher T. Rentsch1; Vincent C. Marconi1; Janet Tate1; Adeel A. Butt1; Matthew S. Freiberg1; Matthew B. Goetz1; Maria Rodriguez-Barradas1; Amy Justice1; David Rimland1
1Emory University, Atlanta, GA, US; 2Atlanta VA Hospital, Decatur, GA, US; 3Yale University, New Haven, CT, US; 4University of Pittsburgh, Pittsburgh, PA, US; 5David Geffen School of Medicine at University of California Los Angeles, Los Angeles, CA, US; 6Baylor College of Medicine, Houston, TX, US
Cardiovascular Disease Risk Prediction in the HIV Outpatient Study (HOPS)
Angela M. Thompson-Paul; Kenneth A. Lichtenstein; Carl Armon; Kate Buchacz; Rachel Debes; Joan S. Chmiel; Frank J. Palella; Stanley C. Wei; Jacke Skarbinski; John T. Brooks
1US Centers for Disease Control and Prevention, Atlanta, GA, US; 2National Jewish Health, Denver, CO, US; 3Cerner Corporation, Vienna, VA, US; 4Northwestern University, Feinberg School of Medicine, Chicago, IL, US

Incidence and Risk of Myocardial Infarction (MI) by Type in the NA-ACCORD
Daniel R. Drozd; Mari M. Kitahata; Keri N. Althoff; Jinbing Zhang; Susan R. Heckbert; Matthew J. Budoff; Frank J. Palella; Daniel B. Klein; Richard D. Moore; Heidi M. Crane
1University of Washington, Seattle, WA, US; 2Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, US; 3University of California Los Angeles, Los Angeles, CA, US; 4Northwestern University, Chicago, IL, US; 5Kaiser Permanente Northern California, Hayward, CA, US; 6Johns Hopkins University, Baltimore, MD, US

Abacavir Use and Risk for Myocardial Infarction in the NA-ACCORD
Frank J. Palella; Keri N. Althoff; Richard Moore; Jinbing Zhang; Mari Kitahata; Stephen J. Gange; Heidi M. Crane; Daniel R. Drozd; John T. Brooks; Richard Eliot

HIV-Infected Veterans and the New ACC/AHA Cholesterol Guidelines: Got Statins?
Meredith E. Clement; Lawrence Park; Ann Marie Navar-Boggan; Nwora L. Okeke; Michael Pencina; Pamela Douglas; Susananna Naggie
1Duke University, Durham, NC, US; 2Duke University, Durham, NC, US; 3Duke University, Durham, NC, US

Evaluation of the ACC/AHA CVD Risk Prediction Algorithm Among HIV-Infected Patients
Susan Regan; James B. Meigs; Joseph Massaro; Ralph B. D’Agostino; Steven Grinspoon; Virginia A. Triant
1Massachusetts General Hospital, Harvard Medical School, Boston, MA, US; 2Massachusetts General Hospital, Harvard Medical School, Boston, MA, US; 3Boston University, Boston, MA, US; 4Massachusetts General Hospital, Harvard Medical School, Boston, MA, US

TUESDAY, FEBRUARY 24, 2015

Session P-P6 Poster Session
2:30 pm – 4:00 pm
Poster Hall
Biomarkers and Atherosclerosis

IL-6 and CD8 Senescence Independently Associate With Atherosclerosis in Treated HIV
Denise C. Hsu; Zonghui Hu; Courtney Carroll; Kristinalisa Maka; Adam Rupert; Steven Deeks; S. C. Kalapus; Priscilla Hsue; Irini Sereti
1National Institute of Allergy and Infectious Diseases, Bethesda, MD, US; 2University of California San Francisco, San Francisco, CA, US; 3Leidos Biomedical Research, Inc, Frederick, MD, US

sCD163 Correlates With IMT and Macrophages in Aorta and Heart With HIV Infection
Joshua A. Walker; Graham A. Beck; Andrew D. Miller; Tricia H. Burdo; Kenneth C. Williams
1Boston College, Chestnut Hill, MA, US; 2Cornell University, Ithaca, NY, US

Non-Classical Monocytes Predict Progression of Carotid Intima-Media Thickness
Dominic C. Chow; Jamie M. Kagihara; Guangxiang G. Zhang; Scott A. Souza; Brooks I. Mitchell; Beau K. Nakamoto; Kalpana J. Kallianpur; Robert J. Matyas; Lishomwa C. Ndihlovu; Cecilia M. Shikuma
1University of Hawaii, Honolulu, HI, US; 2Kaiser Permanente, Honolulu, HI, US

TMAO and HIV-Associated Atherosclerosis
Arjun Sinha; Yifei Ma; Rebecca Scherzer; Courtney Carroll; Steven Deeks; Peter Ganz; Priscilla Hsue
1San Francisco General Hospital, San Francisco, CA, US; 2San Francisco VA Medical Center, San Francisco, CA, US; 3University of California San Francisco, San Francisco, CA, US

Impaired Cardiac Strain and Biomarkers of Immune Activation in HIV
Colleen Hadigan; Julia Purdy; Diana Thiara; Louisa Howard; Chia-Ying Liu; Fabio Raman; Sabrina Mangat; Christopher Sibley; David Bluemke
1National Institutes of Health (NIH), Bethesda, MD, US; 2Oregon Health and Sciences University, Portland, OR, US

Session P-P7 Poster Session
2:30 pm – 4:00 pm
Poster Hall
Endothelial Functions and Cerebral Vasoreactivity

Role of Angiopoietin 1, Angiopoietin 2, and Endothelial Function in HIV
Mark L. Dela Cruz; Yifei Ma; Rebecca Scherzer; Alan Wu; Kristinalisa Maka; Steven Deeks; Peter Ganz; Priscilla Hsue

HIV-Infected Persons With Type 2 Diabetes Have Evidence of Endothelial Dysfunction
Malene Hove; Julie C. Gaardbo; Hedda Hoel; Lillian Kolte; Allan Vaag; Jan Gerstoft; Henrik Ullum; Marius Troseid; Susanne D. Poulsen
1Righospitalet, University Hospital of Copenhagen, Copenhagen, Denmark; 2Hvidovre Hospital, University Hospital of Copenhagen, Hvidovre, Denmark; 3Oslo University Hospital, Ullevål, Norway

Unique Circulating MicroRNA Profiles and Endothelial Function in HIV Infection
Venkata A. Narla; Nirav Bhakta; Jane E. Freedman; Kahraman Tanriverdi; Kristinalisa Maka; Steven Deeks; Peter Ganz; Priscilla Hsue
1San Francisco General Hospital, University of California San Francisco, San Francisco, CA, US; 2University of California San Francisco, San Francisco, CA, US; 3University of Massachusetts Medical School, Worcester, MA, US
Program and Agenda

Poster Listings

760 Cerebral Vasoreactivity Is Impaired in Virally Suppressed HIV-Infected Individuals
Felicia C. Chow1; Claire Mills2; Nerissa Ko1; Courtney Carroll1; Richard Price1; Steven Deeks1; Farzaneh A. Sorond2; Priscilla Y. Hsu3
1University of California San Francisco, San Francisco, CA, US; 2Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, US

Session P-Q1 Poster Session
Poster Hall
2:30 pm – 4:00 pm
Inflammation: Biomarkers and Relationship to Outcomes

761 IL-6 Is a Stronger Predictor of Clinical Events Than hsCRP or D-Dimer in HIV Disease
Álvaro H. Borges1; Jemma L. O’Connor1; Andrew N. Phillips2; James D. Neaton1; Birgit Grund3; Jacqueline Neuhaus4; Michael Vjecha1; Alexandra Calmy5; Kersten K. Koelsch6; Henrik Friis7; Adolfo Díez-Pérez8; Tiziana Quirino9; Ronald Bosch1; Chiara Molteni2
1INSIGHT SMART and ESPRIT Study Groups
2Rigshospitalet, University of Copenhagen, Copenhagen, Denmark; 3University College London, London, United Kingdom; 4University of Minnesota, Minneapolis, MN, US; 5University of Minnesota, Minneapolis, MN, US; 6Geneva University Hospitals, Geneva, Switzerland; 7University of New South Wales, Sydney, Australia; 8Veterans Affairs Medical Center, Washington, DC, US

762 Persistent Inflammation on ART Is Associated With Poor Nutritional Recovery in Zambia
George Praygod1; Meridith Blevins1; Susannah Wood1; Andrea Rehan1; Jeremiah Kidola1; Henrik Friis2; Paul Kelly1; Douglas Heimburger1; Suzanne Fitteu3; John Koethe4
1Vanderbilt University, Nashville, TN, US; 2National Institute of Medical Research, Mwanza, United Republic of Tanzania; 3London School of Hygiene & Tropical Medicine, London, United Kingdom; 4University of Copenhagen, Copenhagen, Denmark; 5University Teaching Hospital, Lusaka, Zambia

763 Smoking and Obesity May Partially Explain the Inflammation and Morbidity Association
Supriya Krishnan1; Ronald Bosch2; Benigno Rodriguez3; Peter W. Hunt4; Cara C. Wilson5; Steven Deeks6; Michael M. Lederman2; Alan Landay7; Carey Lumeng1; Allan Tenorio8
1Center for Biostatistics in AIDS Research, Harvard School of Public Health, Boston, MA, US; 2Division of Infectious Diseases and HIV Medicine, Case Western Reserve University School of Medicine, Cleveland, OH, US; 3Positive Health Program, Dept of Medicine, San Francisco General Hospital, San Francisco, CA, US; 4Division of Infectious Diseases, Univ of Colorado Hospital, Aurora, CO, US; 5Department of Immunology and Microbiology, Rush Univ Medical Center, Chicago, IL, US; 6Univ of Michigan Medical School, Department of Pediatrics, Ann Arbor, MI, US; 7Department of Medicine, Rush University Medical Center, Chicago, IL, US

764 Infectious and Noninfectious Multimorbidity Among HIV Clinic Clients in the African Cohort Study
Julie Ake1; Jonah Maswai2; Francis Kiwewe3; Lucas Maganga4; Milton Omondi5; Babajide Keshinro6; Lindsay Hughes1; Victor G. Vallcour7; Christina Polyak7
1RV 329 AFROS Study Team
2US Military HIV Research Program, Bethesda, MD, US; 3KEMRI/Walter Reed Project, Kericho, Kenya; 4Makerere University Walter Reed Project, Kampala, Uganda; 5Mbeya Medical Research Centre, Mbeya, United Republic of Tanzania; 6KEMRI/Walter Reed Project, Kisumu, Kenya; 7Walter Reed Program - Nigeria, Abuja, Nigeria; 8University of California San Francisco (UCSF), San Francisco, CA, US

Session P-Q2 Poster Session
Poster Hall
2:30 pm – 4:00 pm
Bone Metabolism and ART: Mechanisms and Outcomes

765 Bone Metabolism and Tenofovir: Evidence of Direct Effect on Calcium-Sensing Receptor
Paolo Bonfanti1; Caterina Brasacchio1; Chiara Molteni2; Barbara Menzaghi1; Laura Soldati1; Tiziana Quirino3; Stefano Mora4
1Busto Arsizio Hospital, Busto Arsizio, Italy; 2A. Manzoni Lecco Hospital, Lecco, Italy; 3Department of Health Sciences, University of Milan, Milan, Italy; 4San Raffaele Scientific Institute, Milan, Italy

766 Bone Turnover on DRV/r + Either RAL or TDF/FTC as First-Line ART: NEAT 001 / ANRS 143
Jose I. Bernardino1; Amanda Mocroft2; Laura Richert2; Abdel Babiker2; Antonio Buño2; Antonella Castagna3; Pierre-Marie Girard4; Genevieve Chene5; Jose R Arribas5; François Raffi6
1Hospital Universitario La Paz. IdiPAZ, Madrid, Spain; 2University College London, London, United Kingdom; 3University of Bordeaux, Bordeaux, France; 4MRC Clinical Trials Unit at University College London, London, United Kingdom; 5San Raffaele Scientific Institute, Milan, Italy; 6Hospital St Antoine and Inserm, Paris, France; 7Université Nantes, Nantes, France

767 Tenofovir Replacement in Patients With Osteoporosis Increased Sclerostin Levels
Eugenia Negredo1; Adolfo Diez-Perez2; Pere Domingo2; Nuria Pérez-Alvarez2; Mar Gutierrez2; Gracia Mateu2; Jordi Puig3; Patricia Echeverria3; Anna Bonjoch4; Bonaventura Clotet5
1Lluita Contra la Sida Foundation, Germans Trias i Pujol University Hospital, Universitat Autònoma de Barcelona, Barcelona, Spain; 2Hospital del Mar-IMIM, Universitat Autònoma de Barcelona and RETICEF, Instituto Carlos III Madrid, Barcelona, Spain; 3Hospital La Senda Foundation, Germans Trias i Pujol University Hospital, Universitat Autònoma de Barcelona, Barcelona, Spain; 4Hospital of Vic—Universitat Central de Catalunya, Barcelona, Spain; 5Lluita Contra la Sida Foundation, Germans Trias i Pujol University Hospital, Universitat Autònoma de Barcelona, Barcelona, Spain; 6Lluita Contra la Sida Foundation, Germans Trias i Pujol University Hospital, Universitat Autònoma de Barcelona, Irsicina Foundation, Germans Trias i Pujol University Hospital, Barcelona, Spain; 7Lluita Contra la Sida Foundation, Germans Trias i Pujol University Hospital, Universitat Autònoma de Barcelona, Statistics and Operations Research Department, Universitat Politécnica de Catalunya, Barcelona, Spain
768 Relationship Between Phosphate Reabsorption, Age, Tenofovir and Bone Mineral Density
Lisa Hamzah; Amanda Samarakivramka; Karen Walker-Bone; Yvonne Gillece; Martin Fisher; Frank A. Post
1 Brightton and Sussex Medical School, London, United Kingdom; 2 King’s College London, London, United Kingdom; 3 University of Southampton, Southampton, United Kingdom; 4 Brighton and Sussex Hospitals NHS Trust, Brighton, United Kingdom; 5 King’s College Hospital NHS Foundation Trust, London, United Kingdom

769LB Less Bone Loss With a Maraviroc Regimen in HIV-Infected Treatment-Naïve Subjects
Babafemi Taiwo, Ellen Chan, Carl Fichtenbaum, Heather Ribaudo, Athe Tisbris, Karin Klingman, Joseph J. Eron, Baiba Berzins, Todd T. Brown
ACTG A5303 Study Team
1 Northwestern University, Feinberg School of Medicine, Chicago, IL, US; 2 Statistical and Data Analysis Center, Harvard School of Public Health, Boston, MA, US; 3 University of Cincinnati, Cincinnati, OH, US; 4 Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, US; 5 National Institutes of Health, Bethesda, MD, US; 6 University of North Carolina at Chapel Hill, Chapel Hill, NC, US; 7 Johns Hopkins University School of Medicine, Baltimore, MD, US

Session P-Q3 Poster Session Poster Hall
2:30 pm – 4:00 pm
Bone Disease: Mechanisms of Bone Loss and Fracture Risk

770 Association of Adipokines With Bone Mineral Density in HIV+ and HIV- Women
Anjali Sharma, Yifei Ma, Rebecca Scherzer, Amber L. Wheeler, Madge Cohen, Deborah Gustafson, Michael T Yin, Phyllis C. Tien
1 Albert Einstein College of Medicine, Bronx, NY, US; 2 University of California San Francisco, San Francisco, CA, US; 3 John H. Stroger Jr. Hospital of Cook County, Chicago, IL, US; 4 State University of New York Downstate Medical Center, Brooklyn, NY, US; 5 College of Physicians and Surgeons, Columbia University, New York, NY, US

771 Long-Term Changes in Bone Mineral Density and Insulin Resistance on Statins in HIV
Kristine M. Erlandson, Ying Jiang, Sara M. Debanne, Grace A. McComsey
1 University of Colorado, Aurora, CO, US; 2 Case Western Reserve University, Cleveland, OH, US

772 Immunologic Predictors of Bone Loss in a Contemporary HIV Cohort
1 CDC SUN (Study to Understand the Natural History of HIV/AIDS in the Era of Effective Therapy) Investigators
2 University of Alabama at Birmingham, Birmingham, AL, US; 3 University of Minnesota, Minneapolis, MN, US; 4 Washington University School of Medicine, St. Louis, MO, US; 5 National Jewish Health, Denver, CO, US; 6 Division of HIV/AIDS Prevention, Atlanta, GA, US; 7 National Institute of Allergy and Infectious Disease (NIAID), Bethesda, MD, US

773 RANKL Predicts 96-Week BMD Changes in ATV/r Monotherapy: A MODA Trial Sub-Study
Vincenzo Spagnuolo, Marco Borderi, Giuseppina Musumeci, Laura Galli, Camilla Tincati, Stefano Rusconi, Giovanni Guaraldi, Alba Bigoloni, Adrian Lazzarini, Antonella Castagna
1 San Raffaele Scientific Institute, Milan, Italy; 2 Alma Mater Studiorum University of Bologna, Bologna, Italy; 3 University of Milan, Milan, Italy; 4 University of Modena and Reggio Emilia, Modena, Italy

774 Predictors of Longitudinal Change in Bone Mineral Density in a Cohort of HIV Positive and Negative Subjects
Willard Tinagho, Aoife Cotter, Caroline Sabin, Alan Macken, Eoin Kavanagh, Jennifer Brady, Geraldine McCarthy, Juliet Compston, Patrick W. Mallon
1 HIV UPBEAT Study Group
2 University College Dublin, Dublin, Ireland; 3 Research Department of Infection and Population Health, London, United Kingdom; 4 Mater Misericordiae University Hospital, Dublin, Ireland; 5 Mater Misericordiae University Hospital, Dublin, Ireland; 6 Mater Misericordiae University Hospital, Dublin, Ireland; 7 University of Cambridge, London, United Kingdom

775 Fracture Incidence Is Increased in Aging HIV-Infected Women
Anjali Sharma, Qiuju Shi, Donald R. Hoover, Kathryn Anastas, Phyllis C. Tien, Mary A. Young, Madge Cohen, Deborah Gustafson, Michael T Yin

Session P-Q4 Poster Session Poster Hall
2:30 pm – 4:00 pm
Measuring Bone Density

776 Heel Quantitative Ultrasound to Cut Down on DXA Costs in HIV-infected Patients
Marilia R. Pinzone, Maria Gussio, Daniela Canstronuovo, Adriana Di Gregorio, Benedetto M. Celesia, Bruno Cacopardo, Giuseppe Nunnari
1 University Health Network, Toronto, Canada; 2 Centre for Excellence in Skeletal Health Assessment, Toronto, Canada

777 Novel Radiographic Measures HRpQCT and HSA as Correlates of HIV-Associated Fractures
Darrell H. Tan, Janet Raboud, Leah Szadkowski, Eva Szabo, Hanxian Hu, Queenie Wong, Angela Cheung, Sharon Walsmsley
1 St. Michael’s Hospital, Toronto, Canada; 2 Toronto General Research Institute, Toronto, Canada; 3 University Health Network, Toronto, Canada; 4 Centre for Excellence in Skeletal Health Assessment, Toronto, Canada
WEDNESDAY, FEBRUARY 25, 2015

Session P-Q5 Poster Session

Fat Without Borders: Metabolic Complications in Resource-Limited Settings

778 Obesity and Inflammation in Resource-Diverse Settings of ART Initiation
Kristine M. Erlandson1; Nikhil Gupta2; Javier R. Lama3; Patcharaphan Sugandhavesa1; Thando Mwelase4; Ashwin Balagopal5; David Asmuth6; Thomas B. Campbell1; Amita Gupta1
On behalf of the AST175 and NWCS319 study team
1University of Colorado, Aurora, CO, US; 2Johns Hopkins University, Baltimore, MD, US; 3Impacta Peru Clinical Trials Unit, Lima, Peru; 4Chiang Mai University, Chiang Mai, Thailand; 5University of Witswatersrand, Johannesburg, South Africa; 6University of California Davis, Sacramento, CA, US

779 Body Composition Outcomes at 96 Weeks in the SECOND-LINE RCT DXA Substudy
Mark A. Boyd1; Janaki Amin1; Patrick W. Mallon2; Jennifer F. Hoy3; Samuel Ferret4; Waldo Belluso5; Praphan Phanuphak6; Sean Emery7; David A. Cooper8
SECOND-LINE study group
1University of New South Wales Australia, Sydney, Australia; 2University College Dublin, Dublin, Ireland; 3Monash University/Alfred Hospital, Melbourne, Australia; 4Hospital Saint Louis, Paris, France; 5Hospital Italiano, Buenos Aires, Argentina; 6Thai Red Cross AIDS Research Centre, Bangkok, Thailand

780 Bone Quality by Quantitative Ultrasound at the Radius Does Not Differ in ART-Naïve HIV+ and HIV- Rwandan Women
Eugene Mutimura1; Qiu Hu Shi2; Donald R. Hoover3; Kathryn Anastas4; Emmanuel Rudakemwa5; Jean Claude Dusinenge6; Jean D’Amour Sinayobye7; Michael T Yin8
1Regional Alliance for Sustainable Development, Kigali, Rwanda; 2School of Health Sciences and Practice, New York Medical College, New York, NY, US; 3State University of New Jersey, New Brunswick, NJ, US; 4Albert Einstein College of Medicine and Montefiore Medical Center, Bronx, NY, US; 5King Faisal Hospital, Kigali, Rwanda; 6Columbia University Medical Center, New York, New York, US

781 Predictors and Outcomes of Incident High Cholesterol in Adults on ART in South Africa
Denise Evans1; Alana T. Brennan1; Faith Moyo2; David Spencer3; Kay Mahomed4; Mhairi Maskew5; Lawrence Long1; Sydney Rosen1; Matt P. Fox2
1University of the Witwatersrand, Johannesburg, South Africa; 2Boston University, Boston, MA, US; 3Right to Care, Johannesburg, South Africa

782 Metabolic Changes and Second-Line ART in Africa (2LADY/ANRS 12169 Trial)
Amandine Cournil1; Assiane Diouf1; Sabrina Eymard-Duvernoy1; Adrien Sawadogo1; Liliane Ayangma1; Louise Fortes-Deguenonvo1; Jean-Marc Mben2; Eric Delaporte1; Laura Ciaffi2; Sinayobye6; Jean Mwelase1; Keri N. Althoff1; Joseph B. Margolick1; Mhairi Maskew1; Laura Ciaffi1; Patrick W. Mallon1; Jean Claude Dusingize1
1FMSB/University Yaounde 1, Yaounde, Cameroon; 2IRD/UM 1, Montpellier, France; 3CHU Sourou Sanou, Bobo Dioulasso, Burkina Faso; 4CRCEF, Dakar, Senegal; 5Yaounde Military Hospital, Yaounde, Cameroon; 6FMSB/University Yaounde 1, Yaounde, Cameroon; 7ANRS Research Center, Yaounde, Cameroon

TUESDAY, FEBRUARY 24, 2015

Session P-Q6 Poster Session

Aging: Frailty, Telomeres, and mtDNA

783 Frailty and Cause-Specific Hospitalization Among Persons Aging With HIV and Drug Use
Damani A. Piggott1; Abimekere D. Muzzaale2; Shruti H. Mehta2; Ryan P. Westergaard3; Todd T. Brown3; Kushang V. Patel3; Sean X. Leng4; Gregory D. Kirk1
1Johns Hopkins University, Baltimore, MD, US; 2University of Wisconsin, Madison, WI, US; 3University of Washington, Seattle, WA, US

784 Association of HIV Viral Load and Shorter Telomere Length
Shawn Gogia1; Jue Lin2; Yifei Ma3; Rebecca Scherzer3; Elizabeth Blackburn4; Ramin Farzaneh-Far5; Steven Deeks3; Priscilla Hsu4
1University of California San Francisco, San Francisco, CA, US

785 Novel Mechanisms of Nucleoside Analog Associated Mitochondrial DNA Mutation
Kristian Gardner; Patrick F. Chinnery; Brendan A. Payne
Newcastle University, Newcastle-upon-Tyne, United Kingdom

786 Balance Confidence Predicts Falls Better Than Physical Function Testing in HIV+ Men
Todd T. Brown1; Xiuhong Li2; Lisa P. Jacobson3; Jennifer Schrack4; Frank J. Palella5; Lawrence Kingsley1; Joseph B. Margolick6; Adrian Dobs7; Jordan Lake8; Keri N. Althoff9
1MACS
2University of California San Francisco, San Francisco, CA, US
3Johns Hopkins University School of Medicine, Baltimore, MD, US; 4Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, US; 5Northwestern University, Feinberg School of Medicine, Chicago, IL, US; 6University of Pittsburgh, Pittsburgh, PA, US; 7University of California Los Angeles, Los Angeles, CA, US; 8University of Alabama at Birmingham, Birmingham, AL, US; 9University of Pennsylvania, Philadelphia, PA, US

Session P-Q7 Poster Session

Diabetes and Other Endocrine Disorders

787 Vitamin D Supplementation Does Not Affect Metabolic Changes Seen With ART Initiation
Todd T. Brown1; Ellen Chan2; Edgar T. Overtin3; Pablo Tebas4; Kathy Melbourne5; Royce Hardin6; Heather Ribaudo7; Michael T. Yin7
1ACTG
788 First-Line NRTIs and Risk of New Onset Diabetes in HIV-Infected Adults in Thailand
Prakit Riyatenn; Nicolas Salvadori; Patrinee Traisathit; Nicole Ngo-Giang-Huong; Rapeepan Suaysod; Guttiya Halve; Naruepon Yuththakasemsunt; Aphiwat Chutanunta; Jacqueline Capeau; Gonzague Jourdain
1Chiang Mai University, Chiang Mai, Thailand; 2Institut de Recherche pour le Développement UMI 174-PHPT, Chiang Mai, Thailand; 3Phayao Provincial Hospital, Phayao, Thailand; 4Nong Khai Hospital, Nong Khai, Thailand; 5Samutsakhon Hospital, Samutsakhon, Thailand; 6Sorbonne University, Paris, France

789 Diabetes Mellitus Among HIV-Infected Adults in Care in the United States, 2009–2010
Alfonso C. Hernandez-Romieu
Emory University Rollins School of Public Health, Decatur, GA, US

790 Functional Vitamin D Deficiency With Initiation of Tenofovir-Based ART?
Evelyn Hsieh; Lianna Fransen; Weibo Xia; Yang Han; Michael T Yin; Karl Inogona; Ting Zhu; Taisheng Li
1Yale University School of Medicine, New Haven, CT, US; 2Peking Union Medical College Hospital, Beijing, China; 3Columbia University Medical Center, New York, NY, US; 4Yale University School of Medicine, New Haven, CT, US

791 Determinants of Parathyroid Hormone Levels in HIV-positive Tenofovir-treated Patients with Normal Renal Function
Letizia Marinaro; Andrea Calcagno; Jessica Cuato; Elisabetta Scavaglieri; Marco Simiele; Maria Cristina Tettoni; Laura Trentini; Antonio D’Avolio; Giovanni Di Perri; Stefano Bonora
Unit of Infectious Diseases, Turin, Italy

THURSDAY, FEBRUARY 26, 2015

Session P-Q8 Poster Session
2:30 pm – 4:00 pm
Renal Dysfunction: ART and Biomarkers

792 Elevated Tenofovir Exposure via Intensive PK Monitoring Is Associated With Progressive Kidney Function Decline
Sanjiv M. Baxin; Rebecca Scherer; Ruth M. Greenblatt; Howard Minkoff; Kathryn Anastos; Mardge H. Cohen; Mary A. Young; Monica Gandhi; Michael G. Shlipak
1University of California San Francisco, San Francisco, CA, US; 2State University of New York Downstate Medical Center, Brooklyn, NY, US; 3Georgetown University, Washington, DC, US; 4John Stroger (formerly Cook County) Hospital, Chicago, IL, US; 5Montefiore Medical Center, University Hospital for Albert Einstein College of Medicine, Bronx, NY, US

793 Impact of TDF+PI/r on Renal Function in Sub-Saharan Africa: 2LADY/ANRS 12169 Trial
Arsene Hema; 1Amandine Courli; 2Laura Ciaffi; 3Sabrina Eymard-Duveryay; 4Assane Diouf; 5Nestor Manga; 6Vincent Le Moing; 7Jacques Reynes; 8Sinatra Koulia-Shiro; 9Eric Delaporte
1CHU Sourou Sanou, Bobo Dioulasso, Burkina Faso; 2IRD/UM 1, Montpellier, France; 3Le Centre Régional de Recherche et de Formation à la Prise en Charge Clinique de Fann, Dakar, Senegal; 4Yaounde Military Hospital, Yaounde, Cameroon; 5FMSB/University Yaounde 1, Yaounde, Cameroon

794 Renal Tubular Disease and the Relationship With Tenofovir and Atazanavir Exposure
Lisa Hamzah; John Booth; Catherine Horsfield; Rachael Jones; Jeremy Levy; Deborah Williams; Nadia Khatib; Rachel Hilton; John Connolly; Frank A. Post
1King’s College London, London, United Kingdom; 2University College London, London, United Kingdom; 3Guy’s and St Thomas’ NHS Foundation Trust, London, United Kingdom; 4Chelsea and Westminster Hospital NHS Foundation Trust, London, United Kingdom; 5Imperial College London, London, United Kingdom; 6Brighton and Sussex Hospitals NHS Trust, London, United Kingdom; 7Heart of England NHS Foundation Trust, Birmingham, United Kingdom; 8King’s College Hospital NHS Foundation Trust, London, United Kingdom

795 Safety of Tenofovir Alafenamide in Renal Impairment
Anton Pozniak; Jose R Arribas; Samir K. Gupta; Frank A. Post; Ancheale Avhingsan; Gordon Crofoot; Kenneth A. Lichtenstein; Moti Ramgopal; Ploenchit Chetcutisak; Marshall W. Fordye
1Gilead Sciences Inc, Foster City, CA, US; 2Chelsea and Westminster Hospital NHS Foundation Trust, London, United Kingdom; 3Hospital Universitario La Paz, Madrid, Spain; 4Indiana University School of Medicine, Indianapolis, IN, US; 5King’s College Hospital NHS Foundation Trust, London, United Kingdom; 6HIV-NAT, Thai Red Cross AIDS Research Center and Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand; 7Crofoot Research, Houston, TX, US; 8National Jewish Health, Denver, CO, US; 9Midway Research Center, Ft. Pierce, FL, US; 10Khon Kaen University, Khon Kaen, Thailand

796 Elevated Nonclassical Monocytes and Urinary Fibrotic Markers in HIV Albuminuria
Brooks I. Mitchell; Mary Margeret Byron; Roland C. Ng; Dominic C. Chow; Pichaya O-charoen; Lishomwa C. Ndhlovu; Cecilia M. Shikuma
University of Hawaii, Honolulu, HI, US

797 Kidney Dysfunction and Markers of Inflammation in the Multicenter AIDS Cohort Study
Alison G. Abraham; Annie Darilay; Heather McKay; Joseph B. Margolick; Michelle M. Estrella; Frank J. Palella; Robert Bolan; Charles R. Rinaldo; Lisa P. Jacobson
1Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, US; 2ASTRAZeneca, Gaithersburg, MD, US; 3Northwestern University, Feinberg School of Medicine, Baltimore, MD, US; 4University of Pittsburgh, Pittsburgh, PA, US; 5Los Angeles LGBT Center, Los Angeles, CA, US; 6University of Pittsburgh, Pittsburgh, PA, US
Session P-Q9 Poster Session  
2:30 pm – 4:00 pm  
Renal Transplantation: Long-Term Outcomes

798 Risk Factors for Acute Allograft Rejection in HIV Positive Kidney Transplant Recipients
Esther N. Gathogo1; Mark Harber2; Sanjry R. Bhagani3; Joanne Baxter4; Vincent Lee5; Jeremy Levy6; Rachael Jones7; Rachel Hilton8;
Graham Davies9; Frank A. Post1
1King’s College London, London, United Kingdom; 2Royal Free London NHS Foundation Trust, London, United Kingdom; 3North Manchester General Hospital, Manchester, United Kingdom; 4Central Manchester University Hospitals, Manchester, United Kingdom; 5Imperial College Healthcare NHS Trust, London, United Kingdom; 6Chelsea and Westminster Hospital, NHS Foundation Trust, London, United Kingdom; 7Guy’s and St Thomas’ NHS Foundation Trust, London, United Kingdom

799 Survival in HIV-Positive Transplant Recipients Compared to Matched Registry Controls
Michelle E. Roland1; Burc Barin2; Shirish Huprikar3; Michael Wong4;
Emily Blumberg5; David Simon6; Margaret Ragni7; Don Steablein8;
Peter Stock9
1HIV-TR Study Team
2University of California San Francisco, San Francisco, CA, US; 3EMMES Corporation, Rockville, MD, US; 4Mount Sinai School of Medicine, New York, NY, US; 5Beth Israel Deaconess Medical Center, Boston, MA, US; 6University of Pennsylvania, Philadelphia, PA, US; 7Rush University Medical Center, Chicago, IL, US; 8University of Pittsburgh, Pittsburgh, PA, US

Session P-Q10 Poster Session  
2:30 pm – 4:00 pm  
Pulmonary Disease

800 Risk Factors for Airflow Obstruction Among HIV+ Individuals in Nairobi, Kenya
Engi F. Attiac1; Elizabeth Maleche-Obimboa1; Nelly Yatich1; Lillian Ndruke1; Julia Njoroge1; Sameh Sakra1; Nveeen El Antouny1; F. Mena Attwa1; Kristina Cotherts1; Michael Chung1
1University of Washington, Seattle, WA, US; 2University of Nairobi, Nairobi, Kenya; 3Coptic Hope Center for Infectious Diseases, Nairobi, Kenya

801 Pulmonary Complications of HIV-1 in Youth: The PHACS AMP Study
William T. Shearer1; Erin Leister2; George Siberry3; Denise L. Jacobson2; Russell B. Van Dyke4; Hannah H. Peavy5; Suzanne Siminski5; Meyer Kattan6; Laurie Butler7; Andrew Colín8
1Baylor College of Medicine and Texas Children’s Hospital, Houston, TX, US; 2Harvard School of Public Health, Boston, MA, US; 3National Institutes of Health (NIH), Bethesda, MD, US; 4Tulane University Health Sciences Center, New Orleans, LA, US; 5National Heart, Lung, and Blood Institute, Bethesda, MD, US; 6Frontier Science and Technology Research Foundation, Amherst, NY, US; 7Columbia University Medical Center, New York, NY, US; 8University of Miami Health System Batchelor Research Institute, Miami, FL, US

802 Distinct Airway Methylation and Gene Expression Profiles in HIV-Associated COPD
Janice M. Leung1; Emily Vucic1; Joseph C. Liu2; David Ngan1; Tawimas Shaiapanich3; Julio Montaner4; Stephen Lam5; Don Sin6; Wan Lam5; S. F. Paul Man1
1Centre for Heart Lung Innovation, Vancouver, Canada; 2BC Cancer Research Center, Vancouver, Canada; 3St. Paul’s Hospital, Vancouver, Canada; 4BC Centre for Excellence in HIV/AIDS, Vancouver, Canada

Session P-Q11 Poster Session  
2:30 pm – 4:00 pm  
Body Composition and Risk Factors for Abnormalities

803 Altered Body Composition and Inflammation in HIV Infection With Type 2 Diabetes
Malene Hove1; Julie Abildgaard1; Julie C. Gaardbo1; Allan Vaag1; Jan Gerstoft1; Bente Klarlund Pedersen1; Birgitte Lindegaard1; Susanne D. Poulsen1
Rigshospitalet, University Hospital of Copenhagen, Copenhagen, Denmark

804 Alcohol, Substance Use, and Smoking Associations With Lipoprotein and Lipohypertrophy
Marisela Noorhasan1; Daniel R. Drozd2; Aaron Blashill3; Greer Burkholder4; Karen Cropsey1; Matthew Mimiga5; Katerina Christopoulos6; Carl Grunfeld6; Heidi M. Crane7
Centers for AIDS Research Network of Integrated Clinical Systems

Session P-Q12 Poster Session  
2:30 pm – 4:00 pm  
Complications: Liver Disease Without Viral Hepatitis

805 Antiretroviral Drugs Associated With Chronic ALT Elevations in Persons Without HCV and HBV Infection
Helen Kovari1; Caroline Sabín2; Bruno Ledegerber2; Lene Ryom2; Antonella d’Arminio Monforte3; Matthew G. Law4; Stéphane De Wit4; Andrew N. Phillips5; Jens D. Lundgren6; Rainer Weber5
on behalf of the D:A:D Study Group
1University Hospital Zurich, Zurich, Switzerland; 2University College London, London, United Kingdom; 3University of Copenhagen, Copenhagen, Denmark; 4University of Milan, Milan, Italy; 5University of New South Wales, Sydney, Australia; 6St Pierre University Hospital, Brussels, Belgium

806 APRI and FIB4: Associated With D-Drug Exposure, Low CD4 Count and Monocyte Activation
Katherine W. Koos1; Rosan van Zoest1; Ferdinand W. Wit1; Judith Schouten1; Neeltje Kootstra1; Ineke G. Stolte1; Maria Prins1; Peter Reiss1; Marc van der Valk2
AGEhIV Cohort Study Group
1Amsterdam Institute for Global Health and Development, Amsterdam, Netherlands; 2Academic Medical Center University of Amsterdam, Amsterdam, Netherlands; 3Public Health Service of Amsterdam, Amsterdam, Netherlands
807 HIV and Liver Fibrosis Among Prison Inmates: The iDEA West Africa Collaboration
Antoine Jaquet1, Gilles Wandelier2, Judicael Tine3, Claver Dagnña4, Alain Atti5, Akoua Patass6, Abdoulaye Ndiaye7, Kounavi K. Ekouvevi8, Moussa Seydi9, François Dab1
1Inserm U897, ISPED, Université de Bordeaux, Bordeaux, France; 2Department of Infectious Diseases, Bern University Hospital, Bern, Switzerland; 3Service de Maladies Infectieuses et Tropicales, CRCF, CHU de Fann, Dakar, Senegal; 4Service de Virologie, BIJLUM, Université de Lomé, Lomé, Togo; 5Service de Hépato-Gastroentérologie, CHU de Yopougon, Abidjan, Côte d’Ivoire; 6Service de Maladies Infectieuses et Tropicales, CHU Sylvanus Olympio, Lomé, Togo; 7Service de Médecine Interne, CHU Aristide Le Dantec, Dakar, Senegal; 8Département de Santé Publique, Faculté des Sciences de la Santé, Université de Lomé, Lomé, Togo

808 Clinical Correlates of Alcohol Use Disorders Among HIV-Infected Adults in Zambia
Michael J. Vinikoor1, Masumba Masaninga2, Carolyn Bolton Moore3, Virginia Munamunungu4, Alice Siyunda5, Lloyd Mulenga6, Matthias Egger7, Benjamin H. Chi8, Gilles Wandelier9
1University of North Carolina, Lusaka, Zambia; 2Lusaka District Health Management Team, Lusaka, Zambia; 3University of North Carolina, Chapel Hill, NC, US; 4Centre for Infectious Disease Research in Zambia, Lusaka, Zambia; 5University of Zambia, Lusaka, Zambia; 6Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland

809 Depression and Treatment Outcomes Among Tanzanian Adults Initiating HAART
Christopher R. Sudfeld1, Sylvia Kaaya2, Nilupa S. Gunaratna1, Wafae Fawzi3, Ferdinand Mugusi4, Mary C. Smith Fawzi5
1Harvard School of Public Health, Roxbury Crossing, MA, US; 2University of Health and Allied Sciences, Dar es Salaam, United Republic of Tanzania; 3Harvard Medical School, Boston, MA, US

TUESDAY, FEBRUARY 24, 2015

Session P-R1 Poster Session Poster Hall
2:30 pm – 4:00 pm
Immune Reconstitution Inflammatory Syndrome in Opportunistic Infections

810 Discordant Early Immune Responses Distinguish TB IRIS and Death in HIV/TB Coinfection
Shruti Ravimohan1, Neo Tamuha1, Andrew Steenhoff2, Rona Lethlhogile3, Kebatshabile Nfanyana4, Tumelo Ramtlou5, Robert Gross6, Drew Weissman7, Gregory P. Bisson8
1Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, US; 2Botswana University of Pennsylvania Partnership, Gaborone, Botswana

811 MMPs and Immunopathology in TB Immune Reconstitution Inflammatory Syndrome
Naomi F. Walker1, Katalin A. Wilkinson1, Graeme Meinertjes2, Rene Goliath3, Janique Peypers2, Robert J. Wilkinson1, Jon S. Friedland9, Paul T. Elkington10
1Imperial College London, Cape Town, South Africa; 2University of Cape Town, Cape Town, South Africa; 3Imperial College London, London, South Africa; 4University of Southampton, Southampton, United Kingdom

812 Exuberant Pathogen-Specific Th1 CD4+ T-Cell Responses in MAC-IRIS in HIV Infection
Kimberly F. Faldetta1, Denise C. Hsu1, Virginia Sheikh1, Gregg Roby2, Kenneth Olivier3, Irini Sereti4
1National Institutes of Health (NIH), Bethesda, MD, US; 2National Institutes of Health (NIH), Rockville, MD, US

813 A Paradoxical Treatment of Mycobacterial Immune Reconstitution Inflammatory Syndrome
Denise C. Hsu1, Kimberly F. Faldetta1, Luxin Pei1, Delmyra Turpin1, Virginia Sheikh1, Irini Sereti4
1National Institute for Allergy and Infectious Diseases (NIAID), Bethesda, MD, US

814 CD8 T Cells in Lesions of PML-IRIS Express CCR5: Rationale for the Use of Maraviroc
Guillaume Martin-Blondel1, Jan Bauer2, Emmanuelme Uro-Coste2, Hervé Dumas1, Hans Lassmann6, David Brassat4, Pierre Delobel2, Roland Liblau2, Bruno Marchou1
1University of Vienna, Vienna, Austria; 2Toulouse University Hospital, Toulouse, France; 3Inserm, Toulouse, France

815 Monocyte Immune Responses in Cryptococcal Immune Reconstitution Inflammatory Syndrome
David B. Meya1, Godfrey Zizwa2, Samuel Okurut3, Stephen Cose1, Paul Bohjanen4, Sharon Wahl1, David R. Bouwhare5, Yuka Manabe6, Edward N. Janoff7
1Makerere University College of Health Sciences, Kampala, Uganda; 2Makerere University Walter Reed Project, Kampala, Uganda; 3Medical Research Council, Kampala, Uganda; 4University of Minnesota, Minneapolis, MN, US; 5National Institute for Dental and Craniofacial Research, Bethesda, MD, US; 6Johns Hopkins University School of Medicine, Baltimore, MD, US; 7University of Colorado, Denver, CO, US

816LB Does HIV Infection Reduce the Probability of Transmission of Pulmonary Tuberculosis?
Judith R. Glynn1, José Afonso Guerra-Assunção2, Rein M. Houben3, Themba Mzembe2, Lifted Sichali2, Palwashra Y. Khan4, Ruth McNerney5, Julian Parkhill1, Taane G. Clark6, Amelia C. Crampin7
1London School of Hygiene and Tropical Medicine, London, United Kingdom; 2Karonga Prevention Study, Chilumba, Malawi; 3Wellcome Trust Sanger Institute, Hinxton, United Kingdom
Session P-R2 Poster Session
2:30 pm – 4:00 pm
T-Cell Responses to Tuberculosis Infection

817 The Relationship Between T-Regulatory Cells and Latent Tuberculosis Infection in Household Contacts Exposed to Pulmonary Tuberculosis Infection in Kampala, Uganda
Rhoda Namakula, Irene A. Odanga, Josephine Kasolo, Ekii A. Abuku
1Makerere University–Johns Hopkins Research Collaboration, Kampala, Uganda; 2Makerere University College of Health Sciences, Kampala, Uganda; 3Medical Research Council (Uganda Virus Research Institute), Entebbe, Uganda

818 Antiretroviral Therapy Fails to Restore Mycobacterium Tuberculosis-specific Th1 and Th17 CD4 Responses
Lyle W. Murray, Dominique Goedhals, Iman Satti, Rodney Phillips, Helen McShane, John Frater
1University of Oxford, Oxford, United Kingdom; 2University of the Free State, Bloemfontein, South Africa

819 Treg/Th17 and T-Cell Effector Responses in Tuberculosis Patients Infected with HIV
Christine Lacabaratz, Aurelie Wiedemann, Celine Manier, Laure Bourdery, Mathieu Surenaud, Jean-Daniel Lelièvre, Giovanni Melica, Yves Lévy
1INSERM U955, Université Paris-Est Créteil, Vaccine Research Institute, Créteil, France; 2INSERM U955, Université Paris-Est Créteil, Vaccine Research Institute, CHU H. Mondor-A. Chenevier, Créteil, France; 3CHU H. Mondor-A. Chenevier, Créteil, France

820 HIV-Tuberculosis Coinfection Leads to Increased Turnover of Late-Senescent CD8+ T Cells
Shankar Esaki Muthu, Chong Yee Kien, Alireza Saedidi, Adeeba Kamarulzaman, Vijayakumar Velu, Marie Larsson
1University of Malaya, Kuala Lumpur, Malaysia; 2Emory University, Atlanta, GA, US; 3Linkoping University, Linkoping, Sweden

821 CD8 T-Cell Terminal Differentiation and Its Regulation by DHEA in HIV-TB Coinfection
Guadalupe V. Suarez, Matias T. Angermay, Maria B. Vecchione, Omar Sued, Horacio Salomon, Maria F. Quiroga
1INIBIS (UJA-CONICET), Buenos Aires, Argentina; 2Fondacion Huesped, Buenos Aires, Argentina

Session P-R3 Poster Session
2:30 pm – 4:00 pm
TB Diagnostic Challenges

822 Unsuspected Prevalent TB among HIV-Infected Pregnant Women, South Africa
Jennifer D. Hoffmann, Silvia E. Cohn, Fildah Mashabela, Ziyaad Waja, Christopher J. Hoffmann, Neil Martinson, Richard E. Chaisson
1Johns Hopkins University School of Medicine, Baltimore, MD, US; 2Perinatal HIV Research Unit (PHRU), Johannesburg, South Africa

823 Evaluation of WHO 4-Symptom Tool to Rule Out TB: Data From the XPHACTOR Study
Yasmeen Hanifa, Katherine Fielding, Violet Chihota, Nontobeko Ndlovu, Alan Karstaedt, Lungiswa Adonis, Linda Erasmus, Mark Nicol, Gavin Churchyard, Alison Grant
1London School of Hygiene & Tropical Medicine, London, United Kingdom; 2Aurum Institute for Health Research, Johannesburg, South Africa; 3Chris Hani Baragwanath Hospital, Johannesburg, South Africa; 4Mamelodi Hospital, Pretoria, South Africa; 5National Health Laboratory Service, Johannesburg, South Africa

824 Xpert MTB/RIF Versus AFB Smear to Determine Respiratory Isolation of US TB Suspects
Anne Luetkemeyer, Cynthia Finnhaber, Michelle Kendall, Xingye Wu, Debra Benator, Gerald Mazurek, Diane Havlir, Beatriz Grinsztejn, David Alland
on behalf of the ACTG A5295/TBTC 34 Study Teams
1San Francisco General Hospital, University of California California San Francisco, San Francisco, CA, US; 2Harvard School of Public Health, Center for Biostatistics in AIDS Research, Boston, MA, US; 3Washington DC Veterans Affairs Medical Center, Washington, DC, US; 4US Centers for Disease Control and Prevention, Atlanta, GA, US; 5Instituto de Pesquisa Clínica Evandro Chagas, Rio de Janeiro, Brazil; 6Rutgers New Jersey Medical School, Newark, NJ, US; 7University of Witwatersrand, Johannesburg, South Africa; 8ACTG A5295/TBTC 34 Study Teams, N/A, MA, US

825 Needle Aspirates Highlight Challenges in Defining HIV+ TB Deaths Using Verbal Autopsy
Aaron Karat, Mpho Tlali, Salome Charalambous, Kerrigan McCarthy, Violet Chihota, Gavin Churchyard, Katherine Fielding, Kathleen Kahn, Tanvier Omar, Alison Grant
1London School of Hygiene and Tropical Medicine, London, United Kingdom; 2The Aurum Institute, Johannesburg, South Africa; 3University of the Witwatersrand, Johannesburg, South Africa; 4National Health Laboratory Service, Wits School of Public Health, Johannesburg, South Africa

826 Delta-Like 1 Protein, Vitamin D Binding Protein, and Fetuin Measurement in Cerebrospinal Fluid for Detection of Mycobacterium tuberculosis Meningitis
Nathan C. Bahr, Ryan Halupnick, Grace Linder, Reuben Kiggundu, Henry W. Nabeta, Darlisha Williams, Srinand Srevaratnam, Joshua Rhein, David B. Meya, David R. Boulware
1University of Minnesota, Minneapolis, MN, US; 2Makerere University College of Health Sciences, Kampala, Uganda; 3University of Minnesota, Minneapolis, MN, US

827LB Adherence to Once-Weekly Self-Administered INH and Rifapentine for Latent TB: iAdhere
Robert Belknap, Andrey Borisov, David Holland, Pei-Jean Feng, Joan-Pau Millet, Neil Martinson, Alicia Wright, Michael Chen, Joan Cayla, Jose M. Mida
and the Tuberculosis Trials Consortium (TBTC)
1Denver Health and Hospital Authority, Denver, CO, US; 2US Centers for Disease Control and Prevention, Atlanta, GA, US; 3Emory University, Atlanta, GA, US; 4Tuberculosis Investigation Unit of Barcelona, Barcelona, Spain; 5University of Witwatersrand, Johannesburg, South Africa; 6Vanderbilt University, Nashville, TN, US; 7Hospital Clinic-IDIBAPS, University of Barcelona, Barcelona, Spain
THURSDAY, FEBRUARY 26, 2015

Session P-R5 Poster Session
2:30 pm – 4:00 pm
Cryptococcal Meningitis: Host Response, Treatment, and Outcomes

834 Local and Systemic Humoral Responses to Cryptococcal Meningitis in Patients With AIDS
Erin E. Finn1; Jordan Janoff2; Jeremy Rahkola3; David B. Meyea; Samuel Okurut4; Andrew D. Kambugu5; Paul Bohjanen1; Kirsten Nielsen6; David R. Boulware7; Edward N. Janoff1
1Mucosal and Vaccine Research Colorado, Aurora, CO, US; 2Makerere University College of Health Sciences, Kampala, Uganda; 3University of Minnesota, Minneapolis, MN, US

835 Antiretroviral Therapy Alters the CSF Immune Response in Cryptococcal Meningitis
James E. Scriven1; Britta Urban; Lisa Graham; Charlotte Schütz; Robert J. Wilkinson; David R. Boulware; David Laloo; Graeme Meintjes
1Liverpool School of Tropical Medicine, Liverpool, United Kingdom; 2University of Cape Town, Cape Town, South Africa; 3Imperial College London, London, United Kingdom; 4University of Minnesota, Minneapolis, MN, US

836 Detrimental Outcomes of Unmasking Cryptococcal Meningitis With Recent ART Initiation
Joshua Rhein1; Katherine H. Hullsie2; Nathan C. Bahr; Reuben Kiggundu; Darlisha Williams; Henry W. Nabeta; Abdus Musubire; David B. Meya; David R. Boulware
1University of Minnesota, Minneapolis, MN, US; 2University of Minnesota, Minneapolis, MN, US; 3Makerere University College of Health Sciences, Kampala, Uganda

837 Impact of ART on Mortality in Cryptococcal Meningitis Patients: High-Income Settings
Suzanne M. Ingle1; Jose M. Miro2; Hansjakob Furrer3; Amy Justice4; Michael S. Saag5; Christian Manzardo6; Anna Esteve; Lauren E. Cain7; Jonathan A. Sterne8; Margaret T. May9
1University of Bristol, Bristol, United Kingdom; 2Hospital Clinic–L’Institut D’Investigacions Biomèdiques August Pi i Sunyer, University of Barcelona, Barcelona, Spain; 3Harvard School of Public Health, Boston, MA, US; 4Bern University Hospital and University of Bern, Bern, Switzerland; 5Yale University School of Medicine, VA Connecticut Healthcare System, New Haven, CT, US; 6University of Alabama at Birmingham, Birmingham, AL, US; 7Centre d’Estudis Epidemiològics Sobre ITS/VIH/SIDA de Catalunya, Barcelona, Spain

838 Adjunctive Sertraline for the Treatment of HIV-Associated Cryptococcal Meningitis
Joshua Rhein1; Katherine H. Hullsie2; Bozena Morawski; Kyle Smith; Ali Al-Hadab; Abdus Musubire; Darlisha Williams; Kristen Nielsen1; David B. Meya; David R. Boulware
1University of Minnesota, Minneapolis, MN, US; 2Makerere University College of Health Sciences, Kampala, Uganda
TUESDAY, FEBRUARY 24, 2015

Session P-R6 Poster Session  
2:30 pm – 4:00 pm 
**Syphilis and HIV Coinfection**

839 *Infection With HIV Among Individuals With Primary and Secondary Syphilis: USA, 2013*  
John R. Su; Akbar A. Zaidi; Elizabeth A. Torrone; Hillard S. Weinstock  
US Centers for Disease Control and Prevention, Atlanta, GA, US

840 *Risk Factors for Asymptomatic and Symptomatic Neurosyphilis Differ in HIV-Infected Patients With Syphilis*  
Christina Marra; Trudy Jones; Shelia Dunaway; Emily Ho; Abigail Crooks; Lauren Tantalo; Sharon Sahi  
University of Washington, Seattle, WA, US

841 *High Incidence of Syphilis Among Thai MSM Who Started ART Therapy During Acute HIV Infection*  
Donn J. Colby; Suteeraporn Pinyakorn; Frits van Griensven; Eugene Kroon; Naphassanan Lotrapraynak; Robert O’Connell; Nelson L. Michael; Praphan Phanuphak; Jintanat Ananworanich; Nittaya Phanuphak  
1Thai Red Cross AIDS Research Center, Bangkok, Thailand; 2US Military HIV Research Program, Bethesda, MD, US

Session P-R7 Poster Session  
2:30 pm – 4:00 pm 
**Opportunistic Infections: Odds and End Organs**

843 *The Exposure and Geospatial Risk Factors for AIDS-Associated Penicilliosis in Vietnam*  
Thuy Le; Brian Jonat; Ngo T. Cuc; Nguyen T. Thanh; Danq T. Bich; Cecilia Shikuma; Jeremy Day; Heiman Wertheim; Jeremy Farrar; Marcel Wolbers  
1Oxford University Clinical Research Unit, Ho Chi Minh City, Vietnam; 2New York-Presbyterian University Hospital of Columbia and Cornell, New York City, NY, US; 3Hospital for Tropical Diseases, Ho Chi Minh City, Vietnam; 4National Hospital for Tropical Diseases, Hanoi, Vietnam; 5Hawaii Center for AIDS, University of Hawaii, Ho Chi Minh, Vietnam

844 *AS265 Clinical Trial: Gentian Violet for Oral Candidiasis is as Effective as Nystatin*  
Pranab K. Mukherjee; Lauren Patton; James Hakim; Huichao Chen; Mai T. Pho; Kenneth A. Freedberg; Caroline Shibuski; Mahmoud A. Ghannoum; Robert A. Salata  
Oral HIV/AIDS Research Alliance (OHARA)/ACTG  
1Case Western Reserve University, Cleveland, OH, US; 2University of North Carolina, Chapel Hill, NC, US; 3Harvard School of Public Health, Boston, MA, US; 4University of Zimbabwe - Parirenyatwa, Harare, Zimbabwe; 5University of Chicago, Chicago, IL, US; 6Harvard Medical School, Boston, MA, US; 7University of California San Francisco (UCSF), San Francisco, CA, US

845 *Effective Treatment of Lymphogranuloma Venereum (LGV) With 1g Azithromycin Administered Weekly for 3 Weeks in an HIV-Infected Population*  
José L. Blanco; Irene Fuertes; Jordi Bosch; Ana Gonzalez; Andrea Vergara; Rob Camp; Esteban Martinez; Teresa Estrach; Josep M. Gatell; Merce Alsina  
Hospital Clinic, Barcelona, Barcelona, Spain

846 *Risk Factors for Staphylococcus Aureus Carriage in HIV-Infected Adults in Southern Botswana*  
Michael J. Reid; Rebeca Fischer; Naledi Mannathoko; Eric Brown; Andrew Steenhooff  
1University of California San Francisco, San Francisco, CA, US; 2University of Botswana, School of Medicine, Gaborone, Botswana; 3University of Texas, Texas, Afghanistan; 4University of Pennsylvania, Gaborone, Botswana

847 *Specific Behaviors Predict Staphylococcus aureus Colonization and Skin and Soft Tissue Infections Among HIV-Infected Persons*  
Nancy Crum-Cianfone; Xun Wang; Amy Weintrob; Tahanijat Lalani; Mary Bavaro; Katrin Mende; Michael Ellis; Brian K. Agan  
Infectious Disease Clinical Research Program, San Diego, CA, US

848 *Cytokine Profile in Aqueous Humor of HIV Patients With Ocular Opportunistic Infections*  
Matilde Ruiz-Cruz; Santiago Avila-Rios; Christopher Ormsby; Claudia Alvarado-de la Barrera; Yuria Ablanedo-Terrazas; Gustavo Reyes-Terán  
National Institute of Respiratory Diseases, Mexico City, Mexico

849 *Effects of *H. pylori* Co-infection on Immune Parameters in HIV-1 Patients in Ghana*  
Edmund Osei-Kuffour; Torsten Feldt; Kirsten A. Eberhardt; Fred S. Sarfo; Marieke Soltau; Jan F. Drexler; Gerd D. Burchard; Carsten Münk; Dieter Häussinger  
1HHECO Study Group  
1University Clinic Düsseldorf, Heinrich-Heine-University, Düsseldorf, Germany; 2Bernhard-Nacht-Institute for Tropical Medicine, Hamburg, Germany; 3University of Bonn, Bonn, Germany; 4Kwame Nkrumah University of Science and Technology, Komfo Anokye Teaching Hospital, Kumasi, Ghana

THURSDAY, FEBRUARY 26, 2015

Session P-S1 Poster Session  
2:30 pm – 4:00 pm 
**Access and Engagement**

Wade Ivey; Gabriela Paz-Bailey  
US Centers for Disease Control and Prevention (CDC), Atlanta, GA, US
851 Engagement in the HIV Care Continuum Among Female Sex Workers in Lilongwe, Malawi  
Kathryn E. Lancaster1; Thandile Lungu1; Mina C. Hosseinipour1; Katy Chadwick2; Zoe Dibb3; Vivian F. Go4; Brian W. Pence5; Kimberly A. Powers1; Irving F. Hoffman1; William C. Miller1  
1University of North Carolina, Chapel Hill, NC, US; 2Theatre for a Change, Lilongwe, Malawi; 3University of North Carolina Project—Malawi, Lilongwe, Malawi

852 New HIV Cases and ARV Retention in Pretoria: A Gender Project for High-Risk Women  
Wendee M. Wechsberg1; William A. Zule1; Irene A. Doherty1; Tracy L. Kline1; Jacqueline Ndirangu1; L Davis Lupo1; Janet McNicholl2; Monica Derrico2; Katherine Odem-Davis2; Lauri E. Markowitz2  
1RTI International, Research Triangle Park, NC, US; 2University of North Carolina, Chapel Hill, NC, US

853 Intimate Partner Violence and Antiretroviral Adherence in HIV-Positive Women in Kenya  
Kate S. Wilson1; Krista Yuhas1; Ruth Deya1; Barbra Richardson1; Linnet Masese1; Jane Simon1; Walter Jaoko1; R Scott McClelland1  
1University of Washington, Seattle, WA, US; 2University of Nairobi, Nairobi, Kenya

854 Re-engagement in Care Leads to Sustained Engagement and Viral Suppression  
Brittani D. Saafir-Callaway1; Amanda D. Castel2; Lena Lago1; Christie Olejemeh1; Garret Lum1; Lawrence Frison1; Michael Kharfen1  
1District of Columbia Department of Health, Washington, DC, US; 2University of California Los Angeles, Los Angeles, CA, US

855 Symptoms and Genital HSV-2 and HIV-1 in Coinfected Women, Chiang Rai, Thailand  
Eileen F. Dunne1; Brooke E. Hoots1; Janet McNicholl2; Sara Whitehead3; Thomas A. Peterman4; Lauri E. Markowitz5; Wanna Leelawiwat6; Tammy Evans-Strickfaden7; Cheng Chen1  
1US Centers for Disease Control and Prevention, Bangkok, Thailand; 2US Centers for Disease Control and Prevention, Atlanta, GA, US; 3Thailand Ministry of Public Health—US CDC Collaboration, Nonthaburi, Thailand

856 High-Risk HPV Clustering and Cervical Outcomes in HIV-Infected Women in Rio de Janeiro, Brazil  
Jessica L. Castilho1; José Eduardo Levi1; Paula M. Luz1; Mary Catherine Cambou2; Tazio Vannini2; Angela de Andrade2; Monica Derrico1; Valdilea Veloso1; Beatriz Grinsztejn1; Ruth Friedman2  
1Vanderbilt University School of Medicine, Nashville, TN, US; 2Fundação Oswaldo Cruz, Rio de Janeiro, Brazil; 3University of California Los Angeles, Los Angeles, CA, US; 4United Nations, Lyons, France

857 Comparison of Three Female Genital Tract Sampling Techniques for HIV RNA Recovery  
Catherine S. Todd1; Shameem Jaumlid2; Heidi E. Jones3; Hoyam Gamieldien1; Nontokozo Langwenya1; Landon Myer1; Donald R. Hoover1; Jo-Ann Passmore1  
1FH360, Bangkok, Thailand; 2University of Cape Town, Cape Town, South Africa; 3Hunter College, CUNY School of Public Health, New York, NY, US; 4University of Cape Town, Cape Town, South Africa; 5Rutgers New Jersey Medical School, Piscataway, NJ, US

THURSDAY, FEBRUARY 26, 2015

Session P-S3 Poster Session  
2:30 pm – 4:00 pm  
Hormonal Contraception

858 CCRS Expression in HIV-Uninfected Women Receiving Hormonal Contraception  
Athe Tsibris1; Gaia Sciaranghella2; Cuiwei Wang3; Kenny Murphy3; Zaher Mehr1; Ruth M. Greenblatt1; Mardge Cohen3; Elizabeth Golub3; Heather Watts4; Mary A. Young1  
1Brigham and Women's Hospital, Harvard Medical School, Cambridge, MA, US; 2Ragon Institute of MIT, MGH and Harvard, Boston, MA, US; 3Georgetown University Medical Center, Washington, DC, US; 4Albert Einstein College of Medicine, Bronx, NY, US; 5University of Vermont College of Medicine, Burlington, VT, US; 6University of California San Francisco, San Francisco, CA, US; 7Stroger Hospital and Rush University and CORE Center, Chicago, IL, US; 8Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, US; 9The Eunice Kennedy Shriver National Institute of Child Health and Human Development, Bethesda, MD, US

859 Estrogen Replacement in Healthy Postmenopausal Women Reduces %CCR5+ CD4+ T Cells  
Amie Meditz1; Samantha MaWhinney2; Kerrie Moreau2; Kelsey Melander3; Joy Folkvord4; Wendy Kohrt5; Margaret Wierson; Elizabeth Connick6  
1Boulder Community Health, Boulder, CO, US; 2University of Colorado Anschutz Medical Campus, Aurora, CO, US

860 Progesterone Increases Are Associated With HIV Susceptibility Factors in Women  
Alison Y. Swains1; Tammy Evans-Strickfaden1; L Davis Lupo1; Alfredo Aguirre1; Anandi Sheth1; Igbo Ofotokun2; Clyde E. Hart1; Richard E. Haaland1  
1US Centers for Disease Control and Prevention (CDC), Atlanta, GA, US; 2Emory University School of Medicine, Atlanta, GA, US

861 Changes in Vaginal Microbiota and Cytokines in HIV-1 Seronegative Women Initiating DMPA  
Alison C. Roxby1; David N. Fredricks1; Katherine Odem-Davis1; Kristjana H. Ásbjörnsdóttir1; Linnet Masese1; Tina L. Fiedler1; Walter Jaoko1; James N. Kiari1; Julie M. Overbaugh2; R Scott McClelland1  
1University of Washington, Seattle, WA, US; 2Fred Hutchinson Cancer Research Center, University of Washington, Seattle, WA, US; 3University of Nairobi, Nairobi, Kenya
862  A Thinned Vaginal Stratum Corneum Is a Susceptibility Factor for SHIV Acquisition
Ellen Kersh; Jana Ritter; Katherine Butler; Sharon Dietz Ostergaard; Debra Hanson; Sherif Zaki; Janet McNicholl
US Centers for Disease Control and Prevention, Atlanta, GA, US

866  ART Response Among Pregnant and Postpartum Women With Acute Versus Chronic HIV-1
Alison L. Drake; John Kinuthia; Daniel Matembo; Barbra Richardson; Michael Chung; James N. Kiarie; Sandy Emery; Julie M. Overbaugh; Grace John-Stewart
1University of Washington, Seattle, WA, US; 2University of Nairobi, Nairobi, Kenya; 3Fred Hutchinson Cancer Research Center, Seattle, WA, US

TUESDAY, FEBRUARY 24, 2015

Session P-T1 Poster Session  Poster Hall
2:30 pm – 4:00 pm

863  Specific Effects of ZDV, 3TC and LPV/r on HIV-1 RNA Viral Load During Pregnancy
Patumrat Sripan; Sophie Le Coeur; Lily Ingsrisawang; Tim R. Cressey; Jean-Marc Tréluyer; Naim Bouzza; Frantz Foissac; Gonzague Jourdain; Marc G. Lallemand; Saïk Urien
1ED420, University of Paris-Sud 11, Paris Descartes, Paris, France; 2PHPT-IRD UMI 174, Chiang Mai, Thailand

864  Viral Suppression After Antiretroviral Therapy Initiation in Pregnancy South Africa
Landon Myer; Tamsin Phillips; Nei-Yuan Hsiao; Allison Zerbe; Jo Ramjith; Linda-Gail Bekker; James A. McIntyre; Elaine J. Abrams
1University of Cape Town, Cape Town, South Africa; 2National Health Laboratory Services/University of Cape Town, Cape Town, South Africa

865  Maternal Viral Load in the Context of PMTCT B+ With the Kabeho Study in Kigali
Emily A. Bobrow; Placidie Mugwaneza; Gilles F. Ndayisaba; Dieudonne Ndimatmana; Michelle Gill; Heather J. Hoffman; Cyprien Baribwira; Laura Guay; Anita Asimwe
1Kabeho Study Team
2Elizabeth Glaser Pediatric AIDS Foundation, Washington, DC, US; 3Ministry of Health, Kigali, Rwanda; 4Elizabeth Glaser Pediatric AIDS Foundation, Kigali, Rwanda; 5George Washington University Milken Institute School of Public Health, Washington, DC, US; 6University of Maryland, School of Medicine, Kigali, Rwanda; 7Rwanda University Teaching Hospitals, Kigali, Rwanda

867  No Perinatal Transmission of HIV-1 in Women Efficiently Treated Since Conception
Laurent Mandelbrot; Roland Tubiana; Jérôme Le Chenadec; Catherine Dolfius; Albert Faye; Christine Rouzioux; Anais Perilhou
1Laboratoire Services/University of Cape Town, Cape Town, South Africa; 2National Health Laboratory Services/University of Cape Town, Cape Town, South Africa; 3INSERM CESP U1018, Hôpital Trousseau, Paris, France; 4AP-HP, Hôpital Pitié Salpêtrière - INSERM, U943, Paris, France; 5AP-HP, Hôpital Robert Debre-University Paris 7, Paris, France; 6AP-HP, Hôpital Necker-Enfants Malades, University Paris-Descartes, Paris, France; 7University Paris-Sud - INSERM CESP U1018 - AP-HP Hôpital Bicêtre, Le Kremlin-Bicêtre, France

868  Predictors of Perinatal HIV Transmission in the BAN Study
Sascha R. Ellington; Athena P. Kourtis; Ali Fokar; Charles S. Chasela; Dumbani Kayira; Gerald Tegha; Denise J. Jamieson; Charles M. van der Horst
1The BAN Study Team
2US Centers for Disease Control and Prevention and Control (CDC), Atlanta, GA, US; 3University of North Carolina, Chapel Hill, NC, US; 4University of North Carolina Project Lillingwe, Lilongwe, Malawi; 5University of Witwatersrand, Johannesburg, South Africa

869  High Rate of HIV Superinfection After Delivery: Secondary Analysis of the PEPI Trial
Andrew D. Reed; Sarah Wendel; Andrew Longosa; Jessica M. Fogel; Newton Kumwenda; Sufia Dadabhai; Susan H. Eshleman; Stephen Porcella; Thomas C. Quinn; Taha Taha
1National Institute of Allergy and Infectious Diseases (NIAID), Hamilton, MT, US; 2Johns Hopkins University School of Medicine, Baltimore, MD, US; 3Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, US; 4National Institute of Allergy and Infectious Diseases (NIAID), Hamilton, MT, US

870  Decline in Early Mother-to-Child HIV Transmission (MTCT) Risk Over Time in Botswana
Kathleen M. Powis; Gbolahan Ajoba; Jean Leidner; Kara Bennett; Florence Chilisa; Keabete Bedi; Chipo Petlo; Michael D. Hughes; Roger Shapiro; Shahin Lockman
871 Impact of Maternal Antiretroviral Regimen on Six-Month HIV-Free Survival in Botswana
Rebecca Zash1; Sahjinder Souda; Chazha Hick; Kelebgole Binde; Sirkhulle Myo; Erik van Widenfeld; Jean Leidner; Joseph Makhema; Mompati Mmalane; Roger Shapiro
1Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, US; 2University of Botswana, Gaborone, Botswana; 3Botswana Harvard AIDS Institute, Gaborone, Botswana; 4Harvard School of Public Health, Boston, MA, US

872 Infant Outcomes Among a Cohort of HIV-Infected Pregnant Women With and Without TB in South Africa: The Tshepiso Study
Jennifer D. Hoffmann; Silvia E. Cohn; Nicole M. Salazar-Austin; Filidah Mashabela; Ziyaad Waja; Christopher J. Hoffmann; Sanjay Lal; Richard E. Claissen; Neil A. Martinson
1Johns Hopkins University School of Medicine, Baltimore, MD, US; 2Perinatal HIV Research Unit (PHRU), Johannesburg, South Africa; 3Chris Hani Baragwanath Hospital, Johannesburg, South Africa

Session P-T3 Poster Session
Posters Hall
2:30 pm – 4:00 pm
Option B+: Retention and Transmission

873 Early HIV Infection Rate Trends in Exposed Infants Pre- and Post-Option B+ in Mozambique
Thresia Sebastian; Serena Brusamento; Laurence Aboua; Dario Aly; Stephen M. Arpadi; Chloe A. Teasdale; Fatima Tsiouris; Elaine J. Abrams
ICAP at Columbia University, New York, NY, US

874 Option B+ Scale Up and Comprehensive PMTCT Service Delivery in Central Malawi
Michael E. Herce; Twonge Mtande; Frank Chimbwanda; Innocent Mofolo; Christine Chingondole; Nora Rosenberg; Kathryn Lancaster; Mina C. Hosseinipour; Charles M. van der Horst
1University of North Carolina, Lusaka, Zambia; 2UNC Project-Malawi, Lilongwe, Malawi; 3Malawi Ministry of Health, Lilongwe, Malawi; 4University of North Carolina, Chapel Hill, NC, US

875 Retention Amongst HIV-Infected Pregnant Women Initiating Lifelong Antiretroviral Treatment (Option B+) in Haiti
Jean W. Domosciano; Nancy Puttkammer; Lydia Lu; Kesner Francois; Olbeka Desinor; Reginald Jean-Louis; Michelle Adler; Barbara Marston; Reynold Grand-Pierre

THURSDAY, FEBRUARY 26, 2015

Session P-T4 Poster Session
2:30 pm – 4:00 pm
Health Outcomes of HIV- and ARV-Exposed Infants, Children, and Youth

876 Malnutrition Among HIV-Exposed Uninfected Children in Botswana
Kathleen M. Powis; Quanhong Lei; Yvonne Chinyanga; Esther Turnbare; Nealia Khan; Jacinta Sibila; Erik van Widenfeld; Joseph Makhema; Roger Shapiro
1Massachusetts General Hospital, Harvard Medical School, Boston, MA, US; 2Harvard School of Public Health, Center for Biostatistics in AIDS Research, Boston, MA, US; 3Botswana Ministry of Health, Gaborone, Botswana; 4Elizabeth Glaser Pediatric AIDS Foundation, Harare, Zimbabwe; 5Harvard School of Public Health, Boston, MA, US; 6Botswana Harvard AIDS Institute, Gaborone, Botswana; 7Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, US

877 Hospitalizations Among Uninfected Children Exposed or Unexposed to HIV – A Nationwide Cohort Study
Ellen M. Larsen; Marie Helleberg; Sannie Nordly; Nina Weis; Vibeke Rosenfeldt; Merete Storgaard; Gitte Pedersen; Isik S. Johansen; Suzanne Lunding; Terese L. Katzenstein
1Nordsjællands Hospital, Hillerød, Denmark; 2Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark; 3Copenhagen University Hospital, Hvidovre, Hvidovre, Denmark; 4Aarhus University Hospital, Skejby, Aarhus, Denmark; 5Aalborg University Hospital, Aalborg, Denmark; 6Odense University Hospital, Odense, Denmark

878 Reassuring Birth Outcomes Data With Atripla Used for PMTCT in Botswana
Rebecca Zash; Jennifer Y. Chen; Sahjinder Souda; Scott Dryden-Peterson; Shahin Lockman; Mompati Mmalane; Joseph Makhema; Max Essex; Roger Shapiro
1Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, US; 2Massachusetts General Hospital, Harvard Medical School, Boston, MA, US; 3Botswana Harvard AIDS Institute, Gaborone, Botswana; 4Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, US; 5Harvard School of Public Health, Boston, MA, US

879 Growth and Bone Markers in Malawian Infants Pre- and Postnatally Exposed to Tenofovir
Giuseppe Liotta; Marco Floridia; Mauro Andreotti; Haswell Jere; Clementina Galluzzo; Sandro Mancinelli; Maria Cristina Marazzi; Stefano Vella; Marina Giuliano; Leonardo Palombi
1Istituto Superiore di Sanità, Rome, Italy; 2University of Tor Vergata, Rome, Italy; 3Community of S. Egidio, Blantyre, Malawi; 4Lumsa University, Rome, Italy
880 Lower Insulin, Acylcarnitines, and Branch-Chain Amino Acids in HIV-Exposed Infants
Jennifer Jao; Brian Kirmse; Chnuni Yu; Fanny Eppie; Emmanuel Nshow; Rhoda Sperling; Elaine J. Abrams; Derek LeRoith; Mitchell Geffner; Irwin Kurland
1Icahn School of Medicine at Mount Sinai, New York, NY, US; 2Children’s National Health System, Washington, DC, US; 3Icahn School of Medicine at Mount Sinai, New York, NY, US; 4Cameron Baptist Convention Health Services, Bamenda, Cameroon; 5Icahn School of Medicine at Mount Sinai, New York, NY, US; 6Keck School of Medicine at University of Southern California, Los Angeles, CA, US; 7Albert Einstein College of Medicine, New York, NY, US

881 No Effect of Maternal HIV and In-Utero cART on Infant Leukocyte Telomere Length
Abhinav Ajaykumar; Hugo Soudheyns; Fatima Kakkar; Jason Brophy; Ari Bitnun; Ariane Alimenti; Deborah Money; Ariane Albert; Hélène C. Côté
On behalf of the CIHR Team in Cellular Aging and HIV Comorbidities in Women and Children (CARMA)
1University of British Columbia, Vancouver, Canada; 2Université de Montréal, Montreal, Canada; 3University of Ottawa, Ottawa, Canada; 4University of Toronto, Toronto, Canada; 5Women’s Health Research Institute, Vancouver, Canada

882 Long-Term Effects of In Utero ARV Exposure on Cardiac Function in HIV-Exposed Uninfected Youth
Vitor C. Guerra; Erin Leister; Paige L. Williams; Steven E. Lipshultz; Russell Van Dyke; Rohan Hazzar; Steven D. Colan
1Tulane University, New Orleans, LA, US; 2Harvard School of Public Health, Center for Biostatistics in AIDS Research, Boston, MA, US; 3Wayne State University School of Medicine, Detroit, MI, US; 4Eunice Kennedy Shriver National Institute of Child Health and Human Development, Bethesda, MD, US; 5Boston Children’s Hospital, Harvard Medical School, Boston, MA, US

883 Burden of Malaria in a Birth Cohort of HIV-Exposed Ugandan Infants
Abel Kakuru; Paul Naterueba; Albert Plentiv; Edwin Charlebois; Deborah Cohan; Tamara Clark; Diane Havel; Moses R. Kamya; Grant Dorsey; Theodore Ruel
1University of California San Francisco, San Francisco, CA, US; 2Makerere University-University of California, San Francisco Research Collaboration, Kampala, Uganda; 3Makerere University College of Health Sciences, Kampala, Uganda

884 CMV Transmission From HIV-infected Women Randomized to Formula Versus Breastfeeding
Barbra Richardson; Grace John-Stewart; Vincent Emery; Claire Atkinson; Ruth Nduati; Kristjana H. Ásbjörnsdóttir; Julie M. Overbaugh; Michael Boechk; Jennifer A. Slyker
1University of Washington, Seattle, WA, US; 2University of Surrey, Guildford, United Kingdom; 3University of Nairobi, Nairobi, Kenya; 4University College London, London, United Kingdom; 5Fried Hutchinson Cancer Research Center, University of Washington, Seattle, WA, US

885 Is the Prevalence of M. tuberculosis Infection Higher in HIV-Exposed Children?
Palwasha Y. Khan; Katherine L. Fielding; Dominic Mulawa; Regina Chiimuma; Thembza Mzembe; Olivier Koole; Judith R. Glynn; Amelia C. Crampin
1London School of Hygiene and Tropical Medicine, London, United Kingdom; 2Karonga Prevention Study, Karonga, Malawi

TUESDAY, FEBRUARY 24, 2015

Session P-T6 Poster Session
Poster Hall 2:30 pm – 4:00 pm
ART Adherence, Adverse Effects, and Retention Among Pregnant Women and Infants

886 ARV Adherence Associated with Reduced Breastmilk HIV Viral Load and HIV Transmission
Nicole L. Davis; William C. Miller; Michael G. Hudgens; Charles S. Chasela; Dorothy Sichila; Julie A. Nelson; Joseph Rigdon; Sascha R. Ellington; Athena P. Kourtis; Charles M. van der Horst
1BAN study team
2University of Witswatersand, Johannesburg, South Africa; 3UNC Project-Malawi, Lilongwe, Malawi; 4US Centers for Disease Control and Prevention (CDC), Atlanta, GA, US; 5University of North Carolina, Chapel Hill, NC, US

887 Peripartum Hair Levels of Antiretrovirals Predict Viral Suppression in Ugandan Women
Catherine A. Koss; Peter Bachetti; Deborah Cohan; Paul Natureeaa; Howard Hornig; Tamara Clark; Edwin Charlebois; Moses R. Kamya; Diane Havel; Monica Gandhi
1University of California San Francisco, San Francisco, CA, US; 2Makerere University College of Health Sciences, Kampala, Uganda

888 Side Effects and Treatment Adherence After ART Initiation in Pregnancy in South Africa
Tamsin Phillips; Allison V. Zerbe; Agnes Ronan; Claude A. Mellins; Robert H. Remien; James A. McIntyre; Greg Petro; Elaine J. Abrams; Landon Myer
1University of Cape Town, Cape Town, South Africa; 2ICAP at Columbia University, New York, NY, US; 3New York State Psychiatric Institute and Columbia University, New York, NY, US; 4Anova Health Institute, Johannesburg, South Africa

889 Efficacy of Mobile Phone Use on Adherence to Nevirapine Prophylaxis and Retention in Care Among HIV-Exposed Infants
Lilian M. Kebaya; Dalton Wamalwa; Nyambura Kariuki; Bashir Admani; Ruth W. Nduati
1University of Nairobi, Nairobi, Kenya

890 HIV Care Continuum for Postpartum Women in Philadelphia: Barriers and Facilitators
Joella W. Adams; Kathleen Brady; Yvonne Michael; Baligh R. Yehia; Florence Mormelisari
Session P-T7 Poster Session  
2:30 pm – 4:00 pm  
Pharmacokinetics and Safety of ART During Pregnancy

891  
**Raltegravir Plasma Concentrations on HIV-1 Infected Pregnant Women**  
Emilie Belissa; Amine Benchik; Charlotte Charpentier; Morgane Valentin; Agnes Bourgeois-Moine; Sylvie Lariven; Florence Damond; Yazdan Yazdanpanah; Sophie Matheron; Gilles Peytavin  
APHP Bichat-Claude Bernard Hospital, Paris, France

892  
**Etravirine Pharmacokinetics During Pregnancy and Postpartum**  
Brookie M. Best; Angela Colbers; Jiajia Wang; Graham Taylor; Alice Stek; Marjo van Kasteren; Mark Mirochnick; David Burger  
On behalf of the IMPACT P1026s Protocol Team and the PANNA Network

1University of California San Diego, San Diego, CA, US; 2Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands; 3Center for Biostatistics in AIDS Research, Harvard School of Public Health, Boston, MA, US; 4Imperial College Healthcare NHS Trust, London, United Kingdom; 5University of Southern California School of Medicine, Los Angeles, CA, US; 6St. Elisabeth Hospital, Tilburg, Netherlands; 7Boston University School of Medicine, Boston, MA, US

893  
**Pharmacokinetics of Etravirine in HIV-1–Infected Pregnant Women**  
M Ramgopal; D Osyemie; C Zorrilla; HM Cruwels; R Ryan; K Brown; V Hillewaert; B Baugh  
1Midway Immunology and Research Center, Fort Pierce, FL, US; 2Triple O Research Institute PA, West Palm Beach, FL, US; 3University of Puerto Rico School of Medicine, San Juan, US; 4Janssen Infectious Diseases, Beerse, Belgium; 5Janssen Research & Development, Titusville, NJ, US; 6Janssen Therapeutics, Titusville, NJ, US; 7Janssen Research & Development, Beerse, Belgium

894  
**Pharmacokinetics of Rilpivirine in HIV-Infected Women During Pregnancy and Postpartum**  
Mark Mirochnick; Brookie M. Best; Alice Stek; Regis Kreitchmann; Jiajia Wang; David Shapiro; Elizabeth Smith; Lynne Mofenson; Tim R. Cressey; Edmund Capparelli  
1Boston University School of Medicine, Hingham, MA, US; 2University of California San Diego, San Diego, CA, US; 3University of Southern California, Los Angeles, CA, US; 4Harvard School of Public Health, Boston, MA, US; 5National Institute of Allergy and Infectious Diseases (NIAID), Bethesda, MD, US; 6Enicu Kennedy Shriver National Institute of Child Health and Human Development, Bethesda, MD, US; 7Harvard School of Public Health/Chiang Mai University, Chiang Mai, Thailand; 8Inamandade da Santa Casa de Misericordia de Porto Alegre, Porto Alegre, Brazil

Session P-T8 Poster Session  
2:30 pm – 4:00 pm  
Planning and Preventing Pregnancy

895  
**Safer Conception Delayed by Lack of HIV Viral Suppression**  
Sheree R. Schwartz; Rebecca Phoa; Nompumelelo Yende; Jean Bassett; Nora West; Ian Sanne; Annelies Van Riel  
1University of North Carolina, Chapel Hill, NC, US; 2Witkoppen Health and Welfare Centre, Johannesburg, South Africa; 3University of the Witwatersrand, Johannesburg, South Africa

Sara Saberi; Behroze Sattha; Evelyn Maan; Julie Van Schalkwyk; Deborah Money; Hélène Côté  
On behalf of the CIHR Team in Cellular Aging and HIV Comorbidities in Women and Children (CARMA)

1University of British Columbia, Vancouver, Canada; 2BC Women's Hospital and Health Centre, Vancouver, Canada; 3Women's Health Research Institute, Vancouver, Canada

902  
**Low Prolactin and High 20α-HSD May Contribute to cART-Induced P4 Deficits in Pregnancy**  
Eszter Papp; Lena Srigides  
Toronto General Research Institute, Toronto, Canada
903 Generating HIV Neutralization in Milk With Neutralizing IgG/dIgA Antibodies Infusion
Genevieve Fouda1,2; Josh Eudailey3; Erika Kunz4; Joshua Amos5; Jonathan Himes6; Lisa Colvin6; Xinyue Wang5; Keith Reimann6; Barton Haynes3; Sallie Permar4
1Duke University, Durham, NC, US; 2University of Massachusetts Medical School, Boston, MA, US
904 Specificity of V3-specific Neutralizing Responses in HIV-1 Infected Women
David R. Martinez1; Genevieve Fouda; Nathan Vandergrift; Celia LaBranch; David Montefiori; Xiaoying Shen; Thomas Denny; Georgia Tomaras; Sallie Permar
Duke Human Vaccine Institute, Durham, NC, US
905 Broad, Highly Avid Vaccine-Elicited Anti-V1V2 IgG Responses in HIV-Exposed Infants
Genevieve Fouda1; Coleen Cunningham1; Elizabeth McFarland1; Bill Borkowsky2; Nicole Yates2; Erin McGuire2; Hua-Xin Liao3; Barton Haynes1; Georgia Tomaras1; Sallie Permar1
1Duke University, Durham, NC, US; 2University of Colorado, Aurora, CO, US; 3New York University, New York, NY, US
906 Maternal Neutralization Escape Virus Variants Do Not Predict Infant HIV Infection Risk
Caitlin Milligan1; Maxwel Omenda1; Vasha Chohan1; Katherine Odem-Davis1; Barbra A. Richardson1; Ruth W. Ndutu2; Julie M. Overbaugh1
1Fred Hutchinson Cancer Research Center, University of Washington, Seattle, WA, US; 2University of Nairobi, Nairobi, Kenya
907 ART Failure and Resistance Among Pregnant and Post-Partum Women in South Africa
Christopher J. Hoffmann1; Silvia Cohn1; Fildah Mashabela2; Jennifer Hoffmann1; Kelly E. Dooley2; Richard E. Chaisson3; Neil Martinson2
1The STOP HIV-1 Study Team
2Johns Hopkins University School of Medicine, Baltimore, MD, US; 3Perinatal HIV Research Unit (PHRU), Johannesburg, South Africa
Johanna Ledwaba1; Anna Salimo1; Karl Technau3; Simon Travers1; Lynn Morris1; Gillian Hunt1; Louise Kuhn1
1National Institute for Communicable Diseases, National Health Laboratory Service, Sandringham, South Africa; 2Columbia University, New York, NY, US; 3University of the Western Cape, Modderdam, South Africa
909 NVP Resistance in Infants Infected by HIV-1 via Breastfeeding in the BAN Study
Julie A. Nelson1; Ali Foka1; Michael G. Hudgens1; Kara J. Compliment1; Gerald Tegha2; Deborah Kamwendo2; Athena P. Kourtis1; Denise J. Jamieson1; Charles M. van der Horst3; Susan A. Fiscus4
1Univ of North Carolina at Chapel Hill, Chapel Hill, NC, US; 2University of North Carolina Project–Malawi, Lilongwe, Malawi; 3US Centers for Disease Control and Prevention (CDC), Atlanta, GA, US
910 Birth HIV PCR Testing in South Africa: Diagnostic Challenges and Risk Factor Analysis
Karl-Günter Technau1; Louise Kuhn1; Lucia Hans1; Sergio Carmona1; Ashraf Coovadia2; Gayle Sherman1
1University of the Witwatersrand, Johannesburg, South Africa; 2Columbia University, New York, NY, US; 3National Health Laboratory Service, Johannesburg, South Africa; 4National Institute for Communicable Diseases, Johannesburg, South Africa
911 System Gaps Result in Late Diagnosis and Treatment of Children With HIV in Hospital
Irene N. Njoguna1; Anjuli D. Wagner1; Vincent Otieno2; Lisa Crammer3; Judy Adhambo3; Sarah Benki-Nugent1; Elizabeth Maleche-Obimbo3; Jennifer A. Slyker1; Dalton Wamalwa1; Grace John-Stewart1
1University of Washington, Seattle, WA, US; 2Emory University School of Medicine, Atlanta, GA, US; 3University of Nairobi, Nairobi, Kenya
914 Immune Recovery at 5 Years on ART in HIV+ Children From Four African Countries
Chloe A. Teasdale; Ruby Fayosey; Zenebe Melaku; Duncan Chege; Catarina Casalini; Thresia Sebastian; Elaine J. Abrams
ICAP at Columbia University, New York, NY, US

915 Antiretroviral Therapy in Severely Malnourished, HIV-Infected Children in Asia
David C. Boettiger; Linda Auripubil; Dina Muktiarti; Siew Fong; Pagakrong Lumbiganon; Saphonn Vonthanak; Nguyen Van Lam; Rawiwan Hansudevechakul; Azar Kariminia
On behalf of TREAT Asia Pediatric HIV Observational Database
1University of New South Wales, Sydney, Australia; 2Chiang Mai University, Chiang Mai, Thailand; 3Cipto Mangunkusumo General Hospital, Jakarta, Indonesia; 4Hospital Likas, Kota Kinabalu, Malaysia; 5Khon Kaen University, Khon Kaen, Thailand; 6National Centre for HIV/AIDS Dermatology and STDs, Phnom Penh, Cambodia; 7National Hospital of Pediatrics, Hanoi, Viet Nam; 8Chiangrai Prachanukroh Hospital, Chiang Rai, Thailand

916 Pubertal Development in HIV-Infected African Children on First-Line Antiretroviral Therapy
Mutsa F. Bwakura Dangarembizi
On behalf of the ARROW Trial Team
University of Zimbabwe, College of Health Sciences, Harare, Zimbabwe

917 Mortality of HIV-Infected Youth in the Combination Antiretroviral Therapy (cART) Era
Gayatri Mirani; Paige L. Williams; Miriam Chernoff; Mark Abzug; Myron Levin; James Oleske; George Seage; Rohan Hazra; Russell B. Van Dyke
On behalf of the International Maternal Pediatric Adolescent AIDS Clinical Trials (IMPAACT) Network P1074 Study Team
1Tulane University Health Sciences Center, New Orleans, LA, US; 2Center for Biostatistics in AIDS Research Harvard School of Public Health, Boston, MA, US; 3University of Colorado Anschutz Medical Campus, Aurora, CO, US; 4Division ofPediatric Allergy, Immunology & Infectious Diseases, Newark, NJ, US; 5Emory Kennedy Shriver National Institute of Child Health and Human Development, Bethesda, MD, US; 6University of Colorado School of Medicine and Children's Hospital Colorado, Aurora, CO, US; 7IMPAACT Operations Center FHI 360, Durham, NC, US

918 Transition to Adult Units: Situation and Evolution of Vertically HIV Infected Youths in Spain
Talia Sainz; Carolina Fernandez-Mcphee; Santiago Jimenez de Ory; Maria Isabel Gonzalez-Tome; Rafael Rubio; Jose I Bernardino; Santiago Moreno; Jose Antonio Inbarren; Belen Alejos; Marisa Navarro
On behalf of the Spanish Cohort of AIDS Research (CORIS) and the Pediatric Spanish Cohort of HIV-infected Children (CORISpe)
1Hospital Universitario Gregorio Maranon, Madrid, Spain; 2Hospital Universitario Ramon y Cajal, Madrid, Spain; 312 de Octubre Hospital, Madrid, Spain; 4La Paz University Hospital, Madrid, Spain; 5Hospital de Donostia, San Sebastian, Spain; 6Centro Nacional de Epidemiologia, ISCIII, Madrid, Spain; 7Hospital Gregorio Maranon, Madrid, Spain

Session P-U4 Poster Session
2:30 pm – 4:00 pm
Treatment and Monitoring Strategies in Children

919 Long-Term Consequences of Planned Treatment Interruption in HIV-1–Infected Children
Riccardo Freguia; Hahhah Poulson; Paola Del Bianco; Alexandre Campagnucci; Yacine Saïdi; Carlo Giaquinto; Lynda Harper; Diana M. Gibb; Nigel J. Klein; Anita De Rossi
1AIDS Reference Center, Section of Oncology and Immunology, Padova, Italy; 2Institute of Child Health, London, United Kingdom; 3Istituto Oncologico Veneto-IRCCS, Padova, Italy; 4Inserm SC10, Paris, France; 5Department of Mother and Child Health, Padova, Italy; 6Medical Research Council, London, United Kingdom

920 Can CD4 Monitoring in Virologically Suppressed Children Be Reduced or Stopped?
Mary-Ann Davies; Helena Rabie; Geoff Fatti; Kathryn Denton; Karl Günter Technau; Shobha Savry; Brian Eley; Lynne Mofenson; Andrew Boullie; JeDEA Southern Africa
1University of Cape Town, Cape Town, South Africa; 2University of Stellenbosch, Cape Town, South Africa; 3Kethé’Impala, Cape Town, South Africa; 4University of the Witwatersrand, Johannesburg, South Africa; 5University of Witwatersrand, Johannesburg, South Africa; 6University of Cape Town, Cape Town, South Africa; 7Eunice Kennedy Shriver National Institute of Child Health and Human Development, Bethesda, MD, US; 8University of Cape Town and University of Bern, Cape Town, South Africa

TUESDAY, FEBRUARY 24, 2015

Session P-U5 Poster Session
2:30 pm – 4:00 pm
Determinants of Disease Progression in Children

921 Impact of Sex Differences on Disease Outcome in Pediatric HIV in South Africa
Masahiko Mori; Emily Adland; Alice Swords; Maximilian Muenchhoff; Nora Lavandier; Jacob Hurst; Thumbi Ndung’u; Andy Prendergast; Philip J. Goulder; Pieter Jooste
1University of Oxford, Oxford, United Kingdom; 2University of NwaZulu-Natal, Durban, South Africa; 3Queen Mary University of London, London, United Kingdom; 4Kimberley Hospital, Durban, South Africa

922 CD31 Expression on CD4 Cells Predicts Clinical Outcome of HIV in a Perinatally HIV-Infected Cohort
Ramia Zakhour; Gilhen Rodriguez; Cynthia Bell; Guenet Degaffe; Laura Benjamins; Gabriela DelBianco; Elizabeth Donnachie; Tran Dat; Gloria P. Heresi; James R. Murphy
1University of Texas, Houston, TX, US; 2UTHealth Medical School, Houston, TX, US

923 Premature Aging and Immune Senescence in HIV-1-Infected Children
Ketty Gianesin; Antoni Noquera-Julian; Marisa Zanchetta; Osvalda Rampon; Claudia Fortuny; Mineia Camòs; Carlo Giaquinto; Anita De Rossi
1University of Padova, Padova, Italy; 2Hospital Sant Joan de Déu-Universitat de Barcelona, Barcelona, Spain; 3Istituto Oncologico Veneto-IRCCS, Padova, Italy
924  KIR/HLA Alleles Alter CD4+ Lymphocyte Count and Viral Load in HIV-Infected Children
Kumud Singh1; Min Qin1; Sean Brummel2; Konstantia Angelidou1; Rodney Trout1; Terence Fenorton1; Stephen Spector1
1University of California San Diego, La Jolla, CA, US; 2Harvard School of Public Health, Boston, MA, US

THURSDAY, FEBRUARY 26, 2015

Session P-U6 Poster Session
2:30 pm – 4:00 pm
Complications of HIV and ART: Pulmonary and Cardiovascular Outcomes

925  Arterial Stiffness in HIV+ Youth and Associations With HIV-Related Variables
Allison R. Eckard1; Julia C. Rosebush1; Mary Ann O’Riordan1; Christopher T. Longenecker1; Bridget Wynn1; Monika Uribe Leitz1; Danielle Labbato1; Norma Storer1; Bruce Kinley1; Grace A. McComsey1
1Emory University School of Medicine, Atlanta, GA, US; 2Case Western Reserve University, Cleveland, OH, US

926  Does Early ART Normalize Pulse-Wave Velocity in Children? Evidence From CHER Cohort
Steve Innes1; Zuzikova Magogoyita1; Philip Herbst1; Mark F. Cotton1; Barbara Laughton1; Sara Browne1; Richard Haubrich2
1Stellenbosch University, Cape Town, South Africa; 2University of California San Diego, San Diego, CA, US

927  The Impact of HIV and ART on Markers of Inflammation, Vascular Injury and Disordered Thrombogenesis in Children
Julia M. Kenny1; Sarah Walker1; Adrian Cook2; Victor Musiime3; Priscilla Wavamunno3; Florence Odongo3; Grace Miremebe4; Dorica Masaku4; Diana M. Gibb4; Nigel J. Klein5
1University College London, London, United Kingdom; 2Joint Clinical Research Centre, Kampala, Uganda; 3University Teaching Hospital, Lusaka, Zambia

928  T-Cell Activation and E-Selectin Associated With Coronary Plaque in HIV-Infected Youth
Julia B. Purdy1; Aylin Unsal1; Khaled Abd-Elmoniem1; Adam Rupert1; Joseph A. Kovacs1; Rohan Hazra1; Ahmed Gharib1; Colleen Hadigan2; Julia B. Purdy1
1National Institutes of Health, Bethesda, MD, US; 2Harvard School of Public Health, Boston, MA, US; 3Children’s Hospital Los Angeles, Los Angeles, CA, US; 4University of Miami, Miami, FL, US; 5Tulane University School of Medicine, New Orleans, LA, US; 6Indiana University School of Medicine, Indianapolis, IN, US; 7Harvard School of Public Health, Boston, MA, US; 8Frontier Science and Research Foundation, Amherst, NY, US

931  Vitamin D Status and Bone Outcomes in Perinatally HIV-Infected Children
Denise L. Jacobson1; Mitchell Geffen2; Charles B. Stephens3; Rohan Hazra4; Kunjal Patel5; Tracie L. Miller6; Russell B. Van Dyke7; Angela Ellis8; Linda A. DiMeglio7
For the Pediatric HIV/AIDS Cohort Study
1Harvard School of Public Health, Center for Biostatistics in AIDS Research, Boston, MA, US; 2Children’s Hospital Los Angeles, Keck School of Medicine, Los Angeles, CA, US; 3USDA, Davis, CA, US; 4Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, MD, US; 5University of Miami, Miami, FL, US; 6Tulane University School of Medicine, New Orleans, LA, US; 7Indiana University School of Medicine, Indianapolis, IN, US; 8Harvard School of Public Health, Boston, MA, US

933  APOL1 Gene Variants and Chronic Kidney Disease in Perinatally HIV-Infected Youth
Muriel Purswani1; Kunjal Patel2; Cheryl Winkler3; Stephen Spector4; Rohan Hazra2; George Seage4; Lynne Mofenson5; Gwendolyn Scott6; Russell Van Dyke7; Jeffrey Koppe8
For the Pediatric HIV/AIDS Cohort Study (PHACS)
1Albert Einstein College of Medicine, Bronx, NY, US; 2Harvard School of Public Health, Boston, MA, US; 3National Cancer Institute (NCI), Bethesda, MD, US; 4University of California San Diego, San Diego, CA, US; 5Eunice Kennedy Shriver National Institute of Child Health and Human Development, Bethesda, MD, US; 6University of Miami, Miami, FL, US; 7Tulane University, New Orleans, LA, US; 8National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, US

934  Cystatin C Is a Marker for Both Inflammation and Renal Function in HIV+ Children
Angela Deyá-Martínez1; Claudia Fortuny1; Pere Soler-Palacín2; Ofel Neth3; Emilia Sánchez4; Andrea Martin-Naldí4; Lola Falcón-Neyra5; Anna Vila6; Anna Valls7; Antoni Noguera-Julian8
1Hospital Sant Joan de Déu, Esplugues, Spain; 2Hospital Vall d’Hebron, Barcelona, Spain; 3Hospital Virgen del Rocio, Sevilla, Spain; 4Universitat Raman Llull, Barcelona, Spain

935  Cognitive Performance and IntraCerebral Findings in Perinatally HIV-Infected Children
Sophie Cohen1; Matthan W. Caan2; Jacqueline A. ter Stege3; Henriette J. Scherpber1; Taco W. Kuijpers4; Peter Reiss5; Gert J. Geurtsen6; Charles B. Majoe7; Ben Schmand8; Dasja Pajkrt9
1EMC Children’s Hospital AMC, Amsterdam, Netherlands; 2Academic Medical Center University of Amsterdam, Amsterdam, Netherlands; 3EMC Children’s Hospital, Amsterdam, Netherlands
936 Executive Functions Among Perinatally HIV-Exposed and HIV-Infected Youth
Sharon L. Nichols1; Miriam Chernoff2; Kathleen M. Malee3; Patricia A. Sirosi4; Paige L. Williams5; Betsy L. Kammerer6
the Memory Substudy Team of the Pediatric HIV/AIDS Cohort Study (PHACS)
1University of California, San Diego, La Jolla, CA, US; 2Harvard School of Public Health, Center for Biostatistics in AIDS Research, Boston, MA, US; 3Northwestern University, Feinberg School of Medicine, Chicago, IL, US; 4Tulane University School of Medicine, New Orleans, LA, US; 5Children’s Hospital Boston, Boston, MA, US

937 Sleep Disturbances in a Cohort of HIV-Infected Children and Adolescents on Antiretroviral Treatment: NeuroCoRISpeS
Cristina García-Navarro1; Santiago Jiménez de Ory2; María Luisa Navarro Gómez3; José Tomás Ramos Amador4; María Jose Mellado5; Luis Prieto6; Pablo Rojo Conejo7; Esmeralda Nuñez8; María Isabel González-Tomé9
On behalf of the CoRISpeS, ÄMadrid Cohort
1Hospital Universitario 12 de Octubre, Madrid, Spain; 2Hospital Universitario Gregorio Marañón, Madrid, Spain; 3Hospital Universitario La Paz, Madrid, Spain; 4Hospital Regional Universitario Carlos Haya, Málaga, Spain; 5Hospital Universitario de Getafe, Getafe, Spain; 6Hospital Universitario Clínico San Carlos, Madrid, Spain; 7Madrid, Madrid, Spain

WEDNESDAY, FEBRUARY 25, 2015

Session P-U8 Poster Session Poster Hall
2:30 pm – 4:00 pm
Tuberculosis and Other Coinfections in Children With HIV

938 Tuberculosis Among Children on Antiretroviral Therapy in Swaziland, 2004-2012
Melissa A. Briggs1; Andrew Auld1; Harrison Kamimu2; Harriet Nwagaba-Birbinbwoh3; Velephi Okello4; George Bicego5; Andrew L. Baughman6; Simon Agolory7; Todd V. Ellerbrock8; Peter Ehrenkranz9
1US Centers for Disease Control and Prevention (CDC), Atlanta, GA, US; 2Mailman School of Public Health, New York, NY, US; 3Swaziland Ministry of Health, Mbabane, Swaziland; 4US Centers for Disease Control and Prevention (CDC), Mbabane, Swaziland

939 Mycobacterium TB Disease in HIV-Infected Children Receiving LPV/r or NVP-Based ART
Mohemdran Archary1; Linda Barlow-Mosha2; Avy Violari3; Jane Lindsay4; Lynne Mofenson5; Patrick Jean-Philippe6; Bonnie Zimmer7; Paul E Palumbo8
1University of KwaZulu-Natal, Durban, South Africa; 2MUJHU Care Ltd/ MUJHU Research Collaboration, Kampala, Uganda; 3Perinatal HIV Research Unit, Johannesburg, South Africa; 4Frontier Science, Amherst, NY, US; 5Geisel School of Medicine at Dartmouth, Lebanon, NH, US

940 Safety of Rifabutin in HIV/TB-Coinfected Children on Protease Inhibitor-Based ART
Holly E. Rawizza1; Kristin M. Darin2; Kimberly K. Scarsi3; Biobele Brown4; Regina Oladokun5; Nikri David6; Sulaimon Akamu7; Oluremi Olaitan8; Prosper Onkonwo9; Phyllis Kanki10
On behalf of the APIN PEPFAR Team
1Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, US; 2Northwestern University, Feinberg School of Medicine, Chicago, IL, US; 3University of Nebraska Medical Center, Omaha, NE, US; 4University College Hospital, Ibadan, Nigeria; 5National Institute of Medical Research, Lagos, Nigeria; 6Lagos University Teaching Hospital, Lagos, Nigeria; 7AIDS Prevention Initiative in Nigeria, Abuja, Nigeria; 8Harvard School of Public Health, Boston, MA, US

941 Skin Complaints in African Children Randomized to Stop or Continue Cotrimoxazole
Andrew Prendergast1; Mutsa F. Bwakura2; Dangarembizi3; Peter Mugyenyi2; Joseph Lutaakome4; Adeodata Kekitiinwa5; Diana M. Gibb6; Sarah Walker7
On behalf of the ARROW Trial Team
1Queen Mary University of London, London, United Kingdom; 2University of Zimbabwe, College of Health Sciences, Harare, Zimbabwe; 3JCRF, Kampala, Uganda; 4MRC/UVRI Uganda Research Unit on AIDS, Entebbe, Uganda; 5Baylor-Uganda, Kampala, Uganda; 6MRC Clinical Trials Unit at University College London, London, United Kingdom

942 Disease Progression and Response to Treatment in Vertically HIV/HVC Co-infected Patients
Talia Sainz1; Carolina Fernández McPhee2; Santiago Jiménez de Ory3; Pablo Rojo4; María del Carmen Otero5; Milagros García Lopez-Hortelano6; Olaf Neth7; José Beeceiro8; Maribel González Tomé9; María Luisa Navarro10
On behalf of the Spanish Cohort of HIV-Infected Children and Adolescents (CoRISpe)
1Hospital Universitario Gregorio Marañón, Madrid, Spain; 2Hospital Ramón y Cajal, SEIM-Gesida, Madrid, Spain; 3Hospital 12 de Octubre, Madrid, Spain; 4Hospital La Fe, Valencia, Spain; 5Hospital La Paz, Madrid, Spain; 6Hospital Gregorio Marañón, Madrid, Spain; 7Hospital Virgen del Rocio, Sevilla, Spain; 8Hospital de Alcalá, Alcalá de Henares, Spain

943 Human Papillomavirus and Cervical Cytology in Perinatally Infected Asian Adolescents
Annette H. Sohn1; Stephen J. Kerr2; Rawiwan Hansudewachakul3; Wasana Prasitsuebsai4; Kulkanya Chokephabulkit5; Tran Ngoc Nguyen6; Thoa P. Le7; Thida Sintgoraj8; Nittaya Phanuphak; HPV in Adolescents Study9
1TREAT Asia/amfAR – The Foundation for AIDS Research, Bangkok, Thailand; 2HIV-NAT/Thai Red Cross AIDS Research Centre, Bangkok, Thailand; 3Chiangrai Prachanukroh Hospital, Chiang Rai, Thailand; 4Siriraj Hospital, Mahidol University, Bangkok, Thailand; 5Hunyong Hospital, Ho Chi Minh City, Viet Nam; 6Children’s Hospital 1, Ho Chi Minh City, Viet Nam; 7SEARCH, Thai Red Cross AIDS Research Centre, Bangkok, Thailand
944  Sexually Transmitted Infections in Youth With Controlled and Uncontrolled HIV
Andres F. Camacho-Gonzalez; Miriam C. Chernoff; Paige L. Williams; Ann Chahroudi; James M. Oleske; Rana Chakraborty; Shirley Traite; Murli U. Purswani; Mark J. Abzug
On behalf of the IMPACT P1074 Study Team
1Emory University School of Medicine, Atlanta, GA, US; 2Harvard School of Public Health, Center for Biostatistics in AIDS Research, Boston, MA, US; 3Rutgers New Jersey Medical School, Newark, NJ, US; 4Albert Einstein College of Medicine, Division of Pediatric Infectious Diseases, Bronx Lebanon Hospital Center, Bronx, NY, US; 5University of Colorado School of Medicine, Division of Pediatric Infections Diseases, Aurora, CO, US; 6International Maternal Pediatric Adolescent AIDS Clinical Trials, Durham, NC, US

TUESDAY, FEBRUARY 24, 2015

Session P-U9 Poster Session  Poster Hall
2:30 pm – 4:00 pm  Responses to Vaccines in Children

945  Sustained Responses to Measles Revaccination in HIV-Infected Children on ART in Kenya
Laura Newman; Anne Njorge; Bhavana Chohan; Amalia Magaret; Jonathan Gorstein; Julie M. Overbaugh; Dalton Wamalwa; Elizabeth M. Obimbo; Ruth W. Nduti; Carey Farquhar
1University of Washington, Seattle, WA, US; 2Fred Hutchinson Cancer Research Center, University of Washington, Seattle, WA, US; 3University of Nairobi, Nairobi, Kenya

946  T-Cell Anergy and Activation Are Associated With Suboptimal Humoral Responses to Measles Revaccination in HIV-Infected Children on Antiretroviral Therapy in Nairobi, Kenya
Matthew B. Buechler; Laura Newman; Bhavana Chohan; Anne Njorge; Dalton Wamalwa; Carey Farquhar
1University of Washington, Seattle, WA, US; 2University of Washington, Seattle, WA, US; 3University of Washington, Seattle, WA, US; 4Fred Hutchinson Cancer Research Center, University of Washington, Seattle, WA, US; 5Kenyatta National Hospital, Nairobi, Kenya; 6University of Nairobi, Nairobi, Kenya

947  Molecular Profiles of CXCR5+ CD4 Memory T Cells Associated With Flu Vaccine Response
Lesley R. de Armas; Nicola Cotugno; Suresh Pallickuth; Alberto Cagini; Paolo Palma; Paolo Rossi; Savita Pahwa
1University of Miami Miller School of Medicine, Miami, FL, US; 2Children’s Hospital Bambino Gesu, Rome, Italy; 3Children Hospital Bambino Gesu, Rome, Italy

948  The Potential of BCG and HIV-TB Vaccines to Exacerbate HIV-1 Pathogenesis in Infants
Kara Jensen; Koen K. Van Rompay; William R. Jacobs; Glenn Fennelly; Katie Mollan; Michael G. Hudgens; Mike Piatak; Michelle H. Larsen; Kristina De Paris
1University of North Carolina, Chapel Hill, NC, US; 2California National Primate Research Center, University of California, Davis, CA, US; 3Albert Einstein College of Medicine, New York, NY, US; 4Frederick National Laboratory, Frederick, MD, US

Session P-U10 Poster Session  Poster Hall
2:30 pm – 4:00 pm  Pharmacokinetics, Safety, and Efficacy of ART in Children and Youth

949  Prediction of ARV Drug Clearance in Children
Frantz Feissac; Naom Bouazza; Elodie Valade; Maisys De Sousa; Floris Fauchet; Sihem Benaboud; Deborah Hirt; Stéphane Blanche; Saïk Urien; Jean-Marc Treluyer
EA 08 Université Paris Descartes, Sorbonne Paris Cité, Unité de Recherche Clinique, AP-HP, Hôpital Tarnier, Paris, France, Paris, France

950  Use of Maraviroc in HIV-1-Infected Paediatric Patients in Clinical Practice
Claudia Palladino; Maria Luisa Navarro Gomez; Pere Soler-Palacin; Maria Isabel Gonzalez-Tome; Santiago Jimenez de Ory; Maria Espiau; Juan Antonio León-Leal; Claudia Fortuny; Verónica Brijz
CoRISpe group
1University of Lisbon, Lisbon, Portugal; 2National Center for Microbiology, Madrid, Spain; 3Hospital Sant Joan de Déu, Universitat de Barcelona, Barcelona, Spain; 4Hospital Infantil Universitario Virgen del Rocío, Sevilla, Spain; 5Hospital Universitari Vall d’Hebron, Barcelona, Spain; 6Hospital General Universitario Gregorio Marañón, Madrid, Spain; 7Hospital Universitario Doce de Octubre, Madrid, Spain

951  Safety and Pharmacokinetics of Elvitegravir in HIV-1 Infected Pediatric Subjects
Joseph M. Custodio; Victor Musiime; Aditya Gaur; Elizabeth McFarland; Wasana Prasitsuebsai; Lize Hellingstrom; Xuexian Wei; Rebecca Begley; Srinivasan Ramanathan; Sean R. Bennett
1Gilead Sciences, Inc., Foster City, CA, US; 2Joint Clinical Research Centre, Kampala, Uganda; 3St Jude Children’s Research Hospital, Memphis, TN, US; 4University of Colorado Denver, Aurora, CO, US; 5HIV - NAT, Bangkok, Thailand; 6Be Part Voluntù Centre, Cape Town, South Africa

952  Lack of Emergent Resistance in HIV-1-Infected Adolescents on Elvitegravir-Based STRs
Danielle P. Porter; Sean R. Bennett; Erin Quirk; Michael D. Miller; Kirsten L. White
Gilead Sciences, Inc., Foster City, CA, US

953  Week-24 Data From a Phase 3 Clinical Trial of E/C/F/TAF in HIV-Infected Adolescents
Hilda Kizito; Aditya Gaur; Wasana Prasitsuebsai; Natella Rakhmanina; Eileen Lawson; Yongwu Shao; Sean R. Bennett; Andrew Cheng; Erin Quirk
1Gilead Sciences, Inc., Foster City, CA, US; 2Joint Clinical Research Centre, Kampala, Uganda; 3STI/SA HRES; 4HIV Netherlands Australia Thailand Research Collaboration, Bangkok, Thailand; 5Children’s National Health System, Washington, DC, US

954  Efficacy and Safety of Long-Term Tenofovir DF (TDF) Therapy in HIV-Infected Children
Xavier Saez-Llorens; Jaime G. Deville; Ayesha Mirza; Janet S. Chen; Aditya Gaur; Mobeen Rathore; Dana Hardin; Ya-Pei Liu; Erin Quirk
GS-US-104-0352 Study Team
1Gilead Sciences, Inc., Foster City, CA, US; 2Hospital del Niño, Panama City, Panama; 3University of California Los Angeles, Los Angeles, CA, US; 4University of Florida, Jacksonville, FL, US; 5Drexel University College of Medicine, Philadelphia, PA, US; 6STI/SA HRES; 7El Lilly, Indianapolis, IN, US
955 Acceptability of Lopinavir/r Minitabs, Tablets and Syrups in HIV-Infected Children
Adeodata Kekitiinwa
CHAPAS-2
Baylor College of Medicine Children's Foundation Uganda, Kampala, Uganda

956 Therapeutic Drug Monitoring of Lopinavir in HIV-Infected Children on Second-Line ART
Linda Auripibul1; Wasana Prasitsuebsai3; Tavitiya Sudjaritruk1; Pope Kosalaraks1; Nia Kurniati1; Khanh Huy Truong5; Viet Chau Do5; Sirimya Teeraananchai2; Stephen J. Kerr1
the TASER-Pediatrics Study Group
1Research Institute for Health Sciences, Chaing Mai University, Chiang Mai, Thailand; 2The HIV Netherlands Australia Thailand Research Collaboration, The Thai Red Cross AIDS Research Centre, Bangkok, Thailand; 3Department of Pediatrics, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand; 4Srinagarind Hospital, Khon Kaen University, Khon Kaen, Thailand; 5Children's Hospital, Ho Chi Minh City, Vietnam; 6Cipto Mangunkusumo General Hospital, Jakarta, Indonesia; 7Children's Hospital 2, Ho Chi Minh City, Vietnam

WEDNESDAY, FEBRUARY 25, 2015

Session P-V1 Poster Session
2:30 pm – 4:00 pm
Poster Hall

957 Significant Intolerance of Efavirenz in HIV Occupational Postexposure Prophylaxis
Surasak Wiloonchutikul1; Varaporn Thientong1; Patama Sutha1; Boonchai Kowadisaiburana2; Weerawat Manosuthi1
1Bamrssonarud Infectious Diseases Institute, Nonthaburi, Thailand; 2Bangkok Hospital, Bangkok, Thailand

958 Rilpivirine-Emtricitabine-Tenofovir for HIV Nonoccupational Postexposure Prophylaxis
Rosalind Foster1; John McAllister2; Tim R. Read1; Anna Pierce1; Robyn Richardson1; Anna McNulty3; Andrew Carr1
On behalf of the EPEP Study Researchers
1Sydney Sexual Health Centre, Sydney, Australia; 2St Vincent's Centre for Applied Medical Research, Sydney, Australia; 3Melbourne Sexual Health Centre, Melbourne, Australia; 4The Alfred Hospital, Melbourne, Australia

959 Tenofovir/Emtricitabine Plus LPV/r vs MVC or Raltegravir for PEP: 2 Randomized Trials
Lorna Leal1; Agathe Leon2; Berta Torres; Alecxy Inciarte; Constanza Lucero; Josep Mallolas; Maria Martínez-Rebollar; Ana González-Cordón; José M. Gatell; Feliphe Garcia
Hospital Clinic Barcelona, Barcelona, Spain

960 Effects of Three Regimens of PEP on the Immune System of HIV-Seronegative Individuals
Alberto C. Guardo1; Lorna Leal2; Agathe Leon3; Cristina Rodríguez de Miguel4; Manel E. Bargallo3; Cristina Rovira3; Josep Llach3; Jose M. Gatell4; Feliphe Garcia2; Montserrat Plana1
1Institut D’Investigacions Biomèdiques August Pi i Sunyer, Barcelona, Spain; 2Hospital Clinic, Barcelona, Spain

961 Management of Acute HIV After Initiation of Postexposure Prophylaxis: Challenges and Lessons Learnt
Goli Haidari1; Naomi Fitzgerald2; Sonia Raffel3; Nneka Nwokolo1; Olamide Dosekun4; Mark D. Lawton5; Nickie Mackie1; Julie Fox2; Martin Fisher1; Sarah Fidler1
1St Mary’s Hospital—Imperial College Healthcare NHS Trust, London, United Kingdom; 2Brighton and Sussex Hospitals NHS Trust, Brighton, United Kingdom; 3Chelsea and Westminster Hospital NHS Foundation Trust, London, United Kingdom; 4Guy’s and St Thomas’ NHS Foundation Trust, London, United Kingdom; 5The Royal Liverpool and Broadgreen University Hospitals NHS Trust, Liverpool, United Kingdom; 6St Mary’s Hospital—Imperial College Healthcare NHS Trust, London, United Kingdom; 7Guy’s and St Thomas’ NHS Foundation Trust, London, United Kingdom; 8Brighton and Sussex Hospitals NHS Trust, Brighton, United Kingdom; 9St Mary’s Hospital—Imperial College Healthcare NHS Trust, London, United Kingdom

THURSDAY, FEBRUARY 26, 2015

Session P-V2 Poster Session
2:30 pm – 4:00 pm
PrEP and Microbicide Challenge
Poster Hall

962 FTC/TDF Prevents SHIV Infection in C. trachomatis and T. vaginalis-Infected Macaques
Jessica Radzio; Tara Henning; James Mitchell; Angela Holder; Debra Hanson; Janet McNicholl; Walid Heneine; John Papp; Ellen Kersh; Gerardo Garcia-Lerma
US Centers for Disease Control and Prevention (CDC), Atlanta, GA, US

963 Impact of Sexually Transmitted Infections on the Efficacy of Tenofovir Vaginal Gel in Macaques
Natalia Makarova; Tara Henning; Andrew Taylor; Chuong Dinh; Carol Farshy; Janet McNicholl; John Papp; Walid Heneine; Ellen Kersh; Charles W. Dobard
US Centers for Disease Control and Prevention, Atlanta, GA, US

964 Oral Single-Dose Maraviroc Does Not Prevent Ex Vivo HIV Infection of Rectal Mucosa in Healthy HIV-1–Negative Human Volunteers in Tissue Explants.
Josep Coll1; José Molto2; Jaume Boix3; Laura Ese1; Elisabet Garcia1; Roger Paredes1; David Back; Bonaventura Clotet; Cecilia Cabrera1
1Institut de Recerca de la Sida IrsiCaixa, Institut d’Investigació en Ciències de la Salut Germans Trias i Pujol, Barcelona, Spain; 2Fundación Lluïta Contra la SIDA, Institut d’Investigació en Ciències de la Salut Germans Trias i Pujol, Barcelona, Spain; 3Unidad de Endoscopía Digestiva, Hospital Universitario Germans Trias i Pujol, Barcelona, Spain; 4Pharmacology Research Laboratories, Liverpool, United Kingdom; 5University Hospitals NHS Trust, London, United Kingdom; 6University Hospitals NHS Trust, London, United Kingdom; 7University Hospitals NHS Trust, London, United Kingdom; 8University Hospitals NHS Trust, London, United Kingdom

965 CCR5 Blockade With Maraviroc Does Not Prevent SIVmac Oral Transmission to Macaques
Egidio Brocca-Cofano1; Cuiling Xu2; Dongzhu Ma1; Benjamin Policicchio2; Kevin Raehz1; Tammy Dumsore1; George Richter-Hare1; Brandon F. Keefe1; Ivona Pandrea1; Cristian Apetrei1
1University of Pittsburgh, Pittsburgh, PA, US; 2National Cancer Institute (NCI), Frederick, MD, US
**Session P-V3 Poster Session**

**2:30 pm – 4:00 pm**

**PrEP: Uptake**

**969** Sustained PrEP Use Among High-Risk African HIV Serodiscordant Couples Participating in a PrEP Demonstration Project  
Renee Heffron; Kenneth Levine; Nulu Bulya Semiyanga; Josephine Odoyo; Edna Tindimwebya; Jennifer Morton; Lara Kidoguchi; Mark A. Marzinke; Connie Celum; Jared Baeten  
Partners Demonstration Project Team  
1University of Washington, Seattle, WA, US; 2Jomo Kenyatta University of Agriculture and Technology, Nairobi, Kenya; 3Makerere University College of Health Sciences, Kampala, Uganda; 4Kenya Medical Research Institute, Nairobi, Kenya; 5Kabwohe Clinic Research Center, Kabwohe, Uganda; 6Johns Hopkins University School of Medicine, Baltimore, MD, US

**970** PrEP Engagement for HIV Prevention: Results From the iPrEx Open Label Extension (OLE)  
David V. Glidden; Susan P. Buchbinder; Peter L. Anderson; Vanessa McMahan; K. Rivet Amico; Albert Liu; Sybil Hosek; Megha Mehrotra; Robert M. Grant  
iPrEx Investigators  

**Session P-V4 Poster Session**

**2:30 pm – 4:00 pm**

**PrEP: Measures and Correlates of Adherence**

**975** Urine Assay for Tenofovir to Monitor Adherence to Tenofovir–Emtricitabine as PrEP  
Helen C. Koenig; Chennan Sun; Tsung-Chih Wang; Stephen J. Winters; J. Morgan Sims; Krishna Titus-Jones; Ronald G. Vlahov; Samuel M. Gwadz; Anthony F. D’Agata; Peter H. Salzwedel; William R. Spreen; Yvonne Winters; Todd M. Pannell; Joel L. Hulsey; Gregory J. Cummins; Melissa A. Swiat; David V. Glidden; Robert A. Black; Hunter J. Simonds  

**976** Comparison of Adherence Measures in a Clinical Trial of Preexposure Prophylaxis  
Davis C. Muganza; Jessica Haberer; Yip Boum; Nicholas Musinguzi; Allan Ronald; Connie Celum; Jared Baeten; David R. Bangsberg  
1Mbarara University of Science and Technology, Kampala, Uganda; 2Massachusetts General Hospital, Harvard Medical School, Boston, MA, US; 3University of Washington, Seattle, WA, US; 4University of Manitoba, Winnipeg, Canada

**977** Self-Reported Recent PrEP Use Has Strong Relation to Drug Detection in iPrEx OLE  
Rivet Amico; Vanessa McMahan; Megha Mehrotra; Peter L. Anderson; Juan Guanira; Valdilea Veloso; Robert M. Grant  
1University of Michigan, Ann Arbor, MI, US; 2Gladstone Institute, San Francisco, CA, US
Linda-Gail Bekker1; James Hughes1; Rivet Amico2; Surita Roux2; Craig Hendrix3; Peter L. Anderson1; Bonnie Dye1; Vanessa Elharrar2; Michael J. Stirrat1; Robert Grant13
1Dept of Medicine and Institute of Infectious Disease and Molecular Medicine, Cape Town, South Africa; 2HIV Prevention Trials Network, Seattle, WA, US; 3The Desmond Tutu HIV Centre, Cape Town, South Africa; 4University of Michigan, Ann Arbor, MI, US; 5Johns Hopkins University, Baltimore, MD, US; 6University of Colorado, Aurora, CO, US; 7FHI360, Durham, NC, US; 8PSP/DAIDS/NIAID/NIH, Bethesda, MD, US; 9Center for Mental Health Research on AIDS, Bethesda, MD, US; 10University of California, San Francisco, CA, US

Correlates of Early Adherence in VOICE PrEP Trial Differ Between Oral and Vaginal Products
Ariane van der Straten1; Elizabeth R. Brown1; James Dai1; Craig Hendrix1; Karen Liu1; Cynthia Grossman2; Z M. Chirenje1; Jeanne Marrazzo1
1RTI, San Francisco, CA, US; 2Fred Hutchinson Cancer Research Center, University of Washington, Seattle, WA, US; 3Johns Hopkins University School of Medicine, Baltimore, MD, US; 4National Institute of Mental Health (NIMH), Bethesda, MD, US; 5University of Zimbabwe—University of California San Francisco Research Collaboration, Harare, Zimbabwe; 6University of Washington, Seattle, WA, US

979 Intimate Partner Violence is Associated With Low PrEP Adherence in African Women
Sarah T. Roberts1; Connie Celum1; Nelly Mugo1; Jessica Haberer2; Craig R. Cohen4; Elizabeth Iruungu1; James N. Kirie1; Edwin Were2; Jared Baeten1
On behalf of the Partners PrEP Study Team
1University of Washington, Seattle, WA, US; 2Massachusetts General Hospital, Harvard Medical School, Boston, MA, US; 3Kenya Medical Research Institute, Nairobi, Kenya; 4University of California San Francisco, San Francisco, CA, US; 5Kenyatta National Hospital, Nairobi, Kenya; 6University of Nairobi, Nairobi, Kenya; 7Moi University, Eldoret, Kenya

WEDNESDAY, FEBRUARY 25, 2015

Session P-V5 Poster Session
Poster Hall
2:30 pm – 4:00 pm
PrEP: Evaluating Potential Harm

981 Reversibility of Kidney Function Decline in HIV-1–Uninfected Men and Women Using Preexposure Prophylaxis
Kenneth K. Mugwanya1; Christina Wyatt1; Connie Celum1; Deborah Donnell1; Nelly Mugo1; James N. Kirie1; Allan Ronald1; Jared Baeten1
On behalf of the Partners PrEP Study Team
1University of Washington, Seattle, WA, US; 2Mount Sinai School of Medicine, New York, NY, US; 3Fred Hutchinson Cancer Research Center, Seattle, WA, US; 4Kenya Medical Research Institute, Nairobi, Kenya; 5University of Nairobi, Nairobi, Kenya; 6University of Manitoba, Winnipeg, Canada

982 Minor Drug-Resistant Variants Infrequently Detected in Seroconverters From MTN 003 (VOICE)
Constantinos Panousis1; Elias K. Halvas1; Cliff Kelly2; Jeanne Marrazzo1; Z M. Chirenje3; John W. Mellors1; Urvi M. Parikh1
On behalf of the MTN 003 Protocol Team

983 PrEP-Selected Drug Resistance Fades by Six Months Following Drug Cessation
Julie F. Weis1; Jared Baeten2; Ruth Kanthula3; Connor McCoy3; Lisa Frenkel1; Nelly Mugo1; Frederick Matsen4; Julie M. Overbaugh4; Connie Celum1; Dana A. Lehman1

984 Randomized Controlled Trial on ART Outcomes in Tenofovir Gel Trial Seroconvertors
Anushka Naidoo1; Nivashtee Naicker1; Lise Werner1; Nigel Barrett1; Sarah Dlamini1; Villeshni Asari1; Nelsile Majola1; Cheryl Baxter1; Quarraisha Abdool Karim1; Salim S. Abdool Karim1
Center for the AIDS Program of Research in South Africa, Durban, South Africa

985 Frequent Dapivirine Cross-Resistance of HIV from 1st-line ART Failures in S. Africa
Kerri J. Penrose1; Kristen A. Hamanishi1; Lachlan Gordon2; Raquel V. Viana3; Carole L. Wallis1; John W. Mellors1; Urvi M. Parikh1
1University of Pittsburgh, Pittsburgh, PA, US; 2Lancet Laboratories, Johannesburg, South Africa; 3Lancet Laboratories/BARC-SA, Johannesburg, South Africa

986 Effect of TDF Monotherapy PrEP on Immune Function in Seroconverting Individuals
Marcel E. Curnin1; Michael T. Martin1; Punneeporn Wasin rapee2; Wanna Leelawiwat2; Boonchot Raensakulrach3; Janet McNicholl3; Pravan Suntharasami1; Udomsak Sangkum4; SuPhak Vanichseni4; Kachit Choopanya4
1US Centers for Disease Control and Prevention (CDC), Atlanta, GA, US; 2CAPRISA, University of Kwazulu-Natal, Congella, South Africa; 3National Institute of Allergy and Infectious Diseases, Bethesda, MD, US; 4National Institute of Allergy and Infectious Diseases, Bethesda, MD, US

987 The Impact of Preexposure Prophylaxis on Antibody Maturation in HIV-Infected Women
Oliver B. Laeyendecker1; Andrew D. Redd2; Martha Nason1; Andrew Longoza2; Quarraisha Abdool Karim3; Vivek Naranhbhai3; Nigel Garrett3; Salim S. Abdool Karim1; Thomas C. Quinn1
1National Institute of Allergy and Infectious Diseases, Bethesda, MD, US; 2CAPRISA, University of KwaZulu-Natal, Congella, South Africa; 3National Institute of Allergy and Infectious Diseases (NIAID), Bethesda, MD, US
Program and Agenda

988 Medication Sharing Among African HIV Serodiscordant Couples Enrolled in a PrEP Trial
Kerry A. Thomson; Jessica Haberer; Connie Celum; Andrew Mujugira; Patrick Ndase; Craig Hendrix; Mark A. Marzinke; Allan Ronald; David Bangsberg; Jared Baeten
On behalf of the Partners PrEP Study Team
1 University of Washington, Seattle, WA, US; 2 Johns Hopkins University, Baltimore, MD, US; 3 University of Manitoba, Winnipeg, Canada; 4 Massachusetts General Hospital, Boston, MA, US

THURSDAY, FEBRUARY 26, 2015

989 HIV-1 Transmission Risk Persists During the First 6 Months of Antiretroviral Therapy
Andrew Mujugira; Katherine Thomas; Connie Celum; Deborah Donnelly; Carey Farquhar; Elizabeth Bukusi; Jared Baeten
On behalf of the Partners PrEP Study Team
1 University of Washington, Seattle, WA, US; 2 Fred Hutchinson Cancer Research Center, University of Washington, Seattle, WA, US; 3 Kenya Medical Research Institute, Nairobi, Kenya

990 Long-Term ART Outcomes in Botswana Encouraging Treatment as Prevention Approach
Hermann Bussmann; William C. Wester; Ernest Fetogang; Tony Chebani; Sikalihle Moyo; Naledi M. Mlaudzi; Erik V. Widenfelt; Joseph Makhema; Max Essex; Richard Marlink
1 Vanderbilt University School of Medicine, Nashville, TN, US; 2 Ministry of Health, Gaborone, Botswana; 3 Botswana Harvard AIDS Institute Partnership for HIV Research and Education, Gaborone, Botswana; 4 Harvard School of Public Health, Boston, MA, US

991LB Use of Population Viral Load to Predict HIV-Incidence in a Hyperendemic Population in Rural KwaZulu-Natal, South Africa
Frank Tanser; Julio de Oliveira; Till Barnighausen; Deenan Pillay
1 University College London, London, United Kingdom; 2 Harvard School of Public Health, Boston, MA, US; 3 University of KwaZulu-Natal, Mtubatuba, South Africa

992LB Phase 1 Safety & PK Trial of Polyurethane Tenofovir Disoproxil Fumarate Vaginal Ring
Marla J. Keller; Pedro Mesquita; Mark A. Marzinke; Ryan Teller; Bruce Frank; Mark Mitchnick; Peter L. Anderson; Craig Hendrix; Patrick F. Kiser; Betsy Herold
1 Albert Einstein College of Medicine, Bronx, NY, US; 2 Johns Hopkins University School of Medicine, Baltimore, MD, US; 3 Northwestern University, Evanston, IL, US; 4 Particle Sciences, Inc, Bethlehem, PA, US; 5 University of Colorado, Aurora, CO, US

TUESDAY, FEBRUARY 24, 2015

994 CHARM-01, a Phase 1 Rectal Safety, Acceptability, PK/PD Study of 3 Tenofovir Gels
Ian McGowan; Kathy Duffill; Charlene Dezzuti; Nicola Richardson-Harman; Mark A. Marzinke; Ross D. Cranston; Lisa Rohan; Craig W. Hendrix; Julie Elliott; Peter Anton
1 University of Pittsburgh, Pittsburgh, PA, US; 2 Magee-Womens Research Institute, Pittsburgh, PA, US; 3 Alpha StatConsult LLC, Damascus, MD, US; 4 Johns Hopkins University School of Medicine, Baltimore, MD, US; 5 David Geffen School of Medicine at University of California Los Angeles, Los Angeles, CA, US

995 Female Condom Functionality in the Presence of a Vaginal Ring
Annalene M. Neil; Mildie Leuvennink; Neliette Van Niekerk; Terri Walsh; Ron Frezieres
1 International Partnership for Microbicides, Paarl, South Africa; 2 California Family Health Council Inc, Los Angeles, CA, US

996 Continuous Retention Predicts Viral Suppression Across the US and Canada
Peter F. Rebeiro; Baligh R. Yehia; Kelly Gebo; Bryan Lau; Kenneth H. Mayer; Michael A. Horberg; Mari Kitahata; John Gill; Timothy Sterling; Stephen J. Gange
North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD)
1 Vanderbilt University, Nashville, TN, US; 2 University of Pennsylvania, Philadelphia PA, US; 3 Johns Hopkins University, Baltimore, MD, US; 4 Harvard University, Boston, MA, US; 5 Mid-Atlantic Permenant Research Institute, Kaiser Permenant Mid-Atlantic States, Rockville, MD, US; 6 University of Washington, Seattle, WA, US; 7 University of Calgary, Alberta Health Services, Calgary, Canada

997 Disparities in HIV Viral-Load Suppression Among MSM, the HIV Outpatient Study, 2013
Kate Buchacz; Carl Armon; Ellen Tedaldi; Frank J. Paella; Richard Novak; Doug Ward; Benjamin Young; Rachel Debes; Marcus Durham; John T. Brooks
1 US Centers for Disease Control and Prevention (CDC), Atlanta, GA, US; 2 Cerner Corporation, Vienna, VA, US; 3 Temple University School of Medicine, Philadelphia, PA, US; 4 Northwestern University, Chicago, IL, US; 5 University of Illinois at Chicago, Chicago, IL, US; 6 Dupont Circle Physicians Group, Washington, DC, US; 7 International Association of Providers in AIDS Care, Washington, DC, US

998 Early Linkage to HIV Care and Antiretroviral Therapy Use Among People Who Inject Drugs: 20 US Cities, 2009 and 2012
Brooke Hoots; Teresa Finlayson; Dita Broz; Gabriela Paz-Bailey
US Centers for Disease Control and Prevention (CDC), Atlanta, GA, US
1006 Marijuana Use and Its Nuanced Relationship With HIV Treatment Continuum Metrics
John A. Schneider; Ethan Morgan; Stuart Michaels; Britt Skaathun; Lindsay Young; Robert W. Coombs; Phil Schumm; Dexter Voisin; Sam Friedman
UConnnect Study Team

1007 “Test-and-Treat” in the Netherlands
Ard van Sighem; Luuk Gras; Eline Op de Coul; Daniela Bezemer; Michel van Agtmael; Godelieve de Bree; Peter Reiss
On behalf of the ATHENA National Observational HIV Cohort
1Stichting HIV Monitoring, Amsterdam, Netherlands; 2National Institute for Public Health and the Environment, Bilthoven, Netherlands; 3VU University Medical Centre, Amsterdam, Netherlands; 4Amsterdam Institute for Global Health and Development, Amsterdam, Netherlands

1008 Estimates of HIV Prevalence, Proportion of Diagnosed Patients and Quality of Treatment in Switzerland
Philipp Kohler; Axel J. Schmidt; Bruno Ledergerber; Pietro L. Vernazza
1Cantonal Hospital St. Gallen, St. Gallen, Switzerland; 2Universitätsspital Zürich, Zurich, Switzerland; 3Federal Office of Public Health, Bern, Switzerland

1009 Medical Care Interruptions in HIV-infected Patients: Characteristics and Consequences
Lise Cuzin; Pierre Dellamonia; Yazdan Yazdanpanah; Sabelline Bouchez; David Rey; Bruno Hoen; André Cabié
1Toulouse University Hospital, Toulouse, France; 2University Hospital, Nice, Nice, France; 3University Hospital, Nantes, France; 4University Hospital, Fort de France, France; 5University Hospital, Pointe à Pitre, France; 6University Hospital, Strasbourg, France; 7Hôpital Bichat-Claude Bernard, APHM, Paris, France

1010 Blood Donor Test-Seeking Motivation and Prior HIV Testing Experiences in São Paulo
Hong-Ha M. Truong; Paula Blatytza; Sandra Montebello; Sandra Espositi; Fatima Hangai; Nanci Salles; Alfredo Mendrone; Ester C. Sabino; Willi McFarland; Thelma T. González

999 Late HIV Diagnosis in Metropolitan Areas of the United States and Puerto Rico
H. Irene Hall; Tian Tang; Lorena Espinoza
1US Centers for Disease Control and Prevention (CDC), Atlanta, GA, US; 2ICF International, Atlanta, GA, US

1000 HIV Care During the Last Year of Life
H. Irene Hall; Lorena Espinoza; Shericka Harris; Jing Shi
1US Centers for Disease Control and Prevention (CDC), Atlanta, GA, US; 2ICF International, Atlanta, GA, US

1001 Reductions in the Time From HIV Infection to ART Initiation in New York City
Sarah L. Braunstein; McKaylee Robertson; Julie Myers; Bisrat Abraham; Denis Nash
1New York City Department of Health and Mental Hygiene, Queens, NY, US; 2City University of New York, New York, NY, US; 3Weill Cornell Medical College, New York, NY, US; 4City University of New York School of Public Health, New York, NY, US

1002 Return to HIV-Related Medical Care After a Hiatus of ≥1 Year, New York State, 2013
Carol-Ann Swain; Daniel Gordon; Jessica L. Simpson; Bridget J. Anderson; Bruce D. Agins; Lou C. Smith

1003 Care-Cascade Status of Partners of Persons With New HIV Infections in North Carolina
Anna B. Cope; Lisa Hightow-Weidman; JoAnn D. Kuruc; Jenni Marmormino; Steve Beagie; Philip J. Peters; Cynthia L. Gay
1University of North Carolina, Chapel Hill, NC, US; 2US Centers for Disease Control and Prevention (CDC), Atlanta, GA, US

1004 The Role of HIV Status Disclosure in Retention in Care and Viral-Load Suppression
Latesha E. Elpe; Andrew Westfall; Michael J. Mugavero; Anne Zinski; Greer Burkholder; Edward Hook; Nicholas Van Wagoner
1University of Alabama at Birmingham, Birmingham, AL, US

1005 Alcohol and Substance Use and Timing of Presentation to HIV Care Across the United States
Jesse Abbott Klafter; Daniel R. Drozd; Michael J. Mugavero; Katerina Christopoulos; Christopher W. Mathews; Joseph J. Eron; Kenneth H. Mayer

1011 Treatment Interruptions in ART Programmes in Resource-Limited Settings: 2003 to 2013
Gail B. Cross; Tim Spelman; Daniel P. O’Brien; Nathan Ford; Jane Greig; James H. McMahon
1Monash University/Alfred Hospital, Prahan, Australia; 2Burnet Institute, Melbourne, Australia; 3World Health Organization (WHO), Geneva, Switzerland; 4Médecins Sans Frontières, London, United Kingdom

Session P-W2 Poster Session
2:30 pm – 4:00 pm
HIV Testing and the Continuum of Care in the Developing World

1010 Blood Donor Test-Seeking Motivation and Prior HIV Testing Experiences in São Paulo
Hong-Ha M. Truong; Paula Blatytza; Sandra Montebello; Sandra Espositi; Fatima Hangai; Nanci Salles; Alfredo Mendrone; Ester C. Sabino; Willi McFarland; Thelma T. González

Poster Hall
1012 Time to ART Qualification and Retention Among Patients With Early HIV in Haiti
Rita T. Dadaille; Serena P. Koening; Kelley Henessey; Ellie Cooper; Pierre Cremieux; William J. Pape
Analysis Group; Les Centres GESKIO IT Team
1Gheskio Centers, Port au Prince, Haiti; 2Analysis Group, Boston, MA, US

1013 Awareness of HIV Diagnosis in the Swaziland HIV Incidence Measurement Survey
Tanya M. Ellman; Ruth Emerson; Deborah Donnell; Neena M. Philip; Rejoice Nkambule; Naomi Bock; Peter Ehrenkranz; George Bicego; Jessica E. Justman
1ICAP at Columbia University, New York, NY, US; 2Ministry of Health, Mbabane, Swaziland; 3US Centers for Disease Control and Prevention, Atlanta, GA, US; 4Fred Hutchinson Cancer Research Center, Seattle, WA, US; 5Centers for Disease Control and Prevention, Mbabane, Swaziland

1014 Who Is at Risk of Being Untested and Unaware of HIV-Positive Status in KwaZulu-Natal?
Helena Huerga; Gilles Van Cutsem; Jihane Ben Farhat; Malika Bouhenaia; Matthew Reid; David Maman; Jean-François Etard; Thomas Ellman
1Epicentre, Paris, France; 2Médecins Sans Frontières, Cape Town, South Africa

1015 Impact of Unplanned Care Interruption on Immune Recovery After ART Initiation in Nigeria
Aimalohi A. Ahonkhai; Juliet Adeola; Bolanle Banigbe; Ifeyinwa Onwuatuolo; Ingrid V. Bassett; Elena Losina; Kenneth A. Freedberg; Prosper Okonkwo; Susan Regan
1Massachusetts General Hospital, Harvard Medical School, Boston, MA, US; 2AIDS Prevention Initiative Nigeria, Jabi District, Nigeria; 3Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, US

1016 Linkage to HIV Care Among Men Who Have Sex With Men and Drug Users in India: Getting to 90
Sunil S. Solomon; Allison M. McFall; Aylur K. Srikrishnan; Gregory M. Lucas; Canjeeveram K. Vasudevan; David D. Celentano; Muniratnam S. Kumar; Suniti Solomon; Shruti H. Mehta
1Johns Hopkins University School of Medicine, Baltimore, MD, US; 2Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, US; 3YR Gaitonde Centre for AIDS Research and Education, Chennai, India

Wednesday, February 25, 2015

Session P-W3 Poster Session
Poster Hall
2:30 pm – 4:00 pm
Risk Factors for Transmission in MSM

1017 Sex Pro: A Personalized HIV Risk Assessment Tool for Men Who Have Sex With Men
Hyman Scott; Eric Vittinghoff; Risha Irving; Albert Liu; Sheldon D. Fields; Manya Magnus; Darrell P. Wheeler; Kenneth H. Mayer; Beryl A. Koblin; Susan P. Buchbinder

1018 Unreported Sexual Risk Behavior Among MSM Newly Diagnosed With HIV Infection
Hsiu Wu; Lisa B. Hightow-Weidman; Cindy L. Gay; Tonya Jackson; Emily Pike; Jenni Marmorino; Steve Beagle; Laura Hall; Philip J. Peters

1019LB HIV Transmission in Male Serodiscordant Couples in Australia, Thailand and Brazil
Andrew E. Grulich; Benjamin R. Bavinton; Fengyi Jin; Garrett Prestage; Iryna B. Zablotska; Beatriz Grinsztejn; Nittaya Phanuphak; Richard Moore; Kersten K. Koelsch
On behalf of the Opposites Attract Study Group
1University of New South Wales, Sydney, Australia; 2Instituto de Pesquisa Clinica Evandro Chagas, Rio de Janeiro, Brazil; 3Thai Red Cross AIDS Research Centre, Bangkok, Thailand; 4Northside Clinic, Melbourne, Australia

1020 Seminal Shedding of CMV and HIV Transmission Among Men Who Have Sex With Men
Sara Gianella Weibel; Konrad Scheffler; Sanjay Mehta; Susan J. Little; Lorri Freitas; Sheldon R. Morris; David M. Smith
1University of California San Diego, La Jolla, CA, US; 2County of San Diego Public Health Services, San Diego, CA, US

Martin Hoening; Christy M. Anderson; Sanjay Mehta; Nella L. Green; Davey M. Smith; Susan Little
University of California San Diego, San Diego, CA, US

1022 Influence of Voluntary Repeat HIV Testing on Sexual Risk Behavior Among MSM
Martin Hoening; Davey M. Smith; Christy M. Anderson; Nella L. Green; Sanjay Mehta; Susan J. Little
University of California San Diego, San Diego, CA, US

1023 HIV-Positive MSM With Unsuppressed Viral Load Are More Likely to Engage in Risky Sex: Vancouver, Canada
David Moore; Zishan Cui; Nathan J. Lachowsky; Henry F. Raymond; Eric Roth; Asheligh Rich; Paul Sereda; Julie Montaner; Mark Gilbert; Robert Hogg
1BC Centre for Excellence in HIV/AIDS, Vancouver, Canada; 2San Francisco Department of Public Health, San Francisco, CA, US; 3University of Victoria, Victoria, Canada; 4BC Centre for Disease Control, Vancouver, Canada

1024 Substance Use, Mental Health, and HIV Risk Behavior Among MSM in Vancouver, Canada
Nathan J. Lachowsky; Zishan Cui; Asheligh Rich; Paul Sereda; Thomas L. Patterson; Trevor Cornell; Mark Gilbert; Eric Roth; Robert Hogg; David Moore
1University of British Columbia, Vancouver, Canada; 2BC Centre for Excellence in HIV/AIDS, Vancouver, Canada; 3University of California San Diego, San Diego, CA, US; 4Ontario HIV Treatment Network, Toronto, Canada; 5University of Victoria, Victoria, Canada; 6Simon Fraser University, Burnaby, Canada
1025  Electronic and Online Innovations in Respondent-Driven Sampling Methodology  
Nathan J. Lachowsky1; Allan Lal2; Zisan Cui3; Ashleigh Rich4; Paul Sereda5; Henry Fisher Raymond6; Jamie I. Forrest7; Eric Roth8; Robert Hogg9; David Moore10  
1University of British Columbia, Vancouver, Canada; 2British Columbia Centre for Excellence in HIV/AIDS, Vancouver, Canada; 3University of California San Francisco, San Francisco, CA, US; 4University of Victoria, Victoria, Canada

1026  Incident Symptomatic Gonorrhea Infection Among Men Who Have Sex With Men, Thailand  
Marcel E. Curn1; Sarika Pattanasin; Pikunchai Luechai; Anuwat Sriporn; Jaray Tongtroyai; Eileen F. Dunne; Wichuda Sukwicha; Oranuch Kongpecha; Pachara Sirivongrason; Timothy Holtz  
1US Centers for Disease Control and Prevention (CDC), Apa, US; 2Thailand Ministry of Public Health, Nonthaburi, Thailand

1027  Occupationally Acquired HIV Infection by Healthcare Personnel—United States, 1985-2013  
M Patricia Joyce; David Kuhar; John T. Brooks  
US Centers for Disease Control and Prevention (CDC), Atlanta, GA, US

1028  Analyzing Trends in HIV Risks for Injection Drug Users by Respondent-Driven Sampling  
Kathleen A. Brady; Tanner B. Nassau; Jennifer Shinefield; Catherine Mezzacappa  
Philadelphia Department of Public Health, Philadelphia, PA, US

1029  Sexual Transmission of HIV and Possible Underreporting of Drug Use in Kazakhstan  
Anna Deryabina; Padmaja Patnaik; Charon Gwynn; Wafa M. El-Sadr  
ICAP at Columbia University, Almaty, Kazakhstan

1030  Can We Trust Self-Reported Condom Use? Association Between Reporting Bias and STIs  
Hongjie Liu  
University of Maryland, College Park, College Park, MD, US

1031  Prevalence and Correlates of Exchange Sex Among Low-Income Heterosexual Women in 21 US Cities  
Catlainn Sionean; Rashunda Lewis; Lina M. Nerlander; Gabriela Paz-Bailey  
On behalf of the NHBS Study Group  
US Centers for Disease Control and Prevention (CDC), Atlanta, GA, US

1032  HIV and STIs Among Transgendered Populations: Four Country Survey From Central America  
David Ham1; Sanny Y. Northbrook2; Sonia Morales-Miranda3; Maria Elena Guardado4; Mary Kamb5  
1US Centers for Disease Control and Prevention (CDC), Atlanta, GA, US; 2CDC Central America Region, Guatemala City, Guatemala; 3HIV Unit of Center for Health Studies, Del Valle University of Guatemala, Guatemala City, Guatemala; 4TEPHINET/ The Taskforce for Global Health Inc., Guatemala City, Guatemala; 5University of British Columbia, Vancouver, Canada

1033  Incidence of Curable Sexually Transmitted Infections Among South African Women Recently Infected With HIV  
Jennifer E. Balkus1; Marla E. Husnik1; Thesla Palanee-Phillips2; Ravindre Panchia3; Ishana Haroo4; Arendevi Pathier; Vanesshree Govender; Marthinetal Tajiaard; Pamina Gorbach; Sharon Riddler4  
1Fred Hutchinson Cancer Research Center, Seattle, WA, US; 2University of the Witwatersrand, Johannesburg, South Africa; 3Chris Hani Baragwanath Academic Hospital, Johannesburg, South Africa; 4CAPRISA/University of KwaZulu-Natal, Durban, South Africa; 5Medical Research Council, Durban, South Africa; 6The Aurum Institute, Klerksdorp, South Africa; 7University of California Los Angeles, Los Angeles, CA, US; 8University of Pittsburgh, Pittsburgh, PA, US

1034  Population Mobility, Sexual Behavior and Risk of HIV Infection in Sub-Saharan Africa  
Laurence Palk; Sally Blower  
On behalf of the Center for Biomedical Modeling  
David Geffen School of Medicine at University of California Los Angeles, Los Angeles, CA, US

1035  HIV Transmission Linkage Among Seroconverting Partners in HIV-Discordant Relationships in Kenya  
Bhavna H. Chohan; Brandon L. Guthrie; Brian Khasimwa  
1University of Washington, Seattle, WA, US; 2University of Nairobi, Nairobi, Kenya; 3University of California Los Angeles, Los Angeles, CA, US; 4Fred Hutchinson Cancer Research Center, Seattle, WA, US; 5University of Nairobi, Nairobi, Kenya

1036  Rising School Enrollment & Declining HIV Risk, 15-19y, Rakai, Uganda, 1994-2013  
John Santelli1; Sanyukta Mathur2; Xiao Yu Song3; Tzu-Jung Huang3; Ying Wei3; Tom Lutalo3; Fred Halugoda1; Ronald H. Gray1; David Serwadda3  

1037  Alcohol Use and HIV Risk Factors: Results From the 2011 Uganda AIDS Indicator Survey  
George Aluzimbi  
CDC Center for Global Health, Division of Global AIDS/HIV, Kampala, Uganda

1038  Population Attributable Fraction of HIV Due to Alcohol in Fishing Communities, Uganda  
Noah Kiwanuka1; Ismail Seekandi2; Ali Seeaala3; Annet Nalutaaya2; Juliet Mpendo2; Paul K. Kitandwe4; Jan D. Bont5; Pontiano Kaleebu6; Nelson K. Sewankambo7  
1Makerere University College of Health Sciences, Kampala, Uganda; 2UVRI-IAVI HIV Vaccine Program, Entebbe, Uganda; 3International AIDS Vaccine Initiative, New York, NY, US; 4MRC/UVRI Uganda Research Unit on AIDS, Entebbe, Uganda; 5Makerere University College of Health Sciences, Kampala, Uganda; 6University of KwaZulu-Natal, Durban, South Africa; 7University of Washington, Seattle, WA, US

Program and Agenda
1039 Risky Sexual Behavior and HIV Infection Among Fisher Folk: Lake Kyoga Region, Uganda
Rose Apondi1; Rhoda Wanyenze2; Herbert S. Kiyongi2; Abdou-Maliki Muyinda3; Elizabeth Meassick4; Joy Kusima5; David Servadda6
1CDC Center for Global Health, Division of Global AIDS/HIV, Kampala, Uganda; 2Makerere University School of Public Health, Kampala, Uganda

THURSDAY, FEBRUARY 26, 2015

Session P-W5 Poster Session
2:30 pm – 4:00 pm
Incidence and Prevalence of HIV Infection, Including Acute HIV

1040 Increases in HIV Diagnoses Among MSM in Metropolitan Statistical Areas, United States, 2003–2012
Lorena Espinoza; H. Irene Hall; Tian Tang; Anna Satcher Johnson; Amy Lansky
US Centers for Disease Control and Prevention (CDC), Atlanta, GA, US

1041 Disparities in HIV by Race and Age Among Men Who Have Sex With Men, 20 US Cities
Cyprian Wejnert; Kristen Hess; Chuck E. Rose; Alexandra B. Balaji; Justin C. Smith; Gabriela Paz-Bailey
On behalf of the NHHS Study Group
US Centers for Disease Control and Prevention (CDC), Atlanta, GA, US

Ruth Simmons1; Ruslan Maltyuta2; Nelli Chentssova3; Iryna Kamets4; Gary Murphy5; Antonia Medoeva6; Yuri Kruglov7; Alexander Yurchenko8; Kholoud Porter9; Andrew Copas10
1Medical Research Council at University College London, London, United Kingdom; 2Periodital Prevention of AIDS Initiative, Odessa, Ukraine; 3Kyiv City AIDS Centre, Kyiv City, Ukraine; 4Public Health England, London, United Kingdom; 5Institute of Epidemiology, Kyiv, Ukraine

Laurie Linley; Gian An; Kristen Mahile Gray; Alexandra Oster; Angela L. Hernandez
US Centers for Disease Control and Prevention (CDC), Atlanta, GA, US

1044 Differences in Acute Retroviral Syndrome by HIV-1 Subtype in a Multicentre Cohort Study in Africa
Eduard J. Sanders1; Kimberly A. Powers1; Etienne Karita2; Anatoli Kamali3; William Klimbeme4; Susan Allen5; Eric Hunter6; Omu Anzala7; Pat Fast8; Matthew Price4

1045 Using GPS Data to Construct a Spatial Map of the HIV Epidemic in Malawi
Danielle E. Robbins1; Brian J. Coburn; Sally Blower
David Geffen School of Medicine at University of California Los Angeles, Los Angeles, CA, US

1046 HIV Incidence in Rural Malawi During Widespread Antiretroviral Treatment Availability
Alison Price1; Menard Chihana2; Ndolive Kayumi2; Amelia C. Crampin3; Mily Marston4; Basia Zaba5; Estelle McLean6; Olivier Koole7; Moffat Nyirenda8
1London School of Hygiene and Tropical Medicine, Chilumba, Malawi; 2Karonga Prevention Study, Chilumba, Malawi

1047 HIV-1 Incidence Among Adult STI Clinic Patients in Blantyre, Malawi
Fatima Zulu1; Isaac Singini1; Newton I. Kumwenda1; Johnstone Kumwenda1; Sufia Dadabhaj1
1Johns Hopkins University Research Project, Blantyre, Malawi; 2Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, US

Session P-W6 Poster Session
2:30 pm – 4:00 pm
Disease Progression, Morbidity, and Mortality

1048 CD4 Cell Dynamics in HIV-1 Infection Before and After ART: Overview and Determinants
Anne Cori1; Mike Pickles2; Arv van Sighem3; Luuk Gras4; Daniela Bezemer5; Peter Reiss6; Christoph Steffen7
On behalf of the ATHENA Observational Cohort
1Imperial College London, London, United Kingdom; 2HIV Monitoring Foundation, Academic Medical Centre, University of Amsterdam, Amsterdam, Netherlands

1049 IL-6 Partially Mediates the Effect of HIV Status on Survival
Kaku So-Armah1; Amy Justice2; David Rimland2; Maria Rodriguez-Barradas3; Adeel A. Butt4; David Leaf5; Mike Pickles2; Russel Tracy6; Mohammad Sajadi7; Cynthia Gilbert4; Matthew S. Freireg10
1Yale University School of Medicine, New Haven, CT, US; 2VA Connecticut Healthcare System, West Haven, CT, US; 3Veterans Affairs Medical Center, Atlanta, GA, US; 4Veterans Affairs Medical Center, Houston, TX, US; 5Sheikh Khalifa Medical City, Abu Dhabi, United Arab Emirates; 6Veterans Affairs Medical Center, Greater Los Angeles, CA, US; 7University of Vermont, Burlington, VT, US; 8Veterans Affairs Medical Center, Baltimore, MD, US; 9Veterans Affairs Medical Center, Washington, DC, US; 10Vanderbilt University School of Medicine, Nashville, TN, US

1050 Persistently Elevated Macrophage Activation in HIV+ Women Reporting Heavy Alcohol Use
Seema N. Desai1; Kathleen M. Weber1; Jane Burke-Miller1; Audrey L. French1; Monica Gandhi1; Mark H. Kuniholm1; Elizabeth T. Golub2; Kendall Bryant3; Alan Landay4; Mardge Cohen5
1Rush University Medical Center, Chicago, IL, US; 2CORE Center/Stroger Hospital of Cook County, Chicago, IL, US; 3Hektoen Institute of Medicine, Chicago, IL, US; 4University of California San Francisco, San Francisco, CA, US; 5Albert Einstein College of Medicine, Bronx, NY, US; 6Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, US; 7National Institutes of Health/National Institute on Alcohol Abuse and Alcoholism, Bethesda, MD, US; 8Stroger Hospital of Cook County, Chicago, IL, US
1051 Is Survival Following HIV Seroconversion Still Improving, 17 Years After the Introduction of cART?
Ashley Olson; Caroline Sabin; Maria Prins; Laurence Meyer; Julia del Amo; Genevieve Chene; Osamah Hamouda; Giota Touloumi; Kholoud Porter
On behalf of the CASCADE Collaboration in EuroCoord
1 University College London, London, United Kingdom; 2 Public Health Service of Amsterdam, Amsterdam, Netherlands; 3 INSERM, Paris, France; 4 Instituto de Salud Carlos III, Madrid, Spain; 5 INSERM, Bordeaux, France; 6 Robert Koch Institute, Berlin, Germany; 7 University of Athens, Athens, Greece

1052 National Estimates of Life Expectancy After HIV Diagnosis: US HIV Surveillance Data
Azfar-e-Alam Siddiqi; H. Irene Hall; Xiaohong Hu; Ruiguang Song
US Centers for Disease Control and Prevention (CDC), Atlanta, GA, US

1053 Age-Related Morbidities Among HIV-Infected Adults From 2000 to 2010
Cherise Wong; Stephen J. Gange; Michael A. Horberg; Gregory D. Kirk; Anita Rachlis; John Gill; Jennifer E. Thorne; Robert Hogg; James J. Goedert; Keri N. Althoff
1 Johns Hopkins University, Baltimore, MD, US; 2 Mid-Atlantic Permanente Research Institute, Rockville, MD, US; 3 University of Toronto Sunnybrook Research Institute, Toronto, Canada; 4 University of Calgary, Alberta Health Services, Calgary, Canada; 5 British Columbia Centre for Excellence in HIV/AIDS, Vancouver, Canada; 6 National Cancer Institute (NCI), Rockville, MD, US

1054 A Retrospective Population-Based Examination of Prescription Drug Usage Prior to HIV Diagnosis Among HIV Cases and Their Controls: The Missed Opportunity for Diagnoses Epidemiological Study (MODES)
Souradept Y. Shaw; Laurie Ireland; Tara Carnochan; Nancy Yu; Carla Ens; Yoav Keynan; Ken Kasper; Marissa Becker
On behalf of the MODES Manitoba Team
1 University of Manitoba, Winnipeg, Canada; 2 Nine Circles Community Health Centre, Winnipeg, Canada; 3 Manitoba Health, Winnipeg, Canada; 4 Manitoba HIV Program, Winnipeg, Canada

1055 Elevated Rates of Injury Among HIV-Positive Individuals in British Columbia
Hasina Samji; Dmitriy Shopin; Wendy Zhang; Oghenowede Eyawo; Guillaume Colley; Mark Hull; Julio Montaner; Robert Hogg
On behalf of the COAST Study
1 BC Centre for Excellence in HIV/AIDS, Vancouver, Canada; 2 Simon Fraser University, Burnaby, Canada; 3 University of British Columbia, Vancouver, Canada

1056 Higher Economic Well-Being Among Virally Suppressed HIV-Infected Adults With CD4>500
Harsha Thirumurthy; Aleksandra Jakubowski; James G. Kahn; Norton Seng; Tamara Clark; Edwin Charlebois; Maya Petersen; Moses R. Kanyka; Diane Havlir
SEARCH Collaboration
1 University of North Carolina at Chapel Hill, Chapel Hill, NC, US; 2 University of California San Francisco, San Francisco, CA, US; 3 University of California Berkeley School of Public Health, Berkeley, CA, US; 4 Makerere University College of Health Sciences, Kampala, Uganda; 5 KEMRI, Kisumu, Kenya

Session P-W7 Poster Session
2:30 pm – 4:00 pm
HIV Stigma

1057 Internalized Stigma in a Population-Based Sample of US HIV-Infected Adults in Care
Amy R. Baughner; Linda Beer; Jennifer L. Fagan; Christine L. Mattson; Mark Freedman; Jacek Skarbinski
US Centers for Disease Control and Prevention (CDC), Atlanta, GA, US

Alexandra B. Balaji; Justin C. Smith; Kristina Bowles; Gabriela Paz-Baily
US Centers for Disease Control and Prevention (CDC), Atlanta, GA, US

1059 Has Antiretroviral Treatment Scale-Up in Sub-Saharan Africa Reduced HIV-Related Stigma in the General Population? A Cross-Country Analysis
Brian T. Chan; Alexander Tsai; Mark Siedner
1 Brigham and Women's Hospital, Harvard Medical School, Boston, MA, US; 2 Massachusetts General Hospital, Harvard Medical School, Boston, MA, US

Session P-W8 Poster Session
2:30 pm – 4:00 pm
Serosorting and Seroadaptive Behavior: What’s Your Position?

1060 Trends in Sexual Behaviors Among Men Who Have Sex With Men in the United States, the Role of Antiretroviral Therapy and Seroadaptive Strategies
Gabriela Paz-Baily; Maria Mendoza; Binh Le; Charles E. Rose; Teresa Finlayson; Cyprian Wejnert; Henry F. Raymond; Joseph Prejean
1 US Centers for Disease Control and Prevention (CDC), Atlanta, GA, US; 2 San Francisco Department of Public Health, San Francisco, CA, US

1061 Changes in Condomless Sex and Serosorting Among MSM After HIV Diagnosis
Christine M. Khosropour; Julia C. Dombrowski; David A. Katz; Matthew R. Golden
1 University of Washington, Seattle, WA, US; 2 University of Washington, Seattle, WA, US

1062 Serosorting and Sexual Risk Behavior Influenced by Perceived HIV Serostatus Among MSM
Kathleen A. Brady; Jennifer Shinfeld; Catherine Mezzacappa
Philadelphia Department of Public Health, Philadelphia, PA, US
1063  Use of the Seroadaptive Strategies of Sexual Positioning and Serosorting by MSM in Nigeria
Cristina M. Rodriguez-Hart1; Hongjie Liu2; Ifeanyi K. Orazulike3; Sam Zorowitz4; Sylvia Adeba5; Lindsay Hughes6; Stefan Baral7; Merlin L. Robb8; William Blattner9; Manhattan Charurat1
1University of Maryland School of Medicine, Baltimore, MD, US; 2University of Maryland School of Public Health, College Park, MD, US; 3International Center on Advocacy and Rights to Health, Abuja, Nigeria; 4Massachusetts General Hospital and Harvard Medical School, Boston, MA, US; 5Population Council, Abuja, Nigeria; 6US Military HIV Research Program, Bethesda, MD, US; Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, US

WEDNESDAY, FEBRUARY 25, 2015
Session P-X1 Poster Session
Poster Hall
2:30 pm – 4:00 pm
Linkage to and Retention in Care
1068  A Longitudinal Approach to Retention and Virologic Suppression Across the HIV Care Continuum
Jonathan Colasanti; Carlos del Rio; Wendy Armstrong
Emory University School of Medicine, Atlanta, GA, US
1069  A High Proportion of Persons Diagnosed With Acute HIV Achieve Viral Suppression
Emily Westheimer1; Philip J. Peters2; Rebekkah Robbins3; Sarah L. Braunstein1
1New York City Department of Health and Mental Hygiene, Queens, NY, US; 2US Centers for Disease Control and Prevention (CDC), Atlanta, GA, US; 3New York City Department of Health and Mental Hygiene, Queens, NY, US

TUESDAY, FEBRUARY 24, 2015
Session P-X1 Poster Session
Poster Hall
2:30 pm – 4:00 pm
Paying for Care
1064  Ryan White HIV/AIDS Program Assistance and HIV Treatment Outcomes in the United States
Heather Bradley1; Abigail H. Vall1; Pascale M. Wortley1; Antigone Dempsey1; Heath Hauck2; Jacek Skarbinski1
1US Centers for Disease Control and Prevention (CDC), Atlanta, GA, US; 2US Health Resources and Services Administration, Rockville, MD, US
1065  Combining Multisite Payor Data With Clinical Data to Quantify Medicaid Payments for HIV Care
Anne Monroe1; Cindy Voss1; Richard Moore1; Kelly Gebo2; Allison Agwu1; Richard Rutstein1; Victoria Sharp1; Stephen Boswell1; John Fleishman1
1066  Proportionately More Gay Men in Seattle Insured Following the Affordable Care Act
Julia E. Hood1; Susan E. Buskin1; Elizabeth A. Barash1; Julia C. Dombrowski1; Matthew R. Golden2
1Public Health–Seattle & King County, Seattle, WA, US; 2University of Washington, Seattle, WA, US
1067  Characteristics and Outcomes of Patients Seeking Care at a New “Co-Pay” Convenience Clinic Established to Explore Sustainable Funding Models in Uganda
Rosalind M. Parkes-Ratanshi1; Gerald Mukisa2; Tom Kakeaire2; Faridah Mayanja3; Adeline Tumikye4; Brenda Mitchell5; Shadia Nakalera6; Walter Schlech7
1Dakar Sanatio Medical Center, Dakar, Senegal; 2Makerere University College of Health Sciences, Kampala, Uganda; 3Dalhousie University, Halifax, Canada

1070  Drivers of HIV Treatment Success Among a Population-Based Sample of Younger Black MSM
John A. Schneider1; Britt Skaathun2; Stuart Michael2; Lindsay Young3; Keith Green3; Ethan Morgan4; Robert W. Coombs3; Sam Friedman5; Edward Laumann6
On behalf of UConnect Study Team
1071  Population-Level HIV RNA and CD4+ Distribution in a Rural Ugandan Community With Widespread Community HIV Testing and Universal ART Access
Vivek Jain1; Gabriel Chamie2; Gideon Amanyire3; Dalsone Kwarisimasa4; Jane Kabami5; Maya L. Petersen6; Tamara Clark7; Edwin D. Charlebois8; Moses R. Kamya9; Diane Havlir10
1University of California San Francisco, San Francisco, CA, US; 2Makerere University–University of California San Francisco Research Collaboration, Kampala, Uganda; 3University of California Berkeley School of Public Health, Berkeley, CA, US
1072  Facility-Level Factors Influencing Retention in HIV Care in East Africa
Beth Rachlis1; Giorgios Bakoyannis2; Philippa Easterbrook3; R. Scott Braithwaite4; Craig R. Cohen5; Elizabeth Bukusi6; Andrew D. Kambuubi7; Moses Bosco Bwana8; Elvin H. Geng9; Paula Brattstein10
1Academic Model Providing Access to Healthcare program, Eldoret, Kenya; 2Indian University School of Medicine, Indianapolis, IN, US; 3Infectious Diseases Institute, Kampala, Uganda; 4New York University, New York City, NY, US; 5University of California San Francisco (UCSF), San Francisco, CA, US; 6Kenya Medical Research Institute, Nairobi, Kenya; 7Mbarara University, Mbarara, Uganda
**1074  Successful Down-Referral Even Among Patients With Virologic Failure in South Africa**
Jonathan Colasanti; Darius McDaniel; Brent Johnson; Henry Sunpath; Carlos del Rio; Vincent C. Marconi
1Emory University School of Medicine, Atlanta, GA, US; 2Emory University Rollins School of Public Health, Atlanta, GA, US; 3Emory University Rollins School of Public Health, Atlanta, GA, US; 4Mccord Hospital, Durban, South Africa

**1075  Retention in a Decentralized HIV Care and Treatment Program in North Central Nigeria**
Patricia Agaba; Becky L. Genberg; Solomon Sagay; Oche Agbaji; Nancin Dadem; Grace Kolawole; Prosper Okonkwo; Seema Meloni; Phyllis Kanki; Norma C. Ware
1University of Jos, Jos, Nigeria; 2Brown University, Providence, RI, US; 3AIDS Prevention Initiative, Abuja, Nigeria; 4Harvard School of Public Health, Boston, MA, US; 5Harvard Medical School, Boston, MA, US

Bonita K. Kilama; Candisa Moshiro; Jim Todd; Angela Ramadhani; Donan Mmbando
1National AIDS Control Program, Dar es Salaam, United Republic of Tanzania; 2Muhimbili University of Health and Allied Sciences, Dar es Salaam, United Republic of Tanzania; 3Ministry of Health Of Social Welfare, Dar es Salaam, United Republic of Tanzania; 4London School of Hygiene and Tropical Medicine, London, United Kingdom

**1077  Impact of the Ebola Outbreak on the Quality of Care of People Living With HIV Taking Antiretroviral Treatment at Donka National Hospital in Conakry, Guinea**
Mohamed Cisse; Momadou Saliou Diallo; Cheick Tidiane Tidiane; Cece Kpamou; Justeau Dimitri; Eric Dortonzio; Jacques D. Ndawin
1Solthis International NGO, Paris, France; 2Hôpital National de Donka, Conakry, Guinea; 3Ministère de la Santé et de l’Hygiène Publique, Conakry, Guinea; 4Solthis NGO, Conakry, Guinea

Helena Kwakwa; Rahab Wahome; Oumar H. Gaye; Natasha Z. Mwula
Philadelphia Department of Public Health, Philadelphia, PA, US

---

**THURSDAY, FEBRUARY 26, 2015**

**Session P-X3 Poster Session**
2:30 pm – 4:00 pm

**Guidelines and Their Implementation**

**1079  Starting ART at 500 CD4 in Southern Africa: What Is the Impact on ART Eligibility?**
Helena Huerga; David Maman; Gilles Van Cutsen; Beatrice Kirubi; Charles Masiku; Ruggiero G. Giuliani; Irene Mukui; Benson Chilima; Elisabeth Zszumilin; Jean-François Etard
1Epicentre, Paris, France; 2Hôpital National de Donka, Conakry, Guinea; 3National AIDS and STDs Control Program, Nairobi, Kenya; 4Médecins Sans Frontières, Paris, France

**1080  Impact of South Africa’s HIV Treatment Guidelines on Early Losses: A Cohort Analysis**
Ingrid T. Kata; Richard Kaplan; Garrett Fitzmaurice; Dominick Leone; David R. Bangsberg; Linda-Gail Bekker; Catherine Orrell
1Harvard Medical School, Cambridge, MA, US; 2Desmond Tutu HIV Foundation, Cape Town, South Africa; 3Boston University School of Medicine, Boston, MA, US; 4Harvard School of Public Health, Boston, MA, US

**1081  Mortality Across Two ART Trials Enrolling at ≤200 vs ≤350 CD4 cells/ul in Kenya**
Rachel A. Silverman; Michael Chung; James N. Kiarii; Nelly Yatich; Julia Njoroge; Catherine Kiptinness; Samah Sako; Grace John-Stewart; Lisa Frenkel
1University of Washington, Seattle, WA, US; 2University of Nairobi, Nairobi, Kenya; 3Coptic Hospital, Nairobi, Kenya

**1082  HIV Testing of Persons Aged 15–65 Years at Visits to US Physician Offices, 2009–2010**
Karen Hoover; Shirley Lecher; Roman Gvetadze; Philip Peters
US Centers for Disease Control and Prevention, Atlanta, GA, US

**1083  Frontline Practices With HIV Prevention: A Survey of US Infectious Disease Physicians**
Douglas S. Krakower; Susan E. Beekmann; Philip M. Polgreen; Kenneth H. Mayer
1Emerging Infections Network
2Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, US; 3University of Iowa, Iowa City, IA, US

---

**Session P-Y1 Poster Session**
2:30 pm – 4:00 pm

**Male Circumcision: Risk, Innovation, and Scale-Up**

**1084  HSV-2 Shedding From Male Circumcision Wounds Among HIV-Infected Men**
Mary K. Grabowski; Godfrey Kigozi; Ronald H. Gray; Jordyn L. Manucci; David Servadda; Eshan U. Patel; Fred Nalugoda; Maria J. Wawer; Thomas C. Quinn; Aaron A. Tobian
1Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, US; 2Rakai Health Sciences Program, Kalisizo, Uganda; 3Johns Hopkins University School of Medicine, Baltimore, MD, US; 4Makerere University College of Health Sciences, Kampala, Uganda; 5National Institute of Allergy and Infectious Diseases (NIAID), Bethesda, MD, US
1085  
**Association Between Foreskin Microbiota and Local Cytokines in Men From Rakai, Uganda**

Cindy M. Liu¹; Aaron A. Tobian²; Jessica Proctor³; David Serwadda¹; Godfrey Kigozi¹; Fred Nalugoda¹; Maria J. Wawer¹; Lance Price⁴; Rupert Kaul¹; Ronald H. Gray¹

¹Johns Hopkins University School of Medicine, Baltimore, MD, US; ²Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, US; ³Rakai Health Sciences Program, Rakai, Uganda; ⁴Translational Genomics Research Institute, Flagstaff, AZ, US; ⁵University of Toronto, Toronto, Canada

1086  
**Mobile VMMC Teams in Tanzania See Older Clients and Have Higher Followup Rates**

Augustino M. Hellar¹; Dorica Boyee¹; Hally Mahler¹; Marya Plotkin¹; Touma N'wanakila¹; Kelly Curran²; Tsigitu Ashengo³; Hawa Mziray⁴; Erick Mlanga¹; Sifuni Koshuma⁵

¹Jhpiego, Dar es Salaam, United Republic of Tanzania; ²Jhpiego, Baltimore, MD, US; ³US Agency for International Development, Dar es Salaam, United Republic of Tanzania; ⁴Ministry of Health and Social Welfare, Iringa, United Republic of Tanzania

1087  
**High Acceptability of PrePex™ Device in Routine Programmatic Settings in Rwanda**

Eugene Rugwizangoga¹; Beata Mukurugwiro¹; Jovite Sinzahera¹; Alphonse Mutaburaka¹; Glorioso Abayisenga¹; J. D. Nitakakirabo¹; Ngeruka Leon¹; Eugene Zimulinda¹; Kelly Curran²; Tsigitu Ashengo³; Erick Mlanga¹; Sifuni Koshuma⁵; Alphonse Mutabaruka¹; J. D. Nitakakirabo¹; Ngeruka Leon¹; Eugene Zimulinda¹; Kelly Curran²; Tsigitu Ashengo³

¹Jhpiego, University of Rwanda, Kigali, Rwanda; ²Jhpiego, Rwanda, Kigali, Rwanda; ³Jhpiego, an Affiliate of Johns Hopkins University, Washington, DC, US; ⁴US Department of Defense, Rwanda, Kigali, Rwanda; ⁵Rwanda Military Hospital, Kigali, Rwanda

1088  
**Self-Selection of Circumcision Acceptors, Risk Compensation and Effectiveness of Circumcision Among Service Recipients, Rakai, Uganda**

Joseph Kagayi¹; Xiangrong Kong²; Godfrey Kigozi¹; Fred Nalugoda¹; Steven J. Reynolds¹; David Serwadda¹; Nelson K. Sewankambo¹; Maria J. Wawer¹; Ronald H. Gray¹

¹Rakai Health Sciences Program, Entebbe, Uganda; ²Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, US; ³Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, US; ⁴Makerere University School of Public Health, Kampala, Uganda; ⁵Makerere University College of Health Sciences, Kampala, Uganda

1089  
**Potential Protection From HIV Transmission by Penile Cuttings in Papua New Guinea**

Ivy H. Shih¹; Lester Asugeni²; Matthew David³; Paul Horwood⁴; Parana Hewage Mangalasir¹; David Mc Laren⁴; Rachael Tommbe³; Andrew Vallety¹; Arnold Wayne⁴; Stuart G. Turville¹

¹The Kirby Institute, Sydney, Australia; ²Pacific Adventist University, Port Moresby, Papua New Guinea; ³James Cook University, Cairns, Australia; ⁴University of Papua New Guinea, Port Moresby, Papua New Guinea; ⁵Papua New Guinea Institute of Medical Health, Goroka, Papua New Guinea

**WEDNESDAY, FEBRUARY 25, 2015**

**Session P-Y2 Poster Session**

**Poster Hall**

**2:30 pm – 4:00 pm**

**Linkage to Care and ART Initiation**

1090  
**Linkage to HIV Care Following Home-Based Testing and CD4 in Rural Malawi**

Sophie Masson¹; Jihane Ben Farhat¹; Charles Masiku¹; Benson Chilima¹; Elisabeth Szumilin²; Leon Salumu³; Jean-François Etard¹; David Maman¹

¹Epicentre/Médecins Sans Frontières, Paris, France; ²Ministry of Health, Lilongwe, Malawi; ³Médecins Sans Frontières, Paris, France; ⁴Médecins Sans Frontières Malawi, Lilongwe, Malawi

1091  
**Rapid ART Initiation Reduces Loss Between HIV Testing and Treatment: The RapIT Trial**

Sydney Rosen¹; Mhairi Maskew¹; Matt P. Fox³; Cynthia Nyonzi¹; Constance Mongwenuyan¹; Given Malete³; Ian Sanne³; Julia K. Rohr¹; Lawrence Long¹

¹Boston University, Boston, MA, US; ²University of the Witwatersrand, Johannesburg, South Africa

1092  
**Outcomes of a Clinic-Health Department “Data to Care” Relinkage Intervention**

Joanna M. Bove¹; Matthew R. Golden³; Shireesha Dhanireddy²; Robert Harrington¹; Julie Dombrowski¹

¹University of Washington, Seattle, WA, US; ²University of Washington, Seattle, WA, US

1093  
**HIV Partner Services Can Achieve Near-Universal Linkage to HIV Care**

David A. Katz¹; Julia C. Dombrowski¹; Susan E. Buskin¹; Amy Bennett¹; Elizabeth A. Barash¹; Matthew R. Golden¹

¹University of Washington, Seattle, WA, US; ²Public Health – Seattle & King County, Seattle, WA, US

1094  
**Immunodeficiency at the Start of ART: A Global View**

Klea Panayidou¹; Ole Kirk¹

¹On behalf of the IeDEA Collaboration and the COHERE Collaboration

1095  
**Providers’ Attitudes and Practices Related to ART Use for HIV Care and Prevention**

Kate Buchacz¹; Jennifer Farrior¹; Gheetha Beauchamp¹; Laura McKinstrny¹; Ann Kurth¹; Barry S. Zingman¹; Fred Gordin¹; Deborah Donnell¹; Wafa'a M. El-Sadri¹; Bernard M. Branson¹

¹US Centers for Disease Control and Prevention (CDC), Atlanta, GA, US; ²FH360, Durham, NC, US; ³Fred Hutchinson Cancer Research Center, University of Washington, Seattle, WA, US; ⁴New York University School of Medicine, New York, NY, US; ⁵Montefiore Medical Center and Albert Einstein College of Medicine, New York, NY, US; ⁶Veterans Affairs Medical Center and George Washington University, Washington, DC, US; ⁷Columbia University and Harlem Hospital, New York, NY, US
Session P-Y3 Poster Session  
2:30 pm – 4:00 pm  
HIV Testing: Innovations and Scale-Up

1096 Availability and Quality of Online HIV Self-Test Kits in China and the United States  
Fengying Liu1; Larry Han1; Weiming Tang1; Shujie Huang1; Ligang Yang1; Heping Zheng2; Bin Yang2; Joseph Tucker1  
1University of North Carolina, Guangzhou, China; 2Guangdong Provincial STD Control Center, Guangzhou, China; 3University of North Carolina, Chapel Hill, NC, US

1097 Home HIV Testing and Medical Care: Doing the Right Thing  
Charulata J. Sabharwal; Sharmila Shah; Chi-Chi N. Udeagu  
New York City Department of Health and Mental Hygiene, Queens, NY, US

1098 Using Grindr™, a Social-Media–Based Application, to Increase HIV Self-Testing Among High-Risk Men Who Have Sex With Men in Los Angeles, California, 2014  
Alexandra Medline1; Emily Huang2; Robert Marlin3; Sean D’Young4; Justin Kwok5; Jeffrey D. Klausner2  
1McGill University, Toronto, Canada; 2David Geffen School of Medicine at University of California Los Angeles, Los Angeles, CA, US

1099 Sexually Transmitted Disease Partner Services Increase HIV Testing Among Men Who Have Sex With Men  
Matthew R. Golden1; David A. Katz2; David Kern3; David Heald4; Roxanne Keran1; Julia C. Dombrowski5  

1100 Expanding HIV Testing in Hospital Emergency Departments and Inpatient Admissions  
Pollyanna R. Chavez1; Elizabeth Greene2; Kate Buchacz3; Theresa Gamble4; Steven F. Ehrlinge5; Laura McKinstry6; Gheetha Beauchamp7; Matthew Connor8; Wafa M. El-Sadr9; Bernard M. Branson10  

1101 Universal HIV Testing Using a “Hybrid” Approach in East Africa in the SEARCH Trial  
Gabriel Chamie1; Tamara Clark2; Jane Kabami3; Kevin Kedede4; Dalsone KwasiSima5; Norton Sang6; Maya Petersen7; Moses R. Kamya5; Diane Havelir3; Edwin Charlebois1  
1University of California San Francisco, San Francisco, CA, US; 2Kenyan Medical Research Institute (KEMRI), Nairobi, Kenya; 3Makerere University - University of California Research Collaboration, Kampala, Uganda; 4University of California Berkeley School of Public Health, Berkeley, CA, US; 5University of California San Francisco (UCSF), San Francisco, CA, US

1102 A Household Food Voucher Increases Consent to Home-Based HIV Testing in Rural KwaZulu-Natal  
Mark McGovern1; David Canning2; Frank Tanser3; Kobus Herbst4; Dickman Garetta5; Tinafo Mutvedzi6; Deenan Pillay7; Till Barnighausen1  
1Harvard University, Cambridge, MA, US; 2Wellcome Trust Africa Centre for Health and Population Studies, University of KwaZulu-Natal, KwaZulu-Natal, South Africa

1103 Acceptability and Uptake of Home-Based HIV Self-Testing in Lesotho  
Allison V. Zerbe1; Abby DiCarlo2; Joanne E. Mantelli3; Robert H. Remien4; Daniella D. Morris5; Koen Frederix6; Blanche Pitt7; Zachary J. Peters8; Wafa M. El-Sadr1  

TUESDAY, FEBRUARY 24, 2015

Session P-Z1 Poster Session  
2:30 pm – 4:00 pm  
Costs and Cost Effectiveness

1104 The Lifetime Medical Cost Savings From Preventing HIV in the United States  
Bruce R. Schackman1; John Fleishman2; Amanda Su3; Richard Moore4; Rochelle Walensky5; David Paltiel6; Milton Weinstein7; Kenneth Freedberg8; Kelly Gebo9; Elena Losina10  
1Weill Cornell Medical College, New York, NY, US; 2Massachusetts General Hospital, Harvard Medical School, Boston, MA, US; 3Yale School of Public Health, New Haven, CT, US; 4Harvard School of Public Health, Boston, MA, US; 5Johns Hopkins University School of Medicine, Baltimore, MD, US; 6Agency for Healthcare Research and Quality, Rockville, MD, US

1105 Online Partner Notification: A Cost-Effective Tool to Reduce HIV-1 Epidemic Among MSM  
Brooke E. Nichols1; Hannelore M. Götz2; Eric C. van Gorp3; Annelies Verbon4; Casper Roxy5; Charles Boucher6; David A. van de Vijver1  
1Erasmus University Medical Center, Rotterdam, Netherlands; 2Public Health Service Rotterdam-Rijnmond, Rotterdam, Netherlands; 3Erasmus Medical Center, Rotterdam, Netherlands

1106 Cost-Effectiveness of Preexposure Prophylaxis for High-Risk HIV-Discordant Couples  
Roger Ying1; Renee Heffron2; Jared Baeten3; Connie Celum4; Elly Katahira5; Nulu Bulya6; Ruane V. Barnabas7  
1University of Washington, Bellevue, WA, US; 2Makerere University College of Health Sciences, Kampala, Uganda

1107 Multipurpose Prevention Technologies for HIV and Pregnancy Prevention  
Rebecca Geary; Jennifer Smith; Nidhi Khurana; Ide Cremin; Timothy Hallett  
Imperial College London, London, United Kingdom

1108 Cost-Effectiveness of Isoniazid Preventative Therapy for HIV-Infected Pregnant Women in India  
Sunaina Kapoor; Natasha Chida; Amita Gupta; Maunank Shah; Johns Hopkins University School of Medicine, Baltimore, MD, US

1109 Epidemiologic Benefits and Cost-Effectiveness of Improving Rwanda’s HIV Care Cascade  
Eran Bendavid1; Edward Mills2; Steve Kanters3; Sabin Nsanizima3  
1Stanford University, Stanford, CA, US; 2University of Ottawa, Ottawa, Canada; 3Rwanda Biomedical Center, Kigali, Rwanda
1110 The Cost-Effectiveness of Early ART Initiation in South Africa: A Quasi-Experiment
Jacob Bor; Ellen Moscove; Natsayi Chimbindi; Kobus Herbst; Kevindra K. Naidu; Frank Tanser; Deenan Pillay; Till Barnighausen
1Boston University School of Public Health, Boston, MA, US; 2Harvard School of Public Health, Boston, MA, US; 3Wellcome Trust Africa Centre for Health and Population Studies, Samkelo, South Africa

1111 Community-Based Strategies to Strengthen the Continuum of HIV Care Are Cost-Effective
Jennifer A. Smith; Monisha Sharma; Carol Levin; Jared Baeten; Heidi van Rooyen; Connie Celum; Timothy Hallett; Ruanne V. Barnabas
1Imperial College London, London, United Kingdom; 2University of Washington, Seattle, WA, US; 3Human Sciences Research Council, Sweetwaters, South Africa

1112 The Cost-Effectiveness of CD4 Cell Count Versus HIV RNA Viral Load for ART Initiation
Roger Ying; Brian Williams; Ruanne V. Barnabas; Reuben Granich
1University of Washington, Bellevue, WA, US; 2Joint United Nations Programme on HIV/AIDS, Geneva, Switzerland; 3Stellenbosch University, Stellenbosch, South Africa

1113 Costs of Expanded HIV Testing in 4 EDs: Results From HPTN 065
Bruce R. Schackman; Ashley A. Eggman; Jared A. Leff; Megan Braunlin; Bernard M. Branson
1Weill Cornell Medical College, New York, NY, US; 2US Centers for Disease Control and Prevention (CDC), Atlanta, GA, US

1114 Global Fund Cost Projections for Implementing WHO 2013 Guidelines
Obinna Onyekwena; Ade Fakoya; Michael Johnson; Michael Olszak-Olszewski; Mark Dybul
The Global Fund to Fight AIDS, Tuberculosis and Malaria, Geneva, Switzerland

THURSDAY, FEBRUARY 26, 2015
Session P-Z3 Poster Session Poster Hall 2:30 pm – 4:00 pm
Modeling the Impact of HIV Interventions

1118 Predicted Impact of Antiretroviral Treatment on Preventing New HIV Infections in 53 Low- and Middle-Income Countries With Large HIV Epidemics
Andrew M. Hill; Anton Pozniak; Katherine Heath; Alice Raymond; Mary Mahy; Nathan Ford
1Chelsea and Westminster Hospital, London, United Kingdom; 2St Mary’s Hospital–Imperial College Healthcare NHS Trust, London, United Kingdom; 3Joint United Nations Programme on HIV/AIDS (UNAIDS), Geneva, Switzerland; 4World Health Organization, Geneva, Switzerland

1119 Survival Benefits Attributable to the Brazilian National ART Policy
Paula M. Luz; Michael P. Girouard; Beatriz Grinsztejn; Kenneth Freedberg; Valdieva Veloza; Elena Losina; Claudio Struchiner; Robert Parker; David Paltiel; Rochelle Walensky
1Fundacao Oswaldo Cruz, Rio de Janeiro, Brazil; 2Massachusetts General Hospital, Boston, MA, US; 3Yale School of Public Health, New Haven, CT, US; 4Brigham and Women’s Hospital, Boston, MA, US

1120 A Predictive Risk Model for First-Line Treatment Failure in South Africa
Julia K. Rohr; Prudence Ive; Rebecca H. Berhanu; Kate Shearer; Mhairi Maskew; Lawrence Long; Ian Sanne; Matthew P. Fox
1Boston University School of Public Health, Boston, MA, US; 2University of Witwatersrand, Johannesburg, South Africa; 3Right to Care, Johannesburg, South Africa

1121 U.S. Population Benefits of HIV Preexposure Prophylaxis for Injection Drug Users
Cora Bernard; Margaret L. Brandleau; Douglas K. Owens; Keith Humphreys; Eran Bendavid; Mark Holodniy; Christopher Weyant; Jeremy D. Goldhaber-Fiebert
1Stanford University, Stanford, CA, US; 2VA Palo Alto Health Care System, Palo Alto, CA, US
1122  Procreation in HIV-Serodiscordant Couples: TasP, PrEP, or Assisted Reproduction?
Guillaume Mabileau; Michaël Schwarzinger; Juan Flores; Catherine Patrat; Dominique Luton; Sylvie Épelboin; Laurent Mandelbrot; Sophie Matheron; Yazdan Yazdanpanah
On behalf of ANRS 12008
1Inserm, Paris, France; 2AP-HP, Bichat-Claude Bernard Hospital, Paris, France; 3Louis Mourier Hospital, Colombes, France
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>8:30 AM</td>
<td>Workshop for New Investigators and Trainees 9:00 AM to 12:30 PM Room 6E</td>
<td>Plenary: PReP for HIV Prevention: What We Know and What We Need to Know for Implementation Room 4AB</td>
<td>Plenary: Preventing Pediatric HIV and Managing HIV-Infected Children: Where Are We Now and Where Are We Going? Room 4AB</td>
<td>Plenary: Cardiovascular Disease in HIV Patients: An Emerging Paradigm and Call to Action Room 4AB</td>
</tr>
<tr>
<td>9:00 AM</td>
<td>Plenary: Specific HIV Integration Sites Linked to Clonal Expansion and Persistence of Cells Room 4AB</td>
<td>Plenary: Directing Chronic Virus Infection Through Viral Regulation of Innate Immune Defenses Room 4AB</td>
<td></td>
<td>Plenary: The Price of Selling Sex: HIV Among Female Sex Workers—The Context and the Public Health Response Room 4AB</td>
</tr>
<tr>
<td>9:30 AM</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:00 AM</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>12:15 PM</td>
<td>LUNCH</td>
<td>LUNCH</td>
<td>LUNCH</td>
<td>LUNCH</td>
</tr>
<tr>
<td>1:00 PM</td>
<td>Martin Delaney Presentation</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1:30 PM</td>
<td>1:00 PM to 2:00 PM How to End the HIV Epidemic: Community Perspectives Room 6E</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2:00 PM</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2:30 PM</td>
<td>CONCURRENT WORKSHOPS</td>
<td>POSTER SESSIONS</td>
<td>POSTER SESSIONS</td>
<td>POSTER SESSIONS</td>
</tr>
<tr>
<td></td>
<td>2:30 PM to 4:30 PM How to End the HIV Epidemic: Community Perspectives Room 6E</td>
<td>2:30 PM to 4:00 PM Poster Hall</td>
<td>2:30 PM to 4:00 PM Poster Hall</td>
<td>2:30 PM to 4:00 PM Poster Hall</td>
</tr>
<tr>
<td>4:00 PM</td>
<td>Clinical Trial Design and Analysis Room 6E</td>
<td>CONCURRENT SYMPOSIA</td>
<td>CONCURRENT SYMPOSIA</td>
<td>CONCURRENT SYMPOSIA</td>
</tr>
<tr>
<td></td>
<td>How to End the HIV Epidemic: Community Perspectives Room 6E</td>
<td>4:00 PM to 6:00 PM</td>
<td>4:00 PM to 6:00 PM</td>
<td>4:00 PM to 6:00 PM</td>
</tr>
<tr>
<td></td>
<td>How to End the HIV Epidemic: Community Perspectives Room 6E</td>
<td>S-1: Harnessing Antibodies for Prevention and Treatment Room 4AB</td>
<td>S-1: Making Sense of Sensing: Innate Immunity and HIV Infection Room 4AB</td>
<td>S-1: From Pathways to Paradigms: Applications of Systems Biology to HIV/Host Interactions Room 613</td>
</tr>
<tr>
<td>4:30 PM</td>
<td></td>
<td>S-2: Current Issues in HIV-Related Malignancies Room 613</td>
<td>S-5: Advancing HIV Prevention: Lessons From Biology, Medicine, and Public Health Law Room 613</td>
<td>S-5: Scale-Up of Interventions Room 6D</td>
</tr>
<tr>
<td>5:00 PM</td>
<td>Opening Session 5:00 PM to 7:00 PM N’Galy-Mann Lecture: Hepatitis C: Light at the End of the Tunnel 4AB</td>
<td>ORAL ABSTRACT SESSION</td>
<td>ORAL ABSTRACT SESSION</td>
<td>ORAL ABSTRACT SESSION</td>
</tr>
<tr>
<td>6:00 PM</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>6:30 PM</td>
<td>Special Session 6:30 PM to 7:30 PM Ebola Virus Disease: Responding to the Challenge Room 6E</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>7:00 PM</td>
<td>Welcome Reception 7:00 PM to 9:30 PM Nordstrom Downtown Seattle 500 Pine Street (Cross street 6th Ave)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>